

**MOLECULAR INVESTIGATION OF
BECKWITH-WIEDEMANN SYNDROME AND SILVER-
RUSSELL SYNDROME**

By

BENOÎT LAN-LEUNG

A thesis submitted to the University of Birmingham for the degree of

DOCTOR OF PHILOSOPHY

Institute of Cancer and Genomic Sciences

University of Birmingham

January 2017

UNIVERSITY OF
BIRMINGHAM

University of Birmingham Research Archive

e-theses repository

This unpublished thesis/dissertation is copyright of the author and/or third parties. The intellectual property rights of the author or third parties in respect of this work are as defined by The Copyright Designs and Patents Act 1988 or as modified by any successor legislation.

Any use made of information contained in this thesis/dissertation must be in accordance with that legislation and must be properly acknowledged. Further distribution or reproduction in any format is prohibited without the permission of the copyright holder.

ABSTRACT

The investigation of human imprinting disorders has provided important insights into the role of genomic imprinting in normal health and development. Beckwith-Wiedemann syndrome (BWS) is a congenital overgrowth disorder associated with abnormal function of 11p15.5 imprinted genes that's result, most commonly, from the epimutation (loss of maternal allele methylation) at the imprinting centre *KCNQ1OT1:TSS-DMR* (BWS_IC2). In contrast, Silver-Russell syndrome (SRS) is characterised by pre- and postnatal growth retardation and, most commonly, epimutations (loss of paternal allele methylation) at *H19/IGF2:IG-DMR*. Using Infinium 450K methylation array, I performed methylation profiling at 46 imprinted differentially methylated regions in 90 BWS and 21 SRS patients. I report epimutations at other imprinting centres outside of chromosome 11p15.5 in 40% of BWS_IC2 but not in SRS_IC1. The investigation of the potential underlying causes of this multilocus methylation disturbances (MLID) epigenotype in BWS_IC2 individuals indicated that several factors might contribute to the BWS phenotype and MLID epigenotype. Although not a universal finding, the use of assisted reproductive technology was significantly associated with MLID in my cohort of BWS_IC2 patients. Furthermore, using whole-exome sequencing strategy, I describe new potential candidate genes for *trans*-acting factors regulating methylation at imprinting DMRs.

DEDICATION

To my family for supporting me with this endeavour.

To Hannah, the love of my life, for being you, for everything, for giving me the most beautiful gift in the world.

To Emilie, my daughter, for your beautiful smile that brighten my days.

AKNOWLEDGEMENTS

I would like to thank my supervisor Professor Eamonn Maher for his advice and support throughout this project. Thanks also to Professor Farida Latif for her supervision of this project.

Thanks to my funders, Marie Skłodowska-Curie, without who this project won't be possible.

Special thanks to Scottie for the immeasurable help and advices you gave me during my PhD. Special mention to the invaluable coffee time we had, the English you tried to teach me and your (failed) attempt to making me like your Scottish accent.

Thank you Frenchie for all the hard work you have done for me. I won't forget your kindness and dedication any time soon.

I also wish to thanks my colleagues for your warm welcome, assistance and daily support.

Big thank you 'Copains malins', my old-time friends. You have made my life, to some extent, more enjoyable since I've known you.

My blondie Hannah for your limitless patience, support and love. You were there with me the entire time. I don't know what I would do without you.

And finally my family, Mom and Dad, for their love and support.

TABLE OF CONTENTS

Chapter 1 - General Introduction	1
1.1 Epigenetics	2
1.1.1 DNA methylation	3
1.1.1.1 Life cycle.....	4
1.1.1.2 The machinery.....	6
1.1.1.2.1 De novo DNA methylation	6
1.1.1.2.2 DNA methylation maintenance	7
1.1.1.2.3 DNA demethylation.....	8
1.1.1.2.3.1 Passive DNA demethylation	8
1.1.1.2.3.2 Active DNA demethylation	9
1.1.2 DNA methylation and transcriptional regulation.....	10
1.1.2.1 Direct regulation	11
1.1.2.2 Indirect regulation	11
1.2 Genomic imprinting	14
1.2.1 Historical overview.....	15
1.2.2 Life cycle of genomic imprinting.....	19
1.2.2.1 Imprinting erasure.....	20
1.2.2.2 Imprinting establishment.....	22
1.2.2.3 Imprinting maintenance	23
1.2.3 Consequences of aberrant genomic imprinting	24
1.3 Beckwith-Wiedemann Syndrome.....	27
1.3.1 Molecular defects in BWS aetiology	28
1.3.1.1 Disturbances at H19/IGF2:IG-DMR region	32
1.3.1.2 Disturbances at KCNQ1OT1:TSS-DMR region	35
1.3.1.3 Disturbances at both H19/IGF2:IG-DMR and KCNQ1OT1:TSS-DMR regions.....	37
1.3.1.4 Abnormality detection rate in BWS.....	37
1.4 Silver-Russell Syndrome.....	38

1.4.1	Molecular defects in SRS aetiology	39
1.4.1.1	Disturbances at chromosome 11p15.5.....	40
1.4.1.2	Disturbances at chromosome 7.....	41
1.4.1.3	Disturbances at other chromosome.....	43
1.4.1.4	Abnormality detection rate in SRS.....	44
1.5	Imprinting disorders and multilocus methylation disturbances.....	45
1.6	General summary of this project	47
1.7	Aims of this project.....	49
Chapter 2 - General Methods.....		51
2.1	Buffers recipe	52
2.1.1	1X Transfer buffer	52
2.1.2	1X PBS-Tween 20 (PBST)	52
2.1.3	Blocking buffer	52
2.1.4	4X Laemmli sample buffer	52
2.1.5	RIPA.....	52
2.1.6	2X SSC	53
2.1.7	1X TAE.....	53
2.2	DNA purification	53
2.3	DNA quantification	54
2.4	Sodium bisulfite treatment	55
2.5	Infinium HumanMethylation450 BeadChip.....	56
2.6	Analysis software	57
2.7	DNA fragments analysis of DNA libraries	57
2.7.1	Setting up the chip priming station.....	57
2.7.2	Loading the gel dye mix.....	58
2.7.3	Loading the marker.....	58
2.7.4	Loading the ladder and the samples.....	58
2.7.5	Starting the chip run.....	59
2.7.6	Data analysis	59

Chapter 3 - Development of a novel next generation sequencing strategy for the genomic imprinting methylation profiling of individual with BWS and SRS

.....	60
3.1	Introduction 61
3.1.1	What is NGS? 61
3.1.2	Sequencing-by-synthesis; an Illumina technology 62
3.1.3	What is bisulfite sequencing? 66
3.1.4	NGS based methods for DNA methylation profiling 67
3.1.5	DNA methylation profiling using the bisulfite padlock probes 70
3.1.6	Aim..... 74
3.2	Materials and methods..... 76
3.2.1	DNA purification 76
3.2.2	DNA quantification 76
3.2.3	Sodium bisulfite treatment 76
3.2.4	Amplicon size selection 76
3.2.5	Preparation of sequencing libraries using bisulfite padlock probes .. 77
3.2.5.1	Bisulfite padlock probes design and synthesis 77
3.2.5.2	Bisulfite padlock probes production (for LCSciences only) 78
3.2.5.2.1	Amplification (for LCSciences only) 78
3.2.5.2.2	Nicking digestion (for LCSciences only) 79
3.2.5.2.3	Denaturing PAGE purification (for LCSciences only) 80
3.2.5.3	Multiplex capture of bisulfite treated target regions 82
3.2.5.4	Circularisation of captured sequences 83
3.2.5.5	Enzymatic digestion..... 83
3.2.5.6	Capture circle amplification 83
3.2.5.7	Sequencing..... 85
3.3	Results 85
3.3.1	First experimental design..... 85
3.3.1.1	Design requirements 85
3.3.1.2	Padlock probes to synthesise..... 87

3.3.1.3	Library preparation	87
3.3.1.4	Sequencing.....	89
3.3.2	Second experimental design	90
3.3.2.1	Design requirements	90
3.3.2.2	Library preparation	92
3.3.2.3	Sequencing.....	94
3.4	Discussion.....	95

Chapter 4 - Methylation Profiling in Beckwith-Wiedemann Syndrome and Silver-Russell Syndrome 99

4.1	Introduction	100
4.1.1	DNA methylation profiling using the Infinium HumanMethylation 450K BeadChips.....	100
4.1.2	Aim.....	103
4.2	Materials and methods.....	103
4.2.1	Patient blood DNA	103
4.2.2	DNA quantification	104
4.2.3	Sodium bisulfite treatment	104
4.2.4	DNA methylation profiling using HM450K.....	104
4.2.4.1	Bioinformatic pipeline to analyse HM450K methylation dataset 105	
4.2.4.1.1	HM450K data preprocessing	105
4.2.4.1.2	HM450K data batch correction	106
4.2.4.1.3	Epimutation methodology	106
4.2.4.1.4	DMR hunting.....	108
4.3	Results	109
4.3.1	Data pre-processing	109
4.3.1.1	Normalisation.....	109
4.3.1.2	Filtering	110
4.3.1.3	Batch effect and biological artefacts correction	111

4.3.2	Targeted methylation profiling	114
4.3.2.1	Methodology validation	115
4.3.2.2	Polymorphic imprinted DMRs	116
4.3.2.3	Targeted methylation profiling of SRS patients at imprinted DMRs 119	
4.3.2.3.1	SRS with mUPD7 cohort	119
4.3.2.3.2	SRS with IC1 LOM cohort.....	119
4.3.2.4	Targeted methylation profiling of BWS patients at imprinted DMRs 120	
4.3.2.4.1	BWS with pUPD11 cohort.....	120
4.3.2.4.2	BWS with IC1 GOM cohort.....	121
4.3.2.4.3	BWS with IC2 LOM cohort.....	121
4.3.3	DMR hunting.....	131
4.4	Discussion.....	134
4.4.1	Preprocessing	134
4.4.2	Methodology	135
4.4.3	Polymorphic epimutation	136
4.4.4	Genomic imprinting methylation in SRS_UPD7	136
4.4.5	Genomic imprinting methylation in SRS_IC1.....	136
4.4.6	Genomic imprinting methylation in BWS_UPD11	137
4.4.7	Genomic imprinting methylation in BWS_IC1	137
4.4.8	Genomic imprinting methylation in BWS_IC2.....	138
4.4.9	DMR hunting.....	140
Chapter 5 - Investigations of the underlying causes of MLID in BWS_IC2... 142		
5.1	Introduction	143
5.1.1	Assisted reproductive technologies and MLID.....	143
5.1.1.1	Ovarian stimulation	143
5.1.1.2	In vitro fertilisation.....	145
5.1.1.3	Intra-cytoplasmic sperm injection	145

5.1.1.4	Evidence of ART disrupting genomic imprints	146
5.1.1.5	Evidence of association between ART and imprinting disorders 147	
5.1.1.6	Investigation of potential ART association with MLID in BWS.	148
5.1.2	Trans-imprinting defect and MLID	149
5.1.2.1	Maternal-effect and maternal-zygotic effect genes.....	150
5.1.2.1.1	Zygotic effect	151
5.1.2.1.2	Maternal-effect.....	151
5.1.2.1.3	Maternal-zygotic effect.....	152
5.1.2.2	NLRP7	155
5.1.2.3	ZFP57	157
5.1.2.4	NLRP2	159
5.1.2.5	KHDC3L.....	161
5.1.2.6	NLRP5	162
5.1.2.7	Other candidate genes	163
5.1.3	Aim.....	164
5.2	Materials and methods.....	165
5.2.1	Patient DNA	165
5.2.2	DNA quantification	165
5.2.3	DNA purification	165
5.2.4	Sodium bisulfite treatment	166
5.2.5	DNA methylation profiling using HM450K.....	166
5.2.6	Whole-exome sequencing	166
5.2.6.1	Library preparation and sequencing	166
5.2.6.2	Alignment and variant calling.....	167
5.2.6.3	Filtering and annotation	167
5.2.6.4	Variant call analysis.....	168
5.2.7	Sanger sequencing	175
5.2.7.1	Polymerase chain reaction	175
5.2.7.2	PCR product purification.....	178

5.2.7.3	Sequencing reaction	178
5.2.7.4	Sequencing clean-up	179
5.2.7.5	Sequence electrophoresis	179
5.2.7.6	Sequence data analysis	179
5.3	Results	179
5.3.1	Methylation profiling of BWS_IC2 patients conceived with ART	179
5.3.2	Genetic investigation of BWS_IC2 patients	184
5.3.2.1	Analysis of methylation associated genes	186
5.3.2.2	Analysis of maternal effect genes	189
5.3.2.3	Analysis of imprinted genes	193
5.4	Discussion	196
5.4.1	ART and MLID	196
5.4.2	Trans-mechanism involving a gene associated with methylation pathway 198	
5.4.3	Trans-mechanisms involving maternal-effect genes	199
5.4.4	Trans-mechanism involving imprinting gene network disruption	202
Chapter 6 - Investigations of a novel candidate gene for BWS		205
6.1	Introduction	206
6.1.1	UHRF1, a critical epigenetic modifier	206
6.1.2	Case Report.....	209
6.1.3	Aim.....	210
6.2	Materials and methods.....	211
6.2.1	Cells	211
6.2.2	Plasmids	212
6.2.3	Maintenance of adherent cells	213
6.2.4	Transient transfection	214
6.2.5	Quantitative PCR	215
6.2.5.1	RNA extraction from adherent cells	215
6.2.5.2	DNase treatment.....	216

6.2.5.3	Bioanalyzer RNA 6000 Nano Kit quality check and quantification	216
6.2.5.3.1	Setting up the chip priming station.....	217
6.2.5.3.2	Loading the gel dye mix.....	217
6.2.5.3.3	Loading the marker.....	217
6.2.5.3.4	Loading the ladder and the samples.....	217
6.2.5.3.5	Starting the chip run.....	218
6.2.5.3.6	Data analysis	218
6.2.5.4	cDNA synthesis	218
6.2.5.5	Quantitative PCR.....	219
6.2.5.5.1	Samples preparation.....	219
6.2.5.5.2	Serial dilution preparation for standard curve	219
6.2.5.5.3	Reaction set-up and PCR amplification	220
6.2.5.5.4	Data analysis using the relative standard curve	221
6.2.6	Protein assay	222
6.2.6.1	Protein extraction from adherent cells	222
6.2.6.2	Protein quantification	222
6.2.6.3	Western Blot	223
6.2.6.3.1	SDS-PAGE	223
6.2.6.3.2	Transfer	224
6.2.6.3.3	Immunoblotting	224
6.2.6.3.4	Membrane revelation	225
6.2.6.3.5	Gel analysis	225
6.2.7	Methylation assay	225
6.2.7.1	DNA extraction from adherent cells	225
6.2.7.2	Methylation-sensitive restriction digestion assay.....	226
6.2.7.3	Manual DNA dot-blot	227
6.2.7.3.1	DNA spotting.....	227
6.2.7.3.2	5-mC visualisation	228
6.2.7.3.3	DNA quantity assessment	228

6.2.7.3.4	Membrane analysis.....	229
6.2.7.4	Targeted bisulfite sequencing assay	229
6.2.7.4.1	Library preparation and sequencing	229
6.2.7.4.1.1	First round PCR: target capture	229
6.2.7.4.1.2	Purification of PCR products.....	230
6.2.7.4.1.3	Second round PCR: adaptor tagging and indexing	231
6.2.7.4.1.4	Purification of PCR products.....	231
6.2.7.4.1.5	Sequencing libraries quality assessment.....	232
6.2.7.4.1.6	Sequencing.....	232
6.2.7.4.2	Processing and analysis of NGS data	232
6.2.7.4.3	5-mC quantification.....	233
6.2.7.4.4	PCR bias correction for 5-mC methylation level.....	233
6.3	Results	233
6.3.1	Transfection optimisation	233
6.3.2	Low level of UHRF1 mRNA and protein in HeLa shUHRF1	234
6.3.3	Transfection of UHRF1 does not rescue global methylation	236
6.3.4	Transfection of UHRF1 does not rescue methylation at IGS-rDNA	239
6.4	Discussion.....	243
Chapter 7 - General discussion		247
7.1	Multilocus imprinting disturbances in imprinting disorders, a need for standardisation	248
7.1.1	Where to look?.....	248
7.1.2	Too many platforms might lead to confusion	249
7.1.3	A common informatic approach to detect epimutations.....	249
7.1.4	Need to find a better alternative for diagnostic services	250
7.2	The possible underlying causes of BWS and MLID.....	252
7.2.1	Environmental pressure	252
7.2.2	Genetic component.....	253
7.2.3	Methylation abnormalities outside of imprinted DMRs.....	255

7.2.4	5-hydroxymethylation, a hot topic for the future?	256
7.3	Final conclusions	258
Chapter 8 - Appendix		259
	Appendix 1 - <i>R code used for methylation data preprocessing.</i>	260
	Appendix 2 - <i>R code used for batch effect correction.</i>	262
	Appendix 3 - <i>R code used for genomic imprinting methylation profiling.</i>	264
	Appendix 4 - <i>R code used for bump hunting in BWS_IC1. Similar code was used for other disease group.</i>	276
	Appendix 5 - <i>Shell script used for the trimming, alignment and methylation calling of bisulfite converted reads generated from MiSeq sequencer.</i>	278
	Appendix 6 - <i>R code used for the quantification of 5-mC at H19/IGF2:IG-DMR; KCNQ1OT1:TSS-DMR and IGS-rDNA in each sample.</i>	280
	Appendix 7 - <i>R code used for the PCR amplification bias correction.</i>	286
Chapter 9 - List of References		289

LIST OF FIGURES

Figure 1.1. Interaction between RNA, histone modification and DNA methylation in heritable gene silencing.....	3
Figure 1.2. Dynamic changes in DNA methylation during PGCs maturation, fertilisation and embryo development.....	6
Figure 1.3. De novo methylation mechanism.....	7
Figure 1.4. DNA methylation maintenance mechanism.....	8
Figure 1.5. DNA demethylation mechanism.....	10
Figure 1.6. DNA methylation-mediated gene silencing.....	13
Figure 1.7. Genomic imprinting.....	19
Figure 1.8. Life-cycle of genomic imprinting.....	20
Figure 1.9. Molecular mechanisms leading to imprinting disorders.....	27
Figure 1.10. Localisation of the three breakpoints associated to BWS at chromosome 11p15.....	30
Figure 1.11. Linear map of the BWS locus on 11p15.5.....	31
Figure 1.12. Proposed model for the monoallelic expression of IGF2 and H19.....	34
Figure 1.13. Enrichment of the type of abnormalities describe in the molecular aetiology of BWS.....	38
Figure 1.14. Enrichment of the type of abnormalities describe in the molecular aetiology of SRS.....	45
Figure 3.1. Sequencing-by-synthesis technology used in Illumina.....	65
Figure 3.2. Principle of sodium bisulfite treatment.....	67
Figure 3.3. Bisulfite padlock probes.....	73
Figure 3.4. Preliminary steps used for the probes syntghesised by LCSiencs.....	82
Figure 3.5. BSPP sequencing library preparation (first design).....	88
Figure 3.6. BSPP sequencing library preparation (second design).....	93
Figure 4.1: Overview of the Infinium I and Infinium II bead types.....	102
Figure 4.2: Overview of the genome-wide methylation profiling workflow.....	105

Figure 4.3: Illustration of epimutation methodology.....	107
Figure 4.4: Effect of the correction on methylation value.	110
Figure 4.5: Proportion of retained and removed probes.....	111
Figure 4.6: Effects of technical and biological artefacts.	114
Figure 4.7: Methodology validation.	116
Figure 4.8: Multilocus imprinting disturbances and SRS.....	120
Figure 4.9: Multilocus imprinting disturbances and BWS.	122
Figure 4.10: Comparison of the frequency of epimutated DMRs in BWS_IC2 with MLID patients.	123
Figure 4.11: Meta-analysis of reported MLID frequency in BWS_IC2 cohort.....	126
Figure 4.12: Imprinting disturbances in BWS_IC2 patients.	128
Figure 4.13: Epimutations correlation calculated at epimutated imprinted DMRs in BWS_IC2 MLID patients.	130
Figure 4.14: DMR hunting in BWS.	132
Figure 4.15: KCNAB3 is also aberrantly methylated in BWS_IC2.	134
Figure 5.1: Maternal to zygotic gene transition in the mouse.	151
Figure 5.2: Overview of the whole-exome sequencing workflow.	169
Figure 5.3: ART and genomic imprinting methylation in BWS_IC2.....	181
Figure 5.4: Significance of ART of MLID epigenotype in BWS_IC2 patients.	182
Figure 5.5: ART is not associated with a specific epimutation at imprinted DMRs in BWS_IC2 cohort.....	183
Figure 5.6: Distribution of the sequencing depth of read across the 42 BWS_IC2 individuals.....	184
Figure 5.7: Proportion of the coverage of the exons of gene associated with the methylation pathway.....	188
Figure 5.8: Validation of the variants found in gene associated with the methylation pathway.	189
Figure 5.9: Proportion of the coverage of the exons of maternal-effect genes. ...	192
Figure 5.10: Validation of the variants found in maternal-effect genes.	193
Figure 5.11: Proportion of the coverage of the exons of imprinted genes.....	195

Figure 5.12: Validation of the variants found in imprinted genes.	196
Figure 6.1: Domain structure of UHRF1.....	208
Figure 6.2: Case report of two siblings with BWS_IC2 and a homozygous mutation in the UHRF1 gene.....	210
Figure 6.3: HeLa cells transfection optimisation using pRP plasmid.....	234
Figure 6.4: Efficient knockdown of UHRF1 in HeLa cells.....	235
Figure 6.5: Transfection of pRP UHRF1 WT does not rescue global methylation.	238
Figure 6.6: Transfection of pTag-2C UHRF1 WT does not rescue global methylation.	239
Figure 6.7: Degree of bias introduced by PCR amplification.....	241
Figure 6.8: Transfection of pTag-2C UHRF1 WT does not rescue methylation at KCNQ1OT1:TSS-DMR and IGS-rDNA.....	242

LIST OF TABLES

Table 3.1: List of imprinted DMRs.	75
Table 3.2: List of primers used for the amplification of the padlock probes.	79
Table 3.3: List of primers used for sequencing libraries enrichment.	84
Table 3.4: List of primers used for sequencing using MiSeq sequencer.	85
Table 3.5: Number of padlock probes to synthesise.	87
Table 4.6: An example of statistical test at the imprinted locus PLAGL1_alt-TSS- DMR.	108
Table 4.7: Age distribution in disease and normal individual groups.	112
Table 4.8: Imprinted DMRs with polymorphic epimutations.	118
Table 4.9: Frequency of disturbances reported in the current and seven previous reports.	125
Table 4.10: Candidate differentially methylated regions in BWS and SRS.	133
Table 5.12: List of methylation associated genes.	170
Table 5.13: List of imprinted genes.	174
Table 5.14: Primers used for Sanger sequencing validation.	177
Table 5.15: Summary of interesting variants found by whole-exome sequencing.	185
Table 6.16: shRNA clones used in HeLa cells.	212
Table 6.17: List of primers used to quantify relative UHRF1 mRNA level.	221
Table 6.18: List of primers used for targeted bisulfite sequencing.	230

LIST OF ABBREVIATIONS

5-caC	5-carboxylcytosine
5-fC	5-formylcytosine
5-hmC	5-hydroxymethylcytosine
5-mC	5-methylcytosine
ART	assisted reproductive technology
AS	Angelman syndrome
bisDNA	bisulfite treated deoxyribonucleic acid
bp	base pair
BSPP	bisulfites padlock probes
BWS	Beckwith-Wiedemann syndrome
BWS_IC1	Beckwith-Wiedemann syndrome with gain-of-methylation at H19/IGF2:IG-DMR
BWS_IC2	Beckwith-Wiedemann syndrome with loss-of-methylation at KCNQ1OT1:TSS-DMR
BWS_UPD11	Beckwith-Wiedemann syndrome with paternal uniparental disomy 11
COH	controlled ovarian hyperstimulation
CpG	cytosine-phosphate-guanine
dH ₂ O	distilled water
DMR	differentially methylated region
DNA	deoxyribonucleic acid
ESP	NHLBI Exome Sequencing Project
ExACT	Exome Aggregation Consortium
FBHM	Familial biparental hydatidiform moles
FDR	False discovery rate
FWER	Family-wise error rate
gDNA	genomic deoxyribonucleic acid
GOM	gain-of-methylation

HM450K	Infinium HumanMethylation 450K BeadChips
ICSI	intra-cytoplasmic sperm injection
ID	imprinting disorder
IMAGe	Intrauterine Growth Restriction, Metaphyseal Dysplasia, Adrenal Hypoplasia Congenita, and Genital Anomalies
indel	insertion deletion
IVF	<i>in vitro</i> fertilisation
Kb	kilobase
KOS	Kagami-Ogata syndrome
LOM	loss-of-methylation
Mb	megabase
MeDIP	Methylated DNA immunoprecipitation
MI	methylation index
min	minute
MLID	multilocus imprinting disturbances
NGS	next-generation sequencing
OS	ovulatory stimulation
PCR	polymerase chain reaction
PGC	primordial germ cell
PHD	plant homeodomain
PHP1B	pseudohypoparathyroidism type 1b
PWS	Prader-Willi syndrome
RING	really interesting new gene
RNA	ribonucleic acid
RRBS	reduced representation bisulfite sequencing
SDS-PAGE	sodium dodecyl sulphate polyacrylamide gel electrophoresis
sec	second
SNP	single nucleotide polymorphism
SRA	SET and RING-associated
SRS	Silver-Russell syndrome

SRS_IC1	Silver-Russell syndrome with loss-of-methylation at H19/IGF2:IG-DMR
SRS_UPD7	Beckwith-Wiedemann syndrome with maternal uniparental disomy 7
TBS-seq	targeted bisulfite sequencing
TNDM1	Transient neonatal diabetes mellitus type 1
TRC	The RNAi Consortium
TS	Temple syndrome
TTD	tandem tudor domain
WES	whole-exome sequencing
WGBS	whole genome bisulfite sequencing
WGS	whole-genome sequencing

Chapter 1
General Introduction


1 **1.1 Epigenetics**

2 The term epigenetics was first coined by Waddington in 1942 (Waddington 1942).
3 Originally, it referred to the complex mechanisms at work that link genotype to
4 phenotype. Since then, the term has changed in meaning and the most widely
5 accepted definition designates every mechanism that results in reversible heritable
6 (via meiosis or mitosis) changes altering gene expression without alterations to the
7 DNA sequence itself (Probst et al. 2009).

8

9 The epigenetic mechanisms capable of switching genes from an *ON* to *OFF* state
10 are initiated and sustained by at least three systems. This includes not only DNA
11 methylation, which is the most broadly studied and well-characterised epigenetic
12 modification, but also the post-translational modification of histone proteins and
13 RNA-mediated gene silencing. These systems are highly interactive with each other
14 in order to maintain efficient gene expression regulation (Figure 1.1). Any
15 unscheduled compromise at any of these levels can have dramatic effects on gene
16 expression and *in fine* leads to disease.

17



1

2 **Figure 1.1. Interaction between RNA, histone modification and DNA**
 3 **methylation in heritable gene silencing.**

4 *Chromatin condensation resulting from histone deacetylation or the methylation of*
 5 *the lysine 9 within histone H3 residues can lead to transcriptional repression. The*
 6 *post-translational modification of histones can also attract and trigger the DNA*
 7 *methylation machinery (DNA methyltransferases) which in turn can reinforce the*
 8 *transcriptional silencing initiated by the histone modification patterns. RNA*
 9 *interference could also trigger chromatin remodelling through the modification of*
 10 *histones or the methylation of DNA and therefore results in gene silencing. (Adapted*
 11 *from Egger et al. 2004).*

12

13

14 **1.1.1 DNA methylation**

15 The methylation of DNA is a heritable epigenetic mark referring to the covalent
 16 transfer of a methyl group from S-adenosyl-L-methionine to the fifth carbon of a
 17 cytosine. Consequently, this modification results in a 5-methylcytosine (5-mC)
 18 (Messerschmidt et al. 2014). In mammals, DNA methylation is most frequently found

1 in symmetrical cytosine-phosphate-guanine (CpG) context, although rare non-CpG
2 (CpH, where H is adenine, thymine or cytosine) methylation occurs (Ramsahoye et
3 al. 2000; Ziller et al. 2011).

4

5 In somatic cells, DNA methylation generally affects 70-80% of all CpG sites. Highly
6 methylated sequences are found at repetitive genomic regions, including satellite
7 DNA, long interspersed transposable elements (LINEs) and short interspersed
8 transposable elements (SINEs), at non-repetitive intergenic DNA and at exons of
9 genes. In contrast, CpG islands (CGI), which are on average 1000 base pairs long
10 GC-rich regions with high CpG density, are generally unmethylated. CGI are found
11 predominantly at sites of transcription initiation including the gene promoters of
12 approximately 60% of human genes (Bird 2002; Deaton and Bird 2011; E. Li and
13 Y. Zhang 2014).

14


15 Historically, DNA methylation has been linked to transcriptional repression but other
16 critical roles in the control of genomic imprinting (Bartolomei and Ferguson-Smith
17 2011; Ferguson-Smith 2011) (see section 1.2 - Genomic imprinting) and the
18 inactivation of the X chromosome in females (Sharp et al. 2011) or the maintenance
19 of the genome integrity (Eden et al. 2003) have been described.

20

21 **1.1.1.1 Life cycle**

22 In the life cycle of an individual, the genome undergoes several dynamic changes in
23 DNA methylation (Figure 1.2). These modifications take place at different times and

1 involve different pathways. During the maturation of the primordial germ cells (PGCs)
2 of an embryo, DNA methylation is erased through genome-wide demethylation
3 event. Following sex determination, the male (blue line) and female (red line) germ
4 cells acquire new gametic methylation profile via global *de novo* DNA methylation.
5 This process takes place at different times between the male and female germ cells.
6 In the male embryo, the *de novo* DNA methylation is established during
7 prospermatogonia and is completed before birth. In the female embryo, the *de novo*
8 DNA methylation is established after birth during oocytes growth. In the zygote, a
9 second wave of epigenetic reprogramming occurs. During the pre-implantation
10 period, genome-wide DNA methylation marks from the paternal and maternal
11 genome are erased. This mechanism takes place at different times for both parental
12 genomes. After implantation, the embryo re-acquires a new epigenetic profile, which
13 is associated with cell differentiation, through genome-wide *de novo* methylation.
14 The DNA methylation in genomic imprinted regions escapes this second global
15 epigenetic event (Smallwood and Kelsey 2012) (Figure 1.2).
16



1

2 **Figure 1.2. Dynamic changes in DNA methylation during PGCs maturation,**
 3 **fertilisation and embryo development.**

4 (From Smallwood and Kelsey 2012).

5

6


7 1.1.1.2 The machinery

8 1.1.1.2.1 De novo DNA methylation

9 In mammals, DNA methylation is catalysed by DNA methyltransferase (DNMT)
 10 enzymes. The methylation patterns are established during embryonic development
 11 by the *de novo* methylating enzymes DNMT3A and DNMT3B (Okano et al. 1998;
 12 Okano et al. 1999) and the non-catalytic activating co-factor DNMT3L (Bourc'his et
 13 al. 2001; Bourc'his and Bestor 2004) (Figure 1.3). The deletion of mouse *Dnmt3b*
 14 results in substantial global loss-of-methylation and embryonic lethality (E. Li et al.
 15 1992; Okano et al. 1999; Bostick et al. 2007). Similarly, the *Dnmt3a* knockout mice
 16 lack methylation but are, for a few weeks, partially viable (Okano et al. 1999). Finally,
 17 *Dnmt3L* knockout mice are viable, but lack *de novo* methylation in the germline

1 associated with male sterility and embryonic lethality of maternal null-derived
2 embryos (Bourc'his et al. 2001; Hata et al. 2002; Bourc'his and Bestor 2004).

3



4

5 **Figure 1.3. De novo methylation mechanism.**

6 *De novo methylation is catalysed by the DNA methyltransferases DNMT3A,*
7 *DNMT3B and supported by the non-catalytic DNMT3L.*


8

9

10 **1.1.1.2.2 DNA methylation maintenance**

11 During replication, the maintenance methylating enzyme DNMT1 localises at the
12 replication fork on the parental methylated strand and restores methylation to the
13 newly synthesised unmethylated strand (Leonhardt et al. 1992). For the faithful
14 DNMT1-mediated reproduction of the methylation profile that is present in the parent
15 cell, the maintenance mechanism also requires the protein UHRF1 (ubiquitin like
16 with PHD and ring finger domains 1; also known as NP95 or ICBP90) which
17 recognises and targets DNMT1 to hemi-methylated CpG residues (Figure 1.4). The
18 deletion of mouse *Dnmt1* or *Uhrf1* results in substantial global loss-of-methylation
19 and embryonic lethality (E. Li et al. 1992; Okano et al. 1999; Bostick et al. 2007).

20



1

2 **Figure 1.4. DNA methylation maintenance mechanism.**

3 *The DNA methyltransferase DNMT1, supported by UHRF1, maintains the DNA*
 4 *methylation at hemi-methylated CpG during DNA replication*

5

6

7 **1.1.1.2.3 DNA demethylation**

8 DNA demethylation can be achieved by one of two mechanisms; a passive
 9 replication-dependant process or an active enzyme-catalysed and replication-
 10 independent process.

11

12 **1.1.1.2.3.1 Passive DNA demethylation**


13 Global loss of 5-mC in mitotic cells can be achieved through the gradual passive
 14 dilution of the methylation mark over subsequent cleavage division due to DNA
 15 replication. Additionally, the gradual loss of 5-mC is performed in the absence or
 16 exclusion of both *de novo* and maintenance DNA methylase activity, including
 17 DNMT1, DNMT3A, DNMT3B and DNMT3L, and the key cofactor UHRF1 (P.A.
 18 Jones and Taylor 1980; Seisenberger et al. 2012; Kagiwada et al. 2013).

19

1 **1.1.1.2.3.2 Active DNA demethylation**

2 Loss of 5-mC can also be achieved via indirect and active mechanisms. Active
3 genome-wide DNA demethylation is mostly achieved by the iterative oxidation of 5-
4 mC to 5-hydroxymethylcytosine (5-hmC) and further to 5-formylcytosine (5-fmC) and
5 5-carboxycytosine (5-caC) by the ten-eleven translocation enzymes, TET1 and
6 TET2 (He et al. 2011; Inoue et al. 2011; Ito et al. 2011; Hackett et al. 2013). 5-hmC,
7 5-fmC and 5-caC marks are then lost during replication since it is inefficiently
8 recognised by DNMT1 (Inoue et al. 2011; Hashimoto et al. 2012) (Figure 1.5-bottom
9 panel, red arrow). Alternatively, an enzyme-catalysed DNA demethylation
10 mechanism involves the deamination of 5-mC to thymine by the DNA deaminases
11 AID (activation-induced cytidine deaminase) and APOBEC1 (apolipoprotein B
12 mRNA editing enzyme, catalytic polypeptide 1). The thymine base resulting from the
13 resulting T:G mismatch is recognised and removed by the thymine-DNA glycosylase
14 (TDG) or the methyl-CpG-binding domain protein 4 (MBD4). The base excision
15 repair (BER) machinery recognises the abasic site and reinstates an unmodified
16 cytosine, effectively resulting in removal of the methyl mark (Morgan et al. 2004;
17 Maiti and Drohat 2011) (Figure 1.5-top panel, red arrow). Finally, it is also suggested
18 that TDG, MBD4 or a yet unidentified glycosylase can directly recognise and remove
19 the 5-hmC, 5-fmC and 5-caC marks. The BER pathway will then repair the resulting
20 abasic site and reinstate an unmodified cytosine (He et al. 2011; Inoue et al. 2011;
21 Maiti and Drohat 2011; Shen et al. 2013; Messerschmidt et al. 2014) (Figure 1.5-
22 bottom panel, red arrow).

23



1

2 **Figure 1.5. DNA demethylation mechanism.**

3 *Passive DNA methylation is achieved via absence of DNMT and UHRF1 during*
 4 *subsequent round of cell division (middle panel, blue arrow). Possible active DNA*
 5 *demethylation mechanisms: AID/APOBEC1 can deaminate 5-mC to thymine, which*
 6 *in return can be excised by TDG/MBD4 and repaired by BER (top panel, red arrows).*
 7 *Alternatively, 5-mC can be lost via the TET-mediated oxidation of 5-mC to 5-hmC/5-*
 8 *fC/5-caC. The iterative oxidised 5-mC is then lost during replication or removed by*
 9 *TDG/MBD4 and repaired by BER (bottom panel, red arrows).*

10

11

12 **1.1.2 DNA methylation and transcriptional regulation**

13 Several lines of evidence demonstrated that DNA methylation can regulate gene
 14 expression via either a direct or indirect processes.

15

1 **1.1.2.1 Direct regulation**

2 DNA methylation can mediate gene silencing through the direct inhibition of the
3 binding of specific transcription factors to their targets (Figure 1.6). This was first
4 demonstrated in HeLa cells in which the binding of the transcription factor MLTF
5 (major late transcription factor) to DNA was affected by DNA methylation, hence
6 leading in the silencing of the adenovirus major late promoter (Watt and Molloy
7 1988). The investigation of additional transcription factors, including CREB (cAMP
8 response element-binding protein), c-Myc and E2F (E2 factor), further validated the
9 model (Iguchi-Arigo and Schaffner 1989; Prendergast and Ziff 1991; Campanero et
10 al. 2000).

11

12 **1.1.2.2 Indirect regulation**


13 DNA methylation mediated gene silencing can also be achieved indirectly through
14 the recruitment of methyl-CpG-binding domain (MBD) proteins, including MeCP2
15 (methyl-CpG-binding proteins 2), MBD1, MBD2, MBD3 and MBD4, at methylated
16 promoter regions. In return, MBD proteins recruit at methylated sites additional
17 repressor complexes associated with the remodelling of chromatin and the covalent
18 modification of histones. Finally, this mechanism results in the compaction of the
19 chromatin (i.e. heterochromatin state) leading to transcriptional repression (E. Li and
20 Y. Zhang 2014) (Figure 1.6-a). Several lines of evidence have validated this model.
21 The protein MeCP2 recruits the co-repressor molecule SIN3A (transcriptional
22 regulator, SIN3A) and the histone deacetylases (HDAC) HDAC1 and HDAC2 at
23 CpG methylated sites. The consequent transcriptional repression is then achieved

1 via HDAC-mediated chromatin remodelling (P.L. Jones et al. 1998; Nan et al. 1998).
2 Furthermore, the protein MBD2 was shown to recruit the nucleosome remodelling
3 and deacetylase (NuRD) co-repressor complex, which comprises HDAC enzymes
4 and large ATP-dependent chromatin remodelling proteins CHD3 (chromodomain
5 helicase DNA binding protein 3) and CHD4 (chromodomain helicase DNA binding
6 protein 4), at CpG methylated sites. This results in the deacetylation of histone
7 proteins, the compaction of chromatin and consequently to gene silencing (Feng and
8 Y. Zhang 2001). Finally, the protein MBD1 was shown to recruit the histone lysine
9 methyltransferase SETDB1 (SET domain bifurcated 1) during the S phase of the cell
10 cycle when DNA replication occurs. Subsequently, SETDB1 methylates the lysine 9
11 of the histone H3 (H3K9me) hence resulting in transcriptional repression (Sarraf and
12 Stancheva 2004).

13

14 DNA methylation can also indirectly mediate gene silencing through the DNA
15 methylation-dependant binding of the insulator protein CTCF (CCCTC-binding
16 factor) (Bell et al. 1999; Bell and Felsenfeld 2000; Hark et al. 2000; Murrel et al.
17 2004; Kurukuti et al. 2006). The absence of methylation allows the protein CTCF to
18 bind to the DNA. The binding of CTCF can lead to the formation of chromatin loops
19 and the establishment of an active chromatin domain that could include genes, gene
20 promoters and enhancers and an inactive chromatin domain that could include
21 genes and gene promoters, away from enhancers. The interactions between gene
22 promoters located in the inactive chromatin domain and their enhancers located in
23 the active chromatin domain are blocked by the CTCF insulating activity. This

1 mechanism results in genes silencing (Figure 1.6-b, left panel). In contrast, DNA
 2 methylation prevents the protein CTCF to bind to the DNA and the creation of the
 3 associated chromatin boundaries. Gene promoters previously located within the
 4 inactive chromatin domain are now free to interact with their enhancers, hence
 5 leading to gene expression (Figure 1.6-b, right panel).



6

7 **Figure 1.6. DNA methylation-mediated gene silencing.**

8 (a) DNA methylation inhibits binding of transcription factors, hence leading to gene
 9 silencing. Alternatively, DNA methylation can recruit MBD proteins which in turn
 10 associate with histone modification proteins, hence inducing chromatin remodelling
 11 and gene silencing. (b) The absence of DNA methylation allows the binding of the
 12 insulator protein CTCF which in turn blocks interaction between gene promoters and
 13 enhancers, hence leading to genes silencing. DNA methylation inhibits the binding
 14 of CTCF which in turn allows interaction between gene promoters and enhancers,
 15 hence leading to genes expression. Chromatin looping is the proposed mechanism
 16 by which CTCF boundary elements separate active and silent and active chromatin
 17 domains (grey area).

1 **1.2 Genomic imprinting**

2 Mammals are diploid organisms whose cells possess two matched sets of
3 chromosomes, one inherited from the mother and one from the father. Thus,
4 mammals have two copies of every gene. In usual physiological state, most genes
5 are biallelically expressed which means that both of the maternal and paternal allele
6 of the gene is active. A minority of genes, probably numbering 100 in humans and in
7 mice, are subject to genomic imprinting and show differences in expression
8 according to the parental origin of the allele (Catalogue of Parent of Origin Effects,
9 <http://igc.otago.ac.nz/home.html> (Morison et al. 2001)).

10

11 The machinery regulating genomic imprinting must fulfil different properties. It must
12 influence transcription via the deliberate silencing of one allele of specific genes
13 according to whether the allele comes from the father or the mother. The imprinting
14 marks need to be placed onto parental inherited chromosomes at a time they are not
15 in the same nucleus (i.e. during gametogenesis). Subsequently, following fertilisation
16 the marks needs to be transmitted to the somatic lineages of the male and female
17 offspring. Finally, an erasure mechanism must ensure that the imprinting marks are
18 removed and replaced in the new female or male germline (Bartolomei and
19 Ferguson-Smith 2011; Ferguson-Smith 2011). Considering these properties, DNA
20 methylation fulfils these criteria and is described as one of the main mechanisms
21 regulating genomic imprinting. However, other mechanisms including allele-specific
22 RNA transcription, antisense transcripts, histone modifications and differences in

1 replication timing are also thought to be involved in the genomic imprinting regulatory
2 machinery (Barlow and Bartolomei 2014).

3

4 **1.2.1 Historical overview**

5 The notion of genomic imprinting was first described in a series of experiments
6 aiming to understand the inheritance of the maize kernel coloration (Kermicle 1970).
7 The author noted that the maize kernels were solidly coloured when the R allele (i.e.
8 the allele responsible for the coloration) was carried by the female gametes but,
9 surprisingly, were mottled when carried by the male gametes. The author suggested
10 that the R allele might function differently accordingly to the parental origin of the
11 carrier (Kermicle 1970).

12

13 In 1974, genetic studies on mice demonstrated that the maternal-inheritance of a
14 deletion at the *Tme* (T-associated maternal effect) locus located on chromosome 17
15 resulted in death at birth or *in utero*. In contrast, the paternal-inheritance of the
16 deletion resulted in less abnormal and viable embryos (Johnson 1974). This
17 suggested a differential contribution between the maternal and paternal allele.

18

19 Around that time, the researchers studying familial cases with Beckwith-Wiedemann
20 Syndrome (BWS; see 1.3 - Beckwith-Wiedemann Syndrome) noted that BWS
21 affected male and female offspring were born from female carriers only. These
22 observations supported the idea that a parent-of-origin effect was associated with

1 the familial BWS phenotype (Lubinsky et al. 1974).

2

3 In the 1980's, pronuclear transplantation in newly fertilised mouse eggs aiming to
4 remove and replace the paternal pronucleus with a second maternal one (i.e.
5 generating a parthenogenic conceptus) and *vice versa* (i.e. generating an
6 androgenic conceptus), resulted in the failure of embryos to develop normally. The
7 parthenogenic mouse embryos developed tissues predominantly of embryonic origin
8 but failed to develop the extra-embryonic lineages. In contrast, the androgenic
9 mouse embryos developed predominantly extra-embryonic lineages but lacked, or
10 had very underdeveloped, embryonic components. Consequently, it was suggested
11 that mammalian genomes possess some genes that may be imprinted in different
12 ways on the two parental genomes, making the presence of both maternal and
13 paternal genome essential for normal embryonic development (McGrath and Solter
14 1983; Surani and Barton 1983; McGrath and Solter 1984; Surani et al. 1984).


15

16 In 1985, mouse genome engineering aiming to create regions of uniparental disomy
17 by the introduction of reciprocal translocations resulted in mice with anomalous
18 phenotypes which depart from normal in opposite directions. The discrete regions
19 involved in the anomalous phenotypes were suggested to be subject to parent-of-
20 origin effects (Cattanach and Kirk 1985). Interestingly, the study of non-Mendelian
21 human disorder showed very similar inheritance to phenotypes seen in the disomic
22 mice. As an example, paternally-inherited deletion of a region encompassing
23 chromosome 15q11q13 results in Prader-Willi syndrome whereas the maternal-

1 inheritance of the deletion results in a very different clinical disorder, Angelman
2 syndrome. This suggested that the paternal and maternal contribution of a gene or
3 genes in region 15q11q13 were required for normal human growth and development
4 (Nicholls et al. 1989).

5
6 In the early 1990's, several research groups identified three endogenous imprinted
7 genes (*Igf2r*, *Igf2* and *H19*) in mice. The *Igf2r* gene encodes for the insulin-like
8 growth factor 2 receptor and is located within the *Tme* locus previously described to
9 be subject to a parental-origin effect (see above). *Igf2r* was found to be maternally
10 expressed and paternally silenced (Barlow et al. 1991). The *Igf2* gene encodes for
11 the insulin growth factor 2 and was identified as a paternally expressed imprinted
12 gene and maternally silenced (DeChiara et al. 1991; Ferguson-Smith et al. 1991).
13 Finally, the *H19* gene (imprinted maternally expressed transcript) encodes for a long
14 non-coding RNA that may have a tumour suppressor activity (Hao et al. 1993;
15 Yoshimizu et al. 2008). *H19* was identified as maternally expressed and paternally
16 silenced (Bartolomei et al. 1991). Additionally, *H19* is located 90 kb downstream of
17 the *Igf2* imprinted gene, hence supporting the idea that imprinted genes can be
18 clustered together. Finally, it was shown that the imprinting status of a gene may also
19 be tissue-specific. The biallelic expression of *Igf2* has been described in the choroid
20 plexus and leptomeninges of the brain whilst, as mentioned above, it is exclusively
21 expressed from the paternally-inherited chromosome in the embryo (DeChiara et al.
22 1991). Similarly, the imprinted gene *Dlk1* (Delta-like homologue 1), normally
23 expressed from the paternally-inherited chromosome, has been described to be

1 biallelically expressed in the postnatal neurogenic niche (Ferrón et al. 2011).
2
3 Finally, not long after the identification of the first endogenous imprinted genes it was
4 shown that both parental genomes were differentially marked by DNA methylation at
5 imprinting regions (Bartolomei et al. 1993; Ferguson-Smith et al. 1993; Stöger et al.
6 1993). In these reports, the imprinted differentially methylated regions (DMRs),
7 mainly known as imprinting centres (ICs) or imprinting control regions (ICRs), were
8 shown to be *cis*-acting elements controlling the expression of nearby or distant
9 cluster of imprinted genes (Figure 1.7). Imprinted DMRs can be classified in germline
10 imprinted DMRs and somatic (or secondary) imprinted DMRs. Germline imprinted
11 DMRs exhibit differences in methylation states between the sperm and the egg.
12 These differences are maintained post-fertilisation. In contrast, at somatic imprinted
13 DMRs the DNA methylation is acquired after fertilisation but is still parent-of-origin
14 specific (Woodfine et al. 2011). The parental-specific DNA methylation pattern at ICs
15 is essential to maintain genomic imprinting and the disruption of the normal
16 methylation pattern leads to aberrant imprinted gene expression (E. Li et al. 1993)
17 and to diseases (Robertson 2005).



1

2 **Figure 1.7. Genomic imprinting.**

3 *Gene X, Y and Z are imprinted genes and their gene expression is regulated by a*
 4 *cis-acting imprinting centre (blue oval). Methylation at the maternal imprinting centre*
 5 *leads to the expression of Gene Y and silencing of Gene X and Gene Z. On the*
 6 *paternal chromosome, the imprinting centre is unmethylated which leads to*
 7 *expression of Gene X and Gene Z but silencing of Gene Y.*


8

9

10 **1.2.2 Life cycle of genomic imprinting**

11 The life cycle of genomic imprinting in mammals consists of three major steps:
 12 erasure, establishment and maintenance (Figure 1.8).

13



1

2

3 **Figure 1.8. Life-cycle of genomic imprinting.**

4 *In the primordial germ cells, global methylation, including at imprinted regions, is*
 5 *erased via active and passive demethylation. Once devoid of methylation, the DNA*
 6 *methyltransferases DNMT3A, DNMT3B, further enhanced by DNMT3L, ensure re-*
 7 *methylation of the genome, including imprinted regions, via de novo methylation*
 8 *activity. After fertilisation, ZFP57, DPPA3 and DNMT1 protect the imprinting*
 9 *methylation marks against the epigenetic reprogramming events that take place*
 10 *during the pre-implantation (genome-wide demethylation) and post-implantation*
 11 *(genome-wide de novo methylation) period. (From Sanchez-Delgado et al. 2016).*

12

13

14 **1.2.2.1 Imprinting erasure**

15 Erasure of imprinting methylation occurs in primordial germ cells (PGCs) at an early
 16 stage during differentiation of the female and male germlines. This global
 17 demethylation ensures the somatic cell epigenetic profile is completely erased. This
 18 epigenetic reprogramming is also required for the pluripotency of future germ cells,

1 imprinting switching and for the prevention of the inheritance of epigenetic defects
2 (Morgan et al. 2005). The methylation erasure is achieved in a two-step process
3 involving both passive (see section 1.1.1.2.3.1 - Passive DNA demethylation) and
4 active (see section 1.1.1.2.3.2 - Active DNA demethylation) demethylation. Initially,
5 PGCs proliferate actively, ensuring replication-dependent global passive
6 demethylation (Kagiyada et al. 2013). This mechanism is further enhanced by the
7 transcriptional silencing of the DNA methyltransferases *Dnmt1*, *Dnmt3a*, *Dnmt3b*
8 and *Dnmt3L* and the key cofactor *Uhrf1* (P.A. Jones and Taylor 1980; Kurimoto et al.
9 2008; Seisenberger et al. 2012; Kagiyada et al. 2013). A second wave of global
10 active demethylation takes place during the migration of the PGCs to the genital
11 ridge which are the precursors of the gonads (Hajkova et al. 2002; J. Lee et al. 2002).
12 This active second epigenetic event involves the deamination of 5-mC to thymine by
13 AID/APOBEC1, followed by the thymine excision by TDG or MBD4 and finally the
14 repair of the resulting abasic site by the BER pathway (Morgan et al. 2004; Hajkova
15 et al. 2010; Maiti and Drohat 2011). Alternatively, the TET enzymes can catalyse the
16 oxidation of 5-mC to 5-hmC/5-fC/5-caC (He et al. 2011; Inoue et al. 2011; Ito et al.
17 2011; Hackett et al. 2013). The resulting oxidised products can be lost and replaced
18 by unmodified cytosine through DNA replication (Inoue et al. 2011; Hashimoto et al.
19 2012) or via excision by TDG, MBD4 or an un-identified glycosylase followed by
20 repair by the BER pathway (He et al. 2011; Inoue et al. 2011; Maiti and Drohat 2011;
21 Shen et al. 2013).

22

23

1 1.2.2.2 Imprinting establishment

2 Once devoid of methylation, the PGCs undergo global genome re-methylation to
3 acquire the gametes new epigenetic states. This includes the establishment of
4 germline sex-specific methylation at imprinted loci. The timing of acquisition of
5 imprinting methylation marks is different between the male and female germline. In
6 the male germline, the DNA methylation imprint is established prenatally in
7 prospermatogonia (Davis et al. 1999; Ueda et al. 2000; J.-Y. Li et al. 2004). In the
8 female germline, the DNA methylation imprint is established asynchronously at
9 different loci but in all cases completed postnatally during the oocyte growth (by the
10 metaphase II) (Lucifero et al. 2002; Lucifero et al. 2004). The *de novo* DNA
11 methyltransferase DNMT3A, helped by the enzymatically inactive DNA
12 methyltransferase DNMT3L to stimulate its activity and stabilise its binding to the
13 unmodified lysine 4 of histone 3 (H3K4me0), gives rise to the methylation profile of
14 the gametes including the sex-specific germline imprints (Bourc'his et al. 2001;
15 Kaneda et al. 2004; Suetake et al. 2004; Ooi et al. 2007). Additional mechanisms
16 also take part to this *de novo* DNA methylation establishment. In the oocytes, the
17 acquisition of methylation at the maternal imprinted DMR *Gnas* (GNAS (guanine
18 nucleotide binding protein, alpha stimulating) complex locus) requires the active
19 transcription of the *Nesp* transcript, which initiates furthest upstream in this imprinted
20 domain (Chotalia et al. 2009). This relationship between transcription and
21 establishment of DNA methylation in the oocytes is not exclusive to the imprinted
22 *Gnas* locus. Intragenic methylated CpG islands are enriched at active transcription
23 units compared to intragenic unmethylated CpG islands. Additionally, methylated

1 promoter CpG islands are more frequently found at overlapping transcript regions
2 compared to unmethylated promoter CpG islands (Smallwood et al. 2011). Besides
3 an active transcription, the presence of the histone H3K4 demethylase KDM1B
4 (lysine demethylase 1B) is also required during oogenesis for the acquisition of DNA
5 methylation at a subset of imprinted loci (Cicconne et al. 2009). The establishment
6 of DNA methylation failed at the maternal imprinted DMRs *Mest* (mesoderm specific
7 transcript), *Grb10* (growth factor receptor bound protein 10), *Plagl1* (pleiomorphic
8 adenoma gene-like 1) and *Impact* (impact, RWD domain protein) in KDM1B-deficient
9 oocyte whilst the acquisition of DNA methylation at the maternal imprinted DMRs
10 *Kcnq1ot1* (KCNQ1 overlapping transcript 1), *Snrpn* (small nuclear ribonucleoprotein
11 N) and *Igf2r* are not affected by the absence of KDM1B. In the sperm, the PIWI-
12 interacting RNA machinery is required for the establishment of DNA methylation at
13 the paternal imprinted DMR *Rasgrf1* (RAS protein-specific guanine nucleotide-
14 releasing factor 1) but not at other imprinted paternal loci (Watanabe et al. 2011).

15

16 **1.2.2.3 Imprinting maintenance**

17 The paternal and maternal epigenetic imprints established in the germline are
18 transmitted to the zygote through fertilisation and maintained faithfully throughout
19 development and adulthood. Furthermore, the maintenance mechanism also
20 protects the imprint against global embryonic epigenetic reprogramming events that
21 take place before and after implantation. During pre-implantation, global epigenetic
22 remodelling takes place and consists of erasing the epigenetic information presents
23 on parental genomes. Global methylation is lost via the fast-active demethylation of

1 the paternal genome (Oswald et al. 2000) and the subsequent slow passive
2 demethylation of both paternal and maternal genomes (Rougier et al. 1998; Santos
3 et al. 2002). However, the newly established methylation marks at imprinted regions
4 is strikingly fully resistant to the reprogramming. Several proteins are involved in this
5 protection and maintenance mechanism. This includes the maternal and zygotic
6 DNA methyltransferase DNMT1 (Howell et al. 2001; Hirasawa et al. 2008), the
7 developmental pluripotency-associated protein 3 DPPA3 (also known as STELLA or
8 PGC7) (T. Nakamura et al. 2007) and the Krüppel-associated box (KRAB) domain
9 and 7 zinc fingers protein ZFP57 (X. Li et al. 2008). After implantation, the differential
10 methylation at genomic imprinting regions is maintained by both DNMT1 and UHRF1
11 (Bostick et al. 2007; Sharif et al. 2007). In parallel, the unmethylated imprinted alleles
12 escape another global epigenetic change that takes place at that time. This global
13 epigenetic event consists of a wave of global *de novo* DNA methylation resulting in
14 the hypermethylation of many genes including the totipotency, pluripotency and
15 germ-cell specific genes (Messerschmidt et al. 2014). The insulator protein CTCF,
16 the pluripotency transcription factor POU5F1 (POU class 5 homeobox 1; also known
17 as OCT4) and the permissive histone modification H3K4me2/3 were shown to be
18 involved in this protection pathway (N. Engel et al. 2006; Demars et al. 2010).

19

20 **1.2.3 Consequences of aberrant genomic imprinting**

21 It is widely believed that imprinted genes that are paternally expressed are
22 associated with promoting the foetal growth, which would increase the chance of the

1 offspring to survive and reproduce. In contrast, it seems that imprinted gene that are
2 maternally expressed are more likely to be associated with restricting the foetal
3 growth by limiting access to the mother's nutrients and resources, which would
4 increase her chance to survive and to have future offspring (Moore and Haig 1991).
5 To support this theory, the knockout in mice of paternally expressed genes, such as
6 *Igf2*, mesoderm-specific transcript (*Mest*) and paternally expressed gene 3 (*Peg3*),
7 leads to foetal growth restriction (DeChiara et al. 1990; Lefebvre et al. 1998; L. LI et
8 al. 1999). In contrast, the knockout in mice of maternally expressed genes, such as
9 *Igf2r*, *H19* and *Grb10*, is associated with foetal overgrowth (Lau et al. 1994; Leighton
10 et al. 1995; Charalambous et al. 2003). Consistently, several evidences from the
11 mouse and rare human imprinting disorders suggest that imprinting predominantly
12 occur in genes influencing foetal growth, brain function and neurological behavioural
13 traits (Smith et al. 2006, Ishida and G. E. Moore. 2013, G.E Moore et al. 2015).

14

15 As suggested above, genomic imprinting failures can have dramatic consequences
16 on the normal growth and development of the embryo. Several epigenetic and/or
17 genomic alterations in imprinted gene clusters and in ICs have been associated with
18 a number of human diseases including cancer and imprinting disorders (IDs). The
19 over expression of the growth promoting gene *IGF2* and the low-level expression of
20 the candidate tumour suppressor *H19* have been described in the aetiology of
21 various tumour types including colon, liver, lung, ovarian cancer and Wilms tumour.
22 Loss-of-imprinting is also associated with IDs which are a group of ten rare but
23 probably underdiagnosed congenital diseases mainly characterised by growth,

1 metabolic and neurological abnormalities. These include Angelman syndrome (AS;
2 OMIM n°105830), Prader-Willi syndrome (PWS; OMIM n°176270), transient
3 neonatal diabetes mellitus type 1 (TNDM1; OMIM n°601410),
4 pseudohypoparathyroidism type 1b (PHP1B; OMIM n°603233), Silver-Russell
5 syndrome (SRS; OMIM n° 180860), Beckwith-Wiedemann syndrome (BWS; OMIM
6 n°130650), Temple syndrome (TS; OMIM n°616222), Kagami-Ogata syndrome
7 (KOS; OMIM n°608149), maternal uniparental disomy of chromosome 20 syndrome
8 and precocious puberty syndrome (European Network of Human Congenital
9 Imprinting Disorders, <http://www.imprinting-disorders.eu>). In the molecular aetiology
10 of IDs, the deregulation of the genomic imprinting machinery, and consequently the
11 aberrant expression of imprinted genes, is achieved by four different mechanisms:
12 paternal or maternal uniparental disomy (UPD), genomic imbalances
13 (duplications/deletions), epimutations (disturbed methylation) or point mutations in
14 an imprinted gene (Figure 1.9).


15

16

17

18

19



1

2

3 **Figure 1.9. Molecular mechanisms leading to imprinting disorders.**

4 *The four different mechanisms leading to the deregulation of imprinted gene*
 5 *expression and ultimately to imprinting disorders (adapted from Eggermann et al.*
 6 *2015).*

7

8 **1.3 Beckwith-Wiedemann Syndrome**

9 Beckwith-Wiedemann syndrome is a paediatric overgrowth condition firstly
 10 described in 1963-64 by Dr. J. Bruce Beckwith (Beckwith 1963) and independently
 11 by Dr. H.E. Wiedemann (Wiedemann 1964). BWS occurs once in approximately

1 every 15,000 births (Eggermann, Perez de Nanclares, et al. 2015), and is associated
2 with an increased risk of various tumour types during childhood (DeBaun et al. 1998).
3
4 The clinical phenotype of BWS is highly variable and while some children are
5 relatively mildly affected, others have a wider range of physical problems. The
6 syndrome is most commonly associated with pre- and/or postnatal overgrowth,
7 macroglossia and abdominal wall defects. Additional features include visceromegaly
8 (particularly kidneys, liver and pancreas), neonatal hypoglycaemia,
9 hemihyperplasia, genitourinary abnormalities and placental mesenchymal dysplasia.
10 Embryonal tumours such as Wilms tumour (the most frequent), hepatoblastoma,
11 neuroblastoma, adrenal carcinoma and rhabdomyosarcoma, are observed in
12 approximately 7.5% of BWS patients (J.R. Engel 2000; Bliiek et al. 2001; Weksberg
13 et al. 2010). The vast majority of patients, with adequate treatment following
14 diagnosis, survive infancy and develop normally.

15


16 **1.3.1 Molecular defects in BWS aetiology**

17 Analyses of rare chromosome 11p15 rearrangements have identified three regions,
18 BWSCR1, BWSCR2 and BWSCR3, believed to play a role in BWS (Figure 1.10).
19 BWSCR1 is the most frequent and most documented breakpoint and maps to a
20 region of several imprinted genes including *IGF2*, *H19*, *CDKN1C* (cyclin dependent
21 kinase inhibitor 1C) and *KCNQ1OT1* (*KCNQ1* opposite strand/antisense transcript
22 1) (Hoovers et al. 1995). Genetic and/or epigenetic abnormalities within BWSCR1

1 can disrupt the imprinted gene expression and lead to BWS. The less frequent
2 breakpoints, BWSCR2 and BWSCR3, are located 5 and 7 Mb centromeric to
3 BWSCR1 respectively (Redeker et al. 1995). BWSCR2 is defined by two breakpoints
4 and may be associated with BWS (Alders et al. 2000). Two zinc finger genes,
5 *ZNF214* and *ZNF215*, have been identified within BWSCR2. The *ZNF215* gene is
6 imprinted in a tissue-specific manner and is expressed preferentially from the
7 maternal allele, whereas *ZNF214* is not imprinted (Alders et al. 2000; Sofos et al.
8 2011). Both BWSCR2 breakpoints disrupt two of the five alternatively spliced
9 *ZNF215* transcripts and parts of the 3-prime end of these splice forms are transcribed
10 from the antisense strands of *ZNF214*. These data supported a role for *ZNF215*, and
11 possibly for *ZNF214*, in the aetiology of BWS.

12

13 Through a number of different mechanisms, the primary epigenetic alterations or the
14 genetic alterations resulting in the disruption of the imprinting of several genes
15 located on chromosome 11p15.5 are described in the molecular aetiology of BWS
16 (Figure 1.11).




1

2 **Figure 1.10. Localisation of the three breakpoints associated to BWS at**
 3 **chromosome 11p15.**

4 *The more telomeric breakpoint, BWSCR1, includes IGF2, H19, CDKN1C and*
 5 *KCNQ1OT1 imprinted genes. The more centromeric breakpoints, BWSCR2 and*
 6 *BWSCR3, are respectively located 5 and 7 Mb from BWSCR1. BWSCR2 includes*
 7 *the tissue-specific imprinted gene ZNF215 and not imprinted gene ZNF214.*
 8 *(Adapted from Maher and Reik 2000).*

9



1

2 **Figure 1.11. Linear map of the BWS locus on 11p15.5.**

3 (a) Linear schematic representation of the normal parent of origin-specific imprinted
 4 allelic expression. (b) *H19/IGF2:IG-DMR* gain-of-methylation, (c) *KCNQ1OT1:TSS-*
 5 *DMR* loss-of-methylation, (d) *CDKN1C* mutations and (e) *H19/IGF2:IG-DMR* and
 6 *KCNQ1OT1:TSS-DMR* paternal UPD. Mat, maternal; pat, paternal; OT1, refers to
 7 *KCNQ1* antisense transcript, *KCNQ1OT1*. (Adapted from Choufani et al. 2010).

1 1.3.1.1 Disturbances at H19/IGF2:IG-DMR region


2 The telomeric imprinting centre *H19/IGF2:IG-DMR* (also known as IC1, ICR1 or *H19-*
3 *DMR*) controls the *IGF2* and *H19* imprinted gene expression. *H19/IGF2:IG-DMR* is
4 located within 2kb upstream of *H19*. Both *IGF2* and *H19* imprinted genes interact
5 with the same enhancer located downstream of *H19* in an enhancer-competition
6 manner. The *IGF2* gene encodes an embryonic foetal growth factor essential for
7 normal development. *IGF2* is normally paternally expressed and maternally silenced.
8 *H19* is a maternally expressed gene that encodes for a non-coding RNA that may
9 function as a tumour suppressor (Hao et al. 1993) and is also implicated in growth
10 restriction (Guo et al. 2008).

11

12 *H19/IGF2:IG-DMR* controls the allele-specific imprinted gene expression of *IGF2*
13 and *H19* in two distinct ways. *IGF2* gene expression is regulated by the methylation-
14 sensitive insulator activity of the protein CTCF that can bind to several CTCF binding
15 sites within the *H19-IGF2* imprinted domain. That includes at the *H19/IGF2:IG-DMR*
16 imprinted centre, at a site upstream to the *IGF2* gene, at a centrally conserved region
17 between *IGF2* and *H19* and at a site downstream of the enhancer (Figure 1.11-a).
18 Once bind to the DNA, CTCF recruits the protein complex cohesin and each of the
19 resulting CTCF/cohesin complexes interact with each other, hence forming
20 chromatin loops and generate aboth active and inactive chromatin domain (Figure
21 1.11-a and Figure 1.12). The *H19* gene expression is regulated by a secondary
22 DMRs located within the *H19* promoter. The methylation of the secondary DMR is
23 acquired somatically and is mediated by *H19/IGF2:IG-DMR* (Hark et al. 2000; Bell

1 and Felsenfeld 2000; Srivastava et al. 2000; Murrel et al. 2004; Nativio et al. 2011)
2 (Figure 1.11-a and Figure 1.12).
3
4 In normal conditions, *H19/IGF2*:IG-DMR is unmethylated on the maternal allele and
5 methylated on the paternal allele. The absence of methylation on the maternal
6 *H19/IGF2*:IG-DMR allows the insulator protein CTCF to bind to its target within
7 *H19/IGF2*:IG-DMR, which in turn recruits the cohesin protein complex. The newly
8 formed CTCF/cohesin complex at *H19/IGF2*:IG-DMR can then interact with the other
9 CTCF/cohesin sites located upstream to the *IGF2* gene and downstream to the
10 enhancer. This leads to the formation of chromatin loops that isolate *IGF2* and its
11 promoter to an inactive chromatin domain away from the enhancer. As a result, the
12 *IGF2* gene promoter can't interact with the enhancer and *IGF2* is silenced. *H19* and
13 the enhancer are located within the same active chromatin loop and they are free to
14 interact. This interaction and the absence of methylation at the *H19* secondary DMR
15 lead to *H19* gene expression (Figure 1.11-a and Figure 1.12). In contrast, the
16 presence of DNA methylation on the paternal *H19/IGF2*:IG-DMR prevents the
17 insulator protein CTCF to bind to CTCF binding sites within *H19/IGF2*:IG-DMR. This
18 results in the exclusion of *H19/IGF2*:IG-DMR from the CTCF/cohesin interacting
19 region. The exclusion of *H19/IGF2*:IG-DMR results in *IGF2* and its promoter to locate
20 in an active chromatin domain near to the enhancer. This allows the interaction
21 between *IGF2* promoter with its enhancer and consequently leads to *IGF2* gene
22 expression. The methylation at *H19* promoter inhibits *H19* gene expression and this
23 gene silencing is reinforced by the loss of interaction between *H19* promoter and its

1 enhancer (Hark et al. 2000; Bell and Felsenfeld 2000; Srivastava et al. 2000; Murrel
2 et al. 2004; Nativio et al. 2011) (Figure 1.11-a and Figure 1.12).



3

4 **Figure 1.12. Proposed model for the monoallelic expression of IGF2 and H19.**

5 (Adapted from Nativio et al. 2011).

6

7 In BWS, the biallelic expression and the upregulation of *IGF2* gene play a critical role
8 in the molecular aetiology of BWS (Maher and Reik 2000) and sporadic tumours
9 (Tycko 2000; Schofield et al. 2001). The primary isolated epigenetic alteration or in
10 association with an underlying genomic alteration resulting in the gain-of-methylation

1 (GOM) of *H19/IGF2:IG-DMR* (i.e. both paternal and maternal *H19/IGF2:IG-DMR* are
2 methylated) is responsible for the disruption of *IGF2* and *H19* imprinted gene
3 expression (Figure 1.11-b). The main genomic alterations associated with the GOM
4 of *H19/IGF2:IG-DMR* are variable length maternally inherited microdeletions
5 removing a subset of the CTCF binding sites within the IC (Sparago et al. 2004;
6 Prawitt, Enklaar, Gärtner-Rupprecht, et al. 2005; De Crescenzo et al. 2011; Beygo,
7 Citro, et al. 2013). In addition, *OCT4/SOX2* binding sites located within *H19/IGF2:IG-*
8 *DMR* have been found to be important to maintain the unmethylated profile of the
9 maternal allele (Poole et al. 2012). Accordingly, maternally-inherited point mutations
10 disrupting conserved *OCT4/SOX2*-binding motif located in *H19/IGF2:IG-DMR* have
11 been described in familial cases with BWS.

12

13 **1.3.1.2 Disturbances at *KCNQ1OT1:TSS-DMR* region**

14 The centromeric imprinting centre *KCNQ1OT1:TSS-DMR* (also known as IC2, ICR2
15 or KvDMR1) controls the *CDKN1C* and *KCNQ1OT1* gene expression. The *CDKN1C*
16 (cyclin-dependent kinase inhibitor 1C; also known as p57Kip2) gene encodes for a
17 negative regulator of cell proliferation (M.H. Lee et al. 1995; Tsugu et al. 2000). In
18 human, *CDKN1C* is imprinted and primarily expressed from the maternal allele,
19 though some expression (5 to 30%) is observed from the paternal chromosome
20 (Chung 1996; Hatada et al. 1996). *KCNQ1OT1* is a paternally expressed non-coding
21 RNA with antisense transcription to *KCNQ1* (potassium voltage-gated channel
22 subfamily Q member 1). The 5' end of *KCNQ1OT1* transcript overlaps with the
23 differentially methylated imprinting centre *KCNQ1OT1:TSS-DMR* (M.P. Lee et al.

1 1999; Smilnich et al. 1999; Cerrato et al. 2002) (Figure 1.11-a).

2

3 The expression of the imprinted genes located at the *KCNQ1OT1*:TSS-DMR locus

4 are controlled by the *KCNQ1OT1* non-coding RNA negative regulator of gene

5 expression activity and the CTCF enhancer blocking activity. On the paternal allele,

6 *KCNQ1OT1*:TSS-DMR is unmethylated and results in the expression of

7 *KCNQ1OT1*. Consequently, a nuclear compartment is established in the vicinity of

8 the *KCNQ1OT1* locus and a *KCNQ1OT1* non-coding RNA-mediated bidirectional

9 (i.e. downstream and upstream) gene silencing occurs. Several imprinted genes and

10 enhancers are affected by this negative regulation, including *CDKN1C* and its

11 respective enhancer (Pandey et al. 2008). This repressor activity is further facilitated

12 by the binding of the insulator protein CTCF to the unmethylated paternal

13 *KCNQ1OT1*:TSS-DMR. Similarly to the *H19/IGF2*:IG-DMR, the binding of CTCF to

14 the unmethylated IC represses the interactions between *CDKN1C* and its enhancer

15 located downstream of *KCNQ1OT1*:TSS-DMR. This results in the *CDKN1C* gene

16 silencing. In contrast, the maternal *KCNQ1OT1*:TSS-DMR is methylated and results

17 in the silencing of *KCNQ1OT1*. Subsequently, the absence of the *KCNQ1OT1*

18 transcript leads to *CDKN1C* gene expression. *CDKN1C* gene expression is further

19 enhanced by the lack of the enhancer blocking activity associated with the absence

20 of CTCF binding (Algar et al. 2011) (Figure 1.11-a).

21

22 *KCNQ1OT1* biallelic expression and *CDKN1C* biallelic silencing play critical role in

23 BWS. The primary loss-of-methylation (LOM) of *KCNQ1OT1*:TSS-DMR (i.e. both

1 paternal and maternal *KCNQ1OT1*:TSS-DMR are unmethylated) results in the
2 disruption of *KCNQ1OT1* and *CDKN1C* imprinting. Consequently, this epimutation
3 leading to the biallelic expression of *KCNQ1OT1* and the biallelic silencing of
4 *CDKN1C* results in BWS phenotype (Figure 1.11-c). Chromosome
5 deletion/duplication affecting the *KCNQ1OT1*:TSS-DMR is rarely associated with
6 BWS. However, the rare maternal inherited deletions occurring just in
7 *KCNQ1OT1*:TSS-DMR (Niemitz et al. 2004; Algar et al. 2011) or encompassing a
8 larger locus including *CDKN1C* (Zollino et al. 2010) have been reported. Finally, loss-
9 of-function mutations of the maternally-inherited *CDKN1C* allele are also
10 documented in the aetiology of BWS (Hatada et al. 1997; Lee et al. 1997; Milani et
11 al. 2014) (Figure 1.11-d).

12

13 **1.3.1.3 Disturbances at both H19/IGF2:IG-DMR and KCNQ1OT1:TSS-DMR** 14 **regions**


15 Segmental paternal uniparental disomy (pUPD) affecting chromosome 11p15.5 is
16 also described in BWS aetiology. The reported BWS cases with pUPD show somatic
17 mosaicism with over expression of *IGF2* due to the GOM at *H19/IGF2*:IG-DMR and
18 biallelic silencing of *CDKN1C* due to the LOM at *KCNQ1OT1*:TSS-DMR (Henry et
19 al. 1993; Slatter et al. 1994; Cooper et al. 2007) (Figure 1.11-d).

20

21 **1.3.1.4 Abnormality detection rate in BWS**

22 The LOM at *KCNQ1OT1*:TSS-DMR contributes to approximately 50% of BWS
23 cases. The paternal UPD of chromosome 11p15 is described in approximately 20%

1 of cases. The GOM at *H19/IGF2:IG-DMR* contributes for approximately 5 to 10%
2 of BWS cases. Genetic mutations altering the maternal *CDKN1C* function accounts
3 for approximately 10% of cases (40 to 50% of familial BWS cases). Chromosomal
4 aberrations (i.e. duplications, translocations, inversions) affecting chromosome
5 11p15 are described in a minority of BWS cases (<2-4%). Finally, in 13-15% of BWS
6 cases the molecular defects are yet to be elucidated (Weksberg et al. 2010;
7 Eggermann, Perez de Nanclares, et al. 2015) (Figure 1.13).



8

9 **Figure 1.13. Enrichment of the type of abnormalities describe in the molecular**
10 **aetiology of BWS.**

11

12 **1.4 Silver-Russell Syndrome**

13 Silver-Russell syndrome is a paediatric growth retardation condition first described
14 in 1953 by Dr. Silver (Silver et al. 1953) and independently by Dr. Russell in 1954
15 (Russell 1954). SRS occurs once in approximately every 75,000 to 100,000 births

1 (Eggermann, Netchine, et al. 2015). Most cases are sporadic although a few familial
2 cases have been reported (Duncan et al. 1990).

3
4 The clinical presentation of SRS is variable but the disease is most commonly
5 associated with pre- and/or post-natal growth failure, relative macrocephaly at birth,
6 a frontal bossing in early life, body asymmetry, problems feeding and/or a low body
7 mass index at 2 years. Additional features include clinodactyly of the fifth finger,
8 syndactyly of the second and third toes and shoulder dimples. Finally, congenital
9 malformations are also associated with the disease. These include genital
10 abnormalities (cryptorchidism, hypospadias, Müllerian agenesis), renal and cardiac
11 defects (Netchine et al. 2007; Eggermann, Netchine, et al. 2015).

12

13 **1.4.1 Molecular defects in SRS aetiology**

14 SRS and BWS are very similar diseases in the sense that both syndromes are the
15 clinical mirror to the other. Unlike BWS the exact genes causing SRS are currently
16 unknown. However, several lines of evidence indicate that (epi)genetic alterations
17 leading to the deregulation of the imprinted genes *IGF2*, *CDKN1C*, *MEST*
18 (mesoderm expressed transcript; also known as *PEG1*) located on chromosome
19 7q32 and *GRB10* (growth factor receptor bound protein 10) located on chromosome
20 7p11.2-p13 may be responsible for the disorder. Finally, a few SRS cases were also
21 reported with abnormalities at chromosomes other than chromosome 7 and 11,
22 suggesting that other genes might be involved in SRS molecular aetiology. In some

1 of these patients, additional and atypical features are also described (Abu-Amero et
2 al. 2008).

3

4 **1.4.1.1 Disturbances at chromosome 11p15.5**

5 As discussed above (see section 1.3.1.1 - Disturbances at H19/IGF2:IG-DMR
6 region), the expression of *IGF2* is controlled by the imprinting centre *H19/IGF2:IG-*
7 *DMR*. *IGF2* is preferentially expressed from the paternally-inherited allele and is
8 maternally silenced. In mirror to BWS, the biallelic silencing of *IGF2* is described in
9 SRS aetiology. The LOM at the paternal *H19/IGF2:IG-DMR* resulting in a
10 concomitant decrease in *IGF2* expression was identified in SRS individuals (Gicquel
11 et al. 2005). Other mechanisms leading to the *IGF2* biallelic silencing have also been
12 described. These very rare genetic defects include the mosaic maternal UPD of
13 chromosome 11 (Bullman et al. 2008), the maternal duplication of chromosome
14 11p15 encompassing both *H19/IGF2:IG-DMR* and *KCNQ1OT1:TSS-DMR* domains
15 (Eggermann et al. 2005; Eggermann et al. 2010) or *KCNQ1OT1:TSS-DMR* domain
16 only (Schönherr et al. 2007), the paternal deletions of the *H19/IGF2* enhancer region
17 (Grønskov et al. 2011) and the paternally-inherited *IGF2* loss-of-function mutation
18 (Begemann et al. 2015).

19

20 Another imprinted gene located at chromosome 11p15.5 has been described in SRS
21 aetiology. Gain-of-function mutations in the imprinted gene *CDKN1C* are normally
22 associated with the IMAGe (Intrauterine Growth Restriction, Metaphyseal Dysplasia,
23 Adrenal Hypoplasia Congenita, and Genital Anomalies) syndrome (OMIM n°614732)

1 which is a severe growth retardation condition overlapping with SRS. Interestingly, a
2 rare maternally-inherited gain-of-function mutation in the *CDKN1C* gene has been
3 identified in familial cases with SRS. It was subsequently suggested that the
4 mutation was responsible for the SRS phenotype (Brioude et al. 2013).

5

6 **1.4.1.2 Disturbances at chromosome 7**

7 The identification of several SRS individuals with maternal UPD of chromosome 7
8 (Kotzot et al. 1995; Eggermann et al. 1997; Preece et al. 1997) raised the hypothesis
9 that maternally transcribed imprinted genes with predicted growth suppression
10 activity or paternally transcribed imprinting gene with predicted growth promoting
11 activity were located on chromosome 7 and consequently were likely to be
12 responsible for the observed SRS phenotype. Key candidate genes including the
13 *MEST* and *GRB10* imprinted gene have since been proposed as causative genes.

14

15 The *MEST* gene encodes for a member of the alpha/beta hydrolase superfamily with
16 unknown function. *MEST* is an imprinted gene preferentially expressed from the
17 paternally-inherited allele. *Mest* knockout mice show pre- and postnatal growth
18 restriction when the mutant gene is transmitted from the father (Lefebvre et al. 1998).
19 Due to the high phenotypic similarity between *Mest* knockout mice and maternal
20 UPD 7 SRS cases, the *MEST* imprinted gene was suggested to be responsible for
21 the disease. In one SRS patient, the identification of a 35 Mb segmental maternal
22 UPD at chromosome 7q31-qter, including *MEST*, further supported the hypothesis
23 that *MEST* was involved in SRS aetiology (Hannula et al. 2001). However, despite

1 this evidence, no conclusive reports indicating a clear pathogenic role of *MEST* has
2 been found and, consequently, a *MEST* relevant role in SRS aetiology is
3 questionable. Genetic mutations (e.g. paternal loss-of-function) leading to the
4 deregulation of *MEST* expression have yet to be reported in SRS individuals
5 (Riesewijk et al. 1998). Furthermore, the methylation analysis at the IC controlling
6 *MEST* imprinting, *MEST:alt-TSS-DMR*, didn't reveal epimutations that could
7 deregulate *MEST* expression in SRS (S. Kobayashi et al. 2001; Schöherr et al.
8 2008).

9
10 The *GRB10* gene encodes for a growth factor receptor-binding protein. The SH2
11 (Src Homology 2) domain of human GRB10 was shown to inhibit the insulin receptor
12 and insulin-like growth-factor receptor mediated mitogenesis activity. Therefore,
13 *GRB10* has growth suppressing activity (F. Liu and Roth 1995; O'Neill et al. 1996).
14 The *GRB10* gene is imprinted in an isoform and tissue specific manner. In human
15 foetal brain, the parental specific gene expression is exclusively derived from the
16 paternally-inherited allele. In contrast, the imprinted *GRB10* isoform $\gamma 1$ is maternally
17 expressed in skeletal muscle. However, biallelic expression of all *GRB10* isoforms
18 was found in several other foetal tissues including intestine, kidney and liver
19 (Blagitko et al. 2000; Hitchins et al. 2001). Several pieces of evidence suggested
20 that *GRB10* is a strong candidate in SRS molecular aetiology. Mice with maternal
21 disomy encompassing the mouse orthologous *Grb10* (located on chromosome 11)
22 showed prenatal growth failure whilst the reciprocal paternal disomy resulted in the
23 opposite phenotype, consisting of prenatal overgrowth (Cattanach and Kirk 1985).

1 The disruption of *Grb10* imprinting via maternally inherited *Grb10* mutation results in
2 a disproportionate mice overgrowth phenotype with an *Igf2*-independent mechanism
3 (Charalambous et al. 2003). Finally, the genetic investigation of SRS individuals
4 revealed maternally inherited duplication at chromosome 7p11.2-p13,
5 encompassing the *GRB10* region, hence suggesting that *GRB10* over-expression
6 might be involved in SRS aetiology (Joyce et al. 1999; Monk et al. 2000; Monk et al.
7 2002). However, despite this evidence, conclusive reports involving *GRB10* have yet
8 to be reported in SRS. The methylation analysis of the IC regulating *GRB10*
9 expression, *GRB10*:alt-TSS-DMR, showed no significant changes that would
10 deregulate *GRB10* imprinted gene expression (Arnaud 2003; Monk et al. 2003).
11 Furthermore, genetic alterations leading to *GRB10* over-expression (e.g. maternal
12 duplication) or biallelic expression (e.g. paternal gain-of-function) have not been
13 reported in SRS individuals (Yoshihashi et al. 2000; Hitchins et al. 2001).

14

15 **1.4.1.3 Disturbances at other chromosome**

16 Copy number variations and UPD affecting chromosomes other than chromosome
17 7 and 11 have been identified in cohorts of clinically diagnosed SRS patients with, in
18 some individuals, additional and atypical clinical features. The majority of these rare
19 defects were identified in single cases and the associated prevalence is yet to be
20 determined (Abu-Amero et al. 2008).

21

22 More recently, the hypomethylation of ICs located at chromosome 14,
23 *MEG3/DLK1*:IG-DMR and *MEG3*:TSS-DMR, has been identified in three SRS

1 compatible individuals with no known defects at chromosome 7 or 11 (Azzi et al.
2 2015; Kagami et al. 2015). These ICs control the imprinted gene expression of *DLK1*
3 (delta like non-canonical Notch ligand 1) and *MEG3* (Maternally expressed gene 3).
4 In mice, the low-level expression of *Dlk1* has been implicated in growth retardation
5 and accelerated adiposity (Moon et al. 2002; Cleaton et al. 2016). The imprinted
6 gene *MEG3* is suggested to be a tumour suppressor and the loss of *MEG3*
7 expression has been found in various types of human tumours and tumour cell lines
8 (Zhou et al. 2012). These new findings at chromosome 14 imply that the maternal
9 UPD of chromosome 14 and the epigenetic abnormalities affecting *MEG3/DLK1:IG-*
10 *DMR* and *MEG3:TSS-DMR* constitute a rare, but potentially important, underlying
11 factors leading to SRS. Furthermore, it was interesting to note that the LOM of both
12 ICs is mostly associated with Temple syndrome (TS), which is an imprinting disorder
13 sharing a high degree of phenotypic overlap with SRS. Consequently, this raises the
14 question if TS individuals that fit the SRS description should be classed as SRS.


15

16 **1.4.1.4 Abnormality detection rate in SRS**

17 In the general population, the LOM at *H19/IGF2:IG-DMR* contributes for more than
18 38% of SRS cases and the maternal UPD of chromosome 7 is described in
19 approximatively 10% of cases. The other mechanisms leading to SRS are very rare.
20 The copy number variations (deletion/duplication) affecting *H19/IGF2:IG-DMR* and
21 *KCNQ1OT1:TSS-DMR* imprinted loci, the maternal UPD of chromosome 11 and the
22 genomic abnormalities affecting chromosomes other than chromosome 7 and 11 are
23 responsible for less than 1-2% of SRS cases. An *IGF2* loss-of-function mutation has

1 been identified in one case only. Similarly, a *CDKN1C* gain-of-function mutation has
2 been reported in a single family with SRS. Finally, the molecular defects are yet to
3 be identified for the remaining SRS cases (approximately 40-50%) (Abu-Amero et
4 al. 2008; Eggermann, Perez de Nanclares, et al. 2015) (Figure 1.14).

5



6

7

8 **Figure 1.14. Enrichment of the type of abnormalities describe in the molecular**
9 **aetiology of SRS.**

10

11 **1.5 Imprinting disorders and multilocus methylation** 12 **disturbances.**

13 Genomic imprinting disorders are individually rare and at a clinical level they are
14 usually considered distinct disorders. However, clinical features such as disordered

1 growth are common to several disorders. In some cases, a similar clinical phenotype
2 may result from different types of disordered imprinting. Thus, SRS has been
3 associated with epimutations at *H19/IGF2:IG-DMR* (SRS_IC1) on chromosome
4 11p15.5 but also with maternal uniparental disomy of chromosome 7 (SRS_UPD7)
5 (see section 1.4 - Silver-Russell Syndrome). Occasionally a patient may present with
6 a clinical diagnosis of a specific ID but molecular investigation reveals an epigenetic
7 abnormality that is associated with a clinically distinct disorder. Thus, several studies
8 have reported rare patients referred with a clinical diagnosis of BWS who have LOM
9 of the paternal *H19/IGF2:IG-DMR* allele at 11p15.5, which is characteristically
10 associated with SRS (Tee et al. 2013). By opposition, rare patients were referred
11 with a clinical diagnosis of SRS but have LOM of the maternal *KCNQ1OT1:TSS-*
12 *DMR* allele, which is characteristically associated with BWS (Azzi et al. 2009). Such
13 epigenotype-phenotype inconsistencies may result from the observation that a
14 subset of patients with an ID have epimutations at multiple ICs (Rossignol et al. 2006;
15 Bliiek et al. 2008; Mackay et al. 2008; Azzi et al. 2009; Lim et al. 2009; Turner et al.
16 2010; Court et al. 2013; Poole et al. 2013; Tee et al. 2013; Maeda et al. 2014; Mackay
17 et al. 2015). This phenomenon is also known as multilocus imprinting disturbances
18 (MLIDs).

19

20 The first evidence of MLID was reported in individuals clinically diagnosed with
21 TNDM1 and carrying not only a LOM at the *PLAGL1:alt-TSS-DMR*, epimutation
22 accounting for approximately 20% of TNDM1 cases, but also hypomethylation at
23 *KCNQ1OT1:TSS-DMR*, which is the main epimutation associated with BWS (Arima

1 2005; Mackay et al. 2006) (see section 1.3 - Beckwith-Wiedemann Syndrome).
2 Since then, MLID has been identified in approximately 50% of TNDM1 individuals
3 with LOM at *PLAGL1*:alt-TSS-DMR (Mackay et al. 2008), in approximately 25% of
4 BWS with LOM at *KCNQ1OT1*:TSS-DMR (Rossignol et al. 2006; Bliiek et al. 2008;
5 Azzi et al. 2009; Court et al. 2013; Poole et al. 2013; Tee et al. 2013; Maeda et al.
6 2014), in approximately 10% of SRS individuals with LOM at *H19/IGF2*:IG-DMR
7 (Azzi et al. 2009; Turner et al. 2010) and in approximately 12.5% of PHP1B
8 individuals carrying isolated epimutation at the *GNAS* imprinting region (Perez-
9 Nanclares et al. 2012; Court et al. 2013; Maupetit-Méhouas et al. 2013). Though the
10 MLID phenomenon has now been documented in several IDs, the causes and
11 clinical significance of MLID are, in most cases, not well defined (Eggermann, Perez
12 de Nanclares, et al. 2015; Mackay et al. 2015).

13

14 **1.6 General summary of this project**

15 DNA methylation is a heritable epigenetic mark that is, for historical reasons, mainly
16 associated with transcriptional repression. However, it is now well established that
17 DNA methylation also play critical roles in other mechanisms such as the
18 maintenance of the genome integrity, the inactivation of the X chromosome in female
19 or in the regulation of genomic imprinting.

20

21 Genomic imprinting is an epigenetic phenomenon that results in the deliberate
22 silencing of one copy (allele) of specific genes, according to whether the allele comes

1 from the father or the mother. Those genes, known as imprinted genes, are currently
2 believed to be mainly associated with foetal growth, brain development, and
3 neurological behavioural traits.

4

5 At imprinted domains, both parental genomes are differentially marked by DNA
6 methylation (i.e. methylated on the paternal allele but unmethylated on the maternal
7 allele). These imprinted differentially methylated regions, known as imprinting
8 centres or imprinted DMRs, are *cis*-acting elements controlling the expression of
9 nearby or distant cluster of imprinted genes. The parent-specific DNA methylation
10 marks found at imprinted centres can be established during the development of
11 parental germ cells into egg or sperm. The methylation marks at these germline
12 imprinted centres are maintained post-fertilisation but are erased and then replaced
13 by a new one during the new generation of germ cells. Alternatively, secondary
14 imprinted DMRs are imprinted loci that acquire their parent-specific methylation
15 marks post-zygotically.

16

17 Genomic imprinting is essential for normal growth and development and its
18 deregulation, for example through aberrant methylation at imprinting centres, is
19 associated in with number of human diseases such as the imprinting disorders BWS
20 and SRS. BWS is a paediatric overgrowth condition caused by epigenetic or genetic
21 alterations at the imprinted gene cluster located on chromosome 11p15.5. In
22 contrast, SRS is a paediatric growth restriction condition caused by epigenetic or
23 genetic alterations at imprinted gene clusters located on chromosome 7 and 11.

1 Interestingly, in a subset of BWS patients associated with a LOM at
2 *KCNQ1OT1*:TSS-DMR or SRS patients associated with a LOM at *H19/IGF2*:IG-
3 DMR, multiple epimutations (MLIDs) occurring at imprinted loci other than
4 *KCNQ1OT1*:TSS-DMR (for BWS) and *H19/IGF2*:IG-DMR (for SRS) are also
5 described. These aberrant MLID epigenotypes are not exclusively found in BWS and
6 SRS individuals. MLIDs are also describe in patients diagnosed with other imprinting
7 disorders, including TNDM1 and PHP1B. However, in most cases, the causes,
8 nature, frequency and clinical significance of MLID is currently not well defined yet.

9

10 **1.7 Aims of this project**

11 The principal aim of my thesis was to perform the methylation profiling of imprinted
12 loci in BWS and SRS individual. The resulting comprehensive analysis would have
13 helped to define the nature, frequency and range of MLID in these cohorts. It also
14 would have provided valuable informations on the possible clinical significance of
15 these widespread imprinting failures in BWS and SRS. Additionally, I also aimed to
16 decipher the possible underlying causes that could be responsible for the abnormal
17 MLID epigenotype.

18

19 To that aim, I first sought to develop an affordable and highly sensitive high-
20 throughput method to assess the methylation at imprinted loci in both cohorts.
21 Following the unsuccessful attempt to develop the assay, I carried out the
22 comprehensive methylation profiling using methylation array and my own

1 bioinformatic methodology. I studied the significance of the use of assisted
2 reproductive technologies in BWS_IC2 individuals with MLID and, using whole-
3 exome sequencing, I investigated the possibility that genetic alterations may be
4 responsible for the widespread imprinting methylation disturbances. Finally, by using
5 functional assays, I sought to know if a novel candidate gene variant found in siblings
6 with BWS and LOM at *KCNQ1OT1*:TSS-DMR could be responsible for MLID.

7

8 Taken together, the work undertaken during my thesis could improve not only our
9 knowledge about the molecular aetiology of BWS and SRS, but also our
10 understanding of genomic imprinting and its disturbances.

11

Chapter 2

General Methods

1 **2.1 Buffers recipe**

2 **2.1.1 1X Transfer buffer**

3 192 mM glycine, 25 mM Tris, 10% pure methanol, adjust volume with dH₂O if
4 needed.

5

6 **2.1.2 1X PBS-Tween 20 (PBST)**

7 137 mM NaCl, 12 mM Phosphate, 2.7 mM KCl, 0.1% Tween 20, pH 7.4, adjust
8 volume with dH₂O if needed.

9

10 **2.1.3 Blocking buffer**

11 5 g non-fat milk, 100 ml PBST

12

13 **2.1.4 4X Laemmli sample buffer**

14 240 mM Tris/HCl pH 6.8, 8% SDS, 40% glycerol, 0.04% bromophenol blue, 5% beta-
15 mercaptoethanol, adjust volume with dH₂O if needed.

16

17 **2.1.5 RIPA**

18 50 mM Tris-HCl pH 8.0, 150 mM NaCl, 1% Igepal, 0.5% sodium deoxycholate, 0.1%
19 SDS, 1X protease inhibitors, adjust volume with dH₂O if needed.

20

21

1 **2.1.6 2X SSC**

2 300 mM NaCl, 30 mM sodium citrate, adjust volume with dH₂O if needed.

3

4 **2.1.7 1X TAE**

5 40 mM Tris, 20 mM acetic acid, 1 mM EDTA, adjust volume with dH₂O if needed.

6

7 **2.2 DNA purification**

8 DNA was purified using the QIAquick PCR Purification Kit (QIAGEN). 5 volumes of
9 Buffer PB was added to 1 volume of sample and mixed by pipetting. To bind DNA to
10 the membrane, the sample was loaded into a QIAquick spin column placed in a 2 ml
11 collection tube and centrifuged a 10,000 x g for 30-60 seconds. The flow-through
12 was discarded and the collection tube was reused. To wash the DNA, 750 µl of Buffer
13 PE was added to the QIAquick spin column and the column was centrifuged at
14 10,000 x g for 30-60 seconds. The flow-through was discarded and the collection
15 tube was reused. The column was centrifuged again for 1 minute to remove residual
16 ethanol from Buffer PE. To elute the DNA, the column was transferred in a 1.5 ml
17 tube, 50 µl of Buffer EB (or water) was added to the centre of the Qiaquick
18 membrane, let to incubate for 1 minute and the column was centrifuged at 10,000 x
19 g for 1 minute. The purified DNA was used immediately or stored at -20 °C for later
20 use.

21

22 Alternatively, DNA purification was done by ethanol precipitation. In a 15 ml tube, 2.5

1 volumes of 100% ethanol and 0.1 volume of 3M NaOAc (pH 5.2 or 5.5) were added
2 to 1 volume of sample. The mixture was mixed well and left at -80 °C for at least 30
3 minutes. To precipitate the DNA, the tube was centrifuged at 3,000 rpm (or maximum
4 speed) for 30 minutes at 4 °C. After centrifugation, the supernatant was carefully
5 discarded and 800 µl of cold 75% ethanol was added to the tube. Using a 1 ml tip
6 (with tip pre-cut) the DNA pellet was transferred to a 1.5 ml tube and the tube was
7 centrifuged at 14,000 rpm for 5 minutes. The supernatant was carefully discarded
8 and the pellet was let to air dry for 3-5 minutes. To resuspend the DNA, 10-150 µl of
9 double distilled water (pre-incubated at 37 °C) was added to the pellet and mixed
10 well by pipetting up and down several times. The purified DNA was used immediately
11 or stored at -20 °C for later use.

12

13 **2.3 DNA quantification**

14 2 µl of DNA was loaded on NanoDrop® ND-1000 (Thermo Scientific) and the
15 measured absorbance at 260 nm was used to calculate the DNA concentration. The
16 presence of proteins in DNA samples was evaluated with the measurement of
17 absorbance at 280 nm. A ratio of sample absorbance at 260 nm and 280 nm
18 (A_{260}/A_{280}) greater than 1.8 suggested DNA samples exempt from proteins.
19 Similarly, salt and organic compounds contaminations were evaluated with the
20 measurement of absorbance at 230 nm. A ratio of sample absorbance at 260 nm
21 and 230 nm (A_{260}/A_{230}) greater than 1.5, ideally close to 1.8, suggested minimal
22 or non existant contaminants carryover.

1 DNA concentration was determined by the measurement of absorbance at 260 nm
2 and 280 nm. 2 μ l of DNA was loaded on NanoDrop® ND-1000 (Thermo Scientific)
3 and DNA concentration was obtained with the ratio of sample absorbance at 260 nm
4 and 280 nm (A_{260}/A_{280}).

5
6 Alternatively, DNA concentration was determined by fluorescent dyes method using
7 Qubit® dsDNA HS Assay Kit (Thermo Fisher Scientific). For samples with expected
8 DNA concentration below 100 ng/ μ l, 2 μ l of sample DNA was mixed with 198 μ l of
9 Qubit® dsDNA HS Reagent diluted in 1:200 in Qubit® dsDNA HS Buffer. Samples
10 fluorescence intensities were measured with Qubit® 2.0 Fluorometer and DNA
11 concentration was calculated from the fluorescence intensities of provided low and
12 high standard (10 μ l of low or high Qubit® standard was mixed with 190 μ l of Qubit®
13 dsDNA HS Reagent diluted in 1:200 in Qubit® dsDNA HS Buffer). For samples above
14 100 ng/ μ l, DNA was first diluted in distilled water to bring concentration below 100
15 ng/ μ l and then processed as above.

16

17 **2.4 Sodium bisulfite treatment**

18 Genomic DNA (gDNA) was quantified with NanoDrop® ND-1000 (see section 2.3 -
19 DNA quantification) and 500 ng of DNA was bisulfite treated using EZ DNA
20 Methylation-Lightning™ Kit (Zymo Research). Bisulfite treatment was done as
21 follows: first gDNA was mixed with 130 μ l of Lightning Conversion Reagent and then
22 incubated in a thermal cycle with the following programme: 98 °C for 8 minutes, 54

1 °C for 60 minutes, 4 °C for up to 20 hours. Sample was then mixed with 600 µl of M-
2 Binding Buffer, loaded into a Zymo-Spin™ IC Column placed into a provided
3 Collection Tube and centrifuged at full speed for 30 seconds. To remove conversion
4 reagent 100 µl of M-Wash Buffer was added to the column and centrifuge at full
5 speed for 30 seconds. Complete methylated cytosine to uracil conversion was
6 achieved by adding 200 µl of L-Desulphonation Buffer to the column and let stand at
7 room temperature (20-30 °C) for 15-20 minutes. To stop the desulphonation reaction
8 the tubes were centrifuged at full speed for 30 seconds and then washed twice in
9 200 µl of M-Wash Buffer with centrifugation at full speed for 30 seconds after each
10 wash steps. Elution step was done by adding 15 µl of M-Elution Buffer to the column
11 and centrifuged at full speed for 30 seconds. Recovered bisulfite treated DNA
12 (bisDNA) was used immediately or stored at -20 °C for later use.

13

14 **2.5 Infinium HumanMethylation450 BeadChip**

15 Genomic DNA was quantified with Qubit® dsDNA HS Assay Kits (see section 2.3 -
16 DNA quantification) and 500 ng of gDNA was processed on the Infinium
17 HumanMethylation 450K BeadChips (HM450K) (Illumina). This robust platform can
18 interrogate the methylation status of more than 485,000 CpG across the genome.
19 Processing of the samples on the HM450K array were performed at the Cambridge
20 Genomic Services (Cambridge, UK), according to the manufacturer's protocol
21 (Infinium HD Assay Methylation Protocol Guide). In brief, gDNA was sodium bisulfite
22 converted, denatured, neutralised and whole-genome amplified. Amplified bisulfite

1 treated gDNA was then enzymatically fragmented, purified by isopropanol
2 precipitation and the resulting fragmented purified DNA was hybridized to BeadChip.
3 The chip was then washed to remove all unhybridized and nonspecifically hybridized
4 DNA. Using the capture DNA as template, specific fluorophore labels were added at
5 CpG sites query by single-base extension. Staining detection was done by recording
6 high resolution images of the light emitted from the fluorophore of the single-base
7 extension products after laser excitation. GenomeStudio software (Illumina) was
8 used to extract signal intensities for each probe and generate raw 'idat' files. The
9 resulting raw data files were imported and analysed in R.

10

11 **2.6 Analysis software**

12 Unless stated otherwise, data handling, processing and statistical analysis were
13 performed in R v3.3.0 and in Microsoft Excel v15.24.

14

15 **2.7 DNA fragments analysis of DNA libraries**

16 Bioanalyzer High Sensitivity DNA Kit (Agilent) was used to analyse DNA fragments.

17

18 **2.7.1 Setting up the chip priming station**

19 A new syringe was placed in the chip priming station, the plate base was inserted in
20 position C and the syringe clip was positioned at the lowest position.

21

1 **2.7.2 Loading the gel dye mix**

2 Protected from light, the gel-dye mix was put at room temperature for 30 minutes
3 before use. After equilibration at room temperature, 9 μ l of gel-dye mix was pipetted
4 at the bottom of the well located on the fourth column and third row of the DNA chip.
5 The DNA chip was then placed into the chip priming station. The chip priming station
6 was closed and the plunger of the syringe that was previously positioned at 1 ml was
7 pressed down until held by the clip. The plunger was kept down for exactly 60
8 seconds and then released. The plunger was inspected that it moved back to the 0.3
9 ml mark and after 5 seconds it was slowly pull back to the 1 ml position. Finally, the
10 chip priming station was opened and 9 μ l of gel-dye mix was loaded in the three
11 wells located on the fourth column and first, second and fourth row.

12 **2.7.3 Loading the marker**

13 5 μ l of High Sensitivity DNA marker was pipetted into the wells with a ladder symbol
14 and into each of the 11 sample wells.

15

16 **2.7.4 Loading the ladder and the samples**

17 1 μ l of High sensitivity DNA ladder was pipetted in the well marked with the ladder
18 symbol. 1 μ l of sample was pipetted in each of the 11 sample wells. The chip was
19 placed horizontally in the adapter of the IKA vortex mixer and vortex for 60 seconds
20 at 2400 rpm. Finally, the DNA chip was placed into the Agilent 2100 Bioanalyzer (with
21 chip selector was set to position (1)).

22

1 **2.7.5 Starting the chip run**

2 Using the 2100 Expert software, the appropriate assay was selected from the Assay
3 menu located in the instrument context tab. Then the sample information's were
4 inserted into the sample name table. Finally, the button start was pressed to start the
5 run.

6

7 **2.7.6 Data analysis**

8 Results were analysed directly using the 2100 Expert software built-in analysis
9 module. The detected peaks were labelled in base-pair to indicate the products size.

Chapter 3

**Development of a novel next generation sequencing
strategy for the genomic imprinting methylation profiling
of individual with BWS and SRS**

1 **3.1 Introduction**

2 **3.1.1 What is NGS?**

3 Next-generation sequencing (NGS), also known as high-throughput sequencing or
4 deep sequencing, is a generic term used to describe a number of different modern
5 sequencing technologies. Examples include (i) sequencing-by-synthesis technology
6 used by Illumina in its commercially available sequencers MiSeq, HiSeq, NextSeq
7 and NovaSeq (see section 3.1.2 - Sequencing-by-synthesis; an Illumina technology);
8 (ii) pyrosequencing used by Roche 454 Life Sciences in the now discontinued
9 Genome Sequencer FLX and GS Junior sequencers; (iii) sequencing-by-ligation
10 used by ThermoFisher Scientific in the ABI SOLID sequencers; and (iv) detection of
11 pH changes that follow the release of a hydrogen ion used by ThermoFisher
12 Scientific in the Ion Proton, Ion PGM and Ion S5 sequencers.

13

14 NGS platforms are reliable methods to sequence DNA and have many significant
15 advantages when compared to classical Sanger sequencing. (i) It is quicker. NGS
16 allows the sequencing of 300 Gb of DNA in a single run whilst a single read of 1 kb
17 can be sequenced in a single reaction with Sanger sequencing. (ii) It is cheaper.
18 Nowadays the sequencing of whole human genome with NGS may cost £3,000 or
19 less whilst the predicted cost using Sanger sequencing could be approximatively
20 £6M. (iii) It is more accurate and reliable. In a single NGS reaction, each portion of
21 DNA can be covered by many short overlapping DNA fragments that are sequenced
22 multiple times, hence resulting in reliable base calling. In contrast many time

1 consuming Sanger sequencing reactions will be required to achieve the same level
2 of coverage. (iv) It needs less DNA. Approximately 5 µg of genomic DNA would be
3 required for the sequencing of the whole human genome using NGS. In contrast,
4 Sanger sequencing of a small genomic region of 1 kb will required approximately
5 20 ng of genomic DNA.


6

7 **3.1.2 Sequencing-by-synthesis; an Illumina technology**

8 The sequencing-by-synthesis technology used by Illumina relies on several steps.
9 Using the appropriate method, sequencing libraries are prepared from genomic DNA
10 (Figure 3.1- step 1). In the 5' to 3' order, the libraries consist of a P5 adaptor, possibly
11 index 1 (i5) barcode, sequencing primer for read 1, DNA insert, sequencing primer
12 for read 2, possibly index 2 (i7) barcode and P7 adaptor sequences. Once prepared
13 and ready for sequencing, the double-stranded libraries are denatured and loaded
14 onto the flow cell. The DNA molecules attach through the attachment of either the
15 P5 or P7 adapter of the libraries to the surface of the flow cell (Figure 3.1- step 2).
16 In parallel, the other end that did not attach to the flow cell anneals to a dense lawn
17 of complimentary oligonucleotides that coat the surface of the flow cell, hence
18 forming a kind of bridge (Figure 3.1- step 3). The single-stranded DNA molecules
19 that are now in a bridge shape are double-stranded through the addition of
20 unlabelled nucleotides, primers, buffer and polymerase enzyme (Figure 3.1- step 4).
21 The double-stranded molecules are denatured and the original strands are washed
22 away, leaving behind the strands that had been synthesised and covalently bonded

1 to the flow cell surface in a mixture of orientations (Figure 3.1- step 5). Step 3 to 5
2 are repeated multiple times to create clusters of DNA molecules that contains
3 thousands of identical copies of the same sequence (in a mixture of orientations)
4 (Figure 3.1- step 6). Prior to sequencing cycles, the P5 region is then cleaved,
5 resulting in clusters containing only fragments which are attached by the P7 adaptor
6 region. This is to ensure that all copies are in the same direction. Sequencing
7 primers, polymerase, fluorescently labelled nucleotides with reversible terminator
8 (one fluorescent colour for each base) and buffer are then added to the flow cell. The
9 primers anneal to the P5 end of the fragments, which leads to the incorporation of
10 the first base and therefore begins the sequencing-by-synthesis procedure (Figure
11 3.1- step 7). After the incorporation of the first locked base, the flow cell is washed,
12 hence resulting in removing unincorporated nucleotides and excess of primers. The
13 sequencer starts the acquisition of the clear fluorescent signals and records the
14 identity of the first base that was added to each clusters (Figure 3.1- step 8). The
15 terminator dye and the fluorescent dye of the first base are removed, ultimately
16 resulting in an unblocked and non-fluorescent nucleotide. Subsequently, a new
17 sequencing chemistry cycle is initiated to determine the second base. Sequencing
18 primers, polymerase, fluorescently labelled nucleotides with reversible terminator
19 and buffer are added to the flow cell, which result in the incorporation of another
20 fluorescently labelled nucleotide (Figure 3.1- step 9). The flow cell is then washed
21 and the sequencer acquires the fluorescent signals and records the identity of the
22 second base that was incorporated (Figure 3.1- step 10). The terminator dye and the
23 fluorescent dye are removed which allows the start of a new sequencing cycle. This

1 sequencing procedure is repeated multiple times which leads to the identification of
2 each base of a cluster (Figure 3.1- step 11). Finally, all the acquired sequencing
3 reads are preprocessed and aligned for further analysis (Figure 3.1- step 12).
4



1

2 **Figure 3.1. Sequencing-by-synthesis technology used in Illumina.**

3 (Image

retrieved

from

4 https://www.illumina.com/documents/products/techspotlights/techspotlight_sequencing.pdf).

5


1 **3.1.3 What is bisulfite sequencing?**

2 DNA methylation plays a critical role in normal growth and development and aberrant
3 DNA methylation changes can cause a number of human disorders, including cancer
4 and imprinting disorders. Consequently, it is crucial to characterise methylome states
5 during normal development and under pathological conditions.

6

7 Bisulfite-sequencing (Frommer et al. 1992) is one of the most reliable methods to
8 characterise DNA methylation within a genomic region. It relies on the treatment of
9 a single stranded DNA with a chemical compound, sodium bisulfite, and results in
10 the deamination of unmodified cytosine residues to uracil. In contrast, 5-mC (and the
11 iterative oxidised form 5-hmC/5-fC/5-caC), is protected against the bisulfite
12 treatment. Consequently, cytosine residues that survive the bisulfite treatment are
13 indirectly identified as methylated, whilst cytosines that are converted to thymines
14 after polymerase chain reaction are identified as unmethylated (Figure 3.2). Used in
15 combination with NGS, it constitutes nowadays the method of choice for the high-
16 resolution methylation profiling of genomic regions.

17



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18

Figure 3.2. Principle of sodium bisulfite treatment.

Unmethylated cytosine residues are deaminated to uracil whereas methylated cytosine residues are unaffected. After polymerase chain reaction and sequencing, all cytosines that survive the treatment were methylated cytosine.

3.1.4 NGS based methods for DNA methylation profiling

The status of DNA methylation of a genomic region can be analysed by many different methods that rely on three basic principles: (i) the enzymatic digestion of methylated and unmethylated DNA with a restriction enzyme; (ii) the enrichment of methylated DNA using anti-methylcytosine antibodies or methyl-binding domain proteins; (iii) the sodium bisulfite conversion of genomic DNA which results in the conversion of unmodified cytosine to thymine whereas methylated cytosines remain unchanged. These principles have been integrated into high-throughput analytical applications such as next-generation sequencing (NGS) platforms.

1 Several methods for the large-scale DNA methylation analysis that rely on bisulphite
2 conversion of genomic DNA in combination with NGS have been developed (E.-J.
3 Lee et al. 2013; Plongthongkum et al. 2014). This includes whole-genome bisulphite
4 sequencing (WGBS) (Cokus et al. 2008; Lister et al. 2008; Lister et al. 2009),
5 reduced-representation-bisulphite-sequencing (RRBS) (Meissner et al. 2008; Z.D.
6 Smith et al. 2009; Gu et al. 2011; Boyle et al. 2012), methylated DNA
7 immunoprecipitation sequencing (MeDIP-seq) (Down et al. 2008; Maunakea et al.
8 2010; Taiwo et al. 2012) and targeted capture methods (Deng et al. 2009; Herrmann
9 et al. 2011; Komori et al. 2011; E.-J. Lee et al. 2011; Diep et al. 2012; Guilhamon et
10 al. 2013; Ivanov et al. 2013; Paul et al. 2014).

11

12 Whole-genome bisulfite sequencing (WGBS) is the gold standard method for the
13 single base-pair resolution complete mapping of cytosine methylation across the
14 genome. It has made significant contributions to determine the methylome of
15 individuals and especially in cancer cells (Hansen et al. 2011; Hon et al. 2012).
16 However, despite undeniable advantages, it is an expensive approach especially
17 when applied to a large set of samples.

18

19 RRBS is a large-scale approach that uses CpG-specific restriction enzyme (e.g.
20 MspI, which is methylation-insensitive) digestion to randomly enrich for regions of
21 high CpG content, such as CpG islands and promoters in any genome (Meissner et
22 al. 2008; Z.D. Smith et al. 2009; Gu et al. 2011; Boyle et al. 2012; Junwen Wang et
23 al. 2013). The method allows the profiling of approximately 10-20% of the human

1 CpG content and requires a very low amount of DNA (10-100 ng). However, due to
2 the intrinsic principle of using restriction enzymatic digestion, many CpG-sparse
3 regions could be left uncharacterised. Additionally, the use of a high output
4 sequencer is recommended in order to obtain a good depth of sequencing coverage.

5
6 MeDIP-seq is a large-scale approach that uses monoclonal antibodies directed
7 against 5-mC to precipitate and enrich methylated DNA fragment (MeDIP; (Weber et
8 al. 2005)) before sequencing. It was used to complete the first high resolution
9 methylome of a mammalian (i.e. human) genome (Down et al. 2008). The method
10 has now been refined and requires a low input of DNA (i.e. 50 ng) (Taiwo et al. 2012)
11 for the characterisation of 60-90% of the human CpG content. Similarly to RRBS,
12 sequencing following MeDIP will require a high output sequencer to obtain a good
13 depth of sequencing coverage.

14
15 Targeted capture methods may be designed to interrogate any region of the genome.
16 First developed to conduct whole-exome sequencing at a low cost compared to
17 whole-genome sequencing (Albert et al. 2007; Hodges et al. 2007; Okou et al. 2007;
18 Porreca et al. 2007), these methods were gradually integrated with bisulfite
19 sequencing. Several targeted bisulfite sequencing (TBS-seq) methods have been
20 developed and rely on different capture techniques, including bisulphite padlock probes
21 (Deng et al. 2009; Diep et al. 2012) (see section 3.1.5 - DNA methylation profiling
22 using the bisulfite padlock probes below), microdroplet-based PCR amplification
23 coupled with NGS protocols (Herrmann et al. 2011; Komori et al. 2011; Guilhamon

1 et al. 2013; Paul et al. 2014), on array hybridisation (Hodges et al. 2009) or in solution
2 hybridisation (E.-J. Lee et al. 2011; Ivanov et al. 2013; Allum et al. 2015). TBS-seq
3 offers several advantages over WGBS, RRBS or MeDIP-seq: (i) they are scalable
4 approaches that can adapt to the amount of targeted regions; (ii) they are designed
5 in answer to the hypothesis in question; (iii) depending of the size of the project they
6 can result in high depth of sequencing coverage (>1000x) even when sequenced
7 with a benchtop sequencer (e.g. MiSeq); (iv) they are developed with the scope of
8 processing many samples hence offering a high degree of throughput for sample
9 processing and multiplexing and (v) they don't require, for the majority, a large
10 amount of input DNA (200-500 ng). However, TBS-seq has the disadvantage of (i)
11 limiting findings to the captured targeted regions which consequently excludes
12 possible new discoveries that are located out of these boundaries; (ii) for some
13 methods, the design of capturing probes may be complicated by reduced sequence
14 complexity (resulting from bisulfite treatment) and high GC-rich regions; (iii) they
15 have a starting high cost (e.g. for probe synthesis) but they become much more
16 affordable when used for the analysis of large set of samples.

17

18 **3.1.5 DNA methylation profiling using the bisulfite padlock** 19 **probes**


20 Bisulfite padlock probes (BSPPs) have been suggested as a practical, flexible and
21 cost-effective approach to interrogate the methylation profile of multiple regions of
22 interest across a large set of samples (Ball et al. 2009; Deng et al. 2009; Diep et al.

1 2012). The method requires a very low amount of input DNA (e.g. 200 ng of bisulfite-
2 treated DNA) and is highly specific and reproducible.

3
4 Historically, BSPP was firstly used to assess the methylation status of 66,000 CpG
5 sites in 2,020 CGI on human chromosomes 12 and 20 (Deng et al. 2009). In the
6 same year, another research group used BSPP to profile 7,000 CpG sites within the
7 ENCODE pilot project regions (Ball et al. 2009). Both studies used approximately
8 30,000 padlock probes to capture the targeted regions and both showed that the
9 method is highly specific and reproducible. More recently, a third group released an
10 upgraded version of the protocol and demonstrated the high specificity of the
11 technique by characterising the methylation profile of approximately 500,000 CpG
12 sites across 34 Mb of sequences. For this large-scale project, 330,000 padlock
13 probes were designed, synthesised and used to capture the sequence of interest
14 (Diep et al. 2012). Although the initial cost of BSPP is high, the cost per sample
15 dramatically decreases with increased sample sizes (Diep et al. 2012).

16
17 BSPP are long single stranded DNA oligonucleotides (100-150 mers) designed to
18 hybridise to bisulfite converted genomic DNA targets in a horseshoe manner (Figure
19 3.3-a). The targeted regions for sequence capture are the gap between the two
20 hybridised and locus-specific arms of a padlock probe and their capture are done by
21 filling the gap with a polymerase (Figure 3.3-b). Uncaptured linear DNA is digested
22 (Figure 3.3-c) and the resultant circular DNA is enriched and amplified using the
23 common linker sequence between the two ligation arms with primers containing

1 sequencer's adaptors and barcode (sequencing library preparation) (Figure 3.3-d).
2 BSPP sequencing libraries are mainly designed to be sequenced on Illumina
3 systems. However, the BSPP approach is flexible and can be adapted to another
4 sequencing platform.
5



1

2

3 **Figure 3.3. Bisulfite padlock probes.**

4 (a) Padlock probes bind to bisulfite converted genomic DNA. (b) The sequence of
 5 interest is captured through gap filling step. (c) Linear DNA is digested with nuclease
 6 and (d) circles DNA, which contain sequence of interest, are amplified by PCR with
 7 primers containing P5 and P7 Illumina sequencing adaptors and index sequences.
 8 Both primers are specific to a different portion of the BSPP common linker. (Adapted
 9 from Diep et al. 2012).

1 **3.1.6 Aim**

2 As discussed previously (see section 1.5 - Imprinting disorders and multilocus
3 methylation disturbances), a subset of BWS and SRS individuals have been
4 identified with MLID but the nature, frequency and clinical significance of such
5 aberrant epigenotype has not been clearly defined yet. Additionally, the comparison
6 of different studies of MLID in BWS and SRS is complicated by different strategies
7 for detecting epimutations and different choices of ICs analysed. In order to
8 undertake a comprehensive survey of the frequency and nature of MLID in patients
9 with BWS and SRS I attempted to develop a NGS assay for a highly sensitive
10 methylation profiling at 46 imprinting DMRs (Table 3.1) (Court et al. 2014). The assay
11 was intended to fulfil a list of criteria that includes (i) a streamlined workflow for the
12 processing of a large number of clinical samples; (ii) being cost-efficient; (iii) the
13 characterisation of CpG methylation within the targets at a single base-pair
14 resolution; (iv) a very high depth of sequencing coverage (e.g. > 500x); and (v)
15 requires a low amount of input DNA (e.g. <500 ng). At the time of the project, this
16 was one of the first attempt of genome-wide screening for alteration at multiple
17 imprinted loci using NGS method and applied to a large cohort of BWS and SRS
18 individuals (more than 100). Additionally, although the primary focus was to
19 characterise DNA methylation at imprinting regions in BWS and SRS individuals, the
20 NGS assay could also be used for the genomic imprinting methylation profiling of
21 other diseases, including other IDs and cancer.

22

1 **Table 3.1: List of imprinted DMRs.**

2 (Court et al. 2014)

Imprinted DMR	Chr	Start	End	Number CpGs	Methylation origin	Germline derived
<i>PPIEL</i> :Ex1-DMR	1	40024626	40025540	39	Maternal	Oocyte gDMR
<i>DIRAS3</i> :TSS-DMR	1	68515433	68517545	88	Maternal	Oocyte gDMR
<i>DIRAS3</i> :Ex2-DMR	1	68512505	68513486	39	Maternal	Oocyte gDMR
<i>GPR1-AS</i> :TSS-DMR	2	207066967	207069445	86	Maternal	Oocyte gDMR
<i>ZDBF2/GPR1</i> :IG-DMR	2	207114583	207136544	439	Paternal	Sperm gDMR-secondary DMR
<i>NAP1L5</i> :TSS-DMR	4	89618184	89619237	57	Maternal	Oocyte gDMR
<i>VTRNA2-1</i> :DMR	5	135414802	135416645	76	Maternal	Oocyte gDMR
<i>FAM50B</i> :TSS-DMR	6	3849082	3850359	90	Maternal	Oocyte gDMR
<i>PLAGL1</i> :alt-TSS-DMR	6	144328078	144329888	143	Maternal	Oocyte gDMR
<i>IGF2R</i> :Int2-DMR	6	160426558	160427561	74	Maternal	Oocyte gDMR
<i>WDR27</i> :Int13-DMR	6	170054504	170055618	58	Maternal	Oocyte gDMR
<i>GRB10</i> :alt-TSS-DMR	7	50848726	50851312	171	Maternal	Oocyte gDMR
<i>PEG10</i> :TSS-DMR	7	94285537	94287960	119	Maternal	Oocyte gDMR
<i>MEST</i> :alt-TSS-DMR	7	130130122	130134388	226	Maternal	Oocyte gDMR
<i>HTR5A</i> :TSS-DMR	7	154862719	154863382	55	Maternal	Oocyte gDMR
<i>ERLIN2</i> :Int6-DMR	8	37604992	37606088	37	Maternal	Oocyte gDMR
<i>PEG13</i> :TSS-DMR	8	141108147	141111081	193	Maternal	Oocyte gDMR
<i>FANCC</i> :Int1-DMR	9	98075400	98075744	26	Maternal	Oocyte gDMR
<i>INPP5F</i> :Int2-DMR	10	121578046	121578727	52	Maternal	Oocyte gDMR
<i>H19/IGF2</i> :IG-DMR	11	2018812	2024740	250	Paternal	Sperm gDMR
<i>IGF2</i> :Ex9-DMR	11	2153991	2155112	63	Paternal	No-secondary DMR
<i>IGF2</i> :alt-TSS-DMR	11	2168333	2169768	33	Paternal	Sperm gDMR
<i>KCNQ1OT1</i> :TSS-DMR	11	2719948	2722259	192	Maternal	Oocyte gDMR
<i>RB1</i> :Int2-DMR	13	48892341	48895763	195	Maternal	Oocyte gDMR
<i>MEG3/DLK1</i> :IG-DMR	14	101275427	101278058	64	Paternal	Sperm gDMR
<i>MEG3</i> :TSS-DMR	14	101290524	101293978	188	Paternal	No-secondary DMR
<i>MEG8</i> :Int2-DMR	14	101370741	101371419	43	Maternal	No-secondary DMR
<i>MKRN3</i> :TSS-DMR	15	23807086	23812495	109	Maternal	Oocyte gDMR-secondary DMR
<i>MAGEL2</i> :TSS-DMR	15	23892425	23894029	51	Maternal	No-secondary DMR
<i>NDN</i> :TSS-DMR	15	23931451	23932759	108	Maternal	No-secondary DMR
<i>SNRPN</i> :alt-TSS-DMR	15	25068564	25069481	19	Maternal	No-secondary DMR
<i>SNURF</i> :TSS-DMR	15	25200004	25201976	113	Maternal	Oocyte gDMR
<i>IGF1R</i> :Int2-DMR	15	99408496	99409650	55	Maternal	Oocyte gDMR
<i>ZNF597</i> :3' DMR	16	3481801	3482388	29	Maternal	Oocyte gDMR
<i>ZNF597</i> :TSS-DMR	16	3492828	3494463	76	Paternal	No-secondary DMR
<i>ZNF331</i> :alt-TSS-DMR1	19	54040510	54042212	125	Maternal	Oocyte gDMR
<i>ZNF331</i> :alt-TSS-DMR2	19	54057086	54058425	102	Maternal	Oocyte gDMR
<i>PEG3</i> :TSS-DMR	19	57348493	57353271	221	Maternal	Oocyte gDMR
<i>MCTS2P</i> :TSS-DMR	20	30134663	30135933	47	Maternal	Oocyte gDMR
<i>NNAT</i> :TSS-DMR	20	36148604	36150528	135	Maternal	Oocyte gDMR
<i>L3MBTL1</i> :alt-TSS-DMR	20	42142365	42144040	84	Maternal	Oocyte gDMR
<i>GNAS-NESP</i> :TSS-DMR	20	57414039	57418612	257	Paternal	No-secondary DMR
<i>GNAS-AS1</i> :TSS-DMR	20	57425649	57428033	128	Maternal	Oocyte gDMR
<i>GNAS-XL</i> :Ex1-DMR	20	57428905	57431463	200	Maternal	Oocyte gDMR
<i>GNAS A/B</i> :TSS-DMR	20	57463265	57465201	198	Maternal	No-secondary DMR
<i>WRB</i> :alt-TSS-DMR	21	40757510	40758276	43	Maternal	Oocyte gDMR
<i>SNU13</i> :alt-TSS-DMR	22	42077774	42078873	63	Maternal	Oocyte gDMR

3 Genomic location map the Genome Reference Consortium Human Build 37 (GRCh37/hg19)

1 **3.2 Materials and methods**

2 **3.2.1 DNA purification**

3 See section 2.2 - DNA purification.

4

5 **3.2.2 DNA quantification**

6 See section 2.3 - DNA quantification.

7

8 **3.2.3 Sodium bisulfite treatment**

9 See section 2.4 - Sodium bisulfite treatment.

10

11 **3.2.4 Amplicon size selection**

12 Size selection of a pool of amplicons was done using E-Gel® SizeSelect™ 2% pre-
13 cast agarose gels (Thermo Fisher Scientific). 20-25 µl of sample was loaded in the
14 top wells (lane 1 to 8) of the gel. 5-10 µl of diluted molecular weight markers was
15 loaded into the small middle well (lane M) at the top of the gel. 25 µl of deionised
16 water was loaded into all of the wells (lane 1 to 8) in the lower row and 5-10 µl of
17 deionised water was loaded into the small well of the lower row (lane M). Following
18 sample loading, the gel was inserted into the E-Gel® iBase™ Power System and the
19 amber filter was put over the iBase™ device. For the electrophoresis, the program
20 called 'Run SizeSelect 2%' was selected and an appropriate time (according to 'Run
21 Time Estimation Table') was set to 'Run Time to Reference' (Run Time Estimation
22 Table). Once set, the electrophoresis was run until the band of interest reached the

1 reference line. At that point the electrophoresis was paused, the collection wells were
2 refilled to 25 µl of deionised water, the appropriate time listed under 'Run Time from
3 Reference Line to Collection Well' from the 'Run Time Estimation Table' was entered
4 and the electrophoresis was run. The migration of the band of interest was carefully
5 monitored until it migrates into the Collection Well. At that point the run was stopped
6 and the DNA of the appropriate size was collected from the Collection Well. The
7 collected DNA was used immediately or stored at -20 °C for later use.

8

9 **3.2.5 Preparation of sequencing libraries using bisulfite padlock** 10 **probes**

11 **3.2.5.1 Bisulfite padlock probes design and synthesis**

12 ppDesigner software (Diep et al. 2012) was used to design bisDNA specific padlock
13 probes within regions of interest (Table 3.1). In design 1 (see section 3.3.1 – First
14 experimental design), overlapping probes were designed to cover as much as
15 possible of the regions of interest and CpG inclusion within the probes was allowed.
16 The probes were synthesised by LCSiences. In design 2 (see section 3.3.2 – Second
17 experimental design), one probe was design for each of *PPIEL*:Ex1-DMR,
18 *ZDBF2/GPR1*:IG-DMR, *FAM50B*:TSS-DMR, *H19/IGF2*:IG-DMR, *KCNQ1OT1*:TSS-
19 DMR, *L3MBTL1*:alt-TSS-DMR and *SNU13*:alt-TSS-DMR. CpG inclusion within the
20 probes was not allowed and the probes were synthesised by Integrated DNA
21 Technologies.

22

1 **3.2.5.2 Bisulfite padlock probes production (for LCSciences only)**

2 The following amplification, nicking digestion and purification steps of the padlock
3 probes were done for the one synthesised by LCSciences only (Figure 3.4). The
4 quantity of probes synthesised by LCSciences was very low and consequently it was
5 necessary to amplify them prior target capture step. On the contrary, the quantity of
6 probes synthesised by Integrated DNA Technologies was high and therefore it was
7 not necessary to amplify them prior target capture.

8

9 **3.2.5.2.1 Amplification (for LCSciences only)**

10 To overcome the low concentration of the padlock probes received from LCSciences,
11 amplification primer site 1 (AP1) and amplification primer site 2 (AP2) were added at
12 each end of all probes. The amplification of the single stranded padlock probes was
13 done as previously described (Diep et al. 2012) (Figure 3.4-a). In brief, in 200 µL
14 reaction volume, 1 nM of template oligonucleotides was mixed with 400 nM each of
15 forward primer AP1_F and reverse primer AP2_R (Table 3.2), and 100 µL of KAPA
16 SYBR fast Bio-Rad qPCR Master Mix (Kapa Biosystems). The mixture was placed
17 in a thermocycler for PCR amplification and incubated at 95 °C for 30 sec, 5 cycles
18 of 95 °C for 5 sec; 52 °C for 1 min; and 72 °C for 30 sec, 10-12 cycles of 95 °C for 5
19 sec; 60 °C for 30 sec; and 72 °C for 30 sec, and 72 °C for 2 min. The resulting
20 amplicons were purified using QIAquick PCR purification columns (QIAGEN) (see
21 section 2.2 - DNA purification) and re-amplified by PCR in 32 reactions (100 µL each)
22 with 0.02 nM first round amplicons, 400 nM each of AP1_F primer and AP2_R primer,
23 and 50 µL of KAPA SYBR fast Bio-Rad qPCR Master Mix. For PCR amplification,

1 the mixture was incubated in a thermocycler at 95 °C for 30 sec, 13-15 cycles of 95
2 °C for 5 sec; 60 °C for 30 sec; and 72 °C for 30 sec, and 72 °C for 2 min. The resulting
3 double stranded amplicons were purified by ethanol precipitation and re-purified with
4 QIAquick PCR purification columns (see section 2.2 - DNA purification). The purified
5 amplicons were quantified by Nanodrop (see section 2.3 - DNA quantification) and
6 immediately processed with next step or stored at -20 °C for later use.

7

8 **Table 3.2: List of primers used for the amplification of the padlock probes.**

Primer name	Sequence (5'>3')
AP1_F	TGCCTAGGACCGGATCAACT
AP2_R	GAGCTTCGGTTCACGCAATG

9

10

11 **3.2.5.2.2 Nicking digestion (for LCSciences only)**

12 Nicking digestion was used to remove the amplification primer sites AP_1 and AP_2
13 from the double stranded amplicons (Figure 3.4-b). Approximately 4 µg of the
14 purified amplicons were digested with 100 units of Nt.AlwI (100 U/µl, New England
15 Biolabs, cleaves at 5'-GGATCNNNN/N-3' only on one strand of a double stranded
16 DNA) at 37°C for 1 h in NEBuffer 2 (New England Biolabs). The enzyme was heat
17 inactivated at 80 °C for 20 min. The digested amplicons were then incubated with
18 100 units of Nb.BrsDI (10 U/µl, New England Biolabs, cleaves at 3'-CGTTAC/NN-5'
19 only on one strand of a double stranded DNA) at 65 °C for 1 h. The resulting double
20 stranded nicked DNA was purified by QIAquick PCR purification column (see section
21 2.2 - DNA purification). The nicking digestion of the amplicons with Nt.AlwI and
22 Nb.BrsDI resulted in a double stranded DNA with a 70 bp long top strand (i.e.


1 equivalent to the padlock probes) and a 100 bp bottom strand (i.e. equivalent to the
2 unwanted complementary strand).

3

4 **3.2.5.2.3 Denaturing PAGE purification (for LCSciences only)**

5 To discard the 100 bp complementary strands and to keep the 70 bp padlock probe
6 strands the DNA molecules were purified using denaturing Novex® TBE-Urea Gels
7 6% (Thermo Fisher Scientific) (Figure 3.4-c). In 100 µl final volume, 2 µg of nicked
8 DNA was mixed with 2X Novex® TBE-Urea Sample Buffer in a 1:1 ratio volume. For
9 the DNA ladder, in a 10 µl final volume 1 µg of 10 bp DNA ladder (Thermo Fisher
10 Scientific) was mixed with 1X Novex® TBE-Urea Sample Buffer. The Novex® TBE-
11 Urea gel was put into XCell SureLock™ Mini-Cell Electrophoresis System (Thermo
12 Fisher Scientific), the upper and lower chamber of the electrophoresis system was
13 filled with 0.5X Novex® TBE Running Buffer (Thermo Fisher Scientific) and the gel
14 was pre-run at 200 V for 10-15 minutes. At the same time, the DNA and DNA ladder-
15 loading dye mixtures were incubated at 75 °C for 8-10 minutes and then quickly
16 cooled on ice for at least 1 minute. The wells of the Novex® TBE-Urea gel were
17 flushed with a 1 ml pipette to remove residual urea. The DNA and DNA ladder-
18 loading dye mixtures were quickly loaded into the gel and the gel was run at 200 V
19 for 30 minutes. Once the run finished, the gel was removed from the cassette and
20 stained in 25-50 ml of 0.5X Novex® TBE Running Buffer and 1X SYBR Gold (Thermo
21 Fisher Scientific) for 5 minutes and gentle shaking. The gel was then placed on a
22 clean Saran wrap on a UV transilluminator (UVP). The area of the gel containing the
23 band of approximately 70 bp was cut as close to the band using a clean scalpel (with

1 minimising exposing the gel to UV light). The cut gel was moved to a clean area and
2 chop into small pieces with a scalpel. Two 0.5 ml tubes were pierced at their bottom
3 with a 22G needle and then put into two 1.5 ml DNA LoBind tubes (Eppendorf). The
4 chopped gel was transferred into the two 0.5 ml tubes and then centrifuged at 15,000
5 rpm for 3 minutes at room temperature. The gel remaining in the 0.5 ml tube was
6 transferred to the 1.5 ml tube below with a sterile pipette tip. 400 µl of 1X TAE buffer
7 (see section 2.1.7 - 1X TAE) was then added to the tube, and the mixture was shake
8 vigorously on vortex for at least 45 minutes at 37 °C. Once finished, the clear
9 supernatant was transferred to a Nanosep column (Pall Corporation) and centrifuged
10 at 15,000 rpm for 3 minutes. The lower layer of the flow-through was carefully (i.e.
11 avoiding the large chunk of gel) transferred again to the Nanosep column and then
12 centrifuged for an additional 3 minutes at 15,000 rpm. The supernatant was
13 transferred to a fresh 1.5 ml tube and precipitated with ethanol (see section 2.2 -
14 DNA purification). After ethanol precipitation, the DNA pellet was dissolved with 10-
15 15 µl of distilled water. All probes were pooled and the size of the probes and DNA
16 concentration was estimated using 6% TBE-urea gel. The resulting bisulfite padlock
17 probes were used immediately or stored at -20 °C for later use.
18



1
2
3
4
5
6
7
8

Figure 3.4. Preliminary steps used for the probes synthesized by LCSiences.
 (a) PCR amplification was used to increase bisulfite padlock probes quantity. (b) AP1 and AP2 sites were removed from double stranded amplicons using nicking digestion. The enzymatic digestion resulted in a DNA molecules with 70 bp top strand and 100 bp bottom strand. (c) The unwanted bottom strand (i.e. complementary product) was removed using denaturing urea PAGE.

3.2.5.3 Multiplex capture of bisulfite treated target regions

500 ng of sample gDNA was quantified with Nanodrop (see section 2.3 - DNA quantification) and bisulfite treated (see section 2.4 - Sodium bisulfite treatment). In 25 µl volume reaction, 50 nM of a pool of padlock probes, approximately 500 ng of bisDNA and 1X Ampligase buffer (Epicentre) were mixed and incubated in a thermocycler using the following reaction conditions: 95°C for 10 min, gradual cooling at 70 °C (0.1 °C/sec), 70 °C for 30 min, gradual cooling at 65 °C (0.1 °C/sec), 65 °C for 60 min, gradual cooling at 60 °C (0.1 °C/sec), 60 °C for 120 min, gradual cooling at 55 °C (0.1 °C/sec) and 55 °C for 20 h. The capture reaction was immediately processed with next step.

1 **3.2.5.4 Circularisation of captured sequences**

2 2.5 µl gap-filling mix consisting of 100 µM dNTP, 10 U/µl Titanium Taq (Takara Bio
3 USA), 0.5 U/µl Ampligase and 1X Ampligase buffer (Epicentre) was incubated at 95
4 °C for 1 min, cooled at 55 °C and added to the previous capture reaction. Gap-filling
5 and circularisation reactions were then performed by incubating the reaction at 55
6 °C for 20 h. The gap-filled reaction was then cooled on ice and immediately
7 processed with next step.

8

9 **3.2.5.5 Enzymatic digestion**

10 Linear DNA was digested by adding 4 µl of exonuclease mix (20 U exonuclease I
11 and 200 U exonuclease III, 1X ampligase buffer; New England Biolabs) to the target
12 capture reaction. The reaction was then incubated at 37 °C for 2 h followed by
13 exonuclease inactivation at 95 °C for 2 min and hold at 4 °C indefinitely. Reaction
14 was immediately processed with next step or stored at 4 °C or -20 °C for later use.

15

16 **3.2.5.6 Capture circle amplification**

17 Sequencing library was generated by amplifying the exonuclease treated circle DNA
18 with barcoded primers. In 100 µl volume reaction, all of the circularised DNA was
19 mixed with 400 nM of each forward AmpF_P5 and reverse AmpR_P7_Ind_001
20 primer (for design 1) or forward SLXA_PE_MIPBC_FOR and
21 SLXA_PE_MIPBC_REV_001 primer (for design 2) (Table 3.3), 50 µl of KAPA HiFi
22 2x HotStart ReadyMix Taq (Kapa Biosystems) and PCR-grade water. The mixture
23 was incubated in a thermocycler and PCR amplified using one of condition 1,

1 condition 2 or condition 3 programme (see below). The resulting barcoded
 2 sequencing library was processed immediately after with next steps consisting of
 3 fragment analysis using bioanalyzer (see section 2.7 - Fragment analysis of DNA
 4 libraries), size selection and purification using E-Gel® SizeSelect™ gels (see section
 5 Amplicon size selection), followed by DNA quantification using Qubit® dsDNA HS
 6 (see section 2.3 - DNA quantification). Finally, the libraries were again checked for
 7 correct size using bioanalyzer (see section 2.7 - Fragment analysis of DNA libraries).
 8 The libraries were used immediately after or stored at -20 °C for later use.

9

10 **Table 3.3: List of primers used for sequencing libraries enrichment.**

Primer name	Sequence (5'>3')
<i>FOR FIRST DESIGN</i>	
AmpF_P5	AATGATACGGCGACCACCGAGATCTACACTCGTCGGCAGCGTCAGATGT GTATAAGAGACAG
AmpR_P7_Ind_001	CAAGCAGAAGACGGCATACGAGAT <u>GATCTGGT</u> GACTGGAGTTCCTTGGC ACCCGAGAATTCCA
<i>FOR SECOND DESIGN</i>	
SLXA_PE_MIPBC_FOR	AATGATACGGCGACCACCGAGATCTACACCACTCTCAGATGTTATCGAG GTCCGAC
SLXA_PE_MIPBC_REV_001	CAAGCAGAAGACGGCATACGAGATGTTAAGACGCT <u>AGGAACGAT</u> GAGCC TCCAAC

11

Underlined sequence are index barcode

12

13 PCR programme:

14 Condition 1: 98 °C for 30 sec, 10 cycles of 98 °C for 15 sec; 50 °C for 20 sec; and
 15 72 °C for 20 sec, 20 cycles of 98 °C for 15 sec; 72 °C for 20 sec, and 72 °C for 3
 16 min, and hold at 4 °C.

17 Condition 2: 98 °C for 30 sec, 25 cycles of 98 °C for 15 sec; 58 °C for 20 sec, and
 18 72 °C for 20 sec, and 72 °C for 3 min, and hold at 4 °C.

1 Condition 3: 98 °C for 30 sec, 25 cycles of 98 °C for 15 sec; 50 °C for 20 sec; and
2 72 °C for 20 sec, 72 °C for 3 min, and hold at 4 °C.

3

4 **3.2.5.7 Sequencing**

5 The sequencing of the libraries was performed by the Stratified Medicine Core
6 Laboratory (SMCL) Next Generation Sequencing facility. A MiSeq sequencer was
7 used for the sequencing. The sequencing primer used are listed in Table 3.4.

8

9 **Table 3.4: List of primers used for sequencing using MiSeq sequencer.**

Primer name	Sequence (5'>3')
<i>FOR FIRST DESIGN</i>	
MIPBS_SEQ_NEXT (from Illumina Nextera)	TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG
MIPBS_SEQ_TRUSEQ (from Illumina TruSeq Small RNA)	GTGACTGGAGTTCCTTGGCACCCGAGAATTCCA
MIPBS_SEQ_INDX (from TruSeq Small RNA)	TGGAATTCTCGGGTGCCAAGGA ACTCCAGTCAC
<i>FOR SECOND DESIGN</i>	
MIPBC_SEQ_FOR	TACACCACTCTCAGATGTTATCGAGGTCCGAC
MIPBC_SEQ_REV	GCTAGGAACGATGAGCCTCCAAC
MIPBC_SEQ_INDX	GTTGGAGGCTCATCGTTCCTAGC

10

11

12 **3.3 Results**

13 **3.3.1 First experimental design**

14 **3.3.1.1 Design requirements**

15 I designed BSPP with the following specific requirements: the capture insert size
16 would be of 120-125 nucleotides; the maximum length of the two ligation arms would

1 be of 25 nucleotides; the maximum combined length of the two ligation arms would
2 be of 40 nucleotides. The amplification primer site 1 (AP1) required for padlock
3 probes amplification contains the nicking endonuclease Nt.AlwI sequence. Similarly,
4 the amplification primer site 2 (AP2) contains the nicking endonuclease Nb.BrsDI
5 sequence. The nucleotide composition of the common linker was dictated by the
6 sequencing primer sequences. However, the choice of the sequencing primers to
7 include in the common linker was complicated by several factors. The sequencing
8 libraries were predicted to be sequenced using a MiSeq sequencer. One of the
9 particularities of this sequencer is that it runs hotter (65 °C) than other Illumina
10 sequencers, such as the HiSeq sequencer (55 °C), during the deblocking and
11 extension stages. Consequently, custom sequencing primers have to have a melting
12 temperature above 65 °C to prevent them from dissociating from the target.
13 Additionally, the custom sequencing primers need to meet Illumina
14 recommendations which are 33 bp long, 51.5% GC, with a T_m of 65.5 °C for
15 sequencing primer for read 1 and 37 bp long, 59.5% GC with a T_m of 70.1 °C for
16 sequencing primer for read 2. However, despite fulfilling these requirements, it is not
17 guaranteed the custom sequencing primers will work properly. Finally, Illumina
18 doesn't provide technical support when custom sequencing primers are used.
19 Consequently, I decided to incorporate a mixture of Illumina proprietary sequencing
20 primers, Illumina Nextera sequencing primer for read 1 and Illumina TruSeq Small
21 RNA sequencing primer for read 2, into the common linker. They are both natively
22 recognised by the MiSeq sequencer and they have a limited impact on introducing
23 additional Nt.AlwI and Nb.BrsDI restriction sites.

1 **3.3.1.2 Padlock probes to synthesise**

2 Following the design criteria, 516 overlapping padlock probes were generated *in*
3 *silico* using ppDesigner to capture 61.6 kb of DNA sequence, including the targeted
4 regions. Analysis of the probes sequence revealed CpG sites inclusion within the
5 ligation arms of 412 (80.5%) padlock probes. Therefore, to avoid binding bias
6 towards the methylated allele, a second copy of each of the 412 probes was
7 computed to be specific to the unmethylated allele, which resulted in the design of a
8 total of 928 padlock probes. The pool of 928 oligonucleotides were checked to be
9 free from additional Nt.AlwI and Nb.BrsDI recognition site sequences to avoid un-
10 wanted digestion. Out of 928, the procedure identified 19 (~ 2%) probes with
11 additional Nt.AlwI and Nb.BrsDI recognition site sequences, which consequently
12 were removed from the pool of padlock probes. This resulted in 909 padlock probes
13 to be synthesised (Table 3.5).

14

15 **Table 3.5: Number of padlock probes to synthesise.**

Methylated padlocks	Methylated + unmethylated padlocks	Padlocks containing extra restriction sites for Nt.AlwI and Nb.BrsDI	Final total amount of padlocks
516	928	19	909


16

17

18 **3.3.1.3 Library preparation**

19 Quality control of the sequencing libraries before size selection by Bioanalyzer
20 identified mainly two amplicons of different sizes. The amplicons with a length of
21 approximatively 286 bp were predicted to be the expected sequencing libraries. The

1 amplicons with a length of approximately 237 bp were predicted to be a truncated
 2 form of the sequencing libraries resulting from inefficient amplification (i.e. only one
 3 primer anneals to the DNA template) (Figure 3.5).
 4
 5 The libraries were then size selected (retained product at approximately 280-290
 6 bp) and cleaned-up. qPCR analysis indicated that the resulting libraries were of the
 7 correct size and were at an appropriate concentration for the sequencing reaction
 8 (data not show).



9
 10 **Figure 3.5. BSPP sequencing library preparation (first design).**
 11 *Bioanalyzer analysis identified two kinds of amplicons in the sequencing libraries.*
 12 *One is predicted to be the full-length library construct whilst the other is predicted to*
 13 *be a truncated form of the expected constructs.*
 14

1 **3.3.1.4 Sequencing**

2 The resulting sequencing libraries were sequenced on Illumina MiSeq sequencer.
3 However, no sequencing reads were generated during the sequencing run. The
4 quality control performed during the sequencing run, which mainly checks the cluster
5 generation output, did not indicate any failures with the instrument. After investigation
6 with the core sequencing facility, I formulated several hypothesis that may explain
7 the unsuccessful sequencing. Firstly, balance A/C/G/T bases composition is required
8 for the optimal differentiation of the different clonally amplified DNA molecules
9 spatially separated in the flow-cell. My libraries were generated from bisulfite
10 converted DNA, which meant that the A/C/G/T bases proportion was un-balanced
11 and consequently could have been an issue for the sequencer. However, to avoid
12 this problem, PhiX sequencing control was spiked into my libraries in sufficient
13 quantity, hence resulting in a pool of libraries with a balanced A/C/G/T composition.
14 Secondly, my custom paired-end, single-indexed libraries were pooled with paired-
15 end, dual-indexed libraries, which were provided by other customers. It was
16 conceivable that the mixture of libraries prepared by different methods could interfere
17 with each other (e.g. cross-hybridization) and consequently lead to failure in
18 sequencing. However, I was not able to verify this assumption. Another possible
19 issue associated with the mix of sequencing libraries could originate from the
20 different index 1 (i7) size length used in the different libraries. To achieve sample
21 multiplexing I used a custom six nucleotides barcode for index 1 (i7) (barcode for
22 index 2 (i5) has 8 nucleotides) whilst in the other libraries an eight nucleotides index
23 1 (i7) barcode was used. This could have impacted the whole sequencing process

1 via interference with the index sequencing read stage. It is possible that during the
2 sequencing of index 1 (i7) the sequencer completed the first six sequencing cycles
3 without problems but encountered an un-identified issue during the remaining two
4 cycles. As a result, the sequencer could have interpreted the issue as a major
5 malfunction and consequently discarded the already acquired sequencing data. I
6 was not able to confirm this hypothesis. Alternatively, it is also possible that an issue
7 arose from the demultiplexing procedure that takes place once the whole sequencing
8 run is finished. The software used for the demultiplexing could have struggled to
9 identify my six nucleotides-indexed samples. If it was the case, the acquired
10 sequencing data consisting of sequencing artefacts or sequences that were not
11 assign to a sample, mine included, would have been saved but placed into a
12 'garbage' file. However, no sequences in relation to my target regions were present
13 in that file. Finally, another source of failure may come from the failure of the
14 sequencing primers to anneal to the DNA molecules.

15

16 **3.3.2 Second experimental design**

17 **3.3.2.1 Design requirements**

18 The original BSPP design was modified to take into account and minimise the
19 previously discussed possible sources of errors.

- 20 i. Only seven oligonucleotides were designed to reduce the cost of the
21 experiment. The chosen target regions were *PPIEL*:Ex1-DMR,
22 *ZDBF2/GPR1*:IG-DMR, *FAM50B*:TSS-DMR, *H19/IGF2*:IG-DMR,

1 *KCNQ1OT1*:TSS-DMR, *L3MBTL1*:alt-TSS-DMR, *SNU13*:alt-TSS-DMR
2 imprinting centres.

3 ii. The padlock probes were ordered from Integrated DNA Technologies
4 company, which allowed more freedom in the design. This included the
5 synthesis of a higher oligonucleotides concentration, which meant avoiding
6 the initial round of padlock probes amplification (no need for AP1 and AP2
7 primer sites), digestion and purification; the design of a longer padlock probes
8 (101-111 bp; 70 bp previously) which meant incorporating longer ligation arms
9 (up to 70 bp combined; up to 40 bp previously) for more specificity during the
10 target capture step, and longer common linker for more primers padding
11 sequence during the capture circle amplification step.

12 iii. The size of the target inserts was changed to be between 120 to 185 bp (120
13 to 125 bp previously) which gave more flexibility to ppDesigner software to
14 find regions that fit the design requirements.

15 iv. Custom sequencing primers (Diep et al. 2012) were used in place of the
16 proprietary ones from Illumina. Although this approach is not supported by the
17 company, the custom oligonucleotides were previously reported to perform
18 well with both the library preparation protocol and the sequencing with MiSeq
19 (Diep et al. 2012).

20 v. Different PCR amplification conditions were tested during the capture circle
21 amplification step (see section 3.2.5.6 - Capture circle amplification for
22 condition 1, 2 and 3 details). This may prevent the formation of non-specific,
23 and truncated, products and increase the yield of enrichment. Therefore, this

1 may result in libraries with better quality, hence increasing the chance of
2 optimal sequencing.

3

4 **3.3.2.2 Library preparation**


5 Condition 1, 2 and 3 were used to generate and enrich for the libraries. According to
6 Bioanalyzer analysis performed before size selection and clean-up step, the
7 condition 1 used to amplify the captured targets failed to generate amplicons, which
8 suggested that the PCR condition was inadequate. Condition 2 and condition 3 had
9 similar outcome. Both generated amplicons but the majority of them were likely to
10 be non-specific product. Additionally, Bioanalyzer analysis also indicated that library
11 concentration was within the pg/ μ l range, hence indicated poor yield during
12 amplification (Figure 3.6). This could be explained by non-optimal PCR conditions
13 during the capture circle amplification stage. Alternatively, this could also be
14 explained by the fact that only seven regions were targeted and captured, as oppose
15 of the hundreds in the previous design.

16

17 The libraries were then size selected and cleaned-up. Bioanalyzer analysis failed to
18 detect any product within the samples (data not shown). This suggested that size
19 selection and clean-up procedures led to the complete or partial loss of samples.
20 DNA quantification with Qubit High Sensitivity kit detected very low amount of DNA,
21 hence confirming the size selection and clean-up procedures were, in part,
22 responsible for the loss of samples (data not shown). However, whilst the
23 concentration was too low for the Bioanalyzer detection threshold, it was still

1 concentrated enough for MiSeq sequencing (only 2-10 pM is needed for
 2 sequencing).

3



4

5 **Figure 3.6. BSPP sequencing library preparation (second design).**

6 Sequencing library preparation with second BSPP design and reviewed method. (a)

7 The captured circle amplified with PCR condition 1 did not generate amplicons whilst

8 (b) using PCR condition 2 and (c) condition 3 resulted in a pool of specific and non-

9 specific products

10

11

12

1 **3.3.2.3 Sequencing**

2 The two libraries that were generated using condition 2 and condition 3 were
3 sequenced using MiSeq sequencer. Unfortunately, the sequencing of the samples
4 did not produce a successful outcome. Among the few reads that were acquired
5 during the sequencing run, only a very few (<1%) aligned to my target regions whilst
6 the vast majority (>99%) were either artefacts or garbage sequences that aligned to
7 the common linker of the padlock probes. This was unexpected as the original single
8 stranded free form of the oligonucleotides is expected to be digested during the
9 exonuclease I and III enzymatic treatment. Furthermore, the design of the
10 experiment was done in such way that even in the presence of carried over free form
11 padlock probes, they should not be PCR amplified during the capture circle
12 amplification step. The long primers used for library enrichment during the capture
13 circle amplification step were designed to amplify specifically circle DNA that
14 contains both the common linker of the padlock probes and the target regions but
15 not single stranded linear padlock probes only. Finally, in the absence of
16 amplification, the free form padlock probes should not contain any P5 and P7
17 adaptor sequences, which are both required to bind to the flow-cell. Alternatively, the
18 failed sequencing may have also originated from failure of the custom sequencing
19 primers to bind to the libraries during read 1 or read 2 sequencing stages. However,
20 according to previous reports that made use of them with success (Deng et al. 2009;
21 Diep et al. 2012) it is unlikely that they were responsible for the failed sequencing.

22

23 Taken together, the lack of reads aligning to target regions but instead aligning to

1 padlock probe common linker sequence suggested that the designed method failed
2 to capture and enrich the targets prior to sequencing. Instead, it seems that non-
3 specific products are generated through non-specific PCR amplification of the
4 padlock probes.

5

6 **3.4 Discussion**

7 Padlock probes based assay have been used successfully in the past to complete
8 large projects that include exome sequencing, RNA allelotyping, copy number
9 variation analysis, and SNP identification (Porreca et al. 2007; J.B. Li, Gao, et al.
10 2009; J.B. Li, Levanon, et al. 2009; K. Zhang et al. 2009; H Wang et al. 2010; Gore
11 et al. 2011; Noggle et al. 2011; O'Roak et al. 2012; Carvill et al. 2013; Hiatt et al.
12 2013; Nuttle et al. 2013; Yoon et al. 2015). The method has since been adapted for
13 DNA methylation analysis and BSPPs were found to be highly specific and
14 consistent in the characterisation of DNA methylation of a large number of CpG.
15 Additionally, the method requires a low amount of DNA and can easily be scaled to
16 adapt to the size of the genomic regions of interest and to the sample size of the
17 project (Deng et al. 2009; Diep et al. 2012). Based on these reports, I decided to use
18 BSPPs in the novel high-throughput genomic imprinting methylation assay I aimed
19 to develop.

20

21 Two types of padlock probes design (i.e. first and second design) were tested and in
22 both cases several sequencing libraries were generated using different experimental

1 conditions. Quality control steps using bioanalyzer was performed before and after
2 final size selection and the best candidate libraries (i.e. bioanalyzer profile closer to
3 the theoretical end product, higher yield) for both padlock probes design was sent
4 for sequencing. On overall, the method encountered several issues which led to
5 unsuccessful target capture, enrichment of the targets, sequencing and methylation
6 profiling. The absence of additional quality control steps throughout the method,
7 such as after the target capture (Figure 3.3-a) and after the enzymatic digestion of
8 circulised target sequences (Figure 3.3-c), has made troubleshooting difficult.
9 However, based on several pieces of evidence I hypothesised that the failure of the
10 assay could have originated from different factors:

11

12 (i) In the first design, the size of the BSPPs may have been too short. This was a
13 supplier constraint for which at the time of the project was not able to synthesise a
14 pool of hundreds of oligonucleotides of more than 100 bp. The short size of BSPPs
15 implied having two short locus-specific target recognition and hybridisation arms,
16 hence resulting in a loss of specificity to recognise the bisulfite treated targeted
17 regions. Additionally, the short BSPPs also meant that the common linker was also
18 short (30 bp) and consequently it left little room to design annealing sequences for
19 the two long (60 bp) primers used during the multiplex PCR amplification of capture
20 circle DNA step (15 bp annealing sequence for each primer). The BSPPs size issue
21 was addressed with the second experimental design in which longer
22 oligonucleotides (i.e 100 bp versus 70 bp) were synthesised. However, I was not
23 able to assess how that benefited to the second design as it also failed.

1

2 (ii) The sequencing primers may have been an issue during the sequencing library
3 preparation and/or during sequencing. In the first design I opted for the use of a
4 mixture of Illumina proprietary sequencing primers, hence avoiding possible
5 incompatibility with the MiSeq sequencer. However, the downside of these primers
6 was that their last 15 bp (i.e. the ones that anneal to the common linker) have a
7 melting temperature difference of 5 °C, which meant possible loss of PCR efficiency
8 during the capture circle amplification step and therefore a low efficiency to generate
9 final sequencing libraries. This may have explained the presence of a non-specific
10 amplicon in the pool of sequencing libraries. Alternatively, the mixture of Illumina
11 sequencing primers may have interfered with the sequencing itself as in both
12 sequencing primers are not meant to work in combination on the same sequencing
13 library. To address this possible problem, I opted for the use of the published custom
14 sequencing primers that were originally designed with BSPPs method and were
15 compatible, to some extent, with the MiSeq sequencer (Diep et al. 2012). However,
16 I was not able to assess how that benefited to the second design as it also failed.

17

18 (iii) Finally, although originally not an issue, the 6 nucleotides index used in the first
19 experimental design may have interfered with sequencing once my libraries were
20 pooled with 8 nucleotides indexed sequencing libraries. The differences of index
21 length may have led to sequencer malfunction or issue during demultiplexing. To
22 avoid further complication, I included 8 nucleotides index in the second experimental
23 design. However, I was not able to assess how that benefited to the second design

1 as it also failed.

2

3 In conclusion, various factors that were hypothesised to be a possible source of
4 problems in the first place were taken into account during a second experimental
5 design. However, despite the taken measures, this resulted in an unsuccessful
6 attempt. Whilst the exact causes of failures are still unknown, it is likely that a
7 combination of mentioned and unknown parameters may have influenced the assay
8 and led to the failure in the target capture, enrichment of the targets and sequencing.

Chapter 4

Methylation Profiling in Beckwith-Wiedemann Syndrome and Silver-Russell Syndrome

1 **4.1 Introduction**

2 **4.1.1 DNA methylation profiling using the Infinium** 3 **HumanMethylation 450K BeadChips**

4 The Infinium HumanMethylation 450K BeadChips (HM450K) is an array-based
5 method developed for the genome-wide profiling of DNA methylation. Whilst the
6 platform is limited to the characterisation of a very small proportion of the human
7 CpG content (~ 2%), it remains a popular choice in the analysis of large sample
8 cohorts for which it represents an affordable approach to generate DNA methylome
9 data (Rakyan et al. 2011; Y. Liu et al. 2013; Michels et al. 2013). Furthermore, the
10 method requires a low amount of DNA input (500 ng) which make it suitable for
11 studies in which DNA is a limiting factor.

12

13 The HM450K platform contains more than 485,000 probes distributed throughout the
14 genome. Of the pool of probes, 482,421 interrogate CpG sites (~ 2% of human CpG
15 content), 3091 non-CpG sites and 65 interrogate random single-nucleotide
16 polymorphism sites. They were selected from WGBS data and input from DNA
17 methylation experts and they cover 99% of RefSeq genes with an average of 17
18 probes per gene, 96% of CpG islands from the UCSC database, CpG island shores,
19 DNase I hypersensitive sites and regulatory elements such as enhancers (Bibikova
20 et al. 2011).

21


22 HM450K is constituted of two types of beads, Infinium I and Infinium II. Infinium I

1 beads were designed for the Infinium HumanMethylation27 BeadChip, which is the
2 precursor of HM450K. The design of Infinium I beads consists of two probes per
3 locus, one for the methylated allele and one for the unmethylated allele, and the base
4 extension is the same for the methylated or unmethylated alleles (i.e. the fluorescent
5 signal does not carry any information on the methylation status). Infinium II beads
6 are specific for HM450K. The design of Infinium II beads consists of a single type of
7 probe per locus, and the methylation information is obtained through dual channel
8 single-nucleotide primer extension with labelled dideoxynucleotides on the
9 methylation variable position of a CpG (Figure 4.1) (Bibikova et al. 2011;
10 Dedeurwaerder et al. 2014; Morris and Beck 2015).

11

12 Infinium I and Infinium II also differ in the reported derived methylation values, which
13 for both is reported as beta-value ($\beta = \text{intensity of the Methylated allele (M)} / (\text{intensity}$
14 $\text{of the Unmethylated allele (U)} + \text{intensity of the Methylated allele (M)} + 100)$ and
15 where $\beta = 0$ is equivalent to unmethylated and $\beta = 1$ is equivalent to 100%
16 methylated. Infinium II probes were found to exhibit a much lower dynamic range of
17 methylation values compared to Infinium I probes (0 to 0.922 for Infinium II *versus* 0
18 to 0.971 for Infinium I) (Dedeurwaerder et al. 2011). Infinium II probes were also
19 found to be less sensitive for the detection of extreme methylation values (i.e. 0 and
20 1) and less reproducible than Infinium I (standard deviation = 0.029 for Infinium II
21 *versus* 0.008 for Infinium I) (Dedeurwaerder et al. 2011). Therefore, it is important to
22 normalise the data to correct for the Infinium I and Infinium II probe differences.
23 Several methods have been developed to address these issues (Cazaly et al. 2016).

1 These include Subset-quantile Within Array Normalisation (SWAN) (Maksimovic et
 2 al. 2012), Dasen (Pidsley et al. 2013), Beta-Mixture Quantile dilation (BMIQ)
 3 (Teschendorff et al. 2013) and Functional normalisation (FunNorm) (Fortin et al.
 4 2014).
 5



6
 7 **Figure 4.1: Overview of the Infinium I and Infinium II bead types.**
 8 (a) Infinium I and (b) Infinium II present on the HM450K. M, Methylated; U,
 9 Unmethylated. (From Dedeurwaerder et al.:2011).

10
 11

1 **4.1.2 Aim**

2 Following the unsuccessful design of a novel NGS strategy for the methylation
3 profiling of imprinting regions in BWS and SRS, I undertook the characterisation of
4 the nature and frequency of MLID in a large cohort of BWS and SRS individuals
5 using the robust HM450K platform. To that end, I developed a bioinformatic pipeline
6 that can preprocess and handle large cohort methylation dataset and detect with
7 accuracy epimutations at targeted regions, including imprinting DMRs (Table 3.1), in
8 BWS and SRS individuals. Finally, I screened the patients methylomes to identify
9 genomic regions that appeared to have an aberrant methylation profile and could
10 possibly be involved in the molecular aetiology of the diseases.

11

12

13 **4.2 Materials and methods**

14 **4.2.1 Patient blood DNA**

15 According to the criteria described in the literature (<http://www.geneclinics.org>), BWS
16 was diagnosed in 90 screened patients and SRS was diagnosed in 21 screened
17 patients. For BWS, the molecular diagnostic investigations undertaken in NHS
18 laboratories identified GOM at *H19/IGF2*:IG-DMR (BWS_IC1) in 4 individuals,
19 paternal UPD11 (BWS_UPD11) in 8 individuals and LOM at *KCNQ1OT1*:TSS-DMR
20 (BWS_IC2) in 78 individuals. For SRS, the molecular diagnostic identified LOM at
21 *H19/IGF2*:IG-DMR (SRS_IC1) in 15 individuals and maternal UPD7 (SRS_UPD7) in
22 6 individuals. Written informed consent was obtained and ethical approval was

1 obtained from South Birmingham Research Ethics committee. For the 1472 healthy
2 individuals that were included in my control group, 30 originated in-house whilst the
3 remaining 1442 originated from collaborators.

4

5 **4.2.2 DNA quantification**

6 See section 2.3 - DNA quantification.

7

8 **4.2.3 Sodium bisulfite treatment**

9 See section 2.4 - Sodium bisulfite treatment.

10

11 **4.2.4 DNA methylation profiling using HM450K**


12 In order to obtain the genome wide methylation profiles, genomic DNA from patients
13 with BWS (n=90) or SRS (n=21) and normal control individuals (n=1472; 30
14 individuals in-house and 1442 individuals from collaborators) was bisulfite treated
15 (see section 2.4 - Sodium bisulfite treatment), processed on the HM450K (see
16 section 2.5 - Infinium HumanMethylation450 BeadChip) and analysed as described
17 below (Figure 4.2).

18

19 The sample preparation (i.e. DNA quantification and dilution prior HM450K) of the
20 111 BWS and SRS patients and of 30 out of 1472 normal individuals was done by
21 me. The methylation profiling of these individuals was then done at the Cambridge
22 Genomic Services. The sample preparation of the remaining 1442 normal individuals

1 was done by collaborators and, of those, the methylation profiling of 1402 was also
2 done at the Cambridge Genomic Services. The methylation profiling of the remaining
3 40 normal individuals was done at a different platform in Spain.

4
5



6

7 **Figure 4.2: Overview of the genome-wide methylation profiling workflow.**

8

9

10 **4.2.4.1 Bioinformatic pipeline to analyse HM450K methylation dataset**

11 **4.2.4.1.1 HM450K data preprocessing**

12 Data filtering and normalisation were performed in R with RnBeads (Assenov et al.

13 2014). Samples with detection P-value > 0.01 were filtered out. Infinium probes

1 containing SNPs and sites with excessive missing values were filtered out. In
2 addition, probes with detection P-value > 0.01 and probes that lack signal values in
3 one or more of the DNA samples analysed were also filtered out. Probe intensities
4 were then normalised with beta-mixture quantile (BMIQ) normalisation (Teschendorff
5 et al. 2013). Finally, probes located on sex chromosomes and in a non-CpG context
6 were removed to discard any bias within samples. β values (i.e. equivalent to the
7 absolute DNA methylation levels) and M-value (i.e. logistically transformed β values)
8 were then generated for each probes. The R script used to process the data is
9 available in Appendix 1.

10

11 **4.2.4.1.2 HM450K data batch correction**


12 Methylation data were corrected for technical (e.g. array slides and array positions)
13 and biological (e.g. age) effects. I used ComBat method (Johnson et al. 2007)
14 included in the sva (Leek et al. 2012) R package to perform the correction. The R
15 script used to process the data is available in Appendix 2.

16

17 **4.2.4.1.3 Epimutation methodology**

18 To define LOM and GOM, I extracted the methylation value (β -value) of each
19 HM450K CpG probes within target regions for all patients and normal individuals. I
20 then computed the mean methylation index (MI) at each target regions for all
21 individuals (i.e. patients and controls) and calculated MI standard errors (SE) for all
22 patients. I also calculated the grand mean MI and associated standard deviation

1 (SD) for normal individuals. At each target region, samples were considered
 2 demonstrating GOM (above) or LOM (below) if both conditions were filled:
 3 i. their MI and SE were above or below 3 SDs calculated from the grand mean of
 4 the normal individuals group. 99.73% of values lie within 3 SDs of the mean.
 5 Consequently, using such stringent threshold should significantly limit the
 6 discovery of false positives.
 7 ii. at least 60% of the patient interrogated probes were above or below the 3 SDs
 8 threshold (Figure 4.3).



10

11 **Figure 4.3: Illustration of epimutation methodology.**

12

13 Additionally, polymorphic methylation change at each target regions were assessed
 14 by Fisher's exact test followed by false discovery rate (FDR) correction. Statistical
 15 tests were performed in R. Aberrant methylation, either GOM or LOM, with FDR \geq

1 0.05 were considered polymorphic (Table 4.6).

2

3 **Table 4.6: An example of statistical test at the imprinted locus *PLAGL1_alt-***
4 ***TSS-DMR*.**

<i>PLAGL1_alt-TSS-DMR</i>						
	<i>LOM</i>	<i>Other</i>		<i>GOM</i>	<i>Other</i>	
<i>Cases</i>	5	106		<i>Cases</i>	1	110
<i>Controls</i>	7	1432		<i>Controls</i>	3	1436
<i>FDR</i>	0.003			<i>FDR</i>	0.789	
<i>LOM is not polymorphic</i>			<i>GOM is polymorphic</i>			
<i>LOM, loss-of-methylation; GOM, gain-of-methylation; Other, either GOM + no methylation change or LOM + no methylation change</i>						

5

6

7 Establishing methylation profiles for all BWS and SRS patients across the targeted
8 regions (e.g. imprinted DMRs) was performed in R. Providing the manual input of
9 the required variables, the R script will automatically load methylation data, subset
10 and save methylation data associated with CpG probes overlapping the region of
11 interest, compute GOM and LOM in patient and in control individuals and save a
12 corrected (i.e. all reported loci that are not polymorphic) and uncorrected (i.e. some
13 reported loci may be polymorphic) epimutation table for all patients. The R script
14 used to process the data is available in Appendix 3.

15

16 **4.2.4.1.4 DMR hunting**

17 Bumhunter (Jaffe et al. 2012; Aryee et al. 2014) function was used to identify
18 genomic regions that were differentially methylated between two conditions (e.g.

1 BWS_IC1 patients *versus* control individuals). The function was run in R and the
2 script used to process the data is available in Appendix 4. It first computed a t-statistic
3 with smoothing at each genomic location. Then, it defined a candidate region to be
4 a cluster of probes for which all the t-statistics exceeded a predefined threshold
5 ($\Delta \beta \geq 0.15$ between the two groups) and significance of the candidate regions
6 was calculated using permutations test ($n=1000$). Candidate regions with $FDR >$
7 0.05 , FWER (family-wise error rate) > 0.3 and encompassing less than three probes
8 were filtered out.

9


10 **4.3 Results**

11 **4.3.1 Data pre-processing**

12 **4.3.1.1 Normalisation**

13 In normal conditions, the majority of CpG sites can be either methylated or
14 unmethylated. On the HM450K, this assumption can be defined with a density
15 methylation peak at $\beta \sim 0$ (i.e. 0% methylated) and $\beta \sim 1$ (i.e. 100% methylated). In the
16 uncorrected HM450K dataset (i.e. 21 BWS, 91 SRS and 1471 normal control
17 individuals), I observed a peak of methylation distribution at $\beta \sim 0.2$ (i.e. 20%
18 methylated) and another peak at $\beta \sim 0.7$ (i.e. 70% methylated) (Figure 4.4, red line).
19 This could be explained by the chemistry differences between the two types of
20 probes within HM450K array (i.e. Infinium I and Infinium II). Indeed, Infinium II probes
21 are known to be less accurate than Infinium I probes and therefore, data needed to
22 be corrected prior to analysis (Dedeurwaerder et al. 2011). Hence, methylation

1 values were normalised with Beta Mixture Quantile (BMIQ) normalisation algorithm
2 (Teschendorff et al. 2013) included in RnBeads R package (Assenov et al. 2014).
3 After correction, peaks of density methylation shifted from $\beta \sim 0.2$ to $\beta \sim 0.05$ and from
4 $\beta \sim 0.7$ to $\beta \sim 0.9$ (Figure 4.4, blue line), illustrating the effectiveness of the data
5 normalisation.



6

7 **Figure 4.4: Effect of the correction on methylation value.**

8 *Infinium I and Infinium II β value (i.e. methylation value) were corrected with BMIQ*
9 *normalisation algorithm included in RnBeads.*


10

11

12 **4.3.1.2 Filtering**

13 After normalisation, problematic samples and probes were filtered out. Out of the
14 1583 samples, 33 control individuals were removed due to bad sample P-value
15 (higher than 0.01). Out of the 485577 probes present on the HM450K array, 413997

1 were retained for analysis. The remaining 71580 probes were removed because
2 12416 probes overlapped with SNPs in their last 5 bases of their targets, 29675
3 probes contained non-specific sequences and had a high likelihood of cross-
4 hybridisation, 19071 probes had low quality (P-value > 0.01), 1074 probes were not
5 in CpG contexts and 9344 probes were on sex chromosomes Figure 4.5).



6

7 **Figure 4.5: Proportion of retained and removed probes.**

8 *Probes overlapping SNPs, non-specific, with P-value above 0.01, on sex*
9 *chromosomes or in a non-CpG context were removed from analysis.*

10

11

12 **4.3.1.3 Batch effect and biological artefacts correction**

13 Batch effects (Leek et al. 2010) are systematic biases in the data that are unrelated
14 to the research question but that arise from undesirable differences in sample
15 handling (i.e. chip or instrument used, date of experiment, technician running
16 samples, etc.). The control individuals methylation dataset has been processed on

1 the same platform (Cambridge Genomic Services) but on different date, different
2 HM450K array slides, and by different technicians, resulting in potential batch
3 effects. Although not all technical variabilities were known, the array slides and array
4 positions were accounted for batch effects correction.

5 Biological artefacts are unwanted variations (i.e. gender, sex, tissue, etc.) that could
6 also lead to biases in the data. As an example, loss of DNA methylation is observed
7 in ageing (Wilson et al. 1987; Fraga et al. 2007). BWS and SRS are both paediatric
8 disorders. Hence, it was important to use an age-match control individual population
9 for comparison. Age of patient and control individuals were first estimated ((Horvath
10 2013), <https://labs.genetics.ucla.edu/horvath/dnamage/>). An age difference was
11 observed between the disease patients group (mean: 6.9 years old) and normal
12 individual controls group (mean: 56 years old) (Table 4.7). Age of all individuals were
13 then categorised into 9 groups (A, 0 to <10 years old; B, 10 to <20 years old; C, 20
14 to <30 years old; D, 30 to <40 years old; E, 40 to <50 years old; F, 50 to <60 years
15 old; G, 60 to <70 years old; H, 70 to <80 years old; I, 80 to <90 years old) and the
16 age variable was accounted for biological artefacts correction.

17


18 **Table 4.7: Age distribution in disease and normal individual groups.**

	Mean age (in years)	Standard deviation
Disease patient group (n=111)	6.9	9.6
Normal individual group (n=1439)	56	13.2

19

1 To remove both technical (i.e. array slides and array positions) and biological (i.e.
2 age) effects, I used the ComBat method (Johnson et al. 2007) included in the sva R
3 package (Leek et al. 2012). Principal component analysis before applying ComBat
4 showed variable data (multiple clusters) most likely related to technical and biological
5 effects as further confirmed by principal component regression analysis (Figure 4.6-
6 a and b). After applying ComBat on the normalised methylation data, the variability
7 observed among the 1550 individuals is now mostly associated with the disease
8 status of individuals (i.e. Sample_Group) and most of the bias associated with both
9 technical batch effects (i.e. Sentrix_Position and Sentrix_ID) was efficiently removed
10 from data. Bias associated with age was also removed but in a lesser extent (Figure
11 4.6-c and d). The age of individuals was confounded with their disease status (i.e.
12 young BWS and SRS patients, and old normal control individuals), thus resulting in
13 ComBat being less efficient to address this issue.

14



1

2 **Figure 4.6: Effects of technical and biological artefacts.**

3 On normalised data, the 10000 most variable probes were analysed by principal
 4 component analysis and by principal component regression analysis (a-b) before
 5 and (c-d) after ComBat correction. Principal component regression analysis was
 6 performed in R using ENmix (Xu et al. 2016).

7


8

9 **4.3.2 Targeted methylation profiling**

10 I first investigated and compared the methylation index (MI) at 46 targeted imprinted
 11 DMRs in BWS and SRS patients with the MI in a group of normal individuals. I
 12 defined a MI in patients above or below 3 standard deviations calculated from the
 13 grand mean of the normal individuals as hyper- or hypomethylated respectively.

1 4.3.2.1 Methodology validation

2 My method based on three standard deviations epimutation threshold was validated
3 by investigating MI at *H19/IGF2*:IG-DMR and *KCNQ1OT1*:TSS-DMR in five group of
4 patients (i.e. BWS_IC1, BWS_IC2, BWS_UPD11, SRS_IC1 and SRS_UPD7). In our
5 cohort, MI at both loci have been previously tested in a clinical setting for diagnostic
6 purposes and epimutations, if any, were already known. Using HM450K array and
7 my methodology, the *H19/IGF2*:IG-DMR locus was hypermethylated in all (n=4)
8 BWS_IC1 patients and in 7 out of 8 patients with BWS_UPD11, hypomethylated in
9 all (n=15) SRS_IC1 patients, and a MI within the normal range was observed in all
10 BWS_IC2 (n=78) and SRS_UPD7 (n=6) patients and in 1 out of 8 patient with
11 BWS_UPD11 (Figure 4.7-a). The *KCNQ1OT1*:TSS-DMR locus was hypomethylated
12 in all BWS_IC2 and BWS_UPD11 patients, and normal methylation was observed in
13 all BWS_IC1, SRS_IC1 and SRS_UPD7 patients (Figure 4.7-b). Although this
14 methodology was very stringent and conservative, the results were mostly consistent
15 with the results from clinical molecular testing using methylation-specific multiplex
16 ligation-dependent probe amplification. I found complete correlation between the
17 results from clinical testing and HM450K analysis of the methylation patterns at
18 *H19/IGF2*:IG-DMR and *KCNQ1OT1*:TSS-DMR in 110 of 111 patients. The exception
19 was one individual with BWS diagnosed with pUPD11 in whom the expected
20 methylation profile was LOM at *KCNQ1OT1*:TSS-DMR and GOM at *H19/IGF2*:IG-
21 DMR.



1

2 **Figure 4.7: Methodology validation.**

3 Methylation index (β -value) of all patients was measured at (a) H19/IGF2:IG-DMR
 4 and (b) KCNQ1OT1:TSS-DMR. The black box represents normal individuals range:
 5 top of the box is 3 standard deviations above control individuals grand mean, the
 6 bottom of the box is 3 standard deviations below control individuals grand mean and
 7 the middle line is grand mean of control individuals. BWS_IC1, BWS patient with IC1
 8 GOM; BWS_IC2, BWS patients with IC2 LOM; BWS_UPD11, BWS patients with
 9 pUPD11; SRS_IC1, SRS patients with IC1 LOM; SRS_UPD7, SRS patients with
 10 mUPD7.

11

12

13 **4.3.2.2 Polymorphic imprinted DMRs**

14 Following method validation, methylation profiling was performed at 46 imprinted
 15 DMRs (Table 3.1) across all individuals. Whilst multiple epimutations were observed
 16 in our disease patient group it was necessary to discriminate between methylation

1 abnormalities that were (i) probably linked to the disorder (i.e. outcome of interest),
2 (ii) random epigenetic events or (iii) common within general population (Tee et al.
3 2013). Although discriminating between the random occurrence of epigenetic events
4 and linkage to the disorder was complicated, it was possible to assess whether or
5 not the observation was common in the general population (i.e. polymorphic). In this
6 regard, the number of GOM and LOM findings were calculated for all loci in both
7 populations and compared using Fisher's exact test followed by false discovery rate
8 (FDR) adjustment using the Benjamini-Hochberg procedure (Benjamini and
9 Hochberg 1995). For GOM, out of the 46 investigated imprinted DMRs 12 had MI
10 within normal individual range and 34 loci were hypermethylated, of which 8 were
11 significant (FDR <0.05) and 26 were polymorphic. For LOM, 6 imprinted DMRs had
12 MI within normal individual range and 40 loci were found hypomethylated, of which
13 22 were significant (FDR <0.05) and 18 were polymorphic (Table 4.8).

14

1 **Table 4.8: Imprinted DMRs with polymorphic epimutations.**

Imprinted DMR	Gain-of-methylation			Loss-of-methylation			Number of CpGS	Number of 450K Infinium probes
	Patient with MLID/no MLID	Normal control individuals with MLID/noMLID	Outcome	Patient with MLID/no MLID	Normal control individuals with MLID/noMLID	Outcome		
PPIEL:Ex1-DMR	0/111	0/1439	NA	1/110	2/1437	polymorphic	39	4
DIRAS3:TSS-DMR	0/111	0/1439	NA	8/103	3/1436	significant	88	21
DIRAS3:Ex2-DMR	0/111	0/1439	NA	5/106	2/1437	significant	39	8
GPR1-AS:TSS-DMR	0/111	0/1439	NA	1/110	7/1432	polymorphic	86	3
ZDBF2/GPR1:IG-DMR	6/105	0/1439	significant	0/111	0/1439	NA	439	8
NAP1L5:TSS-DMR	1/110	1/1438	polymorphic	0/111	0/1439	NA	57	15
VTRNA2-1:DMR	0/111	0/1439	NA	0/111	0/1439	NA	76	20
FAM50B:TSS-DMR	0/111	3/1436	polymorphic	8/103	6/1433	significant	90	25
PLAGL1:alt-TSS-DMR	1/110	3/1436	polymorphic	5/106	7/1432	significant	143	17
IGF2R:Int2-DMR	2/109	29/1410	polymorphic	5/106	1/1438	significant	74	2
WDR27:Int13-DMR	0/111	2/1437	polymorphic	0/111	0/1439	NA	58	3
GRB10:alt-TSS-DMR	7/104	0/1439	significant	0/111	0/1439	polymorphic	171	9
PEG10:TSS-DMR	8/103	5/1434	significant	1/110	0/1439	polymorphic	119	54
MEST:alt-TSS-DMR	7/104	1/1438	significant	4/107	2/1437	significant	226	62
HTR5A:TSS-DMR	7/104	4/1435	significant	0/111	3/1436	polymorphic	55	6
ERLIN2:Int6-DMR	0/111	2/1437	polymorphic	2/109	12/1427	polymorphic	37	7
PEG13:TSS-DMR	1/110	4/1435	polymorphic	0/111	0/1439	polymorphic	193	8
FANCC:Int1-DMR	0/111	1/1438	polymorphic	14/97	15/1424	significant	26	2
INPP5F:Int2-DMR	0/111	2/1437	polymorphic	2/109	1/1438	significant	52	4
H19/IGF2:IG-DMR	11/100	0/1439	significant	15/96	1/1438	significant	250	51
IGF2:Ex9-DMR	4/107	7/1432	significant	1/110	0/1439	polymorphic	63	10
IGF2:alt-TSS-DMR	11/100	1/1438	significant	11/100	0/1439	significant	33	1
KCNQ1OT1:TSS-DMR	0/111	4/1435	polymorphic	86/25	5/1434	significant	192	33
RB1:Int2-DMR	0/111	1/1438	polymorphic	0/111	3/1436	polymorphic	195	13
MEG3:TSS-DMR	0/111	4/1435	polymorphic	0/111	1/1438	polymorphic	188	33
MEG8:Int2-DMR	0/111	0/1439	NA	0/111	13/1426	polymorphic	43	1
MKRN3:TSS-DMR	0/111	0/1439	NA	0/111	12/1427	polymorphic	109	13
MAGEL2:TSS-DMR	0/111	1/1438	polymorphic	1/110	0/1439	polymorphic	51	6
NDN:TSS-DMR	0/111	0/1439	NA	1/110	2/1437	polymorphic	108	8
SNRPN:alt-TSS-DMR	0/111	0/1439	NA	1/110	4/1435	polymorphic	19	9
SNURF:TSS-DMR	0/111	0/1439	NA	2/109	1/1438	significant	113	7
IGF1R:Int2-DMR	0/111	8/1431	polymorphic	6/105	2/1437	significant	55	7
ZNF597:3' DMR	1/110	1/1438	polymorphic	0/111	0/1439	NA	29	2
ZNF597:TSS-DMR	2/109	2/1437	polymorphic	0/111	3/1436	polymorphic	76	12
ZNF331:alt-TSS-DMR1	0/111	1/1438	polymorphic	3/108	1/1438	significant	125	12
ZNF331:alt-TSS-DMR2	0/111	1/1438	polymorphic	3/108	1/1438	significant	102	4
PEG3:TSS-DMR	0/111	1/1438	polymorphic	0/111	5/1434	polymorphic	221	37
MCTS2P:TSS-DMR	1/110	11/1428	polymorphic	1/110	2/1437	polymorphic	47	10
NNAT:TSS-DMR	0/111	4/1435	polymorphic	3/108	0/1439	significant	135	37
L3MBTL1:alt-TSS-DMR	1/110	2/1437	polymorphic	11/100	6/1433	significant	84	26
GNAS-NESP:TSS-DMR	2/109	1/1438	polymorphic	0/111	0/1439	NA	257	23
GNAS-AS1:TSS-DMR	0/111	1/1438	polymorphic	3/108	3/1436	significant	128	66
GNAS-XL:Ex1-DMR	0/111	0/1439	NA	2/109	1/1438	significant	200	6
GNAS-AB:TSS-DMR	1/110	0/1439	polymorphic	3/108	2/1437	significant	198	42
WRB:alt-TSS-DMR	0/111	7/1432	polymorphic	3/108	0/1439	significant	43	4
SNU13:alt-TSS-DMR	0/111	0/1439	NA	15/96	18/1421	significant	63	8

polymorphic, FDR≥0.05; significant, FDR<0.05, NA, no methylation change detected in both patient and control individual groups.

2

1 **4.3.2.3 Targeted methylation profiling of SRS patients at imprinted DMRs**

2 **4.3.2.3.1 SRS with mUPD7 cohort**


3 Methylation profiling of 6 individuals in the SRS_UPD7 group showed
4 hypermethylation at *GRB10*:alt-TSS-DMR, *PEG10*:TSS-DMR, *MEST*:alt-TSS-DMR
5 and *HTR5A*:TSS-DMR in all patients. This was expected as these DMRs are located
6 on chromosome 7 and are methylated on the maternal allele. In addition, 1 patient
7 had GOM at *ZDBF2/GPR1*:IG-DMR and LOM at *IGF1R*:Int2-DMR. MLID was
8 detected in only 1 patient out of 6 (17%) (Figure 4.8).

9

10 **4.3.2.3.2 SRS with IC1 LOM cohort**

11 Methylation profiling of 15 individuals in the SRS_IC1 group showed, as expected,
12 hypomethylation at *H19/IGF2*:IG-DMR in all patients. In addition, hypomethylation at
13 *IGF2*:alt-TSS-DMR was also detected in 11 patients out of 15, but this was not
14 considered as MLID as both *H19/IGF2*:IG-DMR and *IGF2*:alt-TSS-DMR belong to
15 the same imprinted cluster. Finally, one SRS_IC1 patient had an additional LOM at
16 *L3MBTL1*:alt-TSS-DMR and, interestingly, one other patient had GOM at imprinted
17 DMRs (*GRB10*:alt-TSS-DMR, *PEG10*:TSS-DMR, *MEST*:alt-TSS-DMR and
18 *HTR5A*:TSS-DMR) located on chromosome 7 and normally associated with
19 SRS_UPD7 aetiology (Figure 4.8). Taken together, these results suggested that
20 MLID occurred in approximately 13% (2/15) of SRS_IC1 patients.

21



1

2 **Figure 4.8: Multilocus imprinting disturbances and SRS.**

3 Epimutations at imprinted DMRs in SRS_UPD7 (n=6) and SRS_IC1 (n=15).
 4 Epimutations distribution in the different SRS group of patients (x-axis) across the
 5 46 interrogated imprinted DMRs (y-axis). Red, loss-of-methylation; green, gain-of-
 6 methylation; black: no epimutations.

7

8

9 **4.3.2.4 Targeted methylation profiling of BWS patients at imprinted DMRs**

10 **4.3.2.4.1 BWS with pUPD11 cohort**

11 As previously mentioned (see section 4.3.2.1 - Methodology validation) methylation
 12 profiling of 8 individuals in the BWS_UPD11 group showed GOM at *H19/IGF2:IG-*
 13 *DMR* and *IGF2:alt-TSS-DMR* in 7 out of 8 patients, GOM at *IGF2:Ex9-DMR* in 1 out
 14 of 8 patients and LOM at *KCNQ1OT1:TSS-DMR* in all patients. For 7 out of 8
 15 patients, these results are consistent with clinical diagnosis. As expected,
 16 *H19/IGF2:IG-DMR* is hypermethylated and *KCNQ1OT1:TSS-DMR* is
 17 hypomethylated. For one patient, we failed to detect hypermethylation at

1 *H19/IGF2*:IG-DMR, but this could be explained by our very stringent methodology.
2 Finally, 1 out of 8 (12.5%) patient has MLID. The patient has hypermethylation at
3 *PEG10*:TSS-DMR (Figure 4.9).

4

5 **4.3.2.4.2 BWS with IC1 GOM cohort**


6 Methylation profiling of 4 individuals in the BWS_IC1 group showed, as expected,
7 hypermethylation at *H19/IGF2*:IG-DMR and *IGF2*:alt-TSS-DMR in all patients and
8 two patients had hypermethylation at *IGF2*:Ex9-DMR. MLID was not detected in this
9 group of patient (Figure 4.9).

10

11 **4.3.2.4.3 BWS with IC2 LOM cohort**

12 Methylation profiling of 78 individuals in the BWS_IC2 group showed, as expected,
13 LOM at *KCNQ1OT1*:TSS-DMR in all patients. Additionally, MLID was detected in 31
14 out of 78 (40%) of patients of this cohort. Of the 31 BWS_IC2 with MLID, 5 (16%)
15 patients had GOM at *ZDBF2/GPR1*:IG-DMR and LOM was observed in 8 (26%) at
16 *DIRAS3*:TSS-DMR, 5 (16%) at *DIRAS3*:Ex2-DMR, 8 (26%) at *FAM50B*:TSS-DMR,
17 5 (16%) at *PLAGL1*:alt-TSS-DMR, 5 (16%) at *IGF2R*:Int2-DMR, 4 (13%) at
18 *MEST*:alt-TSS-DMR, 14 (45%) at *FANCC*:Int1-DMR, 2 (6%) at *INPP5F*:Int2-DMR, 2
19 (6%) at *SNURF*:TSS-DMR, 5 (16%) at *IGF1R*:Int2-DMR, 3 (10%) at *ZNF331*:alt-
20 TSS-DMR1, 3 (10%) at *ZNF331*:alt-TSS-DMR2, 3 (10%) at *NNAT*:TSS-DMR, 10
21 (32%) at *L3MBTL1*:alt-TSS-DMR, 3 (10%) at *GNAS-AS1*:TSS-DMR, 2 (6%) at
22 *GNAS-XL*:Ex1-DMR, 3 (10%) at *GNAS-AB*:TSS-DMR, 3 (10%) at *WRB*:alt-TSS-
23 DMR and 15 (48%) at *SNU13*:alt-TSS-DMR (Figure 4.9 and Figure 4.10).

24



1

2 **Figure 4.9: Multilocus imprinting disturbances and BWS.**

3 *Epimutations at imprinted DMRs in BWS_UPD11 (n=8), BWS_IC1 (n=4) and*
 4 *BWS_IC2 (n=78). Epimutations distribution in the different BWS group of patients*
 5 *(x-axis) across the 46 interrogated imprinted DMRs (y-axis). Red, loss-of-*
 6 *methylation; green, gain-of-methylation; black: no epimutations.*

1 MLID frequency calculated in the current study was significantly higher ($p=0.0051$)
2 than the frequency obtained from seven combined previous reports. However, when
3 compared to two previous studies that also used HM450K for methylation profiling
4 (Court et al. 2013; Maeda et al. 2014), the MLID detection rates were similar
5 ($p=0.421$) (Table 4.9).


6
7 Compared to the imprinted DMRs that were investigated in at least 3 other studies,
8 the frequency of disturbances calculated in my cohort was concordant with previous
9 reports at *PEG10*:TSS-DMR, *H19/IGF2*:IG-DMR, *MEG3*:TSS-DMR, *SNRPN*:alt-
10 TSS-DMR, *PEG3*:TSS-DMR. Those loci were found mostly unaffected in the
11 majority of studies, including mine. However, the frequency of disturbances observed
12 at *PLAGL1*:alt-TSS-DMR, *IGF2R*:Int2-DMR, *GRB10*:alt-TSS-DMR, *MEST*:alt-TSS-
13 DMR, *GNAS-NESP*:TSS-DMR, *GNAS-AS1*:TSS-DMR, *GNAS-XL*:Ex1-DMR was
14 below the 25th percentile calculated from the 7 previous studies at those DMRs.
15 Nonetheless, it was noted that the observed frequency of epimutations reported
16 previously was very variable between studies. As an example, *PLAGL1*:alt-TSS-
17 DMR was epimutated in 16% in our cohort and in 39% (median) with a minimum of
18 7%, a maximum of 63% and a standard deviation of 18.6 in previous studies.
19 Similarly, *MEST*:alt-TSS-DMR was epimutated in 13% in our cohort and in 35%
20 (median) with a of minimum 7%, a maximum of 61% and a standard deviation of
21 17.8 in previous studies.

22

1 **Table 4.9: Frequency of disturbances reported in the current and seven**
 2 **previous reports.**

	MLID	with no MLID	MLID frequency
Current study	31	47	40%
Combined previous reports	113	360	24%
Rossignol et al. 2006	10	30	25%
Bliek et al. 2008	17	64	21%
Azzi et al. 2009	16	52	24%
Poole et al. 2013	8	13	38%
Tee et al. 2013	33	143	18%
Court et al. 2013	14	29	33%
Maeda et al. 2014	15	29	34%
Fisher's exact test (<i>p</i>-value calculated from current study against the 7 previous reports)	0.0051		
Fisher's exact test (<i>p</i>-value calculated from current study against Court et al. and Maeda et al. reports)	0.421		

3




1

2 **Figure 4.11: Meta-analysis of reported MLID frequency in BWS_IC2 cohort.**

3 Comparison of the frequency of disturbances across imprinted DMRs in BWS_IC2
 4 MLID observed in the current study (red triangle) and in 7 previous studies (colour
 5 dots). Box-and-whisker plots were calculated from the 7 previous reports indicated
 6 in plot key.

1 The number of additional epimutated DMRs per patient ranged from 1 to 12. The
2 majority of patient had only 1 (10/31) or 2 (8/31) additional epimutated DMRs and
3 the remaining 13 patients had between 3 and 12 additional epimutated DMRs,
4 indicating that the more additional epimutated DMRs was observed the fewer
5 patients were affected (Figure 4.12-a). Within these 31 patients, I counted a total of
6 139 epimutations affecting 21 imprinted DMRs. Out of the 139 observed
7 epimutations, 134 were LOM affecting 20 maternal imprinted DMRs (*DIRAS3*:TSS-
8 DMR, *DIRAS3*:Ex2-DMR, *FAM50B*:TSS-DMR, *PLAGL1*:alt-TSS-DMR, *IGF2R*:Int2-
9 DMR, *MEST*:alt-TSS-DMR, *FANCC*:Int1-DMR, *INPP5F*:Int2-DMR,
10 *KCNQ1OT1*:TSS-DMR, *SNURF*:TSS-DMR, *IGF1R*:Int2-DMR, *ZNF331*:alt-TSS-
11 DMR1, *ZNF331*:alt-TSS-DMR2, *NNAT*:TSS-DMR, *L3MBTL1*:alt-TSS-DMR, *GNAS*-
12 *AS1*:TSS-DMR, *GNAS-XL*:Ex1-DMR, *GNAS-AB*:TSS-DMR, *WRB*:alt-TSS-DMR,
13 *SNU13*:alt-TSS-DMR). The remaining 5 disturbances were GOM affecting the
14 paternal DMRs *ZDBF2/GPR1*:IG-DMR (Figure 4.12-b). This suggested that LOM
15 was more common than GOM in BWS_IC2, and that LOM occurred at maternal
16 DMRs only whilst GOM was more associated with paternal DMRs. No epimutation
17 preference toward maternal DMRs was found as statistical test failed to reach
18 significance ($p=0.106$, Fisher's exact test) (Figure 4.12-c).
19



1

2 **Figure 4.12: Imprinting disturbances in BWS_IC2 patients.**

3 (a) Comparison of the number of additional epimutated loci in BWS_IC2 with MLID
4 patients. (b) Comparison of the total GOM and LOM in BWS_IC2 with MLID patients.

5 (c) Comparison of the number of aberrantly methylated DMRs between matDMRs
6 and patDMRs. Fisher's exact test was used for statistical analysis. GOM, gain-of-
7 methylation; LOM, loss-of-methylation; matDMR, maternal DMR; patDMR, paternal
8 DMR.

9


10

11 Epimutation correlation and associated significance level were calculated for all
12 imprinted DMRs detected to be epimutated in BWS_IC2 MLID patients. Using an
13 absolute correlation threshold of at least 0.6 and significance level threshold of 0.01,
14 *IGF1R*:Int2-DMR, *GNAS-AS1*:TSS-DMR, *GNAS-XL*:Ex1-DMR and *GNAS A/B*:TSS-

1 DMR had significant positive correlation. The two imprinted DMRs located at
2 *DIRAS3* locus (*DIRAS3*:TSS-DMR and *DIRAS3*:Ex2-DMR) had significant positive
3 correlation. The two imprinted DMRs located at *ZNF331* locus (*ZNF331*:alt-TSS-
4 DMR1 and *ZNF331*:alt-TSS-DMR2) had significant positive correlation. Finally,
5 *NNAT*:TSS-DMR on chromosome 20 had significant positive correlation with
6 *ZNF331*:alt-TSS-DMR1, *ZNF331*:alt-TSS-DMR2 on chromosome 19 and
7 *PLAGL1*:alt-TSS-DMR on chromosome 6 (Figure 4.13).

8

9



1
2
3
4
5
6
7
8
9
10


Figure 4.13: Epimutations correlation calculated at epimutated imprinted DMRs in BWS_IC2 MLID patients.

Pearson's product-moment correlation was used to compute correlation and associated p-value. Numeric values, r correlation; red, toward negative correlation; blue, toward positive correlation; black square, correlation with $|r| \geq 0.6$ and $p \leq 0.01$.

1 **4.3.3 DMR hunting**

2 Bumhunter (Jaffe et al. 2012; Aryee et al. 2014) R package was used to identify
3 genomic regions that were differentially methylated between two conditions (e.g.
4 BWS_IC1 patients *versus* control individuals). Resulting candidate regions were
5 then processed with our epimutation methodology (see section 4.2.4.1.3 -
6 Epimutation methodology) to retain the most interesting ones. Following this
7 procedure, I detected DMRs at most of the well-described loci involved in the
8 aetiology of each group of patients (*H19/IGF2*:IG-DMR, *KCNQ1OT1*:TSS-DMR,
9 *PEG10*:TSS-DMR, *MEST*:alt-TSS-DMR and *GRB10*:alt-TSS-DMR). In addition, I
10 found two new significant DMRs overlapping the promoter of the lymphotoxin alpha
11 (*LTA*) gene (Figure 4.14-a) and in the exon 4 of the solute carrier family 12 member
12 9 (*SLC12A9*) gene (Figure 4.14-b) in BWS_IC2. *LTA* promoter was found
13 hypomethylated in 7 out of the 78 (9%) BWS_IC2 patient and *SLC12A9* exon 4 was
14 found hypermethylated in 34 out of 78 (44%) patients (Figure 4.14-c). I also found
15 two new significant DMRs overlapping *SLC12A9* exon 4 (Figure 4.14-d) and in the
16 promoter of the potassium voltage-gated channel subfamily A regulatory beta subunit
17 3 (*KCNAB3*) gene (Figure 4.14-e) in BWS_UPD11. To be noted that two probes
18 within *SLC12A9* DMR detected in BWS_UPD11 were not found significant in
19 BWS_IC2, resulting in a smaller cluster in the latter group. *SLC12A9* exon 4 was
20 found hypermethylated in 6 out of 8 (75%) BWS_UPD11 patients and *KCNAB3*
21 promoter was found hypomethylated in 4 out of 8 (50%) patients (Figure 4.14-f). No
22 additional significant DMRs were found in BWS_IC1, SRS_IC1 and SRS_UPD7

1 (Table 4.10). Finally, although it was not detected by bumphunter, I also found that
 2 *KCNAB3* promoter was hypomethylated in 14 out of 78 (18%) BWS_IC2 patients
 3 (Figure 4.15-a, b).
 4




5
 6 **Figure 4.14: DMR hunting in BWS.**
 7 (a,b,d,e) Methylation index (y-axis) of HM450K CpG probes (x-axis) of patients
 8 (orange) and normal individuals (blue) at (a) LTA (b) SLC12A9 in BWS_IC2 and at
 9 (d) SLC12A9 and (e) KCNAB3 in BWS_UPD11. Vertical black lines represent DMR
 10 boundaries defined by bumphunter. (c,f) Frequency of (c) BWS_IC2 and (f)
 11 BWS_UPD11 patients with hypo- or hypermethylation at the indicated loci
 12
 13

1 **Table 4.10: Candidate differentially methylated regions in BWS and SRS.**

name	region	description	Entrez	chromosome	start	end	delta β	number of probes	FDR	fwer
BWS_IC1										
H19	promoter	H19/GF2:IG-DMR, imprinted	283120	11	2019079	2020560	-0.264	40	0.000	0
BWS_IC2										
KCNQ1	inside intron	KCNQ1OT1:TSS-DMR, imprinted	3784	11	2721207	2722440	0.331	36	0.000	0
SLC12A9	inside exon 4	solute carrier family 12 member	56996	7	100463583	100464145	-0.158	4	0.005	0.002
LTA	promoter	lymphotoxin alpha	4049	6	31539539	31539735	0.159	3	0.009	0.004
BWS_UPD11										
KCNQ1	inside intron	KCNQ1OT1:TSS-DMR, imprinted	3784	11	2721207	2722062	0.161	22	0.000	0
H19	promoter	H19/GF2:IG-DMR, imprinted	283120	11	2020279	2020560	-0.165	10	0.006	0.058
KCNAB3	promoter	potassium voltage-gated channel subfamily A regulatory beta subunit 3	9196	17	7832769	7833237	0.205	7	0.025	0.217
SLC12A9	inside exon 4	solute carrier family 12 member	56996	7	100463416	100464145	-0.207	6	0.029	0.252
SRS_IC1										
H19	promoter	H19/GF2:IG-DMR, imprinted	283120	11	2019079	2020560	0.202	40	0.000	0
SRS_UPD7										
SGCE	overlaps 5'UTR - exon 1	PEG10:TSS-DMR, imprinted	8910	7	94285327	94287242	-0.350	59	0.000	0
MEST	overlaps 5'UTR - exon 1	MEST:alt-TSS-DMR, imprinted	4232	7	130129946	130132453	-0.350	56	0.000	0
GRB10	inside intron - 5' UTR	GRB10:alt-TSS-DMR, imprinted	2887	7	50849639	50849931	-0.343	4	0.006	0.082

region: genomic features where significant clusters are located; delta β : mean methylation difference between normal and patient individuals; number of probes: number of 450K CpG probes within cluster, FDR: false discovery rate; fwer: family-wise error rate



1

2 **Figure 4.15: KCNAB3 is also aberrantly methylated in BWS_IC2.**

3 (a) Methylation index (y-axis) of HM450K CpG probes (x-axis) of BWS_IC2 patients
 4 (orange) and normal individuals (blue) at KCNAB3 promoter. Vertical black lines
 5 represent DMR boundaries detected in BWS_UPD11. (b) Frequency of BWS_IC2
 6 patients with hypomethylation at KCNAB3 promoter.

7

8

9 4.4 Discussion

10 4.4.1 Preprocessing

11 Data preprocessing was performed with the R package RnBeads, a specialist
 12 bioinformatic pipeline designed to handle HM450K data. Technical and biological
 13 biases were efficiently removed from data using the R package ComBat although
 14 the algorithm started to show its limitations whilst dealing with confounding
 15 covariates such as the age in our dataset. The use of younger normal control
 16 individuals and a better random allocation of the samples to HM450K slides and
 17 HM450K positions (i.e. Satrix_ID and Satrix_Position respectively) to minimise
 18 confounding covariates would have greatly helped to reduce the bias associated with

1 those variables. Additionally, the ComBat algorithm would have performed better for
2 bias correction. However, the methylation data used in this study was generated by
3 multiple groups (i.e. our group and collaborators) and therefore it was hardly possible
4 to elaborate a better experimental design that took into account all of those variables.

5

6 **4.4.2 Methodology**

7 My epimutation methodology was validated by assessing the methylation level at
8 *H19/IGF2:IG-DMR* and at *KCNQ1OT1:TSS-DMR* in all patients. By comparison with
9 clinical diagnostic testing results, my method detected the correct epimutation
10 pattern in all individuals except for one BWS_UPD11 patient for which it failed to
11 detect *H19/IGF2:IG-DMR* GOM. We hypothesised that mosaicism could explained
12 the epimutation detection failure observed in that patient. Indeed, mosaicism is
13 commonly associated with BWS_UPD11 patients (Slatter et al. 1994; Weksberg et
14 al. 2010) and, hence, our method may not be sensitive enough to detect lower-level
15 disomy in that group of patient. Selecting a two standard deviations threshold may
16 have improved epimutation sensitivity detection for low-level disomy but this may
17 have been at the cost of increasing false positive epimutation rate. In conclusion, our
18 method performed well for the methylation profiling of BWS and SRS individuals at
19 *H19/IGF2:IG-DMR* and at *KCNQ1OT1:TSS-DMR* and, therefore, it can be applied
20 to other target regions such as other imprinted DMRs. However, additional care need
21 to be taken when dealing with patients in which low-level mosaicism is expected.

22

1 **4.4.3 Polymorphic epimutation**

2 The epimutation rate at each targeted imprinted DMR was evaluated in both patients
3 and normal individuals. Comparison of both groups using Fisher's exact test followed
4 by FDR adjustment showed that more than half of imprinted DMRs with abnormal
5 methylation findings were in fact polymorphic for GOM or LOM only or for both. This
6 confirmed previous published data where the imprinted DMRs *IGF2R*:Int2-DMR was
7 found polymorphic for GOM but not LOM (Tee et al. 2013).

8

9 **4.4.4 Genomic imprinting methylation in SRS_UPD7**

10 In SRS_UPD7, MLID was detected in 1 out of 6 (17%) patient. The individual had
11 GOM at *ZDBF2/GPR1*:IG-DMR and LOM at *IGF1R*:Int2-DMR. Previous published
12 data has shown hypermethylation at *RB1*, *ANKRD11* and *MCTS2* (Prickett et al.
13 2015) in SRS_UPD7 patients, but none of these loci were found to be epimutated in
14 our cohort. In our study, *RB1* and *MCTS2* were found polymorphic for both GOM and
15 LOM (i.e. high frequency of GOM and LOM is observed in the normal control
16 population) and *ANKRD11* has not been evaluated.

17

18 **4.4.5 Genomic imprinting methylation in SRS_IC1**

19 In SRS_IC1, MLID was detected in 13% (2 out of 15). This is slightly above the
20 published common consensus of 7-10% (9 out of 97 in combined previous reports;
21 $p=0.64$) (Azzi et al. 2009; Turner et al. 2010). Of the two individuals with MLID, one
22 had additional LOM at *L3MBTL1*:alt-TSS-DMR and, interestingly, the other one had

1 additional GOM at *GRB10*:alt-TSS-DMR, *PEG10*:TSS-DMR, *MEST*:alt-TSS-DMR
2 and *HTR5A*:TSS-DMR. This observation was very intriguing as GOM at
3 chromosome 7 is normally associated with SRS_UPD7 and not SRS_IC1.
4 Additionally, methylation disturbances at these loci, if any, are generally LOM
5 according to previous published data (Azzi et al. 2009; Turner et al. 2010; Court et
6 al. 2013). Accordingly, this patient sample was suspected to have been mislabelled
7 as SRS_IC1 instead of SRS_UPD7. Taking the latter patient out of that group, MLID
8 was detected in approximately 7% (1 of 14) of SRS_IC1.

9

10 **4.4.6 Genomic imprinting methylation in BWS_UPD11**

11 Of the 8 BWS_UPD11 patient, 1 (12.5%) had MLID. The patient has GOM at
12 *PEG10*:TSS-DMR. To the best of my knowledge, this is the first time that an
13 additional epimutation affecting another chromosome than chromosome 11 has
14 been identified in BWS_UPD11 cohort. However, the clinical relevance of the
15 findings is yet to be described.

16

17 **4.4.7 Genomic imprinting methylation in BWS_IC1**

18 MLID was not detected in any individuals although a recent report suggested that
19 MLID can occurred in up to 30% (3 in 10) of BWS_IC1 patient (Maeda et al. 2014).
20 In the latter, the germline DMR *INPP5Fv2* was found hypomethylated in two patients
21 and the somatic DMR *NESP* was found hypermethylated in a third patient. In our
22 cohort, only a few patients (n=4) were methylation profiled and, hence, could

1 explained why no MLID was detected.

2

3 **4.4.8 Genomic imprinting methylation in BWS_IC2**

4 MLID was detected in 31 out of 78 (40%) of patients, which was significantly higher
5 ($p=0.0051$) than the common consensus of approximately 24% (all previous
6 studies combined: 113 of 473) (Rossignol et al. 2006; Bliiek et al. 2008; Azzi et al.
7 2009; Court et al. 2013; Poole et al. 2013; Tee et al. 2013; Maeda et al. 2014).
8 However, with the increasing use of modern technics such as Illumina methylation
9 array, imprinted DMRs that were not assessed previously are also shown to be
10 epimutated in BWS. Consequently, the previously reported consensus is likely to
11 underestimate the frequency of MLID in BWS with IC2 LOM as some patients may
12 have additional epimutations at previously unscreened imprinted DMRs but no
13 abnormalities at previously screened imprinted DMRs. To support this hypothesis,
14 the authors of two recent studies used high-throughput methods for the methylation
15 profiling of more than 20 imprinted DMRs and both authors reported MLID in 14 out
16 of 43 (33%) and in 15 out of 44 (34.1%) (Court et al. 2013; Maeda et al. 2014). Taken
17 together with my study, it seems that the methylation profiling of more imprinted
18 DMRs is associated with and increased frequency of MLID discovery through the
19 identification of epimutated DMRs that were not screened in the past. Additionally, it
20 confirmed that MLID is likely to be more frequent than originally thought.

21

22 There was considerable variance in the number of loci affected, ranging from one to

1 12 additional imprinted DMRs and the majority of individuals had less than two
2 disturbed loci. This showed that BWS_IC2 cases with extreme abnormal
3 epigenotype are rare but still exist. It remained to evaluate the consequences of such
4 extreme epigenotype and see if those rare patients have a more severe form of BWS
5 or an unusual phenotype.

6

7 Both paternal and maternal DMRs were affected with GOM associated with paternal
8 DMRs and LOM associated with maternal DMRs. No epimutation preference toward
9 maternal or paternal DMRs was found ($p=0.106$, Fisher's exact test) which contrasts
10 with a previous report where maternal DMRs have been found significantly more
11 epimutated than paternal DMRs ($p=0.042$, Fisher's exact test) (Maeda et al. 2014).

12

13 The somatic locus *ZDBF2/GPR1*:IG-DMR was shown to gain methylation in 5 (16%)
14 of our patient and it was the only interrogated imprinted DMRs that was
15 hypermethylated. This acquisition was believed to being due to a concomitant LOM
16 in the nearby maternally methylated *GPR1-AS*:TSS-DM, which is known to regulate
17 the methylation of the somatic DMR *ZDBF2/GPR1*:IG-DMR in a hierarchical fashion
18 (H. Kobayashi et al. 2013). In my study, methylation profiling at *GPR1-AS*:TSS-DMR
19 did not show LOM but this was expected as *GPR1-AS*:TSS-DMR acquires
20 immediate biparental methylation following implantation (H. Kobayashi et al. 2013).

21

22 Finally, no distinct epimutation correlations were found between 'unrelated DMRs'.

23 Imprinted DMRs belonging to the same imprinting cluster tend to be epimutated

1 simultaneously but this was expected.

2

3 **4.4.9 DMR hunting**

4 DMR hunting revealed 3 new potential candidate regions (*SLC12A9*, *LTA* and
5 *KCNAB3*) that may be involved in BWS_IC2 and BWS_UPD11 aetiology.

6

7 *SLC12A9* belongs to the solute carrier 12 (SLC12) gene family. This gene family
8 encodes electroneutral inorganic cation-chloride cotransporters (CCCs) that are
9 plasma membrane proteins mediating the movement of inorganic sodium (Na^+)
10 and/or potassium (K^+) cations, tightly coupled to the movement of chloride (Cl^-)
11 anions. Mutations and or dysfunctions in members of this gene family have been
12 associated with pathophysiological disorders such as Bartter syndrome, Gitleman
13 syndrome and Andermann syndromes (Gagnon and Delpire 2013). However, little is
14 known about *SLC12A9* for which no protein function has yet been described and
15 relevance to human disease is not known.

16

17 *LTA* gene encodes a cytokine produced by lymphocytes. The protein, belonging to
18 the tumour necrosis factor family, is highly inducible, secreted, and forms
19 heterotrimers with lymphotoxin-beta which anchor lymphotoxin-alpha to the cell
20 surface. This protein also mediates a large variety of inflammatory,
21 immunostimulatory, and antiviral responses, is involved in the formation of
22 secondary lymphoid organs during development and plays a role in apoptosis.

1 Genetic variations in this gene are associated with susceptibility to leprosy type 4,
2 myocardial infarction, non-Hodgkin's lymphoma, and psoriatic arthritis. However,
3 *LTA* clinical relevance in BWS is currently not known.

4

5 *KCNAB3* gene encodes a member of the potassium channel, voltage-gated, shaker-
6 related subfamily. The encoded protein is one of the beta subunits, which are
7 auxiliary proteins associating with functional Kv-alpha subunits. The encoded protein
8 forms a heterodimer with the potassium voltage-gated channel, shaker-related
9 subfamily, member 5 (*KCNA5*) gene product and regulates the activity of the alpha
10 subunit (Leicher et al. 1998). Interestingly, recent published papers reported
11 complete or partial LOM at *KCNAB3* in MLID patients with, in some cases, mutation
12 in NLR family pyrin domain containing 7 (*NLRP7*) gene and in ZFP57 zinc finger
13 protein (*ZFP57*) gene (Beygo, Ammerpohl, et al. 2013; Rezwan et al. 2015; Bak et
14 al. 2016).

15

Chapter 5

Investigations of the underlying causes of MLID in

BWS_IC2

1 **5.1 Introduction**

2 **5.1.1 Assisted reproductive technologies and MLID**

3 Assisted reproductive technology (ART) is a generic term given to describe a number
4 of different treatments, including ovarian stimulation, *in vitro* fertilisation (IVF) and
5 intra-cytoplasmic sperm injection (ICSI), that can be performed to help achieve
6 pregnancy. ART is used primarily for infertility treatment but can also be used for
7 fertile couples to reduce the risk of potential diseases (e.g. when combined with
8 preimplantation diagnosis). The potentially increased frequency of deregulated
9 genomic imprinting in children conceived with the help of ART has raised concerns
10 about how the procedures may predispose the embryos to acquire imprinting
11 disturbances and *in fine* to diseases.

12

13 **5.1.1.1 Ovarian stimulation**

14 Ovarian stimulation (OS) is the induction of ovulation by the injection of a fertility
15 hormone (e.g. clomiphene, gonadotropin). It is usually used to stimulate the
16 development of ovarian follicles to reverse anovulation (where the ovaries do not
17 release an oocyte) or oligoovulation (where ovulation is infrequent or irregular). To
18 achieve ovulation and pregnancy, anovulatory and oligoovulatory patients are given
19 enough hormones to reach a threshold sufficient to initiate growth and development
20 of a number of follicles but ideally only maintain the growth of one follicle or certainly
21 not more than three. When more than one egg is produced, the risk of multiple
22 pregnancy increases.

1 OS can also be used for controlled ovarian hyperstimulation (COH). In contrast to
2 OS in anovulatory and oligoovulatory patients in which the aim is to produce a
3 monofollicular ovulation, COH aims to produce multiple follicular development in
4 order to harvest a suitable number of oocytes. Patients that undergo COH are given
5 a larger dose of hormones than anovulatory and oligoovulatory patients to treat their
6 conditions. COH is used in conjunction with ART procedures such as IVF or ICSI.

7
8 In both OS and COH procedures, a trigger shot of hormones (e.g. human chorionic
9 gonadotropin) can also be administered to patients to induce final maturation of
10 oocytes and/or trigger oocytes release. This would allow scheduling sexual
11 intercourse or intrauterine insemination and thus increasing chances of pregnancy
12 in anovulatory and oligoovulatory patients. In the case of IVF or ICSI, this would avail
13 the retrieval of fully mature eggs.

14
15 Ovarian stimulation is considered a safe procedure but complication may arise in
16 some cases. One of the main risk associated with OS and COH is that patients may
17 develop an ovarian hyperstimulation syndrome (OHSS), which can occur when too
18 much hormone medication is administered. Symptoms of OHSS range from mild
19 abdominal distention due to swollen and painful ovaries alone or with an
20 accompanying fluid shift into the abdomen, to renal failure and death as a result of
21 haemoconcentration and reduced perfusion of organs such as the kidneys, heart
22 and brain (Fiedler and Ezcurra 2012). There is also a risk of multiple pregnancy when
23 an excess of follicles are produced.

1 **5.1.1.2 In vitro fertilisation**

2 IVF treatment involves the fertilisation of an egg (or eggs) outside the body. The
3 treatment can be performed using an individual's own eggs and sperm, or using
4 either donated sperm or donated eggs, or both. IVF is an ART procedure that is
5 recommended in cases where there is underlying unexplained infertility problems,
6 the fallopian tubes are blocked, the male partner has non severe fertility problems,
7 or the embryos need to be tested to avoid passing on a genetic condition. The
8 protocol used for IVF is not fully consistent between places, they can differ between
9 birth centres and countries for example, but the concept remains the same. The IVF
10 procedure starts with COH (see section 5.1.1.1 - Ovarian stimulation). The
11 stimulated and matured eggs are then collected from ovaries and prepared for
12 fertilisation. In parallel, sperm is washed to remove inactive cells and seminal fluid.
13 Prepared eggs and sperm are incubated together in a culture media to achieve
14 fertilisation. The embryos (fertilised eggs) are passed into growth media and cultured
15 until cleavage stage or blastocyst stage. In some cases, preimplantation genetic
16 diagnosis can be performed and one or two cells are removed from the developing
17 embryo and tested for a specific genetic disease. Finally, selected embryos are
18 transferred into the uterus. Non transferred embryos are stored by cryopreservation
19 and may be used in subsequent cycles if pregnancy is not achieved after the first
20 attempt.

21

22 **5.1.1.3 Intra-cytoplasmic sperm injection**

23 ICSI is most commonly used to overcome male fertility problems. The procedure is

1 very similar to IVF and only differs in the techniques used to fertilise the eggs. With
2 ICSI, a matured and healthy single sperm is first selected and then directly injected
3 into an egg. The embryos are cultured and transferred into the uterus in a similar
4 manner to IVF.

5

6 **5.1.1.4 Evidence of ART disrupting genomic imprints**

7 Evidence to suggest that ART may disrupt normal growth and development through
8 epigenetic alterations of genomic imprinting was first seen in animal studies. In large
9 domestic animals, such as cattle and sheep, a considerable number of abnormally
10 large animals were born subsequent to various embryo manipulations before the
11 blastocyst stage. The resulting aberrant overgrowth phenotype seen in the animals
12 was very similar to the human disorder BWS and it was referred to as the large
13 offspring syndrome (LOS) (Young et al. 1998). At the time, it was hypothesised that
14 LOS may be caused by an epigenetic deregulation that would impair gene
15 expression, especially imprinted gene expression, and this could be a consequence
16 of the embryo manipulations. The investigation of sheep fetuses recovered at day
17 125 of gestation (term=147 days) and conceived by ART revealed that 12 out of 48
18 fetuses had LOS (compared to none in naturally conceived fetuses, n=22).
19 Interestingly, the aberrant phenotype observed in the 12 fetuses was associated
20 with a significant reduction in the expression of the imprinted gene *IGF2R*. In 9 of
21 the 12 fetuses, the reduced *IGF2R* gene expression was further explained by a
22 loss-of-methylation of *IGF2R*-DMR2, the imprinting control region regulating *IGF2R*
23 expression (Young et al. 2001). In mice, *IGF2R* was shown to degrade the excess

1 IGF2 (Ludwig et al. 1995) and mouse embryos lacking *Igf2r* were shown to be larger
2 than normal at day 18.5 of gestation and at birth (Ludwig et al. 1996). More recently,
3 the investigators of another study showed that in addition to the increased of
4 bodyweight, LOS hybrid bovine foetuses conceived with ART have also macrosomia,
5 macroglossia, and umbilical hernia, which are primary characteristics of BWS. More
6 importantly, besides the phenotypic similarities the foetuses with LOS and conceived
7 with ART also had epigenetic similarities with BWS. Indeed the investigators found
8 that in these foetuses *KCNQ1OT1*, which is the main locus involved in BWS
9 molecular aetiology (~ 50%), was biallelically expressed and this was due to a loss-
10 of-methylation on the maternal allele of *KCNQ1OT1*:TSS-DMR (Z. Chen et al. 2013).

11

12 **5.1.1.5 Evidence of association between ART and imprinting disorders**

13 In humans, an association between ICSI and Angelman syndrome (AS) due to an
14 imprinting defect was suggested following the report of three children who were
15 conceived in such manner and subsequently developed the syndrome. Methylation
16 profiling revealed complete or partial LOM at the imprinted DMR *SNRPN*:alt-TSS-
17 DMR (Cox et al. 2002; Ørstavik et al. 2003).

18

19 A similar association between ART and BWS has also been reported. In the general
20 population, the prevalence of ART is estimated between 0.8 and 1.3% whilst the
21 prevalence of ART in BWS population is estimated between 4 and 4.6% (DeBaun et
22 al. 2003; Gicquel et al. 2003; Maher et al. 2003). The investigators of a case-control
23 study performed in Australia reported a prevalence of ART in BWS group as high as

1 10.81% whilst in the general population the ART prevalence was of 0.67% (Halliday
2 et al. 2004). Interestingly, across these studies 95% of BWS patients conceived with
3 ART were due to the LOM at *KCNQ1OT1*:TSS-DMR whilst in BWS patients
4 conceived naturally the imprinting disturbance accounts for approximately 50% of
5 cases (DeBaun et al. 2003; Gicquel et al. 2003; Maher et al. 2003; Halliday et al.
6 2004; Weksberg et al. 2010). Taken together, these reports showed clear evidence
7 that ART is associated with BWS due to imprinting defects at *KCNQ1OT1*:TSS-DMR.

8

9 **5.1.1.6 Investigation of potential ART association with MLID in BWS**

10 The study of several BWS with LOM at *KCNQ1OT1*:TSS-DMR (BWS_IC2) cohorts
11 have identified a significant associations between MLID in BWS_IC2 and the use of
12 ART. A first study reported that 3 out of 8 BWS_IC2 patients conceived with ART had
13 MLID compared to 3 out of 47 for naturally conceived patients ($p=0.034$) (Lim et al.
14 2009). In another report, MLID was detected in one BWS_IC2 patient conceived with
15 the help of ART (ICSI) and in one out of five BWS_IC2 patients conceived naturally.
16 Although only one ART patient was available, the authors suggested a possible
17 association between BWS_IC2 and the widespread methylation disturbances (Hiura
18 et al. 2012). Finally, the association was further demonstrated in a third report in
19 which MLID was reported in 7 out of 14 BWS_IC2 ART patients compared to 26 out
20 of 173 of patients conceived naturally ($p=0.0033$) (Tee et al. 2013). However, such
21 associations are not consistent between publications and other research studies
22 have reported there was no significant association between the two. A first study
23 suggesting there was no association reported MLID in 3 out of 11 BWS_IC2 patients

1 conceived with ART and in 7 out of 29 patients conceived normally ($p=1$) (Rossignol
2 et al. 2006). Furthermore, the investigators of another study reported MLID in
3 BWS_IC2 in 4 out of 12 patients conceived with ART and in 12 out of 55 patients
4 conceived naturally and they concluded that ART was not responsible for MLID
5 ($p=0.46$) (Azzi et al. 2009). It remains unclear what is the impact of ART on genomic
6 imprinting methylation but the study of more extensive patient cohort will help to
7 determine whether or not ART predispose embryos to acquire imprinting errors and
8 diseases.

9

10 **5.1.2 Trans-imprinting defect and MLID**

11 The genetic alterations of genes required for establishing and maintaining
12 methylation, or shown to be essential for embryonic development may lead to the
13 disruption of genomic imprinting methylation through *trans*-mechanism defects.
14 Furthermore, several pieces of evidence have demonstrated that a subset of
15 imprinted genes belongs to a co-ordinately regulated network. Within the same
16 imprinted gene network, imprinted genes can modify in *trans* the expression of other
17 imprinted genes (Varrault et al. 2006; Patten et al. 2016; Soellner et al. 2016). As an
18 example, experiments in mouse brain neuroblastoma cell lines and meta-analysis of
19 mouse microarray data sets have shown that the imprinted transcription factor *Plagl1*
20 promotes the expression of several genes, including the imprinted genes *Igf2*, *H19*,
21 *Kcnq1ot1*, *Cdkn1c* and *Dlk1* (Varrault et al. 2006). Therefore, the existence of such
22 network may suggest that the genetic insult of a member of the network may first

1 result in a *cis*-defect, and subsequently to further downstream *trans*-imprinting
2 failures. However, no evidences reporting that this mechanism may acts at the
3 imprinting methylation level were found yet.

4

5 To date, a few pathological mutations affecting maternal-effect genes (*NLRP7*,
6 *KHDC3L* (previously known as *C6ORF221*), *NLRP2* and *NLRP5*) and maternal-
7 zygotic effect gene (*ZFP57*) were identified in syndromes with MLID.

8

9 **5.1.2.1 Maternal-effect and maternal-zygotic effect genes**


10 Maternal-effect genes are a special class of genes that are required for normal
11 embryonic development. The RNA or protein products of those genes are supplied
12 by the mother and are produced or deposited in the oocyte or are present in the
13 fertilised egg or embryo before the expression of zygotic genes is initiated. In
14 contrast, genes whose RNA and protein products are only produced after zygotic
15 genome activation, at or after the maternal to zygotic transition stage, are zygotic
16 genes (Marlow 2010). The maternal to zygotic transition starts during the early two-
17 cell stages in the mouse (L. Li et al. 2010) (Figure 5.1) and by the 4- to 8-cell stages
18 in the human (Schultz 2002).

19

20 To date, the gene knockout and gene knockdown in mammalian animal models
21 (mice) and the study of rare human disorders have helped to identify approximately
22 60 maternal-effect genes for which the zygotic transcription has not rescued the
23 embryonic lethality due to the loss of maternal gene function (Table 5.11) (Condic

1 2016).

2



3

4 **Figure 5.1: Maternal to zygotic gene transition in the mouse.**

5 *Maternal RNA and proteins accumulate during oocytes maturation and will slowly*
6 *degrade starting from the ovulation stage. In contrast, the activation of the embryonic*
7 *genome will start from the 1/2-cell stage (E1.5) and will remain active thereafter.*
8 *(Adapted from L. Li et al. 2010).*

9

10

11 **5.1.2.1.1 Zygotic effect**

12 Recessive mutations disrupting the zygotic gene function will be visible in embryos
13 homozygous for the mutant genotype. The abnormal embryo will inherit one copy of
14 the mutated gene from its father and one copy of the mutated gene from its mother.
15 Both parents will be heterozygous for the pathogenic mutation. Embryos with a
16 heterozygous mutant genotype will appear normal.

17

18 **5.1.2.1.2 Maternal-effect**

19 Recessive mutations disrupting the maternal gene function will be visible in embryos
20 for which the mother is homozygous for the mutant genotype (X. Li 2010; Marlow

1 2010). The embryo genotype, either homozygous or heterozygous for the mutant
2 allele, has no effect on the phenotype.

3

4 **5.1.2.1.3 Maternal-zygotic effect**

5 Recessive mutations disrupting maternal-zygotic gene function will be visible in
6 embryos for which its genotype and its mother genotype are both homozygous for
7 the mutant allele (X. Li 2010; Marlow 2010). If one of the embryo or the mother is
8 heterozygous for the mutant genotype, the embryo may display a reduced or no
9 signs of the abnormal phenotype.

1 Table 5.11: List of mammalian maternal-effect genes.

2 (*Maternal-effect was mainly described in mice (Condic 2016)*).

GENE	DESCRIPTION	ROLE IN DEVELOPMENT	LETHALITY
Cell cycle regulation			
<i>Fmn2</i>	Formin-2	Control of mitotic spindle	embryo
<i>Kpna6</i>	Importin alpha7; karyopherin alpha 6	Nuclear import, spindle assembly	2-cell
<i>MIR181A1</i>	microRNA 181a-1 (human)	Negative regulator of NPM2	early embryo
<i>Npm2</i>	Nucleoplasmin2	Nuclear and nucleolar organization, chromatin remodelling	2-cell
<i>Tcl1</i>	T cell lymphoma breakpoint 1	Cell division, transcriptional regulation	morula
<i>TP73</i>	TAp73; Tumor protein 73	Cell division and ploidy	embryo
<i>Zar1</i>	zygote arrest 1	RNA processing, pronuclear fusion	2-cell
Epigenetic reprogramming/pluripotency			
<i>Ago2</i>	argonaute 2, RISC catalytic component	RNA stability, degradation of maternal factors, zygotic gene activation	2-cell
<i>Atg5</i>	autophagy related 5	Degradation of maternal factors	4-8 cell
<i>Dicer1</i>	dicer 1, ribonuclease type III	Degradation of maternal factors	embryo
<i>Dmap1</i>	DNA methyltransferase 1 associated protein 1	DNA methylation, epigenetic modification	embryo
<i>Dnmt1</i>	DNA methyltransferase (cytosine-5) 1	DNA methylation, epigenetic modification	embryo
<i>Hist1h2aa</i>	TH2A; histone cluster 1, H2aa	Genomic reprogramming, paternal genome activation, pluripotency	embryo
<i>Hist1h2ba</i>	TH2B; histone cluster 1, H2ba	Genomic reprogramming, paternal genome activation, pluripotency	embryo
<i>Hist1h3f</i>	Histone H3; histone cluster 1, H3f	Chromatin structure, epigenetic modification	2-cell
<i>Hist1h4f</i>	Histone H4; histone cluster 1, H4f	Chromatin structure, epigenetic modification	2-cell
<i>Kdm1B</i>	lysine (K)-specific demethylase 1B	DNA methylation, epigenetic modification	mid gestation
<i>Pou5F1</i>	Oct4; POU class 5 homeobox 1	Pluripotency determinant, transcription factor, regulation of PGC7	2-cell
<i>Ring1</i>	ring finger protein 1	Chromatin structure, silencing differentiation genes	2-cell
<i>Rnf2</i>	ring finger protein 2	Chromatin structure, silencing differentiation genes	2-cell
<i>Slbp</i>	stem-loop binding protein	Histone gene regulation	2-cell
<i>Sox2</i>	SRY (sex determining region Y)-box 2	Pluripotency determinant, transcription factor	early embryo
<i>Tet3</i>	tet methylcytosine dioxygenase 3	Paternal genome demethylation	early embryo
<i>Trim24</i>	Tif1A; tripartite motif-containing 24	Chromatin structure, epigenetic modification	2-4 cell
<i>Trim28</i>	Tif1b; tripartite motif-containing 28	Epigenetic modification, interacts with Zfp57	early embryo
<i>Xist</i>	inactive X specific transcripts	Epigenetic modification, X-inactivation	embryo
<i>Dnmt3a</i>	DNA methyltransferase 3A	DNA methylation, genomic imprinting	embryo
<i>Dnmt3l</i>	DNA (cytosine-5-)-methyltransferase 3-like	DNA methylation, genomic imprinting	mid gestation
<i>Dppa3</i>	Pgc7/Stella; developmental pluripotency-associated 3	DNA methylation, genomic imprinting	2-cell

3

1 **Table 5.11: List of mammalian maternal-effect genes (continued).**

2 (Maternal-effect was mainly described in mice (Condic 2016)).

GENE	DESCRIPTION	ROLE IN DEVELOPMENT	LETHALITY
<i>Esr2</i>	estrogen receptor 2 (beta)	Genomic imprinting, endocrine response	embryo
<i>Gja4</i>	gap junction protein, alpha 4	Genomic imprinting, gap-junctional communication	embryo
<i>KHDC3L</i>	ECAT1/C6orf221; KH domain containing 3-like, subcortical maternal complex member (human)	Genomic imprinting, associates with NLRP7	zygote
<i>Nlrp2</i>	NLR family, pyrin domain containing 2	DNA methylation, genomic imprinting	2-cell
<i>NLRP7</i>	NLR family, pyrin domain containing	DNA methylation, genomic imprinting	zygote
Oocyte cytoplasmic lattice			
<i>Khdc3</i>	FILIA; KH domain containing 3, subcortical maternal complex member	Chromosome stability, binds NRLP5, oocyte	embryo
<i>Nlrp5</i>	MATER; NLR family, pyrin domain containing 5	Oocyte cytoplasmic lattice assembly, mitochondrial activation	2-cell
<i>Ooep</i>	Floped; oocyte expressed protein	Oocyte cytoplasmic lattice assembly	2-cell
<i>Padi6</i>	peptidyl arginine deiminase, type VI	Oocyte cytoplasmic lattice assembly	2-cell
<i>Tle6</i>	transducin-like enhancer of split 6,	Oocyte cytoplasmic lattice assembly	2-cell
Transcriptional regulation			
<i>Bnc1</i>	basonuclin 1	Transcription factor	2-cell
<i>Brwd1</i>	bromodomain and WD repeat domain containing 1	Zygotic gene activation, chromatin remodeling	2-cell
<i>Ctcf</i>	CCTC-binding factor	Transcription factor; Epigenetic modification	early embryo
<i>Figla</i>	folliculogenesis specific basic helix-loop-helix	Transcription factor; Genomic imprinting	embryo
<i>Hira</i>	histone cell cycle regulator	DNA transcription and replication	zygote
<i>Hsf1</i>	heat shock factor 1	Transcription factor	zygote
<i>Kmt2d</i>	Mll2; lysine (K)-specific methyltransferase 2D	Zygotic gene activation, DNA methylation	2-cell
<i>Mir196a-1</i>	microRNA 196a-1	Negative regulator of NOBOX	embryo
<i>MIR212</i>	microRNA 212 (human)	Regulates FIGLA stability	embryo
<i>Nobox</i>	NOBOX oogenesis homeobox	Transcription factor	embryo
<i>Pdk1</i>	pyruvate dehydrogenase kinase, isoenzyme 1	Zygotic gene activation	2-cell
<i>Pik3r1</i>	phosphatidylinositol 3-kinase, regulatory subunit, polypeptide 1 (p85 alpha)	Zygotic gene activation	2 cell
<i>Sebox</i>	SEBOX homeobox	Transcription factor	2-cell
<i>Smarca4</i>	Brg1; SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4	Zygotic gene activation	2-cell
<i>Zfp36l2</i>	zinc finger protein 36, C3H type-like	Zinc-finger protein; Degradation of	2-cell
<i>Zfp57</i>	zinc finger protein 57	Zinc finger protein; Genomic imprinting	embryo

3

1 **Table 5.11: List of mammalian maternal-effect genes (continued).**

2 (Maternal-effect was mainly described in mice (Condic 2016)).

GENE	DESCRIPTION	ROLE IN DEVELOPMENT	LETHALITY
Ubiquitin pathway/DNA repair			
<i>Bcas2</i>	breast carcinoma amplified sequence 2	DNA repair/RPA complex	2–4 cell
<i>Pms2</i>	postmeiotic segregation increased 2		early embryo
<i>Rlim</i>	Rnf12; ring finger protein, LIM domain interacting	Ubiquitin ligase; X-inactivation	embryo
<i>Ube2a</i>	Hr6a; ubiquitin-conjugating enzyme	Ubiquitin-conjugating enzyme;	2-cell
<i>Uchl1</i>	ubiquitin carboxy-terminal hydrolase L1	Deubiquitinating enzyme	morula
Undetermined embryonic functions			
<i>BCAR4</i>	breast cancer anti-estrogen resistance 4 (human)	Breast cancer anti-estrogen resistance factor	morula
<i>Gas6</i>	growth arrest specific 6	Cytokine, Axl ligand	zygote
<i>Gclm</i>	glutamate-cysteine ligase, modifier subunit	Glutathione synthesis	blastocyst

3

4

5

6 **5.1.2.2 NLRP7**

7 Familial biparental hydatidiform moles (FBHM) (OMIM 231090) are aberrant human
8 pregnancies in which there is nonexistent or abnormal embryonic development,
9 excessive trophoblastic proliferation, and cystic degeneration of chorionic villi into
10 grape-like structures (Rezaei et al. 2016). Unlike complete hydatidiform moles which
11 are mostly sporadic and wholly androgenic, women with FBHM suffer from recurrent
12 molar pregnancies and the molar tissues are not androgenetic but show a normal
13 pattern of bi-parental diploid inheritance (Van den Veyver and Al-Hussaini 2006).
14 FBHM is associated with global failure in the establishment and or the maintenance
15 of methylation marks at maternal imprinting centres during oocyte growth or post-
16 zygotic development, respectively. The genome-wide methylation analysis of molar

1 tissues showed widespread hypomethylation at maternal DMRs, including placental-
2 specific DMRs (Court et al. 2014), whilst the paternal DMRs (e.g. *H19/IGF2*:IG-DMR
3 and *MEG3/DLK1*:IG-DMR) and non-imprinted regions are unaffected (Judson et al.
4 2002; El-Maarri 2003; Djuric et al. 2006; Kou et al. 2008; Hayward et al. 2009;
5 Sanchez-Delgado et al. 2015). The genetic investigations of FBHM identified
6 recessive mutations in the maternal-effect gene *NLRP7* in approximately 70% of
7 cases. Consequently, it was suggested that the *NLRP7* maternal loss of function was
8 responsible for FBHM phenotype (Murdoch et al. 2006; Kou et al. 2008; Hayward et
9 al. 2009). To date, 59 pathogenic recessive mutations in *NLRP7* have been
10 described in the aetiology of FBHM (Reddy et al. 2016).

11

12 *NLRP7* (NLR family pyrin domain containing 7) is a maternal-effect gene for which
13 the transcript product has been documented in a large number of human tissues
14 including liver, lung, placenta, spleen, thymus, peripheral blood leukocytes, testis
15 and ovaries (Slim and Wallace 2013). *NLRP7* transcripts are found in all oocyte and
16 preimplantation embryo stages (Murdoch et al. 2006). Its transcript concentration
17 decreases during oocyte maturation until the morula stage where it reaches its
18 lowest level. The transcript level then increases rapidly from day 3 to day 5, which
19 corresponds to the blastocyst stage and the activation of the embryonic genome
20 (Murdoch et al. 2006; P. Zhang et al. 2008; Slim and Wallace 2013). *NLRP7* gene
21 product was also found to be involved in cell proliferation, although its precise role
22 has not been fully described yet (Okada et al. 2004; Khare et al. 2012). Some studies
23 have suggested that *NLRP7* silencing induces growth inhibition (Okada et al. 2004)

1 whilst others have suggested the opposite (Khare et al. 2012). *NLRP7* is also known
2 to be a negative feedback regulator of the interleukin 1 beta (IL-1B) cytokine and
3 consequently plays a role in the inflammatory pathway (Kinoshita et al. 2005;
4 Messaed et al. 2011). The inflammasome is an important mechanism during pre-
5 implantation of the embryo. It facilitates the implantation of the blastocyst, regulates
6 the protease network and controls the extent to which the trophoblast may invade
7 the maternal endometrium (Karmakar and Das 2002; Strakova et al. 2002; Murdoch
8 et al. 2006). Finally, pathogenic mutations in *NLRP7* may also be associated with
9 the global maternal genomic imprinting alteration in FBHM, hence suggesting that
10 *NLRP7* may have a role in regulating genomic imprinting methylation in an
11 unrecognised manner.

12

13 **5.1.2.3 ZFP57**

14 Transient neonatal diabetes mellitus type 1 (TNDM1) is a form of diabetes mellitus.
15 TNDM1 is caused by the over-expression of the *PLAGL1* imprinted gene (paternally
16 expressed) located at chromosome 6q24 (Gardner et al. 2000; Kamiya et al. 2000).
17 The loss-of-methylation of the imprinting centre *PLAGL1:alt-TSS-DMR*, which is
18 normally maternally methylated and regulates *PLAGL1* gene expression, accounts
19 for approximately 20% of TNDM1 cases. Among these patients, approximately
20 half of them also have mosaic pattern of hypomethylation affecting other maternally
21 methylated imprinted DMRs (Mackay et al. 2006). Recessive homozygous and
22 compound heterozygous mutations in the maternal-zygotic gene *ZFP57* have been
23 identified in approximately 50% of TNDM1 with MLID patients, consequently

1 suggesting that MLID may be the result of a *trans*-mechanism defects involving
2 *ZFP57* (Mackay et al. 2008).
3
4 *ZFP57* (*ZFP57* zinc finger protein) is a maternal-zygotic gene that encodes for a
5 protein containing a *Krüppel*-associated box (KRAB) domain and 7 zinc fingers. The
6 maternal and zygotic products are both required for normal embryonic development.
7 In mice, the single loss of zygotic *Zfp57* results in partial neonatal lethality whilst the
8 lost of both the maternal and the zygotic function results in a highly penetrant
9 embryonic lethality (X. Li et al. 2008). *Zfp57* was shown to be required for the
10 establishment of DNA methylation at some maternally methylated DMRs but overall
11 that it was not an essential factor for general maternal germline imprinting. Indeed,
12 the loss of *Zfp57* maternal function in oocytes results in the failure to establish
13 methylation at the maternally methylated *Snrpn* DMR but not at *Peg1*, *Peg3*, and
14 *Peg5/Nnat* DMRs (X. Li et al. 2008). *ZFP57* is also essential for faithful maintenance
15 of DNA methylation at paternal and maternal imprinted DMRs. The maintenance of
16 DNA methylation at the paternally methylated IG-DMR and at the maternally
17 methylated *Snrpn*, *Peg1*, *Peg3*, and *Peg5/Nnat* DMRs failed in embryos lacking both
18 maternal and zygotic *Zfp57* functions. In embryos lacking *Zfp57* maternal function
19 only, the loss of DNA methylation is rescued by the zygotic *Zfp57*, whilst the
20 maintenance of DNA methylation is sometimes compromised in embryos lacking the
21 zygotic *Zfp57* only (X. Li et al. 2008). In humans, the study of TNDM1 patients
22 showed that pathogenic mutations in *ZFP57* was associated with mosaic pattern of
23 MLID, hence demonstrating the critical role of *ZFP57* in the maintenance of genomic

1 imprinting methylation (Mackay et al. 2008). Finally, the investigation of mouse
2 embryonic stem cells revealed that ZFP57 recognises and binds specifically to the
3 methylated TGCC[met]GC hexanucleotide motif and subsequently associates with
4 TRIM28 (also known as KAP1), the H3K9 methyltransferase SETDB1 and the
5 heterochromatin HP1 (Quenneville et al. 2011; Zuo et al. 2012). The protein complex
6 is particularly enriched at all known imprinting centres, protect the DNA methylation
7 from the genome-wide epigenetic reprogramming occurring after fertilisation and
8 maintain the DNA methylation status during development, consequently preserving
9 the parent of origin-specific gene expression (Quenneville et al. 2011). The knockout
10 of Zfp57 in mouse embryonic stem cells demonstrated that the loss of Zfp57 results
11 in hypomethylation at multiple imprinted loci (Quenneville et al. 2011; Zuo et al. 2012)
12 and that the loss of the epigenetic memory at these DMRs was irreversible (i.e. not
13 re-established) even upon re-introduction of exogenous Zfp57 (Zuo et al. 2012).

14

15 **5.1.2.4 NLRP2**

16 A *trans*-mechanism involving the maternal-effect gene *NLRP2* (NLR family pyrin
17 domain containing 2) has been described in BWS with MLID. *NLRP2* is a member
18 of the NACHT, LRR and PYD domains-containing protein family and is highly
19 homologous to *NLRP7*. A recessive homozygous frameshift mutation affecting
20 *NLRP2* and resulting in a truncated protein has been found in the unaffected mother
21 of three children, of which two were diagnosed with BWS. Complex consanguinity
22 was described in the family and the mother was also suspected to have a
23 hydatidiform mole pregnancy. One child had LOM at *KCNQ1OT1:TSS-DMR* and

1 was homozygous for the mutation. The second child with BWS had LOM at both
2 *KCNQ1OT1*:TSS-DMR and at *MEST*:alt-TSS-DMR and was heterozygous for the
3 mutation. Consequently, it was suggested that the BWS phenotype was likely due to
4 *NLRP2* maternal-effect mutation rather than the loss of *NLRP2* zygotic function. To
5 date, it is the only report linking imprinting disorders to mutations in *NLRP2*, which
6 suggests that *NLRP2*-induced imprinting disorders is very rare and appears to affect
7 a small minority of cases.

8
9 *NLRP2* has been shown to negatively regulate the activation of the transcription
10 factor NFκB induced by various pro-inflammatory stimuli, including tumour necrosis
11 factor alpha (TNFα) and interleukin 1 beta (IL1B) (Bruey et al. 2004). The interaction
12 of *NLRP2* with PYCARD, a member of the caspase-associated recruitment domains-
13 containing adaptor protein family, was shown to enhance caspase 1 activation and
14 IL1B secretion (Bruey et al. 2004). Multiple evidences have suggested that *NLRP2*
15 is a maternal-effect gene required for early embryonic development. Similarly to
16 *NLRP7*, *NLRP2* transcripts are found in all oocyte and pre-implantation embryo
17 stages (Murdoch et al. 2006) and *NLRP2* transcript level is at the highest in the
18 oocyte, then slowly decrease from the germinal vesicle stage to day 3 embryos and
19 finally increase again on day 5 (P. Zhang et al. 2008). The knockdown of *Nlrp2* in
20 mouse oocytes results in normal maturation of the oocytes but the development of
21 parthenogenetic embryos derived from *Nlrp2* knockdown oocytes mainly arrest at
22 the 2-cell stage. In contrast, 60% of the control parthenogenetic embryos reached
23 the blastocyst stage (Peng et al. 2012). Similarly, the depletion of maternal *Nlrp2* in

1 zygotic embryos also showed an early embryonic development arrest between the
2 2- to 8- cells stage (Peng et al. 2012). Finally, as mentioned above, a maternal-effect
3 mutation in *NLRP2* was linked to MLID and BWS phenotype. Therefore, it was
4 suggested that *NLRP2* might play a role in the establishment and or maintenance of
5 the DNA methylation at imprinted regions, but the exact mechanism remains
6 unknown (Meyer et al. 2009).

7

8 **5.1.2.5 KHDC3L**

9 *KHDC3L* (KH domain containing 3 like, subcortical maternal complex member), is a
10 maternal-effect gene that has been found responsible for approximately 5% of
11 *NLRP7*-negative familial biparental hydatidiform moles cases (Parry et al. 2011). To
12 date, 6 maternal-effect recessive mutations in *KHDC3L* gene have been described
13 in the aetiology of FBHM (Parry et al. 2011; Reddy et al. 2013; Rezaei et al. 2016).

14

15 *KHDC3L* precise protein function remains unknown but the protein belongs to the
16 *KHDC1* (KH homology domain containing 1) protein family which are known to bind
17 RNA. Several pieces of evidence suggest that *KHDC3L* is a maternal-effect gene
18 and may have similar or overlapping functions to *NLRP7* in the oocyte and in early
19 embryonic development. As mentioned above, pathogenic maternal recessive
20 mutations in *KHDC3L* are associated with abnormal embryonic development in
21 FBHM (Parry et al. 2011). *KHDC3L* has a very similar expression pattern than
22 *NLRP7*; *KHDC3L* transcript levels appear to be at their highest in germinal vesicle
23 oocytes and then decrease during preimplantation development and become

1 undetectable at the blastocyst stage (Parry et al. 2011). *KHDC3L* colocalises with
2 *NLRP7* to the microtubule organising centre and the Golgi apparatus in human
3 hematopoietic cells (Messaed et al. 2011; Reddy et al. 2013), and at the cytoskeleton
4 of the oocytes where they are both particularly abundant at the cortical region
5 (Akoury et al. 2014). Finally, *KHDC3L* forms with *NLRP5* (NLR family pyrin domain
6 containing 5), *OOEP* (oocyte expressed protein) and *TLE6* (transducin like enhancer
7 of split 6) the human subcortical maternal complex (SMC) protein (Zhu et al. 2015).
8 The human SMC may have a very similar role to the SMC counterpart in mice, which
9 was found to be essential for developmental progression beyond the first zygotic cell
10 divisions (L. Li et al. 2008; Yu et al. 2014). The MLID at maternal imprinted DMRs
11 associated with *KHDC3L*-positive FBHM cases also suggests that *KHDC3L* may
12 play a role in the establishment or maintenance of methylation at maternal imprinted
13 DMRs during oogenesis and early embryogenesis respectively. However, and similar
14 to *NLRP7*, this mechanism currently remains unknown.

15

16 **5.1.2.6 NLRP5**

17 Seven individuals with MLID were recently reported in five families. The clinical
18 features of the affected individuals were heterogeneous, with three children
19 diagnosed with BWS and MLID, two with SRS and MLID and two with non-specific
20 phenotype and MLID. Pregnancy losses and infertility issues were also reported in
21 some families. Genetic investigations of proband's family pedigree have identified
22 pathogenic homozygous and compound heterozygous mutations in the maternal-
23 effect gene *NLRP5* in the proband's mother. It was consequently suggested that the

1 maternal *NLRP5* depletion was responsible for the diseases phenotype and the
2 pregnancy losses and was likely involved in the genomic imprinting disturbances
3 (Docherty et al. 2015).

4

5 *Nlrp5*, also known as *Mater*, is exclusively expressed in the oocyte and was first
6 described as an antigen associated with ovarian autoimmunity in mice (Tong and
7 Nelson 1999). *Nlrp5* was later found to be a maternal-effect gene required for normal
8 embryonic development (Tong et al. 2000). The *Nlrp5* null female mice have normal
9 oocyte maturation and ovulation, but they are sterile. The *Nlrp5* maternal loss of
10 function results in embryonic developmental arrest at the 2-cell stage. Similar
11 phenotypes were also observed in rhesus macaque monkeys, in which the maternal
12 depletion of NLRP5 resulted in embryonic developmental arrest between the 8-cell
13 and the 16-cell stage (Wu 2009). Some data also showed that the depletion of
14 NLRP5 in mice disrupts the assembly of the subcortical maternal complex, which
15 was found to be essential for developmental progression beyond the first zygotic cell
16 divisions (L. Li et al. 2008; Yu et al. 2014). Finally, both paternal and maternal
17 imprinted DMRs are disturbed in MLID patients with a maternal depletion of *NLRP5*
18 (Docherty et al. 2015), hence suggesting an unrecognised role in the maintenance
19 of genomic imprinting methylation.

20

21 **5.1.2.7 Other candidate genes**

22 In addition to the few known causative genes described in the aetiology of MLID,
23 other candidates have been proposed to be involved in the disruption of genomic

1 imprinting via *trans*-mechanism defects. This includes the maintenance DNA
2 methyltransferase DNMT1, the active *de novo* DNA methyltransferases DNMT3A,
3 DNMT3B and the enzymatically inactive DNMT3L, the ZFP57 co-factor TRIM28, the
4 DNA-binding protein CTCF, the methyl-CpG-binding proteins MBD3 and the
5 developmental pluripotency-associated protein DPPA3 (Begemann et al. 2011; Azzi
6 et al. 2014; Caliebe et al. 2014). However, to date no additional causative gene
7 mutations have been described in MLID pathway.

8

9 **5.1.3 Aim**

10 The underlying causes resulting in MLID are still not clearly understood but a few
11 hypotheses have been formulated to explain the widespread methylation defects
12 observed in imprinting disorders. As seen previously, environmental insults such as
13 ART could directly disrupt the genomic imprinting. Additionally, mutations occurring
14 in maternal-effect genes have been found in patients with MLID, hence suggesting
15 those genes might play a critical role in MLID aetiology. Although it has not been
16 reported yet, I also hypothesised that mutations in genes associated to the
17 methylation pathway could cause methylation disturbances at imprinted loci via a
18 *trans*-mechanism. Finally, many imprinted genes belong to a complex imprinted
19 gene network. I hypothesised that pathogenic mutations occurring in one of the
20 member of the network may result to *cis*-defects and then to possible subsequent
21 *trans*-methylation disturbances at other members of the network. In that regards, in
22 order to gain additional insights into the underlying causes responsible for MLID in

1 BWS I performed methylation profiling using the HM450K platform and my
2 bioinformatic pipeline (see section 4.2.4 - DNA methylation profiling using HM450K)
3 of BWS_IC2 patients conceived with the help of ART and studied the effects of the
4 ART procedures on genomic imprinting methylation. Additionally, using whole-
5 exome sequencing (WES) I compared the genetics of BWS_IC2 individuals with and
6 without MLID to identify potential genetic components responsible for the
7 widespread genomic imprinting disturbances.

8

9 **5.2 Materials and methods**

10 **5.2.1 Patient DNA**

11 According to the criteria described in the literature (<http://www.geneclinics.org>), BWS
12 was diagnosed in 78 screened patients. The molecular diagnostic investigations
13 undertaken in NHS laboratories identified LOM at *KCNQ1OT1:TSS-DMR*
14 (BWS_IC2) as the cause of the BWS phenotype. 13 of these patients were reported
15 as conceived with the help of ART (2 following OS, 3 following IVF and 8 following
16 ICSI). The use of ART was not reported in the remaining 65 BWS_IC2 individuals.

17

18 **5.2.2 DNA quantification**

19 See section 2.3 - DNA quantification.

20

21 **5.2.3 DNA purification**

22 See section 2.2 - DNA purification.

1 **5.2.4 Sodium bisulfite treatment**

2 See section 2.4 – Sodium bisulfite treatment.

3

4 **5.2.5 DNA methylation profiling using HM450K**

5 See section 4.2.4 - DNA methylation profiling using HM450K.

6

7 **5.2.6 Whole-exome sequencing**

8 In order to investigate the potential genetic causes that could lead to MLID, 25
9 BWS_IC2 patients with MLID and 17 BWS_IC2 patients with no MLID were
10 processed for whole-exome sequencing and analysed as described below (Figure
11 5.2).

12

13 **5.2.6.1 Library preparation and sequencing**

14 gDNA was quantified with Qubit® dsDNA HS Assay Kits (see section 2.3 - DNA
15 quantification) and 50 ng was used to perform whole-exome sequencing. Library
16 preparation (Nextera Rapid Capture Exomes (Dual Indexed), Illumina) and
17 sequencing (NextSeq500, High Output 300 cycle (2x150bp Paired End), Illumina)
18 was performed at the Stratified Medicine Core Laboratory (SMCL) Next Generation
19 Sequencing facility hosted at the Department of Medical Genetics, University of
20 Cambridge.

21

22

1 **5.2.6.2 Alignment and variant calling**

2 Read alignments and variant calling were kindly done by Dr. Ezequiel Martín
3 Rodríguez. The bioinformatic pipeline relies on freely available bioinformatic tools
4 such as Burrows–Wheeler transformation (BWA) v0.7.5a-r405 for
5 sequences alignment to the Genome Reference Consortium Human Build 38 patch
6 release 6 (GRCh38.p6), samtools (H. Li et al. 2009) v0.1.19 for manipulating files
7 and removing reads duplicates and Genome Analysis Toolkit (GATK)
8 (McKenna et al. 2010; DePristo et al. 2011) v3.3-0-g37228af for realigning
9 complicated regions such as insertion-deletion (indel), recalibration of base quality
10 scores (i.e. Q scores) and variant calling.

11

12 **5.2.6.3 Filtering and annotation**

13 vcfutils (Danecek et al. 2011) v0.1.12b was used to filter out low quality score (Q
14 <30), low read depth coverage (DP <20x) and homozygous variants for the reference
15 allele. Filtered files were then annotated with Annovar (Kai Wang et al. 2010) using
16 available database. This includes, but not limited to, gene, transcript and protein
17 names (e.g. NCBI Reference Sequence (RefSeq)), single nucleotide polymorphism
18 (e.g. avSNP147), allele frequency (e.g. 1000 Genome Project, Exome Aggregation
19 Consortium (ExAC), NHLBI GO Exome Sequencing Project (ESP)), genomic
20 variation and its relationship to human health (e.g. ClinVar, Catalogue of Somatic
21 Mutations in Cancer (COSMIC)), effects of amino acid substitution or indels on the
22 structure and function of a human protein (e.g. SIFT (Henikoff and M.M. Smith 2015)),


1 PROVEAN (Choi et al. 2012), PolyPhen-2 (Adzhubei et al. 2010)) and effects of
2 genetic variants on human splicing (e.g. ada-boost and random forest dbscSNV
3 scores (Jian et al. 2014), SPIDEX™ (Xiong et al. 2015)).

4

5 **5.2.6.4 Variant call analysis**

6 Filtered variant call files were analysed in R. Variants occurring in exonic or splicing
7 regions with minor allele frequency below 1% in the frequency databases 1000
8 Genome Project, ExAC and ESP and affecting protein function or splicing were
9 retained for analysis. Based on literature research, I elaborated a list of candidate
10 genes for which I believed genetic mutation altering their functions may have
11 dramatic consequences in the establishment, maintenance or erasure of genomic
12 imprinting. Consequently, rare variants occurring in gene shown to have a maternal-
13 effect in mammalian species (Table 5.11) or associated with methylation pathways
14 (Table 5.12) were flagged as potential disease causing candidates. Furthermore, due
15 to the existence of complex interactions between imprinted genes (i.e. imprinted
16 gene network (Varrault et al. 2006; Patten et al. 2016; Soellner et al. 2016)), rare
17 variants occurring in imprinted genes (Table 5.13) were also flagged as potential
18 disease causing candidates. Finally, web-tools such as ToppGene (J. Chen et al.
19 2009) were also used to prioritise candidate genes.

20



1

2 **Figure 5.2: Overview of the whole-exome sequencing workflow.**

1 **Table 5.12: List of methylation associated genes.**

GENE	LOCATION	DESCRIPTION
<i>BAZ2A</i>	12q13.3	bromodomain adjacent to zinc finger domain 2A
<i>BAZ2B</i>	2q24.2	bromodomain adjacent to zinc finger domain 2B
<i>MBD1</i>	18q21	methyl-CpG binding domain protein 1
<i>MBD2</i>	18q21	methyl-CpG binding domain protein 2
<i>MBD3</i>	19p13	methyl-CpG binding domain protein 3
<i>MBD4</i>	3q21.3	methyl-CpG binding domain 4, DNA glycosylase
<i>MBD5</i>	2q23.2	methyl-CpG binding domain protein 5
<i>MBD6</i>	12q13.2	methyl-CpG binding domain protein 6
<i>MECP2</i>	Xq28	methyl-CpG binding protein 2
<i>SETDB1</i>	1q21	SET domain bifurcated 1
<i>SETDB2</i>	13q14	SET domain bifurcated 2
<i>SUV39H1</i>	Xp11.23	suppressor of variegation 3-9 homolog 1
<i>SUV39H2</i>	10p13	suppressor of variegation 3-9 homolog 2
<i>EHMT2</i>	6p21.3	euchromatic histone lysine methyltransferase 2
<i>EHMT1</i>	9q34.3	euchromatic histone lysine methyltransferase 1
<i>KMT2A</i>	11q23	lysine methyltransferase 2A
<i>KMT2B</i>	19q13.12	lysine methyltransferase 2B
<i>KMT2C</i>	7q36	lysine methyltransferase 2C
<i>KMT2D</i>	12q13.12	lysine methyltransferase 2D
<i>KMT2E</i>	7q22.1	lysine methyltransferase 2E
<i>SETD1A</i>	16p11.2	SET domain containing 1A
<i>SETD1B</i>	12q24.31	SET domain containing 1B
<i>ASH1L</i>	1q22	ASH1 like histone lysine methyltransferase
<i>SETD2</i>	3p21.31	SET domain containing 2
<i>NSD1</i>	5q35	nuclear receptor binding SET domain protein 1
<i>SMYD2</i>	1q32.3	SET and MYND domain containing 2
<i>SMYD1</i>	2p11.1	SET and MYND domain containing 1
<i>SMYD3</i>	1q44	SET and MYND domain containing 3
<i>DOT1L</i>	19p13.3	DOT1 like histone lysine methyltransferase
<i>KMT5A</i>	12q24.31	lysine methyltransferase 5A
<i>KMT5B</i>	11q13.2	lysine methyltransferase 5B
<i>KMT5C</i>	19q13.42	lysine methyltransferase 5C
<i>SETD7</i>	4q31.1	SET domain containing lysine methyltransferase 7
<i>PRDM2</i>	1p36	PR/SET domain 2
<i>KDM1A</i>	1p36.12	lysine demethylase 1A
<i>KDM1B</i>	6p22.3	lysine demethylase 1B
<i>KDM2A</i>	11q13.1	lysine demethylase 2A
<i>KDM2B</i>	12q24.31	lysine demethylase 2B
<i>KDM3A</i>	2p11.2	lysine demethylase 3A
<i>KDM3B</i>	5q31	lysine demethylase 3B
<i>KDM4A</i>	1p34.1	lysine demethylase 4A
<i>KDM4B</i>	19p13.3	lysine demethylase 4B
<i>KDM4C</i>	9p24-p23	lysine demethylase 4C
<i>KDM4D</i>	11q21	lysine demethylase 4D

2

1 **Table 5.12: List of methylation associated genes (continued).**

GENE	LOCATION	DESCRIPTION
<i>KDM4E</i>	11q21	lysine demethylase 4E
<i>KDM5A</i>	12p13.33	lysine demethylase 5A
<i>KDM5B</i>	1q32.1	lysine demethylase 5B
<i>KDM5C</i>	Xp11.22-p11.21	lysine demethylase 5C
<i>KDM5D</i>	Yq11	lysine demethylase 5D
<i>KDM6A</i>	Xp11.2	lysine demethylase 6A
<i>KDM6B</i>	17p13.1	lysine demethylase 6B
<i>KDM7A</i>	7q34	lysine demethylase 7A
<i>PHF8</i>	Xp11.22	PHD finger protein 8
<i>PHF2</i>	9q22	PHD finger protein 2
<i>KDM8</i>	16p12.1	lysine demethylase 8
<i>HDAC1</i>	1p34	histone deacetylase 1
<i>HDAC2</i>	6q21	histone deacetylase 2
<i>HDAC3</i>	5q31.1-q31.2	histone deacetylase 3
<i>HDAC8</i>	Xq13	histone deacetylase 8
<i>HDAC4</i>	2q37.3	histone deacetylase 4
<i>HDAC5</i>	17q21	histone deacetylase 5
<i>HDAC7</i>	12q13.1	histone deacetylase 7
<i>HDAC9</i>	7p21.1	histone deacetylase 9
<i>HDAC6</i>	Xp11.23	histone deacetylase 6
<i>HDAC10</i>	22q13.31	histone deacetylase 10
<i>HDAC11</i>	3p25.1	histone deacetylase 11
<i>SIRT1</i>	10q21	sirtuin 1
<i>SIRT2</i>	19q13	sirtuin 2
<i>SIRT3</i>	11p15.5	sirtuin 3
<i>SIRT4</i>	12q24.31	sirtuin 4
<i>SIRT5</i>	6p23	sirtuin 5
<i>SIRT6</i>	19p13.3	sirtuin 6
<i>SIRT7</i>	17q25.3	sirtuin 7
<i>PHC1</i>	12p13	polyhomeotic homolog 1
<i>PHC2</i>	1p34.3	polyhomeotic homolog 2
<i>PHC3</i>	3q26.32	polyhomeotic homolog 3
<i>CBX6</i>	22q13.1	chromobox 6
<i>CBX2</i>	17q25.3	chromobox 2
<i>CBX4</i>	17q25.3	chromobox 4
<i>CBX7</i>	22q13.1	chromobox 7
<i>CBX8</i>	17q25.3	chromobox 8
<i>PCGF1</i>	2p13.1	polycomb group ring finger 1
<i>PCGF2</i>	17q12	polycomb group ring finger 2
<i>PCGF3</i>	4p16.3	polycomb group ring finger 3
<i>BMI1</i>	10p13	BMI1 proto-oncogene, polycomb ring finger
<i>PCGF5</i>	10q23.33	polycomb group ring finger 5
<i>PCGF6</i>	10q24.33	polycomb group ring finger 6
<i>RING1</i>	6p21.3	ring finger protein 1

2

1 **Table 5.12: List of methylation associated genes (continued).**

GENE	LOCATION	DESCRIPTION
<i>RNF2</i>	1q25.3	ring finger protein 2
<i>EZH1</i>	17q21.1-q21.3	enhancer of zeste 1 polycomb repressive complex 2 subunit
<i>EZH2</i>	7q35-q36	enhancer of zeste 2 polycomb repressive complex 2 subunit
<i>SUZ12</i>	17q21	SUZ12 polycomb repressive complex 2 subunit
<i>EED</i>	11q14.2-q22.3	embryonic ectoderm development
<i>ACTL6A</i>	3q26.33	actin like 6A
<i>ACTL6B</i>	7q22	actin like 6B
<i>ARID1A</i>	1p36.1-p35	AT-rich interaction domain 1A
<i>ARID1B</i>	6q25.3	AT-rich interaction domain 1B
<i>ARID2</i>	12q13.11	AT-rich interaction domain 2
<i>PBRM1</i>	3p21	polybromo 1
<i>SMARCA2</i>	9p24.3	SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2
<i>SMARCA4</i>	19p13.3	SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4
<i>SMARCA5</i>	4q31.1-q31.2	SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 5
<i>SMARCB1</i>	22q11.23	SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily b, member 1
<i>SMARCC1</i>	3p21.31	SWI/SNF related, matrix associated, actin dependent regulator of chromatin subfamily c member 1
<i>SMARCC2</i>	12q13.2	SWI/SNF related, matrix associated, actin dependent regulator of chromatin subfamily c member 2
<i>SMARCD1</i>	12q13-q14	SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily d, member 1
<i>SMARCD2</i>	17q23.3	SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily d, member 2
<i>SMARCD3</i>	7q35-q36	SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily d, member 3
<i>SMARCE1</i>	17q21.2	SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily e, member 1
<i>BCL11A</i>	2p16.1	B-cell CLL/lymphoma 11A
<i>BCL11B</i>	14q32	B-cell CLL/lymphoma 11B
<i>BCL7A</i>	12q24.1	BCL tumor suppressor 7A
<i>BCL7B</i>	7q11.23	BCL tumor suppressor 7B
<i>BCL7C</i>	16p11	BCL tumor suppressor 7C
<i>BRD7</i>	16q12.1	bromodomain containing 7
<i>BRD9</i>	5p15.33	bromodomain containing 9
<i>SS18</i>	18q11.2	SS18, nBAF chromatin remodeling complex subunit
<i>DPF1</i>	19q13.12	double PHD fingers 1
<i>DPF2</i>	11q13.1	double PHD fingers 2
<i>DPF3</i>	14q24.2	double PHD fingers 3
<i>DNMT1</i>	19p13.2	DNA methyltransferase 1
<i>DNMT3A</i>	2p23	DNA methyltransferase 3 alpha

2

1 **Table 5.12: List of methylation associated genes (continued).**

GENE	LOCATION	DESCRIPTION
<i>DNMT3B</i>	20q11.2	DNA methyltransferase 3 beta
<i>DNMT3L</i>	21q22.3	DNA methyltransferase 3 like
<i>TET1</i>	10q21	tet methylcytosine dioxygenase 1
<i>TET2</i>	4q24	tet methylcytosine dioxygenase 2
<i>TET3</i>	2p13.1	tet methylcytosine dioxygenase 3
<i>TDG</i>	12q24.1	thymine DNA glycosylase
<i>TRIM28</i>	19q13.4	tripartite motif containing 28
<i>CBX1</i>	17q21.32	chromobox 1
<i>CBX3</i>	7p15.2	chromobox 3
<i>CBX5</i>	12q13.13	chromobox 5
<i>CREBBP</i>	16p13.3	CREB binding protein
<i>EP300</i>	22q13.2	E1A binding protein p300
<i>PRAM1</i>	19p13.2	PML-RARA regulated adaptor molecule 1
<i>PCNA</i>	20p13-p12.3	proliferating cell nuclear antigen
<i>MLH1</i>	3p22.3	mutL homolog 1
<i>UHRF1</i>	19p13.3	ubiquitin like with PHD and ring finger domains 1

2

3

1 **Table 5.13: List of imprinted genes.**

GENE	LOCATION	DESCRIPTION
<i>DIRAS3</i>	1p31	DIRAS family GTPase 3
<i>TP73</i>	1p36.3	tumor protein p73
<i>LRRTM1</i>	2p12	leucine rich repeat transmembrane neuronal 1
<i>ZDBF2</i>	2q33.3	zinc finger DBF-type containing 2
<i>GPR1</i>	2q33.3	G protein-coupled receptor 1
<i>GPR1-AS</i>	2q33.3	GPR1 antisense RNA
<i>NAP1L5</i>	4q21-q22	nucleosome assembly protein 1 like 5
<i>RHOBTB3</i>	5q15	Rho related BTB domain containing 3
<i>FAM50B</i>	6p25.2	family with sequence similarity 50 member B
<i>LIN28B</i>	6q21	lin-28 homolog B
<i>AIM1</i>	6q21	absent in melanoma 1
<i>PLAGL1</i>	6q24-q25	PLAG1 like zinc finger 1
<i>HYMAI</i>	6q24.2	hydatidiform mole associated and imprinted (non-protein coding)
<i>PHACTR2</i>	6q24.1	phosphatase and actin regulator 2
<i>SLC22A2</i>	6q25.3	solute carrier family 22 member 2
<i>SLC22A3</i>	6q25.3	solute carrier family 22 member 3
<i>GRB10</i>	7p12.2	growth factor receptor bound protein 10
<i>CALCR</i>	7q21.3	calcitonin receptor
<i>TFPI2</i>	7q	tissue factor pathway inhibitor 2
<i>SGCE</i>	7q21.3	sarcoglycan epsilon
<i>PEG10</i>	7q21	paternally expressed 10
<i>CPA4</i>	7q32	carboxypeptidase A4
<i>MEST</i>	7q32	mesoderm specific transcript
<i>MESTIT1</i>	7q32.2	MEST intronic transcript 1, antisense RNA
<i>COPG2IT1</i>	7q32	COPG2 imprinted transcript 1 (non-protein coding)
<i>COPG2</i>	7q32	coatomer protein complex subunit gamma 2
<i>KLF14</i>	7q32.3	Kruppel like factor 14
<i>DLGAP2</i>	8p23	DLG associated protein 2
<i>ZFAT-AS1</i>	8q24.22	ZFAT antisense RNA 1
<i>KCNK9</i>	8q24.3	potassium two pore domain channel subfamily K member 9
<i>INPP5F</i>	10q26.13	inositol polyphosphate-5-phosphatase F
<i>WT1</i>	11p13	Wilms tumor 1
<i>WT1-AS</i>	11p13	WT1 antisense RNA
<i>ZNF215</i>	11p15.4	zinc finger protein 215
<i>H19</i>	11p15.5	H19, imprinted maternally expressed transcript (non-protein coding)
<i>IGF2</i>	11p15.5	insulin like growth factor 2
<i>MIR483</i>	11p15.5	microRNA 483
<i>IGF2-AS</i>	11p15.5	IGF2 antisense RNA
<i>INS</i>	11p15.5	insulin
<i>KCNQ1</i>	11p15.5	potassium voltage-gated channel subfamily Q member 1
<i>KCNQ1OT1</i>	11p15.5	KCNQ1 opposite strand/antisense transcript 1 (non-protein coding)
<i>KCNQ1DN</i>	11p15.5	KCNQ1 downstream neighbor (non-protein coding)

2

1 **Table 5.13: List of imprinted genes (continued).**

GENE	LOCATION	DESCRIPTION
<i>CDKN1C</i>	11p15.5	cyclin dependent kinase inhibitor 1C
<i>SLC22A18AS</i>	11p15.5	solute carrier family 22 member 18 antisense
<i>SLC22A18</i>	11p15.5	solute carrier family 22 member 18
<i>PHLDA2</i>	11p15.4	pleckstrin homology like domain family A member 2
<i>ANO1</i>	11q13.2	anoctamin 1
<i>WIF1</i>	12q14.2	WNT inhibitory factor 1
<i>RB1</i>	13q14.2	RB transcriptional corepressor 1
<i>RTL1</i>	14q32.2	retrotransposon-like 1
<i>DLK1</i>	14q32.2	delta like non-canonical Notch ligand 1
<i>MEG3</i>	14q32.2	maternally expressed 3 (non-protein coding)
<i>MEG8</i>	14q32.31	maternally expressed 8 (non-protein coding)
<i>MKRN3</i>	15q11-q13	makorin ring finger protein 3
<i>MAGEL2</i>	15q11.2	MAGE family member L2
<i>NDN</i>	15q11.2	necdin, MAGE family member
<i>PWRN1</i>	15q11.2	Prader-Willi region non-protein coding RNA 1
<i>NPAP1</i>	15q11.2	nuclear pore associated protein 1
<i>SNURF</i>	15q11.2	SNRPN upstream reading frame
<i>UBE3A</i>	15q11.2	ubiquitin protein ligase E3A
<i>NAA60</i>	16p13.3	N(alpha)-acetyltransferase 60, NatF catalytic subunit
<i>ZNF597</i>	16p13.3	zinc finger protein 597
<i>TCEB3C</i>	18q21.1	transcription elongation factor B subunit 3C
<i>DNMT1</i>	19p13.2	DNA methyltransferase 1
<i>AXL</i>	19q13.1	AXL receptor tyrosine kinase
<i>ZNF331</i>	19q13	zinc finger protein 331
<i>MIMT1</i>	19q13.43	MER1 repeat containing imprinted transcript 1 (non-protein coding)
<i>PEG3</i>	19q13.4	paternally expressed 3
<i>ZIM2</i>	19q13.4	zinc finger imprinted 2
<i>BLCAP</i>	20q11.23	bladder cancer associated protein
<i>NNAT</i>	20q11.2-q12	neuronatin
<i>MCTS2P</i>	20q11.21	malignant T-cell amplified sequence 2, pseudogene
<i>L3MBTL1</i>	20q13.12	l(3)mbt-like 1 (Drosophila)
<i>GNAS</i>	20q13.2-q13	GNAS complex locus
<i>SGK2</i>	20q13.2	SGK2, serine/threonine kinase 2
<i>SNU13</i>	22q13	SNU13 homolog, small nuclear ribonucleoprotein (U4/U6.U5)

2

3

4

5 **5.2.7 Sanger sequencing**

6 **5.2.7.1 Polymerase chain reaction**

7 For polymerase chain reaction (PCR) amplification, patient gDNA was quantified with

1 NanoDrop® ND-1000 (see section 2.3 - DNA quantification) and 30 ng of gDNA was
2 mixed with 0.125 µl of 5 U/µl AmpliTaq Gold DNA Polymerase (Thermo Fisher
3 Scientific), 2.5 µl of 10X PCR Buffer I, 0.5 µl of 10 mM dNTP mix, 0.5 µl of each 10
4 µM forward and reverse primers (see Table 5.14) and distilled water for a final
5 reaction volume of 25 µl. The mixture was mixed by pipetting up and down several
6 times and then placed in a thermocycler. The reaction was then incubated at 95 °C
7 for 10 minutes, 30 cycles of 95 °C for 1 minute; 65 °C for 45 seconds and 72 °C for
8 45 minutes, 72 °C for 10 minutes and then hold at 4 °C. PCR products and 1 kb DNA
9 ladder (Bioline) were loaded on a 1.5% agarose gel electrophoresis (1.5 g agarose
10 dissolved in 100 ml 1X TAE (see section 2.1.7 - 1X TAE), 2 µl of SYBR Safe) and
11 the gel was run for 40 minutes at 100 V. Once finished, the gel was placed into Gel
12 Doc XR+ System (Bio-Rad) for UV exposition. The size of amplicons was compared
13 to the 1 kb DNA ladder and successful amplified PCR products (i.e. the one with
14 correct size) were used immediately after or stored at -20 °C for later use.

15

1 **Table 5.14: Primers used for Sanger sequencing validation.**

Gene	Name	Chr	Start	End	Ref	Alt	Function	Exonic function	dbSNP147	Forward primer (5'>3')	Reverse primer (5'>3')	Amplicon size (bp)
TDG	variant 1	12	103984920	103984920	-	A	exonic	frameshift insertion	rs764159587	AGCTCTGCTATGTTATGCCATCATC	AGAGCACTGGCTGCGAATA	534
TDG	variant 2	12	103984921	103984921	G	A	splicing			AGCTCTGCTATGTTATGCCATCATC	AGAGCACTGGCTGCGAATA	534
TDG	variant 3	12	103984922	103984922	T	G	splicing		rs760400700	AGCTCTGCTATGTTATGCCATCATC	AGAGCACTGGCTGCGAATA	534
TDG	variant 4	12	103980073	103980073	G	A	splicing		rs780554309	GAGACTCATGTTGGGACTGTAAGAG	GACACCAATTTACCACCAAAAGGAT	512
TDG	variant 5	12	103984747	103984747	A	C	splicing			ATTCTCTGTACATGCCATTTGGA	AGTAATGAACTTTGCTTTGGGCTC	534
TDG	variant 6	12	103984748	103984748	G	T	splicing			ATTCTCTGTACATGCCATTTGGA	AGTAATGAACTTTGCTTTGGGCTC	534
TDG	variant 7	12	103985729	103985729	G	T	splicing		rs762057949			
PHF10	variant 8	6	169715806	169715806	A	C	exonic non-synonymous SNV		rs562092150	AACACACACATAGGTGGTACAA	TTGGTCTAAAAATAGGCTTAACAGCAT	505
PHF10	variant 9	6	169715755	169715755	G	A	exonic non-synonymous SNV		rs77919800	AACACACACATAGGTGGTACAA	TTGGTCTAAAAATAGGCTTAACAGCAT	505
PHF10	variant 10	6	169715761	169715761	A	C	exonic non-synonymous SNV		rs144595699	AACACACACATAGGTGGTACAA	TTGGTCTAAAAATAGGCTTAACAGCAT	505
BNC1	variant 11	15	83264026	83264026	G	T	exonic non-synonymous SNV			AGTATCCAGGCGTGTGCTA	GCCAAAGTGAAGCCTGAGAGGAA	503
CTCF	variant 12	16	67636779	67636779	C	T	exonic non-synonymous SNV		rs145727304	TTTTCTTTTCATCTCCACCACCCCTTCT	TTCAAAACCCGCCACACATTAAAC	504
NLRP2	variant 13	19	54982915	54982915	C	G	exonic non-synonymous SNV		rs139903547			
NLRP2	variant 14	19	54986222	54986222	C	T	exonic non-synonymous SNV		rs200375320			
NLRP2	variant 15	19	54990056	54990056	G	A	exonic non-synonymous SNV			TGAGGTGGTCTCTATTCTCCCA	CATGACCATTGCTGCTGTGTG	278
ZDBF2	variant 16	2	206304878	206304878	T	G	exonic stop-gain		rs755604527	GACTGCCTGGATTCCCTTGTCTTTA	ACTAGCAGGAGCATTACAAATCAC	508
ZDBF2	variant 17	2	206310752	206310752	G	T	exonic non-synonymous SNV		rs36095066	AGTTGAATTTCTGCATCATGTACT	TGGAGAGATTTTGACAAACATCATGATT	514
KCNQ1	variant 18	11	2585225	2585225	C	T	exonic non-synonymous SNV			CACTGACCATACCTGGCCTTC	GTGAGGGCTGGATGCAACAATA	274

Primers were selected from Primer Designer™ Tool database (Thermo Fisher Scientific)

1 **5.2.7.2 PCR product purification**

2 Excess of primers and other types of singled stranded DNA contaminants were
3 removed from the successfully amplified PCR products using MultiScreen-PCR₉₆
4 Filter Plate (Millipore). All the PCR product were pipetted into the filter plate. The
5 plate was placed on a vacuum manifold and pressed down until a vacuum is created.
6 The plate was let on the vacuum manifold until the filter was dry (approximately 3
7 minutes). The plate was then removed from the vacuum manifold, 20-25 µl of distilled
8 water was added to the purified product and the plate was left at room temperature
9 for 20 minutes. To dissolve completely the DNA, the water was mixed by pipetting
10 up and down several times and the resulting purified DNA was transferred into a new
11 plate. The purified DNA was used immediately after or stored at -20 °C for later use.

12

13 **5.2.7.3 Sequencing reaction**

14 The sequencing reaction was set up in PCR plates (Starlab) and sealed with Thermo
15 Seal Film (Starlab). In a PCR plate, 2 µl of purified PCR product was mixed with 1 µl
16 of BigDye Terminator 3.1 (Applied Biosystems), 4 µl of BigDye Terminator
17 sequencing buffer, 1 µl of 10 µM forward (or reverse) primer (see Table 5.14) and 11
18 µl of distilled water. The plate was placed in a thermocycler and incubated at 96 °C
19 for 5 minutes and 25 cycles of 96 °C for 10 seconds; 50 °C for 5 seconds and 60 °C
20 for 4 minutes, and hold at 4 °C. Products of BigDye termination sequencing reactions
21 were used immediately after or stored at -20 °C for later use.

22

23

1 **5.2.7.4 Sequencing clean-up**

2 Prior sequence data collection, the sequencing reaction was cleaned-up using
3 ethanol precipitation (see section 2.2 - DNA purification). However, the purified pellet
4 was kept dry and stored at -20 °C until ready to put the reaction on the sequencer.

5

6 **5.2.7.5 Sequence electrophoresis**

7 The dry pellet was resuspended in 10 µl of distilled water and 10 of µl HiDi™
8 formamide (Applied Biosystems). The mixture was denatured at 96 °C for 2 minutes,
9 and then cooled down on ice protected from lights. The mixture was then ready to
10 be place in an ABI 3730 capillary sequencer (Applied Biosystems) for sequencing
11 electrophoresis.

12

13 **5.2.7.6 Sequence data analysis**

14 Sequencing data were analysed using Sequencher v5.4.5 (Gene Codes). In
15 Sequencher, the sequencing reads were first aligned against an appropriate gene
16 specific reference file (GenBank file) downloaded from NCBI and the discrepancies
17 were detected and highlighted by the software.

18

19 **5.3 Results**


20 **5.3.1 Methylation profiling of BWS_IC2 patients conceived with**

21 **ART**

22 Among the 78 BWS_IC2 patients, 13 were conceived with the help of ART: 2 were

1 following ovarian stimulation (OS) only, 3 were following *in vitro* fertilisation (IVF) and
2 8 were following intra-cytoplasmic sperm injection (ICSI). ART was not reported in
3 the 65 other patients. Additionally to LOM at *KCNQ1OT1:TSS-DMR*, methylation
4 profiling of ART patients revealed MLID in 1 out of 2 (50%) patient conceived with
5 the help of OS, 2 out of 3 (67%) patient conceived with the help of IVF and 6 out of
6 8 (75%) patients conceived with the help of ICSI. Although 1 patient conceived with
7 OS had MLID, I didn't draw a conclusion regarding the prevalence of MLID in this
8 group as a limited number of cases were studied. IVF and ICSI follow similar clinical
9 procedures and therefore were grouped. Taken together, MLID was detected in 8 out
10 of 11 (73%) patients conceived with the help of IVF/ICSI. Out of the 65 naturally
11 conceived patients 22 had MLID (34%) (Figure 5.3). MLID frequency in the IVF/ICSI
12 group was compared to the MLID frequency in the no ART reported group. Statistical
13 analysis using Fisher's exact test showed that ART procedures (i.e. IVF and ICSI)
14 were significantly associated with MLID in *BWS_IC2* ($p=0.021$) (Figure 5.4). Finally,
15 the frequency of epimutation at imprinted DMRs in IVF/ICSI MLID group was
16 compared to the frequency of epimutation at imprinted DMRs in the no ART reported
17 MLID group. Whilst some DMRs appeared to be more frequently epimutated in one
18 group than in the other (e.g. *MEST:alt-TSS-DMR*: 25% in ART, 9% in non-ART;
19 *FAM50B:TSS-DMR*: 12.5% in ART, 32% in non-ART) no significant association
20 between the IVF/ICSI procedures and epimutations at imprinted DMRs was found
21 (p-value threshold of 0.05 using Fisher's exact test) (Figure 5.5).

22




1

2 **Figure 5.3: ART and genomic imprinting methylation in BWS_IC2.**

3 *Multilocus imprinting disturbances and ART. Epimutations distribution at 46 imprinted*
 4 *DMRs (y-axis) in BWS_IC2 patients conceived with or without the help of assisted*
 5 *reproductive technology (x-axis). Red, loss-of-methylation; green, gain-of-*
 6 *methylation; black: no epimutations. OS, n=2; IVF, n=3; ICSI, n=8, ART not reported,*
 7 *n=65.*

1



2


3 **Figure 5.4: Significance of ART of MLID epigenotype in BWS_IC2 patients.**

4 *Comparison of the number of BWS_IC2 patients conceived with or without the help*
5 *of ART (IVF/ICSI) and with or without MLID. ART, assisted reproductive technology;*
6 *MLID, multilocus imprinting disturbances; statistical analysis was done using*
7 *Fisher's exact test.*

1 **5.3.2 Genetic investigation of BWS_IC2 patients**

2 WES was performed on 42 BWS_IC2 patients (25 with MLID and 17 with no MLID).
3 The sequencing read depth was assessed in all samples and at least 87% of bases
4 in 41 samples and at least 80% of bases in 1 sample were sequenced at least 20
5 times (i.e. 20x) (Figure 5.6). This meant a reliable bases calling, hence a good
6 certainty for further variants analysis. In total, WES analysis revealed 18 rare genetic
7 alterations that were predicted to be damaging for the protein function or splicing and
8 therefore might potentially be related to the presence of MLID in the BWS patients
9 (Table 5.15).

10



11

12 **Figure 5.6: Distribution of the sequencing depth of read across the 42**
13 **BWS_IC2 individuals.**

14

1 **Table 5.15: Summary of interesting variants found by whole-exome**
 2 **sequencing.**

3

Name	Chr	Start	End	Ref	Alt	dbSNP147	Gene	Function	Exonic function	Gene field	Number of affected individuals	Variant validation: (Continued)	Allele in EACCT	Number of homozygotes in EACCT	Allele in ESP	Number of homozygotes in ESP	Polyphen2	RVAR	SIFT	PROVEAN	ada-boost	random forest	dPSI (z-score)	
variant 1	12	103984620	103984620	A	A	rs764159587	TDG	exonic	frameshift insertion	NM_003211.exon8:c.965dupA>A;E32% NM_003211.exon8:c.964+1G>A	33 het	31 (0) not reported	not reported	not reported	1	0.838	-16.2185	-3.111						
variant 2	12	103984621	103984621	G	A		TDG	splicing		NM_003211.exon8:c.964+2T>G	28 het	28 (0) not reported	not reported	not reported	1	0.828	-21.0087	-3.21						
variant 3	12	103984622	103984622	T	G	rs760400700	TDG	splicing		NM_003211.exon8:c.968+1G>A	32 het	31 (0) not reported	not reported	not reported	1	0.854	-2.1676	-1.951						
variant 4	12	103984623	103984623	G	A	rs760554309	TDG	splicing		NM_003211.exon8:c.969+1G>A	4 het	4 (0) not reported	not reported	not reported	0.9999	0.888	-11.8888	-2.862						
variant 5	12	103984747	103984747	A	C		TDG	splicing		NM_003211.exon8:c.793>A>C	13 het	13 (0) not reported	not reported	not reported	1	0.866	-3.1573	-3.372						
variant 6	12	103984748	103984748	G	T		TDG	splicing		NM_003211.exon8:c.793>G>T	14 het	14 (0) not reported	not reported	not reported	1	0.866	-3.1573	-3.372						
variant 7	12	103984739	103984739	G	T	rs762057948	TDG	splicing		NM_003211.exon8:c.793>G>T	11 het	11 (0) not reported	not reported	not reported	1	0.866	-3.1573	-3.372						
variant 8	6	169715755	169715755	A	C	rs502092150	PHF10	exonic non-synonymous SNV		NM_0162268.exon6:c.1565G>T;198D	2 het	2 (0) 0.000350	0 not reported	0.009	1	0.003	-2.07							
variant 9	6	169715755	169715755	A	C	rs77919800	PHF10	exonic non-synonymous SNV		NM_0162268.exon6:c.C646T;p.R216W	3 het	3 (0) 0.000190	0 not reported	0.002	1	0.003	-4.79							
variant 10	6	169715761	169715761	A	C	rs144595698	PHF10	exonic non-synonymous SNV		NM_0162268.exonic:c.T840G;p.L214V	3 het	3 (0) 0.000190	0 not reported	0.009	0.952	0.562	-2.48							
variant 11	15	83264026	83264026	G	T		BNCT	exonic non-synonymous SNV		NM_001301266.exon4:c.C728A;p.P432T	1 het	1 (1) not reported	not reported	not reported	1	0.999	0.002	-0.85						
variant 12	19	54892015	54892015	C	G	rs14577354	NR2P2	exonic non-synonymous SNV		NM_001174282.exon7:c.C115T;p.P34S	1 het	1 (1) not reported	not reported	0.993	0.98	0.082	-4.11							
variant 13	19	54892015	54892015	C	G	rs39035847	NR2P2	exonic non-synonymous SNV		NM_001174282.exon7:c.C115T;p.P34S	1 het	1 (1) not reported	not reported	0	0.00690	0	-4.11							
variant 14	19	54892022	54892022	C	T	rs200375320	NR2P2	exonic non-synonymous SNV		NM_001174282.exon7:c.C220T;p.L738M	1 het	0	0.00077	0	0.987	0.15	-2.33							
variant 15	19	54892056	54892056	G	A	rs117066558	NR2P2	exonic non-synonymous SNV		NM_001174282.exon8:c.G2335A;p.A179T	2 het	1 (1) 0.00293	10 0.010810	0	0.314	0.118	0.42	-1.42						
variant 16	2	206304678	206304678	T	G	rs755904527	ZDRF2	exonic	stop-gain	NM_020923.exonic:c.T350G;p.L117X	1 het	1 (1) not reported	not reported	not reported	0	0.894	0.753	0.006	-2.7					
variant 17	2	206310732	206310732	G	T	rs35095066	ZDRF2	exonic non-synonymous SNV		NM_020923.exon8:c.G924T;p.R2075M	1 het	1 (1) 0.00334	2 0.00458	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	-3.1971 (-2.169)
variant 18	11	54892025	54892025	A	G		CHCH1	exonic non-synonymous SNV		NM_0056278.exon5:c.C106T;p.S306L	1 het	1 (1) not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	-5.84
variant 19	11	54892025	54892025	A	G		CHCH1	exonic non-synonymous SNV		NM_0056278.exon5:c.C106T;p.S306L	1 het	1 (1) not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	-5.84

Chromosomes are numbered by human genome build (hg19). Gene names are in boldface. Allele frequencies are in brackets. The asterisk (*) indicates a variant with a difference percent of transcripts with the exon spliced in across tissues (as indicated in brackets). het., individuals heterozygote for the reference allele; hom., individuals homozygote for the alternative allele; variant validation in individuals was done by Sanger sequencing.

1 **5.3.2.1 Analysis of methylation associated genes**


2 I analysed WES data for the 138 genes identified as important in or associated with
3 methylation pathways (see Table 5.12 in section 5.2.6.4 - Variant call analysis) and
4 interesting variants were validated by Sanger sequencing wherever possible. An
5 average of the proportion of exons successfully sequenced for each gene for all
6 patients was calculated. Out of 138, 6 genes had a very poor to average (<60%)
7 proportion of exons sequenced and 132 had a high to complete coverage (>60%)
8 (Figure 5.7).

9

10 No stop-gain affecting a gene associated with methylation pathways were found. A
11 single frameshift insertion in the thymine DNA glycosylase (*TDG*) gene (variant 1:
12 NM_003211, c.965dupA, p.E322fs, rs764159587) was found in 33 patients; all were
13 heterozygotes for the variant. Additionally, 6 heterozygotes splicing variants in *TDG*
14 (variant 2: NM_003211, c.964+1G>A; variant 3: NM_003211, c.964+2T>G,
15 rs760400700; variant 4: NM_003211, c.408+1G>A, rs780554309; variant 5:
16 NM_003211, c.793-2A>C; variant 6: NM_003211, c.793-1G>T; variant 7:
17 NM_003211, c.1090+1G>T, rs762057949) affecting in total 28, 32, 4, 13, 14 and 11
18 individuals respectively were found. Finally, three non-synonymous variants
19 occurring in the PHD finger protein 10 (*PHF10*) gene were found; variant 8
20 (NM_018288 c.T595G, p.Y199D, rs562092150) was present in two individuals.
21 These two individuals, as well as one additional patient, also carried variant 9
22 (NM_018288, c.C646T, p.R216W, rs77919800) and variant 10 (NM_018288,
23 c.T640G, p.L214V, rs144595699). All variants in each patient were in a heterozygous

1 state. Sanger sequencing of an independent PCR product for variant 1 in 31 of 33
2 individuals, variant 2 in 28 of 28 individuals, variant 3 in 31 of 32 individuals, variant
3 4 in 4 of 4 individuals, variant 5 in 13 of 13 individuals and variant 6 in 14 of 14
4 individuals in the *TDG* gene and for variant 8 in 2 of 2 individuals, variant 9 in 3 of 3
5 individuals and variant 10 in 3 of 3 individuals in the *PHF10* gene did not successfully
6 confirmed the results obtained from WES for those patients (Figure 5.8 and Table
7 5.15). Further investigation with the sequencing facility revealed that those variants
8 were also commonly detected in other sequencing project, hence suggesting that
9 they were sequencer specific sequencing artefacts. Sanger sequencing of variant 7
10 was not attended

11



1

2 **Figure 5.8: Validation of the variants found in gene associated with the**
 3 **methylation pathway.**

4 *Sanger sequencing of an independent PCR product of variant 1, 2, 3, 4, 5 and 6*
 5 *(TDG) and variant 8, 9 and 10 (PHF10). Top, patient sequencing trace; bottom,*
 6 *control individual sequencing trace; blue inverted triangle, variant position.*

7

8


9 **5.3.2.2 Analysis of maternal effect genes**

10 I analysed WES data for the 63 genes identified as maternal-effect genes in
 11 mammals (see Table 5.11 in section 5.1.2.1 - Maternal and maternal-zygotic genes).

12 An average of the proportion of exons successfully sequenced for each gene for all
 13 patients was calculated. Out of 63, 7 genes had a very poor to average (<60%)

1 proportion of exons sequenced and 56 had high to complete coverage (>60%)
2 (Figure 5.9).
3
4 No stop-gain, frameshifting indel or splicing mutations were found in maternal-effect
5 gene. A non-synonymous variant in the basonuclein 1 (*BNC1*) gene (variant 11:
6 NM_001301206, c.C1204A, p.P402T) was found in a heterozygous state in one
7 patient with GOM at *ZDBF2/GPR1:IG-DMR* and LOM at *IGF2R:Int2-DMR*,
8 *MEST:alt-TSS-DMR*, *FANCC:Int1-DMR*, *KCNQ1OT1:TSS-DMR*, *SNU13:alt-TSS-*
9 *DMR*. A non-synonymous variant in the CCCTC-binding factor (*CTCF*) gene (variant
10 12: NM_001191022, c.C943T, p.P315S, rs145727304) was found in a heterozygous
11 state in one patient with LOM at *DIRAS3:TSS-DMR*, *DIRAS3:Ex2-DMR*,
12 *FAM50B:TSS-DMR*, *FANCC:Int1-DMR*, *KCNQ1OT1:TSS-DMR*, *IGF1R:Int2-DMR*,
13 *L3MBTL1:alt-TSS-DMR*, *GNAS-AS1:TSS-DMR* and *SNU13:alt-TSS-DMR*. Finally,
14 three non-synonymous variants in the *NLRP2* gene (variant 13: NM_001174082,
15 c.C1151G, p.T384R, rs139903547; variant 14: NM_001174082, c.C2207T, p.T736M,
16 rs200375320; variant 15: NM_001174082, c.G2335A, p.A779T, rs117066658) were
17 found. One patient was a homozygous for variant 13 and had LOM at *FAM50B:TSS-*
18 *DMR* and *KCNQ1OT1:TSS-DMR*. One patient was heterozygous for both variant 14
19 and variant 15 and had LOM at *KCNQ1OT1:TSS-DMR*, *L3MBTL1:alt-TSS-DMR* and
20 *SNU13:alt-TSS-DMR*. Finally, one patient was heterozygous for variant 15 only and
21 had LOM at *DIRAS3:TSS-DMR*, *DIRAS3:Ex2-DMR*, *FAM50B:TSS-DMR*,
22 *IGF2R:Int2-DMR*, *PLAGL1:alt-TSS-DMR*, *MEST:alt-TSS-DMR*, *FANCC:Int1-DMR*,
23 *KCNQ1OT1:TSS-DMR*, *ZNF331:alt-TSS-DMR1*, *ZNF331:alt-TSS-DMR2*,

1 *NNAT*:TSS-DMR, *SNU13*:alt-TSS-DMR. For which DNA was available, Sanger
2 sequencing of an independent PCR product for variant 11 in 1 individual (*BNC1*),
3 variant 12 in 1 individual (*CTCF*), and variant 15 in 1 of 2 individual (*NLRP2*)
4 successfully confirmed the results obtained from WES (Figure 5.10 and Table 5.15).
5 The Sanger sequencing of one individual with variant 13, one individual with variant
6 14 and one of two individual with variant 15 was not attended due to the lack of DNA
7 for those patients.
8



1

2 **Figure 5.10: Validation of the variants found in maternal-effect genes.**

3 Sanger sequencing of an independent PCR product of variant 11 (*BNC1*), 12 (*CTCF*)
 4 and 15 (*NLRP2*). Top, patient sequencing trace; bottom, control individual
 5 sequencing trace; blue inverted triangle, variant position.

6

7


8 5.3.2.3 Analysis of imprinted genes

9 I analysed WES data for the 76 genes identified as imprinted or potentially imprinted
 10 (see Table 5.13 in section 5.2.6.4 - Variant call analysis). An average of the
 11 proportion of exons successfully sequenced for each gene for all patients was
 12 calculated. Out of 76, 8 genes were not sequenced, 29 genes had a very poor to
 13 average (<60%) proportion of exons sequenced and 39 had high to complete
 14 coverage (>60%) (Figure 5.11).

15

16 A stop-gain variant (variant 16: NM_020923, c.T350G, p.L117X, rs755604527) in a
 17 individual in heterozygous state with LOM at *FAM50B*:TSS-DMR and
 18 *KCNQ1OT1*:TSS-DMR and a non-synonymous variant (variant 17: NM_020923,

1 c.G6224T, p.R2075M, rs36095066) in another individual in heterozygous state with
2 LOM at *FANCC*:Int1-DMR, *INPP5F*:Int2-DMR, *KCNQ1OT1*:TSS-DMR, *IGF1R*:Int2-
3 DMR, *GNAS-AS1*:TSS-DMR, *GNAS-XL*:Ex1-DMR, *GNAS-AB*:TSS-DMR were
4 found in the zinc finger DBF-type containing 2 (*ZDBF2*) imprinted gene. Finally, a
5 non-synonymous variant (variant 18: NM_000218, c.C1046T, p.S349L) in the
6 potassium voltage-gated channel subfamily Q member 1 (*KNCQ1*) imprinted gene
7 was found in a heterozygous state in one patient with LOM at *FANCC*:Int1-DMR,
8 *INPP5F*:Int2-DMR, *KCNQ1OT1*:TSS-DMR, *IGF1R*:Int2-DMR, *GNAS-NESP*:TSS-
9 DMR, *GNAS-AS1*:TSS-DMR and *GNAS-XL*:Ex1-DMR. The Sanger sequencing of
10 an independent PCR product for variant 16 and 17 (*ZDBF2*) and variant 18 (*KNCQ1*)
11 successfully confirmed the results obtained from the WES data (Figure 5.12 and
12 Table 5.15)
13



1

2 **Figure 5.12: Validation of the variants found in imprinted genes.**

3 *Sanger sequencing of an independent PCR product of variant 16 and 17 (ZDBF2)*
 4 *and variant 18 (KCNQ1). Top, patient sequencing trace; bottom, control individual*
 5 *sequencing trace; blue inverted triangle, variant position.*

6

7

8 **5.4 Discussion**

9 **5.4.1 ART and MLID**

10 Among the 11 patients conceived with the help of ART (IVF/ICSI), 8 had MLID (73%).
 11 This was significantly higher ($p=0.021$, Fisher's exact test) than the frequency
 12 observed in the no ART reported group in which 22 out 65 (34%) patients had MLID.
 13 This result corroborates with previous studies in which a significant association
 14 between ART and MLID in BWS_IC2 were found (Lim et al. 2009; Hiura et al. 2012;
 15 Tee et al. 2013) (it should be noted that the cohort I studied may overlap with those
 16 in the Lim et al. and Tee et al. reports). However, my observation also contrasts with
 17 other studies in which ART was not reported to be associated with MLID in BWS_IC2
 18 (Rossignol et al. 2006; Azzi et al. 2009).

1 The number of disturbances reported at a given imprinted DMRs were variable
2 between ART and no ART reported BWS patients. Some DMRs appeared to be more
3 frequently epimutated in one group than in the other but statistical analysis did not
4 reveal a significant association between the use of ART and the disturbances at
5 specific imprinted DMRs. In conclusion, with the exception of *KCNQ1OT1:TSS-*
6 DMR, ART seems to disrupt genomic imprinting in a random manner.

7

8 Taken together, my data suggests that ART is associated with MLID in BWS_IC2.
9 However, it remains to be understood if the imprinting disturbances are the direct
10 consequences of ART alone, the products of other factors such as the parental
11 infertility or the age of the individuals, or the results of a combination of all. If ART is
12 involved, how does it disrupt the genomic imprint and which step of the procedure is
13 involved in this mechanism? The ovarian stimulation and the use of an immature
14 oocyte may affect the establishment of DNA methylation of genomic imprinting whilst
15 the fertilisation, the embryo culture and the uterus implantation steps may disrupt the
16 maintenance of this epigenetic mechanism (Hiura et al. 2014). The genome-wide
17 methylation analysis using next-generation sequencing and microarrays of animal
18 models and extensive patient cohorts will hopefully provide a better picture of the
19 extent and implications of ART-induced imprinting changes in human disorders.

20

21

22

1 **5.4.2 Trans-mechanism involving a gene associated with** 2 **methylation pathway**

3 WES analysis revealed rare variants that have the potential to alter protein function
4 or splicing of the *TDG* and *PHF10* genes, both described to be associated with the
5 methylation pathway. Though the heterozygous state of the BWS with MLID
6 individuals indicated that the *TDG* and *PHF10* potential pathogenic variants raised
7 the possibility of being responsible for genomic imprinting disturbances following an
8 autosomal dominant mode of inheritance, the identified candidate genetic alterations
9 were not validated by Sanger sequencing and were found to be sequencer specific
10 sequencing artefacts and so were not considered further.

11

12 In summary, I did not identify candidate mutations in a methylation associated gene
13 that is likely to be responsible for BWS phenotype and MLID in our cohort. To date,
14 no additional candidate mutations in one of these genes have been associated with
15 MLID and BWS. Therefore, with the exception of *ZFP57* in a subset of *TNDM1*
16 patients, causative pathogenic mutations of such genes are very rare events in the
17 aetiology of imprinting disorders with MLID. However, it should be noted that the
18 identification of pathogenic mutations is complicated by (i) the increasing burden that
19 represents the analysis and interpretation of WES and (ii) some type of mutation,
20 such as internal exon deletion, might not be detected by WES. It has been
21 established that a sequenced exome of an individual can harbour between 20,000
22 to 50,000 variants. Of these, several steps of filtering criteria to remove false-positive

1 calls (e.g. reads quality, out of coding sequence, synonymous coding variants,
2 common in dbSNP) and prioritisation strategy (e.g. non-synonymous variants,
3 splicing variants) will reduce the list of potential candidates and retain
4 approximatively 150 to 500 variants. Of these, further analysis and interpretation in
5 the context of the phenotype will be undertaken to hopefully identify the potential true
6 pathogenic variants (Gilissen et al. 2012; Robinson et al. 2014). It should be noted
7 that this would be true on the assumption that the pathogenic mutations was not
8 filtered out during upstream filtering and prioritisation processes, such as a patient
9 with heterozygous missense substitution might be undetected compound
10 heterozygotes.

11

12 **5.4.3 Trans-mechanisms involving maternal-effect genes**

13 I identified five rare variants that may be responsible for BWS phenotype and MLID
14 in the maternal-effect genes *BNC1*, *CTCF* and *NLRP2*. These variants were found
15 in four distinct individuals with MLID and all variants were predicted to be protein
16 damaging. One of the five variants (*NLRP2*, variant 13) was found in a homozygous
17 state whilst the four others (*BNC1*, variants 11; *CTCF*, variant 12; *NLRP2*, variants
18 14 and 15) were found in a heterozygous state. Finally, all these variants were
19 reported as rare in ESP and ExAC database (variants 11, not reported in ESP and
20 ExAC; variant 12, ESP: T=57/C=12939, ExAC: T=258/C=120954; variant 13: ESP:
21 G=87/C=12917, ExAC: G=690/C=118704; variant 14: ESP: T=1/C=13005, ExAC:
22 T=7/C=121367; and variant 15: ESP: A=138/G=12868, ExAC: A=1126/G=120172).

1 Taking into consideration the rarity of the variants and their potential damaging
2 effects on the protein, I hypothesised that they may have been pathogenic and
3 associated to BWS and MLID.

4 To further investigate the potential significance of these findings it would be
5 necessary to sequence the mothers of these cases to see if they were homozygous
6 for the variants (or were compound heterozygotes). If this were to be found then it
7 could be hypothesised that the genetic variants found in *BNC1*, *CTCF* and *NLRP2*
8 might predispose to BWS and MLID in a maternal-effect inheritance manner.
9 Additionally, the absence of the variants in the fathers would further support this
10 hypothesis.

11

12 *BNC1* encodes for a zinc-finger protein found in abundance in oocytes and regulates
13 the rRNA transcription. *BNC1* deficiency in mouse oocytes perturbs both RNA
14 polymerase I- and II- mediated transcription and it affects the morphology and
15 biochemistry of oocytes. The fertilised *Bnc1*-deficient eggs failed to develop beyond
16 the two-cell stage (Ma et al. 2006; Kim and K.-A. Lee 2014). If the maternal-effect
17 inheritance in this patient could be confirmed, this would be the first description of
18 *BNC1* in BWS aetiology. Moreover, the additional epimutations associated with the
19 patient may also indicate that the variant is likely to cause MLID and consequently
20 could have an unrecognised role in genomic imprinting.

21

22 *CTCF* encodes for a highly conserved transcription factor with 11 zinc-finger DNA
23 binding domains. Using different combinations of zinc fingers domains to bind DNA,

1 CTCF can function as a transcriptional insulator, repressor, or activator, depending
2 on the context of the binding site (Ohlsson et al. 2001). Depletion of *Ctcf* in fertilised
3 *Ctcf*-deficient eggs arrest at the morula stage or at various stages prior to morula
4 compaction and only a very small proportion of the embryos are able to develop to
5 the blastocyst stage (Fedoriw et al. 2004; Wan et al. 2008). CTCF is critical for
6 regulating genomic imprinting at multiple loci including the *Igf2/H19* locus. The
7 protein binds the unmethylated maternal allele of *Igf2/H19* DMR and inhibits the
8 maternal *Igf2* gene expression via enhancer blocking activity (Bell and Felsenfeld
9 2000; Hark et al. 2000). The depletion of *Ctcf* in mouse oocytes also results in the
10 hypermethylation of *Igf2/H19* DMR during oocyte growth, indicating that CTCF is
11 required to maintain the unmethylated status of the locus (Fedoriw et al. 2004).
12 Similarly, the maternal transmission of microdeletion removing CTCF binding sites
13 within *H19/IGF2:IG-DMR* is associated with hypermethylation of the locus, biallelic
14 silencing of H19, biallelic expression of *IGF2* and, *in fine*, to BWS phenotype
15 (Sparago et al. 2004; Prawitt, Enklaar, Gartner-Rupprecht, et al. 2005; Sparago et
16 al. 2006).

17

18 As seen previously (see section 5.1.2.4 - NLRP2), maternal-effect mutation in
19 *NLRP2* was previously reported to be associated with the BWS phenotype and MLID
20 (Meyer et al. 2009). Hence sequencing of parental samples would be indicated to
21 determine if the variants were of paternal or maternal inheritance and if the mother
22 was homozygous or compound heterozygous.

23

1 Further studies, including sequencing of the parents of the probands, are necessary
2 to determine a more precise role of these variants in the molecular aetiology of MLID
3 and BWS.

4 **5.4.4 Trans-mechanism involving imprinting gene network** 5 **disruption**

6 The complex co-regulation of multiple imprinted genes and the existence of
7 imprinted gene networks (Varrault et al. 2006; Patten et al. 2016; Soellner et al. 2016)
8 suggested that the genetic insults of a member of a network might have dramatic
9 consequences on not only the imprinted gene itself but also on the other imprinted
10 gene members of the network. I hypothesised this may act at the methylation level
11 and may be involved in the abnormal imprinted epigenotype seen in BWS patients
12 with MLID.

13

14 The exons of 37 out of the 76 imprinting genes were not sequenced or had a poor
15 coverage. This can be explained by the fact that a majority of these genes are non-
16 protein coding genes. The library preparation method used for WES was not
17 designed to capture these non-protein coding regions. However, despite the lack of
18 sequencing coverage I identified one stop-gain (not reported in ESP and ExAC) and
19 one non-synonymous (ESP: T=77/G=11847; ExAC: T=756/G=118228) rare variants
20 in the *ZDBF2* imprinted gene and one rare non-synonymous (not reported in ESP
21 and ExAC) variant in the *KCNQ1* imprinted gene (*KCNQ1* variant did not overlap
22 with *KCNQ1OT1* genomic region). Mutations in *KCNQ1* have been associated with

1 hereditary long QT syndrome 1 (Q Wang et al. 1996), short QT syndrome 2 (Bellocq
2 et al. 2004) and familial atrial fibrillation (heart conditions) (Y.-H. Chen et al. 2003),
3 and Jervell and Lange-Nielsen syndrome (a hearing loss condition) (Neyroud et al.
4 1997) but not with an imprinting disorder. The three variants were reported as rare
5 and were predicted to be damaging for the protein by several scoring databases,
6 hence suggesting they might be pathogenic.

7

8 In placental tissue, the imprinted expression of *ZDBF2* is expressed from the
9 paternal allele, although stochastic maternal expression of *ZDBF2* is detected. In
10 somatic tissue, *ZDBF2* paternal expression is maintained whilst maternal *ZDBF2* is
11 silenced. I hypothesised that the stop-gain and the non-synonymous dominant
12 variant could affect the *ZDBF2* paternal gene expression, which in return would (i)
13 induce aberrant methylation at other imprinting regions through *trans*-imprinting
14 mechanism and (ii) result in aberrant embryonic development. To support my
15 hypothesis, the author of a recent study has found that the knockout of *Liz* (Long
16 isoform of *Zdbf2*) in mice results in the absence of *ZDBF2* expression and in an
17 abnormal growth phenotype (methylation profiling at other imprinting DMRs was not
18 performed) (Greenberg et al. 2017). However, the authors found that the lack of
19 *ZDBF2* activation was associated with growth restriction rather than growth
20 promotion, which *in fine* was not compatible with my hypothesis.

21

22 *KCNQ1* is located within *KCNQ1OT1*:TSS-DMR region, which is the main locus
23 involved in BWS aetiology. I hypothesised that the non-synonymous variant could

1 be a dominant maternally-inherited mutation affecting a regulatory sequence
2 required for the *cis* methylation of the maternal *KCNQ1OT1*:TSS-DMR IC.
3 Consequently, this would primarily result in maternal *KCNQ1OT1*:TSS-DMR
4 hypomethylation, biallelic expression of *KCNQ1OT1*, bisilencing of *CDKN1C* and, *in*
5 *fine*, to BWS phenotype. Furthermore, through a mechanism that would by-pass the
6 *KCNQ1OT1*-mediated transcriptional repression activity, the non-synonymous
7 mutation could result in the translation of an altered KCNQ1 protein that would
8 disrupt genomic imprinting methylation at other loci. Although it was an interesting
9 hypothesis, several lines of evidence contradicted this hypothesis. Firstly, it seems
10 that the variant does not affect a regulatory element required for the methylation of
11 the IC. Secondly, the mechanisms that would explain the by-pass of *KCNQ1OT1*-
12 mediated gene silencing are yet to be identified. Finally, there is a lack of evidence
13 suggesting that *KCNQ1* (as opposed to *KCNQ1OT1*) has a role in imprinting.

14

15 In conclusion, further investigations are required to further characterise these
16 variants. However, the current line of evidence suggests that the *ZDBF2* and *KCNQ1*
17 variants are non-pathogenic and consequently are not involved in the molecular
18 aetiology of BWS and MLID.

Chapter 6

Investigations of a novel candidate gene for BWS

1 **6.1 Introduction**

2 **6.1.1 UHRF1, a critical epigenetic modifier**

3 Ubiquitin-like with PHD and RING finger domains 1 (UHRF1), also known as inverted
4 CCAAT box protein of 90 kDa (ICBP90) in human and NP95 in mouse, is a nuclear
5 multi-structural domain and functional protein. UHRF1 has been shown to promote
6 cell proliferation in various cancers, including breast, colon, prostate, and lung
7 cancer (Bronner et al. 2013). In these, it was demonstrated that the over expression
8 of *UHRF1* contributed to the silencing of tumour suppressor genes, the inhibition of
9 the DNA repair pathway, the tumour growth and metastasis (Bronner et al. 2013).
10 The down-regulation of *UHRF1* in human colon colorectal carcinoma cells was
11 shown to induce cell cycle to arrest at the G1/S transition, hence suggesting that
12 UHRF1 is required for progression in the cell cycle (Y. Arima et al. 2004). UHRF1 is
13 also known to be essential for the maintenance of DNA methylation through
14 recruiting DNMT1 to the replication fork in S phase of the cell cycle (Bostick et al.
15 2007; Sharif et al. 2007). The depletion of UHRF1 in human cells, mouse embryonic
16 stem cells and in zebrafish results in the reduction of global DNA methylation and at
17 locus specific DNA methylation, including IGS-rDNA (intergenic spacer of ribosomal
18 DNA) and imprinted loci such as *H19*, *Kcnq1ot1*, *Nnat*, *Igf2r*, *Dlk1* (Bostick et al.
19 2007; Sharif et al. 2007; Tittle et al. 2011; Rothbart et al. 2012; Qi et al. 2015).
20 However, the transient expression of wild-type *UHRF1* in knockdown *UHRF1* human
21 cells, or in *Uhrf1* null embryonic stem cells, was reported to restore the loss-of-
22 methylation associated with *UHRF1* knockdown (Rothbart et al. 2012; X. Liu et al.


1 2013). This also includes methylation rescue in only a small subset of mouse
2 imprinted loci, *H19*, *Nnat*, *Dlk1* (Qi et al. 2015). Consequently, this line of evidences
3 demonstrated that UHRF1 is a key epigenetic modifier.

4

5 UHRF1 harbours at least five functional domains: a N-terminal ubiquitin-like domain
6 (UBL), followed by a tandem tudor domain (TTD), a plant homeodomain (PHD), a
7 SET and RING-associated (SRA) domain, and a C-terminal really interesting new
8 gene (RING) domain (Figure 6.1). The SRA domain preferentially binds to hemi-
9 methylated CpG, which during semiconservative replication of DNA recruits DNMT1
10 at the replication fork to copy the methylation pattern onto the daughter strand (Sharif
11 et al. 2007). This process may also involve the RING domain through the
12 ubiquitylation of H3K23 and H3K18, which creates ubiquitylated docking sites for
13 DNMT1 (Nishiyama et al. 2013; Qin et al. 2015). The isolated TTD domain was
14 shown to recognise and bind preferentially to H3K9me3 (Nady et al. 2011) whilst the
15 isolated PHD domain binds to the unmodified extreme H3 N terminus, and more
16 particularly to unmodified histone H3 arginine residue 2 (Hu et al. 2011; Rajakumara
17 et al. 2011). Through the existence of functional cooperation in reading histone
18 modifications, both TTD and PHD domains were suggested to play a role in the DNA
19 methylation maintenance mechanism. Interestingly, whilst some studies suggested
20 that these domains were essential for the maintenance of DNA methylation (Rothbart
21 et al. 2012; Rothbart et al. 2013), others suggested that both domains promoted DNA
22 methylation maintenance but were not essential to it (X. Liu et al. 2013; Zhao et al.
23 2016). The crosstalk between both epigenetic marks (i.e. DNA methylation and

1 histone modifications) is to date not well understood. However, a few recent studies
 2 had started to decipher possible mechanisms that might link both epigenetic marks.
 3 In a recent report, the existence of a poly basic region (PBR) between the SRA and
 4 RING domains was suggested. The PBR was shown to facilitate the recognition of
 5 semi-methylated DNA by the SRA (Fang et al. 2016) and to mediate the interaction
 6 of the TTD domain with H3K9me3 and the interaction of the PHD domain with
 7 H3K4me0 (Gelato et al. 2014; Fang et al. 2016). This mechanism was dependant
 8 on the presence or absence of phosphatidylinositol 5-phosphate (PIP5). The binding
 9 of PIP5 to the PBR was shown help to stabilise UHRF1 and then DNMT1 to genomic
 10 regions containing H3K9me3 and undergoing replication. In the absence of PIP5,
 11 UHRF1 and then DNMT1 stabilise at genomic regions undergoing replication that
 12 contain H3K4me0 (Gelato et al. 2014).

13



14

15

16 **Figure 6.1: Domain structure of UHRF1.**

17 *UBL, ubiquitin-like domain; TTD, tandem tudor domain; PHD, plant homeodomain;*
 18 *SRA, SET and RING-associated; RING, really interesting new gene; PBR, polybasic*
 19 *region. (From Gelato et al. 2014).*

20

1 **6.1.2 Case Report**


2 Two siblings born to consanguineous parents were diagnosed with BWS. Previous
3 molecular genetic analysis had demonstrated that both siblings had loss-of-
4 methylation at *KCNQ1OT1*:TSS-DMR. The methylation profiling at imprinted loci
5 other than *KCNQ1OT1*:TSS-DMR was not performed and is currently under
6 investigation. Whole-exome sequencing was performed prior to my study and the
7 data was inspected to identify candidate mutations that might cause a *trans*-
8 imprinting defect. No candidate mutations were identified in *NLRP2*, *NLRP5* (a
9 heterozygous candidate mutation would be present in the siblings if the mother was
10 a homozygote or compound heterozygote for mutations in these genes) or in *ZFP57*.
11 In view of the parental consanguinity a candidate mutation would be predicted to be
12 homozygous in both siblings and therefore rare homozygous variants were identified
13 in the exome data and evaluated as potential candidate mutations.

14

15 It was noted that both siblings had a novel homozygous missense variant in *UHRF1*
16 (Figure 6.2-a) (the variant was not present in ESP nor in ExAC databases). The
17 guanine to cytosine substitution at position 4954693 of chromosome 19 (Build
18 GRCh38) resulted in an amino acid substitution of lysine to asparagine at position
19 667 (NM_001048201.2, c.2237G>C, p.K667N). The rare non synonymous missense
20 variant was predicted to be protein damaging by Mutation Taster (score: 0.999) and
21 SIFT (score: 0.015) and probably damaging by PolyPhen-2 (score: 0.991) (Figure
22 6.2-b). Additionally, the affected amino acid was found to be conserved across

1 species including mice, zebrafish and *Xenopus tropicalis* (Figure 6.2-c). Finally, the
 2 variant is located near to the polybasic region (PBR) within UHRF1. As discussed
 3 previously, this region may also be involved in the faithful DNMT1-mediated DNA
 4 methylation maintenance mechanism during replication.

5



6

7 **Figure 6.2: Case report of two siblings with BWS_IC2 and a homozygous**
 8 **mutation in the UHRF1 gene.**

9 (a) Family pedigree of the two affected siblings. Both siblings have a novel
 10 homozygous missense variant affecting UHRF1 (g.49544693G>C, GRCh38). (b)
 11 Deleterious scores obtained with Mutation taster, PolyPhen-2, SIFT and PROVEAN.
 12 (c) The affected amino acid (lysine 667 in human) is conserved across species.

13

14

15 6.1.3 Aim

16 To date several *trans*-acting factors have been described in the molecular aetiology
 17 of familial MLID disorders including *KHDC3L* (also known as *C6ORF221*), *NLRP2*,

1 *NLRP5*, *NLRP7* and *ZFP57* (see section 5.1.2 - Trans-imprinting defect and MLID).
2 However, an underlying genetic defect responsible for MLID in BWS is very rare and
3 only two of these genes have been linked to MLID in BWS (*NLRP2* and *NLRP5*)
4 (Meyer et al. 2009; Docherty et al. 2015). In this chapter I describe investigations
5 into the potential pathogenicity of a homozygous variant in the *UHRF1* gene found
6 in two siblings with BWS_IC2. It was suggested that the missense substitution in
7 *UHRF1* p.K667N might partially or fully disturb the function of the protein and
8 compromise normal DNA methylation maintenance mechanisms at imprinted DMRs.
9 If this hypothesis was correct then *UHRF1* would be the third described *trans*-acting
10 factor responsible for methylation disturbances associated with BWS. However in
11 the absence of additional families with a similar phenotype the candidacy of *UHRF1*
12 remained unproven. Therefore it was decided to investigate, *in vitro*, whether the
13 missense substitution could be shown to compromise *UHRF1* function. I therefore
14 proceeded to assess whether wild-type and mutant *UHRF1* could rescue methylation
15 abnormalities in human HeLa cells in which *UHRF1* gene expression had been
16 knocked down by shRNA lentiviral transduction.

17

18 **6.2 Materials and methods**

19 **6.2.1 Cells**

20 HeLa cells knockdown for *UHRF1* (HeLa sh*UHRF1*) and control HeLa cells (HeLa
21 shLuc) were a generous gift from Dr. Scott Rothbart (Rothbart et al. 2012). The
22 shRNA were designed to target the 3' UTR region of the *UHRF1* and *Luciferase*

1 gene, hence allowing subsequent rescue experiments. The shRNA used to
2 knockdown targeted genes were obtained from the RNAi Consortium and were used
3 following standard TRC lentivirus production and infection protocols (Table 6.16).

4

5 **Table 6.16: shRNA clones used in HeLa cells.**

6 (From Rothbart et al. 2012).

shRNA	TRC clone name	TRC clone ID	Target sequence	Region
control	promegaLuc_221s1c1	TRCN0000072246	CAAATCACAGAATCGTCGTAT	3' UTR
UHRF1	NM_013282.3-3485s21c1	TRCN0000273256	GCCTTTGATTTCGTTCTTCTT	3' UTR

7

8

9 **6.2.2 Plasmids**

10 The plasmids pRP+EV (i.e. empty vector) and pRP+WT (i.e. full-length human cDNA
11 of wild-type UHRF1) were designed and ordered from Vector Builder. The pRP
12 expression vector contains a cytomegalovirus (CMV) promoter, a cDNA sequence
13 coding for the enhanced green fluorescent protein (EGFP) marker, and the C-
14 terminus of the protein of interest (UHRF1) has a dual FLAG and HA tags.

15

16 The plasmids pTag-2C+EV (i.e. empty vector), pTag-2C+WT (i.e full-length human
17 cDNA of wild-type UHRF1) and pTag-2C+Y188A (i.e full-length human cDNA of
18 UHRF1 Y188A mutant) were a generous gift from Dr. Scott Rothbart (Rothbart et al.
19 2012). The pTag-2C expression vector contains a CMV promoter and the N-terminus
20 of the protein of interest (UHRF1) has a FLAG tag.

1 **6.2.3 Maintenance of adherent cells**

2 Complete growth medium, PBS 1X and Trypsin 1X solutions were warmed up at
3 37°C in water bath for approximately 30 minutes prior starting procedure. In a class
4 II cabinet growth medium was removed from cells container (i.e. Flasks (StarLab)/
5 Petri Dishes (Corning)). In order to completely remove growth medium the cells were
6 rapidly washed by adding a small quantity of sterile PBS 1X and by gently rocking
7 the container. Supernatant was then discard from container. To detach adherent cells
8 from the bottom of the container a small amount of Trypsin 1X - EDTA 0.02% solution
9 was added to the container. Cells were then placed into CO₂ incubator at 37 °C until
10 they start to detach. Once the cells are detached the container was transferred back
11 to class II cabinet and complete growth medium was added to the cells to stop the
12 reaction of the Trypsin. To remove dead cells and Trypsin the cell suspension was
13 transferred in a falcon tube and then centrifuged for 5 minutes at 2000 rpm.
14 Supernatant was removed and cell pellet was resuspended carefully but thoroughly
15 in an appropriate volume of complete growth medium. Cell counting was performed
16 on LUNA™ Automated Cell Counter (logos biosystems). 10 µl of sample was mixed
17 with 10 µl of 0.4% trypan blue stain. 10~12 µl of the mixture was loaded into the
18 chamber port on the LUNA™ counting slide, slide was inserted into slide port of the
19 counter, focus was done if necessary and live cells (i.e. bright centres and dark
20 edges while dead cells have blue colour with no bright centres) were counted. Once
21 the cell concentration was determined, the required volume of cell suspension was
22 transferred into a new container and an appropriate volume of fresh complete growth

1 medium was added to the container. The new container was then placed into CO₂
2 incubator at 37 °C.

3

4 **6.2.4 Transient transfection**

5 One day prior to transfection HeLa shLuc and HeLa shUHRF1 cells were seeded in
6 sterile 6 cm Petri Dish (Corning) (see section 6.2.3 - Maintenance of adherent cells)
7 in normal growth medium for an expected cells at confluence of 70-80% the next
8 day. At the day of transfection, growth medium was removed from Petri Dish and 9
9 ml of fresh antibiotic free growth medium was gently added to the plate. For 1 Petri
10 Dish plate, transfection reagents were prepared as followed: *TransIT-LT1* Reagent
11 (Mirus) was put at room temperature and vortexed gently before using. In a 1.5 ml
12 sterile tube (Eppendorf), 250 µl of Opti-MEM I Reduced-Serum Medium (Thermo
13 Fisher Scientific) was mixed gently with 1.5 µl of 1 µg/µl plasmid DNA (one of
14 pRP+EV; pRP+WT; pTag-2C+EV; pTag-2C+WT; pTag-2C+Y188A). 3-9 µl of *TransIT-*
15 *LT1* Reagent was added to the tube and mixed completely by pipetting. The diluted
16 *TransIT-LT1* Reagent was incubated at room temperature for 15-30 minutes. The
17 resulting *TransIT-LT1* Reagent:DNA complexes were added drop-wise at different
18 area of the plate. The Petri Dish was rocked gently to distribute the *TransIT-LT1*
19 Reagent:DNA complexes evenly and then put into CO₂ incubator at 37 °C.
20 Visualisation and analysis of transfected cells were performed 48 hours after
21 transfection.

22

1 **6.2.5 Quantitative PCR**

2 **6.2.5.1 RNA extraction from adherent cells**

3 Total RNA of adherent cells was extracted using RNeasy Mini Kit (Qiagen). Cells
4 were trypsinized (see section 6.2.3 - Maintenance of adherent cells) and pelleted in
5 falcon tube by centrifugation at 500 x g for 5 minutes. The cells were washed with
6 1.5 ml of PBS 1X and centrifuged at 500 x g for 5 minutes at 4 °C. To lyse the cells,
7 supernatant was removed and 350 µl of Buffer RLT was added directly to the cells
8 pellet. Pellet was resuspended by vortexing 4-6 seconds and the lysate was directly
9 pipet into a QIAshredder spin column in a 2 ml collection tube and centrifuge at
10 10,000 x g during 2 minutes for homogenisation. 350 µl of freshly prepared 70%
11 ethanol was added to the homogenised lysate and the mixture was mixed well by
12 pipetting. Up to 700 µl of sample, including any precipitate that may have formed, to
13 an RNeasy spin column placed in a 2 ml collection tube. The lid was close gently
14 and the tube was centrifuged at 10,000 x g for 15 seconds. The flow-through was
15 discarded from collection tube. 700 µl of Buffer RW1 was added to the RNeasy spin
16 column in a 2 ml collection tube. The lid was closed gently and the tube was
17 centrifuged at 10,000 g for 15 seconds. The flow-through was discarded and the
18 collection tube was reuse. To wash the spin column membrane, 500 µl of Buffer RPE
19 was added to the RNeasy spin column in a 2 ml collection tube. The lid was closed
20 gently and the tube was centrifuged at 10,000 g for 15 seconds. The flow-through
21 was discarded and the collection tube was reuse. To wash the spin column
22 membrane, 500 µl of Buffer RPE was added to the RNeasy spin column in a 2 ml

1 collection tube. The lid was closed gently and the tube was centrifuged at 10,000 g
2 for 2 minutes. To eliminate any carryover of buffers, the RNeasy spin column (with
3 lid close) was then placed in a new 2 ml collection tube and was centrifuge at 10,000
4 x g for 1 minute. To elute the RNA, the RNeasy spin column was put in a new 1.5 ml
5 collection tube and 30-50 μ l of RNase-free water was directly added to the spin
6 column membrane and the tube was centrifuged at 10,000 x g for 1 minute. The
7 eluted RNA was used immediately or stored at -20 °C for future use.

8

9 **6.2.5.2 DNase treatment**

10 DNase treatment of freshly extracted RNA was done using the TURBO DNA-free™
11 Kit (Thermo Fisher Scientific). 0.1 volume of 10X TURBO DNase Buffer and 1 μ l of
12 TURBO DNase were added to the RNA and mixed gently. The mixture was incubated
13 for 20-30 minutes at 37 °C. 0.1 volume of resuspended DNase Inactivation Reagent
14 was added to the sample and mixed well. With occasional mixing, the mixture was
15 incubated for 5 minutes at room temperature. Finally, the tube was centrifuged at
16 10,000 x g for 1.5 minutes and the treated RNA was transferred to a fresh tube. The
17 DNase treated RNA was used immediately or stored at -20 °C for future use.

18

19 **6.2.5.3 Bioanalyzer RNA 6000 Nano Kit quality check and quantification**

20 RNA integrity and quantity were assessed using Bioanalyzer RNA 6000 nano kit
21 (Agilent).

22

23

1 **6.2.5.3.1 Setting up the chip priming station**

2 A new syringe was placed in the chip priming station, the plate base was inserted in
3 position C and the syringe clip was positioned at the top position.

4

5 **6.2.5.3.2 Loading the gel dye mix**

6 Protected from light, the gel-dye mix was put at room temperature for 30 minutes
7 before use. After equilibration at room temperature, 9 μ l of gel-dye mix was pipetted
8 at the bottom of the well located on the fourth column and third row of the RNA chip.
9 The RNA chip was then placed into the chip priming station. The chip priming station
10 was closed and the plunger of the syringe that was previously positioned at 1 ml was
11 pressed down until held by the clip. The plunger was kept down for exactly 30
12 seconds and then released. Finally, the plunger was inspected that it moved back to
13 the 0.3 ml mark and after 5 seconds it was slowly pull back to the 1 ml position. After
14 waiting 5 seconds, the plunger was gently pull back and 9 μ l of gel-dye mix was
15 pipetted in the wells located at the fourth column and first and second row.

16

17 **6.2.5.3.3 Loading the marker**

18 5 μ l of RNA 6000 Nano marker was pipetted into the wells with a ladder symbol and
19 into each of the 12 sample wells.

20

21 **6.2.5.3.4 Loading the ladder and the samples**

22 Before use, the ladder aliquots were thaw and kept on ice. Before loading, the
23 samples were heat denatured at 70 °C for 2 minutes, hence minimising the formation

1 of secondary structure. 1 µl of the RNA ladder was pipetted in the well marked with
2 the ladder symbol. 1 µl of sample was pipetted in each of the 21 sample wells. The
3 chip was then placed horizontally in the adapter of the IKA vortex mixer and vortex
4 for 60 seconds at 2400 rpm. Finally, the RNA chip was placed into the Agilent 2100
5 Bioanalyzer (with chip selector was set to position (1)).

6

7 **6.2.5.3.5 Starting the chip run**

8 Using the 2100 Expert software, the appropriate assay was selected from the Assay
9 menu located in the instrument context tab. Then the sample informations were
10 inserted into the sample name table. Finally, the button start was pressed to start the
11 run.

12

13 **6.2.5.3.6 Data analysis**

14 RNA integrity and concentration were assessed directly using the 2100 Expert
15 software built-in analysis module.

16

17 **6.2.5.4 cDNA synthesis**

18 Complementary DNA (cDNA) was synthesised using the High Capacity cDNA
19 Reverse Transcription kit (Thermo Fisher Scientific). In a PCR tube on ice, 10 µl of
20 RNA (equivalent to 1µg; see section 6.2.5.3 - Bioanalyzer RNA 6000 Nano Kit quality
21 check and quantification) was mixed with 10 µl of 2X RT Master mix (2 µl of 10X RT
22 Buffer; 0.8 µl of 25X dNTP mix (100 mM); 2 µl of 10X RT random primers; 1 µl of
23 MultiScribe Reverse Transcriptase; 1 µl of RNase inhibitor; and 3.2 µl of nuclease-

1 free water). The mixture was mixed by pipetting up and down several times and kept
2 on ice. The mixture was then placed in a thermocycler and incubated at 25 °C for 10
3 minutes, 37 °C for 120 minutes, 85 °C for 5 minutes and then hold at 4 °C. The
4 synthesised cDNA was used immediately or stored at -20 °C for future use.

5

6 **6.2.5.5 Quantitative PCR**

7 **6.2.5.5.1 Samples preparation**

8 10 µl of sample cDNA (i.e. from untransfected HeLa shUHRF1, untransfected HeLa
9 shLuc) was mixed with 90 µl of RNase free water, hence resulting in a diluted sample
10 cDNA at 5 ng/µl.

11

12 **6.2.5.5.2 Serial dilution preparation for standard curve**

13 A mixture of both untransfected HeLa shLuc and untransfected HeLa shUHRF1
14 cDNA was used to generate the standard curve.

15

16 5 µl of 50 ng/µl of untransfected HeLa shLuc cDNA was mixed with 5 µl of 50 ng/µl
17 of untransfected HeLa shUHRF1 cDNA and 90 µl of RNase free water, hence
18 resulting in a diluted mixture of cDNA 'D1' at 5 ng/µl. 4 µl of D1 was mixed with 16 µl
19 of RNase free water hence resulting in a diluted cDNA 'D2' at 1 ng/µl. 4 µl of D2 was
20 mixed with 16 µl of RNase free water hence resulting in a diluted cDNA 'D3' at 200
21 pg/µl. 4 µl of D3 was mixed with 16 µl of RNase free water hence resulting in a diluted
22 cDNA 'D4' at 40 pg/µl.

23

1 **6.2.5.5.3 Reaction set-up and PCR amplification**

2 All the following reactions were done in triplicate to ensure accuracy. In a
3 MicroAmp™ Fast Optical 96-Well Reaction Plate (Thermo Fisher Scientific),

4 • 4 µl of diluted samples was mixed with 10 µl of SYBR Select 2X Mix (Thermo
5 Fisher Scientific), 0.4 µl of each 10 µM forward and reverse primers (Table
6 6.17) and 5.2 µl of water.

7 • 4 µl of each of D1, D2, D3 and D4 was mixed with 10 µl of SYBR Select 2X Mix,
8 0.4 µl of each 10 µM forward and reverse primers (Table 6.17) and 5.2 µl of
9 water.

10 • 4 µl of negative controls (i.e. water) was mixed with 10 µl of SYBR Select 2X Mix,
11 0.4 µl of each 10 µM forward and reverse primers (Table 6.17) and 5.2 µl of
12 water.

13 The plate was sealed using MicroAmp™ Optical Adhesive Film (Thermo Fisher
14 Scientific) and centrifuged at 1,500 rpm for 30 seconds. The plate was then placed
15 in StepOne Plus system (Thermo Fisher Scientific) and incubated at 50 °C for 2
16 minutes, 95 °C for 5 minutes and 40 cycles of 95 °C for 15 seconds; 60 °C for 1
17 minute; fluorescent signal acquisition.

18

19

1 **Table 6.17: List of primers used to quantify relative UHRF1 mRNA level.**
 2 *UHRF1* and *GAPDH* primers were chosen from PrimerBank database (X Wang
 3 2003; Xiaowei Wang et al. 2012).

Primer name	Sequence (5'>3')	Amplicon size
UHRF1_FW	GCCATACCCTCTTCGACTACG	237 bp
UHRF1_RV	GCCCAATTCCGTCTCATCC	
GAPDH_FW	GGAGCGAGATCCCTCCAAAAT	197 bp
GAPDH_RV	GGCTGTTGTCATACTTCTCATGG	

*Primers were chosen from PrimerBank open database
 Wang et al. 2003; Wang et al. 2012*

4
 5
 6
 7
 8
 9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19

6.2.5.5.4 Data analysis using the relative standard curve

Relative standard curve method was used to determine the relative target quantity in samples. The StepOne software (Thermo Fisher Scientific) measures amplification of the target (*UHRF1*) and of the endogenous control (*GAPDH*) in sample (i.e. HeLa shUHRF1), in a reference sample (i.e. HeLa shLuc), and in a standard dilution series (i.e. D1, D2, D3 and D4). Measurements are normalised using the endogenous control *GAPDH*. Data from the standard dilution series are used to generate the standard curve. Using the standard curve, the software interpolates *UHRF1* quantity in the sample HeLa shUHRF1 and in the reference sample HeLa shLuc. The software determines the relative quantity of *UHRF1* in HeLa shUHRF1 by comparison to target quantity in the reference sample HeLa shLuc.

1 **6.2.6 Protein assay**

2 **6.2.6.1 Protein extraction from adherent cells**

3 Cells were trypsinized (see section 6.2.3 - Maintenance of adherent cells) and
4 pelleted in falcon tube by centrifugation at 500 x g for 5 minutes. The cells were
5 washed with 1.5 ml of PBS 1X and centrifuged at 500 x g for 5 minutes at 4 °C. To
6 lyse the cells and extract proteins, 150 µl of ice-cold RIPA buffer (see section 2.1.5 -
7 RIPA) was added to the pellet and the mixture was mixed thoroughly by vortexing
8 for 10 seconds. The mixture was placed on ice for 15 minutes with vortexing every
9 5 minutes for 10 seconds. Tubes were then centrifuged at 16,000 x g for 15 minutes
10 at 4 °C. The supernatant was collected and transferred to ice-cold 1.5 ml tube
11 (Eppendorf). Protein lysates were used immediately or stored at -20 °C for later use.

12

13 **6.2.6.2 Protein quantification**

14 Proteins were quantified using Quick Start™ Bradford Protein Assay (Bio-Rad).
15 Before starting, the 1x dye reagent were removed from 4 °C storage, let to warm at
16 ambient temperature and inverted few times before use. Bovine serum albumin was
17 diluted into RIPA buffer to make a series of 8 protein standards ranging from 0 to
18 2000 µg/ml. In triplicate, 5 µl of each standards and samples were added to
19 FLUOTRAC 200 microplate (Greiner Bio-One) and mixed with 250 µl of 1x dye
20 reagent. The microplate was incubated for 5 min at room temperature and then
21 placed into a microplate reader (PHERAstar® FS, BMG LABTECH). The
22 absorbance at 595 nm was measured for each standards and samples. To determine

1 samples concentration, absorbance of each triplicate was averaged and the blank
2 (i.e. 0 µg/mL of protein) value was subtracted from all standards and samples. Linear
3 equation was generated by finding the line of best fit of the absorbance of each
4 standard and their respective protein concentration. Samples protein concentration
5 were estimated by solving x in the linear equation $y = ax + b$, where y is the
6 absorbance, x is the protein concentration, a is the slope of the line and b is the y -
7 intercept.

9 **6.2.6.3 Western Blot**

10 **6.2.6.3.1 SDS-PAGE**

11 20 µg of protein lysate (see section 6.2.6.1 - Protein extraction from adherent cells
12 and 6.2.6.2 - Protein quantification) was mixed with 5 µl of 4X Laemmli sample buffer
13 (see section 2.1.4 - 4X Laemmli sample buffer) and, if needed, deionized water for
14 a total volume of 20 µl. Samples were then heated at 100 °C for 10 minutes, vortexed
15 and quickly centrifuged. NuPAGE™ Novex™ 4-12% Bis-Tris Protein Gels (Thermo
16 Fisher Scientific) was put into XCell SureLock™ Mini-Cell Electrophoresis System
17 (Thermo Fisher Scientific). Upper chamber of the electrophoresis system was filled
18 with 200 ml of 1X NuPAGE® MOPS SDS Running Buffer (Thermo Fisher Scientific)
19 with 500 µl NuPAGE® Antioxidant (Thermo Fisher Scientific) and the lower chamber
20 was filled with 600 ml of 1X NuPAGE® MOPS SDS Running Buffer only. Samples
21 were then loaded on gel and run at 200 V constant for 50 minutes.

1 **6.2.6.3.2 Transfer**

2 Proteins were transferred onto a membrane of nitrocellulose (GE Healthcare Life
3 Sciences). Sponges, Whatman papers (Thermo Fisher Scientific), nitrocellulose
4 membrane and protein gel were incubated for 5 minutes in pre-cooled 1X transfer
5 buffer (see section 2.1.1 - 1X Transfer buffer). They were then assembled into a
6 “sandwich” making sure no bubbles were present between layers in the following
7 order: black side transfer - sponge - Whatman paper - gel - membrane - Whatman
8 paper - sponge - red side transfer. The ‘sandwich’ was then loaded into a transfer
9 apparatus filled with pre-cooled 1X transfer buffer. Transfer was performed for 90
10 minutes at 100 V constant and at 4 °C. After transfer, the nitrocellulose membrane
11 was incubated in blocking buffer (see section 2.1.3 - Blocking buffer) for 1 hour at
12 room temperature and on a rocking platform for gentle agitation.

13

14 **6.2.6.3.3 Immunoblotting**

15 The blocked nitrocellulose membrane was incubated with primary antibody against
16 UHRF1 (mouse monoclonal; 1:1,000 in blocking buffer; BD Biosciences) or beta-
17 actin (goat polyclonal; 1,2000 in blocking buffer, Santa Cruz Biotechnology)
18 overnight at 4 °C and on rocking platform. Membrane was then washed with 1X
19 PBST (see section 2.1.2 - 1X PBS-Tween 20 (PBST)) 3 times for 10 minutes and
20 incubated in HRP-conjugated secondary antibody for 1 hour at room temperature
21 and on rocking platform. Membrane was washed again 3 times for 10 minutes with
22 1X PBST on rocking platform.

23

1 **6.2.6.3.4 Membrane revelation**

2 The chemiluminescence reaction was done by incubating for 1 minute and gentle
3 agitation the nitrocellulose membrane with an equal mixed volumes of the Enhanced
4 Luminol Reagent and the Oxidizing Reagent included in the Western Lightning Plus
5 ECL kit (Perkin Elmer). Excess of chemiluminescence reagent was removed by
6 draining and the membrane was placed in plastic sheet protector. Protein
7 visualisation was done by chemiluminescence imaging using an automatic image
8 capture GeneGnome XRQ (Syngene).

9

10 **6.2.6.3.5 Gel analysis**

11 ImageJ (<http://imagej.nih.gov>) was used to compare protein band densities. Density
12 of protein of interest (i.e. UHRF1) was measured using ImageJ gel analysis module
13 (top menu: Analyze>Gels), normalised to the measured loading control density (i.e.
14 beta-actin) and scaled between 0 and 1.

15

16 **6.2.7 Methylation assay**

17 **6.2.7.1 DNA extraction from adherent cells**

18 Genomic DNA of adherent cells was extracted using Quick-DNA™ Miniprep Kit
19 (Zymo Research). Cells were trypsinized (see section 6.2.3 - Maintenance of
20 adherent cells) and pelleted in a falcon tube by centrifugation at 500 x g for 5
21 minutes. To lyse the cells, supernatant was removed and 500 µl of Genomic Lysis
22 Buffer was added directly to the cells pellet. Pellet was resuspended by vortexing 4-

1 6 seconds and let stand for 5-10 minutes at room temperature. After lysis, the mixture
2 was transferred to a Zymo-Spin™ Column in a Collection Tube and centrifuged at
3 10,000 x g for 1 minute. Zymo-Spin™ Column was transferred to a new Collection
4 Tube, 200 µl of DNA Pre-Wash Buffer was added to the spin column and centrifuged
5 at 10,000 x g for 1 minute. 500 µl of g-DNA Wash Buffer was added to the spin
6 column and centrifuged at 10,000 x g for 1 minute. For elution, the spin column was
7 transferred to a clean micro centrifuge tube, 50 µl of DNA Elution Buffer was added
8 to the spin column and let incubated for 2-5 minutes at room temperature. The spin
9 column was centrifuged at 10,000 x g for 30 seconds. The eluted DNA was quantified
10 by Nanodrop (see section 2.3 - DNA quantification) and immediately used or stored
11 at -20 °C for future use.

12

13 **6.2.7.2 Methylation-sensitive restriction digestion assay**

14 The genomic DNA was extracted from the different cell lines (see section DNA
15 extraction from adherent cells) and digested with Msp I and Hpa II (New England
16 Biolabs). Restriction digestion reaction was prepared as followed: in 2 different tubes
17 2 units of Msp I or 2 units of Hpa II were mixed with 1 µg of gDNA, 1X CutSmart®
18 Buffer (New England Biolabs) and deionized water if needed for a total final volume
19 of 50 µl. Both tubes reactions were incubated at 37 °C for 2 hours. The digested DNA
20 samples were resolved on a 1% (w/v) agarose gel (1 g agarose dissolved in 100 ml
21 1X TAE buffer (see section 2.1.7 - 1X TAE) containing SYBR® Safe DNA gel staining
22 (Thermo Fisher Scientific) for 30 min at 100 V constant. The gel was then placed into
23 Gel Doc XR+ System (Bio-Rad) for UV exposition and image capture. ImageJ was

1 used to determine the top gel band density and the associated level of enzymatic
2 digestion. HpaII cuts at unmethylated sites (bright band) whilst methylated sites
3 remain protected to the enzyme (darker band).

4

5 **6.2.7.3 Manual DNA dot-blot**

6 **6.2.7.3.1 DNA spotting**

7 In 6 µl final volume reaction, 100 ng of sample genomic DNA (see section 2.3 - DNA
8 quantification) or a set of calibrated human methylated DNA (Zymo Research;
9 standard curve at 0%, 25%, 50%, 75%, 100% methylated DNA) was mixed with 0.6
10 µl of 0.1 M EDTA, 0.48 µl of 5 M NaOH and, if necessary, dH₂O. Samples were
11 denatured at 99 °C for 10 minutes and let cool down at room temperature without
12 snap-cooling. Charged nylon membrane (Zeta-Probe Membranes, Bio-Rad) was wet
13 in autoclaved dH₂O, and placed face-up on Whatman paper (Thermo Fisher
14 Scientific) to remove the excess of water. Denatured DNA samples were quickly but
15 carefully manually spotted on the membrane whilst the latter was still wet. Nylon
16 membrane was let air-dried for at least 10 minutes and rinsed face down in a clean
17 box containing 100-200 ml of 2x SSC buffer (see section 2.1.6 - 2X SSC) for 1–2
18 minutes at room temperature and gentle agitation. The membrane was oven baked
19 at 80 °C for 1 hour to immobilise the DNA onto it and then blocked in blocking buffer
20 (see section 2.1.3 - Blocking buffer) for 1 hour at room temperature and gentle
21 agitation.

22

1 **6.2.7.3.2 5-mC visualisation**

2 The blocked nylon membrane was incubated with primary monoclonal antibody
3 against 5-mC (Eurogentec) diluted at 1:1,000 in blocking buffer (see section 2.1.3 -
4 Blocking buffer) overnight at 4 °C and on rocking platform. Membrane was then
5 washed with 1X PBST (see section 2.1.2 - 1X PBS-Tween 20 (PBST)) 3 times for
6 10 minutes and incubated in HRP-conjugated secondary antibody (1:2,000 in 1X
7 PBS-T) for 1 hour at room temperature and on rocking platform. Membrane was
8 washed again 3 times for 10 minutes with 1X PBST on rocking platform. The
9 chemiluminescence reaction was done by incubating for 1 minute and gentle
10 agitation the nylon membrane with an equal mixed volume of the Enhanced Luminol
11 Reagent and the Oxidizing Reagent included in the Western Lightning Plus ECL kit
12 (Perkin Elmer). Excess of chemiluminescence reagent was removed by draining and
13 the membrane was placed in plastic sheet protector. Protein visualisation was done
14 by chemiluminescence imaging using an automatic image capture GeneGnome
15 XRQ (Syngene).

16

17 **6.2.7.3.3 DNA quantity assessment**

18 Following 5-mC detection, the nylon membrane was washed 2 times 1 minute in 1x
19 PBST. DNA staining was done by incubating the membrane in 1x SYBR® Gold
20 (Thermo Fisher Scientific) in 1x TAE (see section 2.1.7 - 1X TAE) for 5-10 minutes
21 and gentle agitation. Membrane was quickly washed 2-3 times in 1X PBST to remove
22 the excess of SYBR® Gold and then placed into Gel Doc XR+ System (Bio-Rad) for
23 UV exposition and image capture.

1 **6.2.7.3.4 Membrane analysis**

2 ImageJ (<http://imagej.nih.gov>) and the MicroArray Profile plugin (Bob Dougherty and
3 Wayne Rasband, http://www.optinav.info/MicroArray_Profile.htm) were used to
4 analyse the membrane. The measured 5-mC density of the standard curve and of
5 the samples was normalised to their corresponding measured DNA loading control
6 density. The methylation level in the samples was calculated by resolving x in the
7 linear equation $y = ax + b$ derived from the methylated standard points regression
8 analysis.

9

10 **6.2.7.4 Targeted bisulfite sequencing assay**

11 **6.2.7.4.1 Library preparation and sequencing**

12 The following library preparation method was developed by Dr. Eguzkine Ochoa.
13 The data were generated by Dr France Docquier. The data processing and analysis
14 were performed by me.

15

16 **6.2.7.4.1.1 First round PCR: target capture**

17 500 ng (see section 2.3 - DNA quantification) of gDNA or a set of calibrated human
18 methylated DNA (Zymo Research; standard curve at 0%, 25%, 50%, 75%, 100%
19 methylated DNA) was bisulfite treated (see section 2.4 - Sodium bisulfite treatment).
20 1 μ l of bisulfite converted DNA was mixed with 8.5 μ l of ZymoTaq™ PreMix (Zymo
21 Research), 0.85 μ l of each 10 μ M forward and reverse primers (Table 6.18) and 5.8

1 µl of distilled water. The mixture was placed in a thermocycler and incubated at 95
 2 °C for 10 min, 40 cycles of 95 °C for 30 sec; 58 °C for 40 sec and 72 °C for 1 min,
 3 72 °C for 7 min and then hold at 4 °C. PCR reaction was loaded on a 1.5% agarose
 4 gel electrophoresis (1.5 g agarose dissolved in 100 ml 1X TAE (see section 2.1.7 -
 5 1X TAE), 1X SYBR Safe) and the gel was run for 40 minutes at 100 V. Once finished,
 6 the gel was placed into Gel Doc XR+ System (Bio-Rad) for UV exposition. The size
 7 of amplicons was compared to the 1 kb DNA ladder. The PCR products were used
 8 immediately after or stored at -20 °C for later use.

9

10 **Table 6.18: List of primers used for targeted bisulfite sequencing.**

11 *KvDMR1 primers amplify a region within the imprinting centre KCNQ1OT1:TSS-*
 12 *DMR. H19 primers amplify a region within the imprinting centre H19/IGF2:IG-DMR.*
 13 *KvDMR1 and H19 primers were designed by Dr. Eguzkine Ochoa. IGS-rDNA*
 14 *primers amplify a region within the intergenic spacer of ribosomal DNA (Rothbart et*
 15 *al. 2012).*

Primer Name	Sequence (5'>3')	Amplicon size
KvDMR1_Fw	TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGNATGTTATTYGGGTTTAGATTGGTTTAG	163 bp
KvDMR1_Rv	GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGNNCACCCCAAATAATAAACACATCAC	
IGS-rDNA_Fw	TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGNNNNGAGGGGTATTTTATAGATTTTTTTT	274 bp
IGS-rDNA_Rv	GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGNNNNNTCTCACTCACTCTACAACCTAAACC	

in red, common sequence used for multiplex 2nd round PCR amplification (adaptor tagging and indexing).
in blue, sequence specific to targeted region.

16

17

18

19 **6.2.7.4.1.2 Purification of PCR products**

20 The PCR products were purified using QIAquick PCR purification kit and eluted in
 21 50 µl of double distilled water (see section 2.2 - DNA purification). The purified PCR
 22 products were used immediately after or stored at -20 °C for later use.

1 **6.2.7.4.1.3 Second round PCR: adaptor tagging and indexing**

2 5 µl of purified PCR products was mixed with 25 µl of 2X KAPA HiFi HotStart
3 ReadyMix (Kapa Biosystems), 5 µl of each Nextera XT Index forward and reverse
4 primers (Nextera XT Index Kit v2 Set A, Illumina) and 10 µl of distilled water. The
5 mixture was placed in a thermocycler and incubated at 95 °C for 3 min, 8 cycles of
6 95 °C for 30 sec; 55 °C for 30 sec and 75 °C for 30 sec, 72 °C for 5 min and then
7 hold at 4 °C. The PCR products were used immediately after or stored at -20 °C for
8 later use.

9

10 **6.2.7.4.1.4 Purification of PCR products**

11 The resulting adaptor-tagged and indexed PCR product was purified and size
12 selected using AGENCOURT® AMPURE® XP (Beckman Coulter). The PCR product
13 was transferred to a 300 µl round bottom plate (Thermo Fisher Scientific). The
14 AMPure XP bottle was gently mixed to resuspend the magnetic particles that may
15 have settled. 90 µl of AMPure XP was added to the PCR reaction and then mixed
16 thoroughly by pipetting up and down 10 times. The mixed sample was incubated for
17 5 minutes at room temperature. To separate the beads from the solution, the plate
18 was placed onto an Agencourt SPRIPlate 96 Super Magnet Plate (Beckman Coulter)
19 for 2 minutes. The cleared solution was aspirated from the reaction plate and
20 discarded. With the plate still on the magnetic stand, the beads were washed by
21 adding carefully (i.e. without disturbing the separated magnetic beads) 200 µl of
22 freshly prepared 70% ethanol to the well of the reaction plate and let to incubate for
23 30 seconds at room temperature. The ethanol was carefully removed and the wash

1 step was repeated for a total of two washes. Once the ethanol removed, the plate
2 was let to air dry for 3 minutes. The plate was then removed from the magnetic stand
3 and the sequencing libraries were eluted by adding 56 µl of distilled water to it and
4 mixing by pipetting up and down 10 times. The eluted DNA was used immediately
5 after or stored at -20 °C for later use.

6

7 **6.2.7.4.1.5 Sequencing libraries quality assessment**

8 The resulting purified sequencing libraries were quantified using Qubit® dsDNA HS
9 Assay Kit (see section 2.3 - DNA quantification) and their size were checked using
10 Bioanalyzer High Sensitivity DNA Kit (see section 2.7 - Fragment analysis of DNA
11 libraries). The sequencing libraries were then diluted to 4 nM, pooled if necessary
12 (i.e. in case of sample multiplexing) and stored at -20 °C until sequencing.

13

14 **6.2.7.4.1.6 Sequencing**

15 The sequencing of the libraries was performed by the Stratified Medicine Core
16 Laboratory (SMCL) Next Generation Sequencing facility. A MiSeq sequencer was
17 used for the sequencing.

18

19 **6.2.7.4.2 Processing and analysis of NGS data**

20 Trim Galore v0.4.0 was used to remove and trim low-quality sequences and
21 sequencer adaptors from bisulfite converted reads. Bismark v0.14.4 (Krueger and
22 Andrews 2011) was used to align the trimmed sequencing reads to an *in silico*
23 bisulfite converted human genome (GRCh38.p6). Bismark Methylation Extractor

1 v0.14.4 was used for cytosine methylation calling. The shell code used to trim, align
2 and extract 5-mC level from the sequencing reads is available in Appendix 5.

3

4 **6.2.7.4.3 5-mC quantification**

5 The resulting methylation called file was used to assess the methylation level for
6 each amplicons (i.e. *H19/IGF2:IG-DMR*; *KCNQ1OT1:TSS-DMR* and IGS-rDNA).
7 The level of 5-mC in each locus was estimated by calculating the average of 5-mC
8 level reported at each CpG sites within each locus. The R script used for 5-mC
9 quantification is available in Appendix 6.

10

11 **6.2.7.4.4 PCR bias correction for 5-mC methylation level**

12 To account for the PCR amplification bias, the degree of experimental methylation
13 measured in each samples at each loci was corrected by resolving x in the cubic
14 polynomial equation $y = ax + cx^2 + dx^3 + e$ derived from the methylated standard
15 points regression analysis (Moskalev et al. 2011). The R script used to adjust the
16 methylation data is available in Appendix 7.

17


18 **6.3 Results**

19 **6.3.1 Transfection optimisation**

20 The following data were generated by Dr France Docquier and further analysed by
21 myself. Optimal transfection efficiency was evaluated on parental non-knocked down

1 HeLa cells. Different concentrations of transfecting reagents were mixed with a
2 constant amount of plasmid DNA (plasmid pRP, 1.5 µg) and transfection efficiency
3 was evaluated by visual estimation of GFP positive cells using fluorescent
4 microscope. The best condition of transfection was achieved using 1.5 µg of plasmid
5 DNA and 9 µl of transfecting reagents (Figure 6.3). This condition was used to
6 transfect wild-type and mutant UHRF1 in HeLa cells in which *UHRF1* was knocked
7 down.

8



9

10 **Figure 6.3: HeLa cells transfection optimisation using pRP plasmid.**

11 *For the transfection of the pRP plasmid into HeLa cells, different concentration of*
12 *transfection reagent was used as indicated and transfection efficiency (level of GFP*
13 *positive cells) was visually evaluated by fluorescent cell imager. Top, brightfield;*
14 *bottom, green channel. (Data were generated by Dr France Docquier and analysed*
15 *by myself).*


16

17 **6.3.2 Low level of UHRF1 mRNA and protein in HeLa shUHRF1**

18 The following data were generated by Dr France Docquier and further analysed by
19 myself. Quantitative PCR measuring *UHRF1* mRNA level showed efficient

1 knockdown of more than 80 % of *UHRF1* between control HeLa cells (i.e. HeLa
2 shLuc) and HeLa *UHRF1* knockdown cells (i.e. HeLa shUHRF1) (Figure 6.4-a). This
3 result was further confirmed by Western-blot. Compared to HeLa shLuc, UHRF1
4 protein level in HeLa shUHRF1 decreased by more than 80 %, thus indicating
5 efficient gene silencing of *UHRF1* by shRNA (Figure 6.4-b).

6



7

8

9 **Figure 6.4: Efficient knockdown of *UHRF1* in HeLa cells.**


10 *UHRF1* shRNA knockdown efficiency was compared to a control luciferase shRNA
11 in HeLa cells (a) by qPCR and (b) by Western blot (top: Western blot, bottom: *UHRF1*
12 gel band relative density obtained with ImageJ). HeLa shLuc, HeLa cells transduced
13 with shRNA targeting luciferase; HeLa shUHRF1, HeLa cells transduced with shRNA
14 targeting *UHRF1*. (Data were generated by Dr France Docquier and analysed by
15 myself).

1 **6.3.3 Transfection of UHRF1 does not rescue global methylation**

2 The following data were generated by Dr France Docquier and further analysed by
3 myself. In comparison to the control cells HeLa shLuc, the digestion of HeLa
4 shUHRF1 cells by the methylation-sensitive restriction enzyme HpaII suggested that
5 the knockdown of *UHRF1* induced a global reduction of DNA methylation. However,
6 the transient expression of wild-type *UHRF1* seemed to fail to restore the methylation
7 to a similar level than observed in the control cells (Figure 6.5-a). These qualitative
8 observations provided unexpected suggestions as a methylation rescue was
9 expected following the transient expression of wild-type *UHRF1*. DNA dot-blot
10 assays were carried out to confirm this trend. In comparison to the control cell HeLa
11 shLuc, in which the methylation level was 60.3%, the *UHRF1* knockdown in HeLa
12 shUHRF1 induced the global methylation to drop to 23%. However, although the
13 transient expression of wild-type *UHRF1* in HeLa shUHRF1 cells seemed to induce
14 the methylation to increase slightly to 27.4%, it seemed to fail to restore the
15 methylation to a similar level than observed in the control cells (Figure 6.5-b). *UHRF1*
16 protein level was assessed by Western-blot and significant *UHRF1* over expression
17 was observed after transient transfection of wild-type *UHRF1* in both HeLa shLuc
18 and HeLa shUHRF1 (Figure 6.5-c). Altogether, these results suggested that although
19 it was expressed in cells, the exogenous *UHRF1* might have been non-functional. I
20 hypothesised that this could be linked to the pRP vector backbone or the FLAG and
21 HA protein tags. To address these issues, a plasmid construct identical to the one
22 used in previous studies (Rothbart et al. 2012; Rothbart et al. 2013) was tested on

1 control and UHRF1 knockdown cells for DNA methylation rescue. In comparison to
2 the control cells HeLa shLuc in which the methylation level was 70.7%, the
3 knockdown of UHRF1 in HeLa shUHRF1 seemed to reduce the global methylation
4 level to 37.9%. However, similar to experiments using the plasmid pRP, the transient
5 expression of wild-type *UHRF1* expressed from the new vector backbone pTag-2C
6 seemed to fail to rescue the methylation to the level seen in the control cells.
7 Interestingly, the transient expression of wild-type UHRF1 seemed to induce a small
8 loss-of-methylation (drop to 60.8%) in the control cells HeLa shLuc. As expected,
9 the transient expression of the mutant UHRF1 Y188A, used here as a positive control
10 for loss of protein function (Rothbart et al. 2012), seemed to have no effect on DNA
11 methylation in HeLa shUHRF1 cells (Figure 6.6-a). UHRF1 wild-type and UHRF1
12 Y188A protein levels were assessed by Western-blot in HeLa shUHRF1 cells and
13 significant over expression was observed for both constructs (Figure 6.6-b). It has to
14 be noted that in this set of experiment, the level of repeatability between my
15 biological replicates was very low, hence the necessity to draw careful interpretations
16 in regard to the obtained results.

17



1
2
3
4
5
6
7
8
9
10
11
12
13

Figure 6.5: Transfection of pRP UHRF1 WT does not rescue global methylation.

The global methylation level in HeLa shLuc and HeLa shUHRF1 transfected with different pRP plasmid (as indicated) was assessed by (a) digestion using methylation-sensitive restriction enzymes (n=1) and by (b) DNA dot-blot (n=2). (c) UHRF1 protein level in HeLa shLuc and HeLa shUHRF1 transfected with indicated plasmid was assessed by Western-blot. +NT, not transfected; +EV, empty vector; +WT, UHRF1-WT. (Data were generated by Dr France Docquier and analysed by myself).





Figure 6.6: Transfection of pTag-2C UHRF1 WT does not rescue global methylation.

(a) The global methylation level in HeLa shLuc and HeLa shUHRF1 transfected with different pTag-2C plasmids (as indicated) was assessed by DNA dot-blot (n=2). (b) UHRF1 protein level in HeLa shLuc and HeLa shUHRF1 transfected with indicated plasmids was assessed by Western-blot. +NT, not transfected; +EV, empty vector; +WT, UHRF1-WT; +Y188A, UHRF1-Y188A. (Data were generated by Dr France Docquier and analysed by myself).

6.3.4 Transfection of UHRF1 does not rescue methylation at IGS-rDNA

The following data were generated by Dr France Docquier and further analysed by myself. Targeted bisulfite sequencing was used to measure methylation levels at a CpG island within the intergenic spacer of ribosomal DNA (IGS-rDNA), a known target of UHRF1 (Bostick et al. 2007; Rothbart et al. 2012; Rothbart et al. 2013), and


1 at the imprinted locus *KCNQ1OT1*:TSS-DMR. Both targets were amplified by
2 bisulfite-PCR followed by next-generation sequencing on an Illumina sequencing
3 platform (MiSeq). Using calibrated DNA standards, preferential amplification of the
4 methylated alleles (4.41 fold at IGS-rDNA and 3.02 fold at *KCNQ1OT1*:TSS-DMR)
5 was observed at both loci (Figure 6.7). Consequently, the degree of experimental
6 methylation measured in each samples was corrected for PCR amplification bias
7 (Moskalev et al. 2011). The interpretation of the adjusted values showed that in
8 agreement with previous studies (Bostick et al. 2007; Rothbart et al. 2012; Rothbart
9 et al. 2013), *UHRF1* knockdown seemed to induce a loss-of-methylation (~ 57-59%)
10 at IGS-rDNA. However, and similar to our findings on global methylation (Figure 6.5
11 and Figure 6.6), the transient expression of wild-type *UHRF1* expressed from the
12 pRP and pTag-2C expression vector seemed to fail to restore the DNA methylation
13 at IGS-rDNA (~ 57-58% LOM compare to control cells) (Figure 6.8-a). Similarly, DNA
14 methylation at the imprinted locus *KCNQ1OT1*:TSS-DMR seemed to decrease by
15 approximatively 48-50% in *UHRF1* knockdown cells but the transient expression of
16 wild-type *UHRF1* seemed to fail to restore the DNA methylation (~ 46-53% LOM
17 compare to control cells) to a similar level than observed in control cells (Figure 6.8-
18 b).
19



1

2 **Figure 6.7: Degree of bias introduced by PCR amplification.**

3 *IGS-rDNA and KCNQ10T1:TSS-DMR amplification bias was calculated from*
 4 *calibrated methylated DNA standards (0%, 25%, 50%, 75%, 100% methylated). The*
 5 *experimental degree of methylation observed after amplification (y-axis) was plotted*
 6 *as a function of the actual methylation percentage (x-axis). The value of b, equivalent*
 7 *to the PCR bias, was calculated by averaging individual b values calculated for each*
 8 *curve point with the following equation: $b = [y \times (100 - x)]/[x \times (100 - y)]$ where y is*
 9 *the uncorrected experimental and x is the real value. Red line, cubic polynomial*
 10 *regression line derived from calibrated DNA standards; black dotted line, derived*
 11 *theoretical regression line derived from un-bias amplification. (Data were generated*
 12 *by Dr France Docquier and analysed by myself).*



1

2 **Figure 6.8: Transfection of pTag-2C UHRF1 WT does not rescue methylation**
 3 **at KCNQ1OT1:TSS-DMR and IGS-rDNA.**

4 *Methylation at IGS-rDNA and at KCNQ1OT1:TSS-DMR loci were obtained by*
 5 *bisulfite-PCR followed by next-generation sequencing. Corrected methylation*
 6 *estimated in HeLa shLuc and HeLa shUHRF1 cells transfected with the indicated*
 7 *construct at (a) IGS-rDNA and (b) KCNQ1OT1:TSS-DMR. +NT, not transfected;*
 8 *+EV, empty vector; +WT, wild-type UHRF1; +Y188A, UHRF1 Y188A mutant. (Data*
 9 *were generated by Dr France Docquier and analysed by myself).*

1 **6.4 Discussion**

2 I hypothesised that the novel homozygous missense variant in the *UHRF1* gene
3 (NM_001048201.2, c.2237G>C, p.K667N) found in the two siblings with BWS_IC2
4 would affect the maintenance of DNA methylation at imprinted DMRs such as
5 *KCNQ1OT1:TSS-DMR* without disrupting global DNA methylation. To test this
6 hypothesis I undertook DNA methylation rescue assays in HeLa cells knockdown for
7 *UHRF1* (HeLa shUHRF1). Those cells were a generous gift from Dr. Scott Rothbart
8 and they were previously shown to have decreased DNA methylation genome-wide
9 and at IGS-rDNA compared to control HeLa cells (i.e. HeLa shLuc). Additionally, it
10 was shown that transient expression of wild-type UHRF1 in those cells should rescue
11 the loss of DNA methylation resulting from the knockdown of UHRF1 (Rothbart et al.
12 2012).

13

14 Before evaluating the effects that the *UHRF1* variant may have on DNA methylation,
15 experiments were undertaken to assess the effects of the transient expression of
16 wild-type *UHRF1* using pRB expression vector in HeLa shUHRF1 cells. However,
17 the choice of assessing the global level of methylation by DNA digestion using
18 methylation-sensitive restriction enzymes was not indicated for my objectives. This
19 method only provided the qualitative, and not quantitative, assessment of the global
20 level of DNA methylation. The use of manual DNA dot-blot assays revealed to be
21 more quantitative and appropriate for my objectives. However, the second set of
22 experiments using the pTag-2C plasmid achieved a very low level of repeatability,

1 hence indicating the lack of both biological and technical replicates. Therefore,
2 additional biological and technical replicates were required to gain more accuracy
3 and confidence in the results. Consequently, the conclusions I drawn from these
4 experiments are limited to the suggestion of possible changes in DNA methylation.

5
6 Global and targeted DNA loss-of-methylation associated with *UHRF1* knockdown
7 seemed not to be rescued following the transient expression of wild-type *UHRF1*.
8 This result was unexpected as it appeared to contradict the previous published
9 results reported by Dr. Scott Rothbart and colleagues (Rothbart et al. 2012). I
10 hypothesised that the presence of a dual FLAG and HA protein tags in C-terminus
11 may prevent the exogenous UHRF1 from rescuing the DNA methylation defect. To
12 test this hypothesis, Dr. France Docquier performed experiments using wild-type
13 *UHRF1* expressed from pTag-2C expression vectors. This plasmid construct, a
14 generous gift from Dr. Scott Rothbart, displayed a single FLAG tag in N-terminus and
15 was previously shown to be efficient in rescuing DNA methylation abnormality
16 (Rothbart et al. 2012). Similar to the results obtained using pRB, the transient
17 expression of wild-type *UHRF1* using pTag-2C seemed to fail to rescue the global
18 loss-of-methylation associated with *UHRF1* knockdown. Additionally, no DNA
19 methylation rescue was observed at IGS-rDNA and *KCNQ1OT1*:TSS-DMR whilst it
20 was expected that both loci would re-gain DNA methylation after transient expression
21 of wild-type *UHRF1*.

22
23 Following these failed attempts to rescue the DNA methylation associated with

1 *UHRF1* knockdown by expressing wild-type *UHRF1* with both the pRB and pTag-2C
2 expression vector, I did not continue with the analysis of the *UHRF1* missense variant
3 found in the siblings with BWS. After carefully reviewing the experimental procedures
4 and discussion with Dr. Scott Rothbarts' collaborators, I hypothesised that in my
5 experiments *UHRF1* was too overexpressed and this may have deregulated *UHRF1*
6 function, ultimately leading to a loss of DNA methylation. To support this hypothesis,
7 a small loss-of-methylation was observed in HeLa controls cells following the
8 transient expression of wild-type *UHRF1* whilst no DNA methylation change was
9 expected. Additionally, *UHRF1* overexpression had been associated with DNA
10 hypomethylation in cancer such as hepatocellular carcinoma and esophageal
11 squamous cell carcinoma (Mudbhary et al. 2014; K. Nakamura et al. 2016).
12 However, although these observations would be compatible with my hypothesis,
13 further studies would be required to confirm these.

14

15 The potential causal link between the mutant *UHRF1_K667N* and the DNA
16 methylation maintenance failure at *KCNQ1OT1:TSS-DMR* is still under
17 investigation. Further DNA methylation rescue experiments involving the use of an
18 expression vector including a tag free protein and a weak promoter, such as the
19 human ubiquitin C promoter, for gene expression is considered. Another approach
20 using gene knockin in mice is currently being discussed. The CRISPR/Cas9 system
21 could be used to generate a NP95 p.K662N (NP_035061) mouse line (p.K662N in
22 mice is equivalent to p.K667N in human). Using this model would have the
23 advantages of being able to investigate in more detail the effects of the mutant in the

1 maintenance of DNA methylation. Furthermore, although UHRF1 has mainly been
2 described as a DNA methylation maintenance protein, the genome-edited mouse
3 line may provide potential insights on the role of the protein (and the mutant) in the
4 establishment of DNA methylation.

Chapter 7

General discussion

7.1 Multilocus imprinting disturbances in imprinting disorders, a need for standardisation

Aberrant DNA methylation at imprinting control regions plays a critical role in the molecular aetiology of imprinting disorders (IDs) such as BWS and SRS. In the current report, I combined the use of a reliable and robust genome-wide methylation array and an accurate and efficient bioinformatic pipeline to identify widespread methylation disturbances across multiple imprinting control regions in a subset of BWS and SRS cohorts. Though my findings were consistent with previously published reports (Rossignol et al. 2006; Bliiek et al. 2008; Azzi et al. 2009; Court et al. 2013; Poole et al. 2013; Tee et al. 2013; Maeda et al. 2014), they also highlighted a current need to harmonise the way in which aberrant DNA methylation in ID individuals is defined, analysed and reported. Indeed, the variability in *(i)* the loci investigated, *(ii)* the platform used to perform the methylation profiling and *(iii)* the methodology used to identify methylation change complicated comparisons with other studies (discussed below). To address these issues, the research community has begun adopting different measures that would help standardisation of results and consequently leading to better comparison between studies (Monk et al. 2016).

7.1.1 Where to look?

To define the frequency of multilocus imprinting disturbances (MLIDs) in ID cohort researchers focused on a subset of arbitrary loci. In the current study I analysed DNA methylation at 46 imprinted differentially methylated regions (DMRs), which

contrasts with the limited number of loci that were assessed in others (e.g. 7 in Azzi et al. 2009; 4 in Tee et al. 2013). As discussed in Chapter 4, it seems that the more loci being investigated, the higher the reported MLID frequency. Therefore, whilst assessing all imprinted DMRs might not be possible in all cases (e.g. technical constraints associated with the used platform), it will be beneficial to define a core set of imprinted DMRs that would need to be included in all reports.

7.1.2 Too many platforms might lead to confusion

The use of different platforms to assess methylation may also hamper comparison between studies. Whilst some studies, including mine, used high-throughput genome-wide methylation array, others relied on combined bisulphite restriction analysis and methylation-specific PCR (Bliek et al. 2008), allele-specific methylated multiplex real time quantitative PCR (Azzi et al. 2009), or pyrosequencing (Poole et al. 2013). The sensitivity to detect subtle changes in DNA methylation and low-level mosaicism may differ between platforms, hence leading to the identification, or exclusion, of findings that may be relevant to the research question and to diagnostic testing.

7.1.3 A common informatic approach to detect epimutations

A standardised method to define a loss- or a gain-of-methylation should be defined. Should the method rely on a cut-off threshold calculated from normal control individuals? How many normal control individuals should be used for the

comparison? In the current study, I developed a method relying on a cut-off threshold of \pm three standard deviations calculated from the mean of a cohort of more than 1400 normal control individuals. Whilst this is an impressive number that should increase the robustness of statistical analysis, it is unlikely that such large amounts of data would be available to all laboratories. To overcome this issue, alternative informatics methodologies have been developed, such as a single case-control comparison test that requires 20 normal control individuals only and which is based on Crawford-Howell t-test (Rezwan et al. 2015).

7.1.4 Need to find a better alternative for diagnostic services

With the scope to address these issues, I originally undertook the development of a novel NGS strategy for the genomic imprinting methylation profiling of individual with BWS and SRS, and more globally with a clinically diagnosed ID. The methodology was based on bisulfite padlock probes, a potentially reliable and sensitive method that was previously used to characterise 66,000 CpG sites within 2,020 CpG islands on human chromosome 12, chromosome 20, and 34 selected regions (Deng et al. 2009), and 500,000 CpG sites within genomic regions known to contain differentially methylated regions or sites, CTCF binding sites, DNase I hypersensitive regions, all microRNA genes and all promoters for human NCBI Reference Sequence genes (Diep et al. 2012). Although the development of the method was not successful, it could have offered a highly sensitive method to characterise at a single base pair resolution the majority of CpGs within all the currently known imprinted DMRs (Court

et al. 2014) in a single multiplex reaction. The method was intended to allow the sequencing of a large number of samples using the bench top MiSeq sequencer whilst maintaining great depth of sequencing coverage (>150 samples at >500x). Consequently, this could have resulted in very precise detection of DNA methylation change at a given region and CpG site level, hence improving accuracy in epimutation identification rate even in samples with low level mosaicism. Finally, the method could have been used for the genomic imprinting methylation profiling in several tissues, hence leading to the characterisation of the nature and frequency of MLID in these.

In conclusion another NGS-based method, if successfully developed and applied, might be part of the answer to standardise findings in the scope of better comparison of findings between studies. In the meantime, until such NGS-based method is successfully developed, I would recommend the use of HM450K for the clinical diagnostic of individuals with suspected ID. Despite some limiting factors, such as low probe coverage at some loci or presence of technical and biological batch effects, it provided 100% sensitivity and >99% specificity in identifying all of my BWS and SRS patients and similar efficiency has been seen in other studies focussing on other ID (Court et al. 2013; Docherty et al. 2014; Maeda et al. 2014; Prickett et al. 2015; Rochtus et al. 2016). Finally, the HM450K allows in a single analytic procedure the comprehensive and simultaneous assessment of DNA methylation at not only the disease-causing loci but also at other regions not known to be involved in the molecular aetiology of the disease which allows potential new discovery.

7.2 The possible underlying causes of BWS and MLID

The underlying causes of MLID in BWS, and more globally in most ID, remain to date unknown. However, several hypotheses that could explain the aberrant epigenotype have been formulated.

7.2.1 Environmental pressure

It is well established that assisted-reproductive technology (ART) is associated with the LOM of *KCNQ1OT1*:TSS-DMR in BWS individuals (DeBaun et al. 2003; Gicquel et al. 2003; Maher et al. 2003; Halliday et al. 2004; Weksberg et al. 2010). Consequently, it was natural to suggest that ART might also be implicated in the MLID epigenotype. To that end, several studies, including the current one, undertook the characterisation of MLID in BWS_IC2 individuals conceived with ART. Whilst I and others found an association (Lim et al. 2009; Hiura et al. 2012; Tee et al. 2013), others reported the opposite (Rossignol et al. 2006; Azzi et al. 2009). The discrepancy between reports might be explained by several factors that might include (i) the platform/methodology used to identify the epimutation (which could relate to the discussion above), (ii) the overlap between cohort used for the different studies (the current one may overlap with Lim et al. 2009 and Tee et al. 2013) and therefore the possible bias in the findings and (iii) differences between the ART procedures themselves. For the latter, it is conceivable that the techniques used to perform the ART may differ to some degree between hospitals and countries. Consequently, some aspects of a procedure may interfere with DNA methylation

differently, hence resulting in different epigenotype.

Overall, although it is not a universal finding, cohort studies suggested that ART might be associated with MLID epigenotype. However, it is yet to be determined if the methylation disturbances result directly from the ART procedures themselves, other factors such as the infertility or the age of the parents, or a combination of all. Furthermore, there is a need to identify which step of the ART procedures is involved in this mechanism. Therefore, the study of more extensive cohort will bring some clarity in the characterisation of ART in MLID epigenotype.

7.2.2 Genetic component

Recently, the identification of MLID in a subset of individuals with IDs has triggered a particular interest in performing WES screening to determine if there might be potential underlying genetic causes that are responsible for MLID. However, despite much effort, only a few causative *trans*-acting mutations have been found. These include the maternal-zygotic gene *ZFP57* and the maternal genes *NLRP7*, *KHDC3L*, *NLRP2* and *NLRP5* (Murdoch et al. 2006; Mackay et al. 2008; Meyer et al. 2009; Parry et al. 2011; Docherty et al. 2015). In the current study I undertook WES with the scope to identify new pathogenic mutations that might explain BWS and MLID phenotype. In addition to a homozygous missense variant in the *UHRF1* gene for which the potential pathogenicity is currently being assessed through functional studies within our group, I report additional potential candidate gene mutations that

affect maternal-effect genes (*BNC1*, *CTCF*, *NLRP2*) and could be implicated in BWS phenotype and MLID epigenotype. However, the potential pathogenicity of these still require further validation. Overall, taking into consideration the current study and previous reports (Begemann et al. 2011; Azzi et al. 2014; Caliebe et al. 2014) it appears that the number of disease-causing mutations found by targeted exome and WES is very rare in individuals with an ID. Alternatively, it is possible that the potential pathological variants may have been missed due to the complexity that poses the analysis and interpretation of WES. The filtering and prioritisation criteria are critical in WES analysis such as using wrong parameters might result in either too many variants left for interpretation (resulting in false positives) or in losing the pathogenic disease-causing ones (resulting in false negatives).

On the other hand, it is possible that the underlying genetic causes reside elsewhere in the genome (e.g. intronic or other genomic material such as non-coding RNA) or is not well detected by WES (e.g. internal exon deletion, copy number variation, chromosomal rearrangement, repeats variations). Consequently, it is worth considering performing whole-genome sequencing (WGS) to obtain the most comprehensive view of the genomic informations. However, using such approach also comes with some limitations. (i) Whilst the WGS of a very small subset of carefully selected individuals is financially possible, the processing of large sample size cohort is unlikely. Hence the notion of carefully selected individuals. Under which criteria should a patient have his genome sequenced? Should the ones with more severe phenotype, a family history or a negative WES be prioritised? (ii) If WES is

challenging to interpret WGS will be prove even more so since the process is expected to yield millions of variants. Consequently, appropriate filtering and prioritisation criteria will be the key to remove false-positive variants without filtering-out the pathogenic ones.

7.2.3 Methylation abnormalities outside of imprinted DMRs

Finally, it is possible that the underlying causes of BWS and MLID are not of a genetic nature but an epigenetic origin. Besides methylation disturbances at imprinted DMRs, it is conceivable that other genomic regions might also present a pathogenic methylation profile that could participate to the BWS phenotype and MLID epigenotype. In the current study, using a genome-wide approach, I identified three additional regions outside of imprinted DMRs, *SLC12A9*, *LTA*, and *KCNAB3*, that display aberrant DNA methylation. However, the clinical significance of these findings is currently unknown and further investigations are needed to define their role in BWS and MLID aetiology. It should be noted that my analysis was restricted to the captured sequences on the arrays. Indeed, the Infinium HumanMethylation 450K BeadChips allows the characterisation of more than 485,000 CpG sites, which is equivalent to approximatively 2% of the human CpG content. Consequently, it is possible that pathologic methylation changes at an undocumented important locus might be associated with BWS and MLID but remain unidentified due to the lack of coverage by the array. The use of a more comprehensive method such as whole-genome bisulfite sequencing (WGBS), reduced-representation-bisulphite-

sequencing (RRBS) (Meissner et al. 2008; Z.D. Smith et al. 2009; Gu et al. 2011; Boyle et al. 2012) or methylated DNA immunoprecipitation sequencing (MeDIP-seq) could be an answer to alleviate this issue. Although they are more costly, especially to process large sample size cohorts, they will undoubtedly cover greater amount of CpG sites (WGBS, >90% of human CpG content; RRBS, 10-20%; MeDIP-seq, 60-90% (Plongthongkum et al. 2014)), hence allowing new discoveries that were not possible with methylation array alone.

7.2.4 5-hydroxymethylation, a hot topic for the future?

5-hydroxymethylcytosine (5-hmC) is a cytosine modification recently described to be an intermediate in the DNA demethylation pathway (see section 1.1.1.2.3 - DNA demethylation). The modification results from the oxidation of 5-methylcytosine (5-mC) by the ten-eleven translocation enzymes, TET1 and TET2 (He et al. 2011; Inoue et al. 2011; Ito et al. 2011; Hackett et al. 2013). The levels of 5-hmC varied in different organs with highest content found in the brain, followed by the rectum, liver and colon. In contrast, the level of 5-hmC is very low in the heart, breast and placenta (W. Li and M. Liu 2011). In mouse embryonic stem cells, 5-hmC was found to be mostly associated with euchromatin and, unlike 5-mC, was particularly enriched at CpG islands, gene promoters, particularly the ones marked with H3K4me3 and H3K27me3, and enhancers, particularly the ones marked with H3K4me1 and H3K27ac (Ficz et al. 2011; Pastor et al. 2011). Consequently, it was suggested that 5-hmC has functional significance in gene expression regulation. Since the recent

development of methods that allow the discrimination of 5-mC to 5-hmC (oxidative bisulfite sequencing), several studies undertook the characterisation of the impact of 5-hmC in diseases. Subsequently, multiple suggestive data indicated that 5-hmC might potentially be involved in the pathophysiology of diseases (Jingyu Wang et al. 2014) such as Rett syndrome (Szulwach et al. 2011), Huntington diseases (Fengli Wang et al. 2013), melanoma (Lian et al. 2012; Gambichler et al. 2013), gastrointestinal stromal tumours (Mason and Hornick 2013) and hepatocellular carcinoma (M.-L. Chen et al. 2013).

As an epigenetic regulator, it was natural to think that aberrant change in 5-hmC level might be implicated in the molecular aetiology of imprinting disorders via either directly deregulating imprinted DMRs or indirectly through the silencing or activation of a *trans*-acting factor. Accordingly, a report exploring the relationship between 5-hmC and Kagami-Ogata syndrome has recently been published (Matsubara et al. 2015). The authors concluded that the hypermethylation of the two imprinting control regions *MEG3/DLK1*:IG-DMR and *MEG3*:TSS-DMR was not due to an increased level of 5-hmC. Additionally, the analysis of blood taken from the patients did not revealed conclusive evidence of global changes of the levels of 5-hmC that could explain the disease phenotype. However, although inconclusive this report was the very first one to explore the relationship between 5-hmC and ID. The analysis of more individuals with an ID, including BWS, will surely help deciphering the potential implication of this epigenetic modification in the molecular aetiology of a such disorder.

7.3 Final conclusions

Genomic imprinting is a fascinating but incompletely understood process. Whilst breakthrough discoveries have been made via in-depth molecular investigation of model organisms, particularly mice, the study of imprinting disorders has provided additional critical insights into both the pathogenesis and associated phenotypic consequences of aberrant imprinting. Application of high-throughput NGS-based techniques to large cohorts of ID patients has the potential to provide further insights and this would be further facilitated by data-sharing and international collaborative efforts such as the INGENIUM training network.

Chapter 8

Appendix

Appendix 1

R code used for methylation data preprocessing.

```
> library("RnBeads")
# Set and create result directory folder
> resultDir <- "/path/to/result/directory/"
> dir.create(resultDir, showWarnings = FALSE, recursive =
TRUE)
# Set data directory (idat and sample sheet files need to be
both located in that folder)
> data.source <- "/path/to/data/directory/"
# Set directory where the output should be written to
> analysis.dir <- file.path(resultDir)
# Set directory where the report files should be written to
> report.dir <- file.path(analysis.dir, "reports")
# Initialising reports
> rnb.initialize.reports(report.dir)
# Enable multicore
> logger.start(fname = NA)
> num.cores <- 20
> parallel.setup(num.cores)
# Loading raw methylation data (idat file format) in R
> result.raw <- rnb.run.import(data.source = data.source,
data.type = "infinium.idat.dir", dir.reports = report.dir)
> rnb.set.raw <- result.raw$rnb.set
# Generate quality check report
> rnb.run.qc(rnb.set.raw, report.dir)
# Set options for filtering and normalisation
> rnb.options(disk.dump.big.matrices = FALSE,
  identifiers.column = "Sample_Name",
  filtering.context.removal = c("CC", "CAG", "CAH", "CTG",
"CTH", "Other"),
  filtering.snp = "5", filtering.greedyicut = TRUE,
```

```

filtering.greedy.cut.pvalue.threshold = 0.01,
filtering.sex.chromosomes.removal = TRUE,
filtering.cross.reactive = TRUE,
filtering.coverage.threshold = 0,
filtering.low.coverage.masking = FALSE,
filtering.missing.value.quantile = 0,
normalization = TRUE,
normalization.method = "bmiq",
normalization.background.method = "methy lumi.noob",
normalization.plot.shifts = TRUE,
qc.snp.boxplot = TRUE)
# Perform normalisation with BMIQ method
> result.norm.filt <- rnb.run.preprocessing(rnb.set.raw,
dir.reports = report.dir)
> rnb.set.norm.filt <- result.norm.filt$rnb.set
# Extract normalised methylation data (M-value)
> datMval <- as.data.frame(mval(rnb.set.norm.filt, row.names
= TRUE, epsilon = 1e-05))
# Remove CpG probes with missing data in all samples
> datMval <- datMval[complete.cases(datMval), ]
# Save normalised methylation data
> write.csv(datMval, paste(resultDir, "mval_norm.csv",
sep=""), row.names = TRUE, quote = FALSE)

```

Appendix 2

R code used for batch effect correction.

```
# Import data in CSV file format
> library("sqldf")
# Set and create result directory folder
> resultDir <- "/path/to/result/directory/"
> dir.create(resultDir, showWarnings = FALSE, recursive =
TRUE)
# Import data (in .csv format)
> Data = read.csv.sql("/path/to/data.csv", header = T)
rownames(Data) <- gsub("\\\"", "", Data$X)
> Data[1] <- NULL
# Batch effect correction with ComBat
> library("sva")
# Import phenotype file (tab separated file format) Phenotype
file is in general the same as the samplesheet provided for
the 450K
> Pheno <- read.table("/path/to/phenotype.txt", header = T,
sep = "\t")
# Batch correction step 1 (Sentry_ID correction)
> DataBat.1 <- ComBat(dat = Data, batch = Pheno$Sentry_ID,
mod = model.matrix(~as.factor(Sample_Group) +
as.factor(Sentry_Position) + as.factor(Age), data = Pheno))
# Batch correction step 2 (Sentry_Position correction)
> DataBat.2 <- ComBat(dat = DataBat.1, batch =
Pheno$Sentry_Position, mod =
model.matrix(~as.factor(Sample_Group) + as.factor(Age), data
= Pheno))
# Batch correction step 3 (age correction)
> DataBat.3 <- ComBat(dat = DataBat.2, batch = Pheno$Age, mod
= model.matrix(~as.factor(Sample_Group), data = Pheno))
# Save normalised and batch effect corrected methylation data
```

```
> write.csv(DataBat.3, paste(resultDir,  
"mval_norm_combat.csv", sep = ""), row.names = TRUE, quote =  
FALSE)
```

Appendix 3

R code used for genomic imprinting methylation profiling.

```
##### Set variables below #####
# Need to be edited Character vector indicated group of
interest. It has to match with the "Disease" column in
phenotype file (i.e. Pheno$Disease)
GroupOfInterest <- c("Patient")
# Character vector indicated from what standard deviation
will be calculated from. It has to match with the "Disease"
column in phenotype file (i.e. Pheno$Disease)
GroupOfControl <- "Control"
# Indicate standard deviation threshold
nbSd <- 3
# Fill with target names to remove from analysis. Can be
empty
TargetToRemove <- c("MEG3-DLK1_IG-DMR")
# Indicate where results should be saved
resultDir <- "/path/to/result/directory/"
# Indicate where methylation data is located (CSV file
format, row: CpG probes, column: samples)
dataFile <- "/path/to/data.csv"
# Indicate where phenotype file is located (tab separated
file)
phenoFile <- "/path/to/phenotype.txt"
# Indicate where target file (i.e. region of interests) is
located (bed file format with .txt file extension). Column
names need to include 'chr', 'start', 'end'
targetFile <- "/path/to/target.file.txt"
##### Set variables above #####

##### Import files Create result directory folder
```

```

dir.create(resultDir, showWarnings = FALSE, recursive = TRUE)
# Import phenotype file
Pheno <- read.table(phenoFile, header = T, sep = "\t")
# Import target file
target <- read.table(targetFile, header = TRUE, sep = "\t")
target$chr <- paste("chr", target$chr, sep = "")
library("GenomicRanges")
grTarget <- makeGRangesFromDataFrame(target, seqnames.field =
"chr", start.field = "start", end.field = "end",
keep.extra.columns = TRUE, ignore.strand = TRUE, seqinfo =
NULL)
# Set final target specify
FinalTarget <- as.character(grTarget$Name[!grTarget$Name %in%
TargetToRemove])
FinalTarget <- factor(FinalTarget, levels =
unique(FinalTarget))
# Import data file
library("sqldf")
Data = read.csv.sql(dataFile, header = T)
rownames(Data) <- gsub("\\"", "", Data$X)
Data[1] <- NULL
# Convert data in Beta value if necessary
library("lumi")
Data <- as.data.frame(m2beta(Data))

##### Convert methylation data into GenomicRanges object
library("FDb.InfiniumMethylation.hg19")
library("GenomicRanges")
hm450 <- as.data.frame(get450k())
hm450 <- hm450[rownames(hm450) %in% rownames(Data), ]
hm450 <- hm450[order(hm450$seqnames, hm450$probeTarget), ]
Data.2 <- as.data.frame(Data[match(rownames(Data),
rownames(hm450)), ])
Data.2$chr <- hm450$seqnames

```

```

# Df.2$chr <- gsub('chr', '', Data.2$chr) #Need to un-comment
if chromosome is indicated as 1,2,3,... and not chr1, chr2,
chr3 in target file
Data.2$start <- hm450$probeTarget
grData.2 <- makeGRangesFromDataFrame(df = Data.2,
seqnames.field = "chr", start.field = "start", end.field =
"start", keep.extra.columns = TRUE, ignore.strand = TRUE,
seqinfo = NULL)

##### Subset data regarding target files
dir.create(paste(resultDir,
"Methylation.analysis/meth.score/", sep = ""), showWarnings =
FALSE, recursive = TRUE)
setwd(paste(resultDir, "Methylation.analysis/meth.score/",
sep = ""))
# Extract and save CpG beta value for all samples within
regions of interest
meth.score <- list()
for (i in seq(grTarget)) {
  x <- as.data.frame(subsetByOverlaps(grData.2,
grTarget[i]))
  x <- x[, -(1:5)]
  write.table(x, paste(resultDir,
"Methylation.analysis/meth.score/", grTarget[i]$Name, sep =
""), sep = "\t", row.names = FALSE, quote = FALSE)
  meth.score[[i]] <- x
}
names(meth.score) <- grTarget$Name

setwd(resultDir)

##### Compute methylation index at target loci in all
individuals (patients and controls).
##### Compute 3 standard deviations from grand mean of control
individuals

```

```

library("plotrix")
# For GroupOfInterest (i.e. Patient) Put a list in a list
GroupPatient <- list()
for (j in seq(GroupOfInterest)) {
  y <- list()
  for (i in seq(grTarget)) {
    x <- meth.score[[i]][Pheno$Disease %in%
GroupOfInterest[j]]
    y[[i]] <- x
  }
  names(y) <- grTarget$Name
  y[TargetToRemove] <- NULL
  GroupPatient[[j]] <- y
}
names(GroupPatient) <- GroupOfInterest

# Calculate mean for all patients
GroupPatientMean <- list()
for (j in seq(GroupOfInterest)) {
  x <- as.data.frame(lapply(GroupPatient[[j]], colMeans))
  GroupPatientMean[[j]] <- x
}

# Calculate standard error for all patients
GroupPatientStdError <- list()
for (j in seq(GroupOfInterest)) {
  for (i in 1:nrow(Pheno[Pheno$Disease %in%
GroupOfInterest, ])) x <- lapply(GroupPatient[[j]],
std.error)
  x <- do.call(cbind, x)
  x[is.na(x)] <- 0
  GroupPatientStdError[[j]] <- x
}
names(GroupPatientStdError) <- GroupOfInterest

```

```

# For GroupOfControl (i.e. Control)
GroupControl <- list()
for (i in seq(grTarget)) {
  x <- meth.score[[i]][Pheno$Disease %in% GroupOfControl]
  GroupControl[[i]] <- x
}
names(GroupControl) <- grTarget$Name
GroupControl[TargetToRemove] <- NULL

# Compute mean of control group, grand mean of control group
and standard deviation
GroupControlMean <- lapply(GroupControl, colMeans)

GroupControlMean <- do.call(cbind, GroupControlMean)
GroupControlGrandMean <-
as.data.frame(colMeans(GroupControlMean))
rownames(GroupControlGrandMean) <- FinalTarget

library("matrixStats")
GroupControlSd <- as.data.frame(colSds(GroupControlMean))
rownames(GroupControlSd) <- FinalTarget

# Create data.list table with 'patient.Mean',
'patient.StdError', 'control.GrandMean' and
'control.Stdeviation'
DataMI.P <- list()
for (j in seq(GroupOfInterest)) {
  for (i in 1:length(FinalTarget)) {
    y <- cbind(GroupPatientMean[[j]][, i],
GroupPatientStdError[[j]][, i], GroupControlGrandMean[i, ],
GroupControlSd[i, ])
    colnames(y) <- c("patient.Mean", "patient.StdError",
"control.GrandMean", "control.Stdeviation")
    DataMI.P[[i]] <- as.data.frame(y)
  }
}

```

```

}
names(DataMI.P) <- FinalTarget

#### Compute hypomethylation (i.e. LOM) and hypermethylation
(i.e. GOM) in patient group.
#### Standard deviation threshold: cf. nbSd variable above.
#### 60% of interrogated probes need to be over or below Sdev
threshold
dir.create(paste(resultDir,
"Methylation.analysis/epimutation/", sep = ""), showWarnings
= FALSE, recursive = TRUE)
setwd(paste(resultDir, "Methylation.analysis/epimutation/",
sep = ""))

PatientEpimut <- list()
y <- data.frame(matrix(NA, nrow = nrow(Pheno[Pheno$Disease
%in% GroupOfInterest, ]), ncol = 1))
for (i in 1:length(FinalTarget)) {
  for (j in 1:nrow(Pheno[Pheno$Disease %in%
GroupOfInterest, ])) {
    for (k in 1:length(GroupOfInterest)) y[j, 1] <-
ifelse((DataMI.P[[i]][j, 1] > DataMI.P[[i]][j, 3] +
DataMI.P[[i]][j, 4] * nbSd & sum(GroupPatient[[k]][[i]][, j]
> DataMI.P[[i]][j, 3] + DataMI.P[[i]][j,
4] * nbSd) * 100/length(GroupPatient[[k]][[i]][,
j]) > 60), 1, ifelse((DataMI.P[[i]][j, 1] < DataMI.P[[i]][j,
3] - DataMI.P[[i]][j, 4] * nbSd &
sum(GroupPatient[[k]][[i]][, j] <
DataMI.P[[i]][j, 3] - DataMI.P[[i]][j, 4] * nbSd)
* 100/length(GroupPatient[[k]][[i]][, j]) > 60), -1, 0))
    PatientEpimut[[i]] <- as.data.frame(y)
  }
}
names(PatientEpimut) <- FinalTarget

```

```

PatientEpimut <- do.call(cbind, PatientEpimut)
rownames(PatientEpimut) <- rownames(DataMI.P[[1]])
colnames(PatientEpimut) <- FinalTarget
tmpPatientMap <- PatientEpimut
tmpPatientMap[tmpPatientMap == -1] <- "LOM"
tmpPatientMap[tmpPatientMap == 1] <- "GOM"
tmpPatientMap[tmpPatientMap == 0] <- "."
write.table(tmpPatientMap, paste(resultDir,
"Methylation.analysis/epimutation/", "Patient_epimut.txt",
sep = ""), sep = "\t", quote = FALSE)
rm(tmpPatientMap)

# Subset control group and define hypo/hypermethylated loci
in control group For GroupOfControl (ie. Control)
GroupControl <- list()
for (i in seq(grTarget)) {
  x <- meth.score[[i]][Pheno$Disease %in% GroupOfControl]
  GroupControl[[i]] <- x
}
names(GroupControl) <- grTarget$Name
GroupControl[TargetToRemove] <- NULL

# Compute mean of control group, grand mean of control group
and standard deviation
GroupControlMean <- lapply(GroupControl, colMeans)
GroupControlMean <- do.call(cbind, GroupControlMean)
GroupControlMean <- as.data.frame(GroupControlMean)

GroupControlGrandMean <-
as.data.frame(colMeans(GroupControlMean))

GroupControlSd <-
as.data.frame(colSds(as.matrix(GroupControlMean)))
rownames(GroupControlSd) <- FinalTarget

```

```

GroupControlStdError <- lapply(GroupControl, std.error)
GroupControlStdError <- do.call(cbind, GroupControlStdError)
GroupControlStdError <- as.data.frame(GroupControlStdError)
GroupControlStdError[is.na(GroupControlStdError)] <- 0

# Create data.list table to compute 3 standard deviations
DataMI.C <- list()
for (j in seq(GroupOfControl)) {
  for (i in 1:length(FinalTarget)) {
    y <- cbind(GroupControlMean[, i],
GroupControlStdError[, i], GroupControlGrandMean[i, ],
GroupControlSd[i, ])
    colnames(y) <- c("control.Mean", "control.StdError",
"control.GrandMean", "control.Stdeviation")
    DataMI.C[[i]] <- as.data.frame(y)
  }
}
names(DataMI.C) <- FinalTarget

#### Create list to store data
#### Determine if Control individual are epimutated
ControlEpimut <- list()
y <- data.frame(matrix(NA, nrow = nrow(Pheno[Pheno$Disease
%in% GroupOfControl, ]), ncol = 1))
for (i in 1:length(FinalTarget)) {
  for (j in 1:nrow(Pheno[Pheno$Disease %in% GroupOfControl,
])) {
    y[j, 1] <- ifelse((DataMI.C[[i]][j, 1] >
DataMI.C[[i]][j, 3] + DataMI.C[[i]][j, 4] * nbSd &
sum(GroupControl[[i]][, j] > DataMI.C[[i]][j, 3] +
DataMI.C[[i]][j, 4] * nbSd) * 100/length(GroupControl[[i]][,
j]) > 60), 1, ifelse((DataMI.C[[i]][j, 1] <
DataMI.C[[i]][j, 3] - DataMI.C[[i]][j, 4] * nbSd &

```

```

sum(GroupControl[[i]][, j] < DataMI.C[[i]][j, 3] -
DataMI.C[[i]][j, 4] * nbSd) *
      100/length(GroupControl[[i]][, j]) > 60), -1, 0))
  ControlEpimut[[i]] <- y
}
}
names(ControlEpimut) <- FinalTarget

```

```

ControlEpimut <- do.call(cbind, ControlEpimut)
rownames(ControlEpimut) <- rownames(DataMI.C[[1]])
colnames(ControlEpimut) <- FinalTarget
tmpControltMap <- ControlEpimut
tmpControltMap[tmpControltMap == -1] <- "LOM"
tmpControltMap[tmpControltMap == 1] <- "GOM"
tmpControltMap[tmpControltMap == 0] <- "."
write.table(tmpControltMap, paste(resultDir,
"Methylation.analysis/epimutation/", "Control_epimut.txt",
sep = ""), sep = "\t", quote = FALSE)
rm(tmpControltMap)

```

```

#### Create contingency table (2x2) for hypomethylated and
hypermethylated loci in cases versus controls
#### Calculate Fisher's exact test P-value and FDR P-value
# Create hypomethylation contingency table
hypo <- list()

```

```

for (i in 1:length(PatientEpimut)) {
  case.hypo <- data.frame(Hypo = sum(PatientEpimut[, i] ==
-1), Other = sum(PatientEpimut[, i] != -1))
  control.hypo <- data.frame(Hypo = sum(ControlEpimut[, i]
== -1), Other = sum(ControlEpimut[, i] != -1))
  o <- rbind(case.hypo, control.hypo)
  rownames(o) <- c("Cases", "Controls")
  colnames(o) <- c("Hypo", "Other")
}

```

```

    hypo[[i]] <- o
  }
  names(hypo) <- FinalTarget
  rm(case.hypo, control.hypo, o)

# Perform Fisher's exact test and FDR correction for
hypomethylation observations
hypoFisherTest <- data.frame(matrix(NA, nrow =
length(FinalTarget), ncol = 1))
for (i in 1:length(hypo)) {
  x <- fisher.test(hypo[[i]])
  hypoFisherTest[i, ] <- x
}
colnames(hypoFisherTest) <- "p.value"
rownames(hypoFisherTest) <- names(hypo)

hypoFisherTest <- cbind(hypoFisherTest,
p.adjust(hypoFisherTest$p.value, method = "BH"))
colnames(hypoFisherTest) <- c("p.value", "FDR (Benjamini &
Hochberg)")
write.table(hypoFisherTest, paste(resultDir,
"Methylation.analysis/epimutation/", "hypoFisherTest.txt",
sep = ""), sep = "\t", quote = FALSE)

# Create hypermethylation contingency table
hyper <- list()

for (i in 1:length(PatientEpimut)) {
  case.hyper <- data.frame(Hypo = sum(PatientEpimut[, i] ==
1), Other = sum(PatientEpimut[, i] != 1))
  control.hyper <- data.frame(Hypo = sum(ControlEpimut[, i]
== 1), Other = sum(ControlEpimut[, i] != 1))
  o <- rbind(case.hyper, control.hyper)
  rownames(o) <- c("Cases", "Controls")
  colnames(o) <- c("Hyper", "Other")
}

```

```

    hyper[[i]] <- o
  }
  names(hyper) <- FinalTarget
  rm(case.hyper, control.hyper, o)

# Perform Fisher's exact test and FDR correction for
# hypermethylation observations
hyperFisherTest <- data.frame(matrix(NA, nrow =
length(FinalTarget), ncol = 1))
for (i in 1:length(hyper)) {
  x <- fisher.test(hyper[[i]])
  hyperFisherTest[i, ] <- x
}
colnames(hyperFisherTest) <- "p.value"
rownames(hyperFisherTest) <- names(hyper)

hyperFisherTest <- cbind(hyperFisherTest,
p.adjust(hyperFisherTest$p.value, method = "BH"))
colnames(hyperFisherTest) <- c("p.value", "FDR (Benjamini &
Hochberg)")
write.table(hyperFisherTest, paste(resultDir,
"Methylation.analysis/epimutation/", "hyperFisherTest.txt",
sep = ""), sep = "\t", quote = FALSE)

##### Correct epimutation following hypo/hyper FDR p.value
PatientEpimutCorrected <- list()
for (i in 1:length(PatientEpimut)) {
  h <- ifelse((PatientEpimut[i] == -1 & hypoFisherTest[i,
2] < 0.05), -1, ifelse((PatientEpimut[i] == 1 &
hyperFisherTest[i, 2] < 0.05), 1, 0))
  PatientEpimutCorrected[[i]] <- h
}

```

```
PatientEpimutCorrected <- as.data.frame(do.call(cbind,  
PatientEpimutCorrected))  
colnames(PatientEpimutCorrected) <- FinalTarget  
rownames(PatientEpimutCorrected) <- rownames(PatientEpimut)
```

Appendix 4

R code used for bump hunting in BWS_IC1. Similar code was used for other disease group.

```
# Import data in CSV file format
> library("sqldf")
> Data = read.csv.sql("/path/to/data.csv", header = T)
rownames(Data) <- gsub("\\", "", Data$X)
> Data[1] <- NULL
# Convert data in Beta value if necessary
> library("lumi")
> Data <- as.data.frame(m2beta(Data)) #Comment this line if
data is b-value and not m-value
# Import phenotype file in tab separated file format)
> Pheno <- read.table("/path/to/phenotype.txt", header = T,
sep="\t")
# Set and create result directory folder
> resultDir <- "/path/to/result/directory/"
> dir.create(resultDir, showWarnings = FALSE, recursive =
TRUE)
# Import 450K annotation file and reorder methylation data
> library("FDb.InfiniumMethylation.hg19")
> hm450 <- as.data.frame(get450k())
> hm450 <- hm450[rownames(hm450) %in% rownames(Data), ]
> hm450 <- hm450[order(hm450$seqnames, hm450$probeTarget), ]
> Data.2 <- as.data.frame(Data[match(rownames(Data),
rownames(hm450)), ])
# Subset data for bump hunting: cases (e.g. BWS_IC1 patients)
versus controls (e.g. normal individuals)
> DataSubset <- Data.2[colnames(Data.2) %in%
Pheno$Sample_Name[Pheno$Sample_Group %in% c("BWS_IC1",
"Control")]]
```

```

# Subset phenotype for bumphunting: cases (e.g. BWS_IC1
  patients) versus controls (e.g. normal individuals)
> PhenoSubset <- Pheno[Pheno$Sample_Group %in%
c("BWS_IC1", "Control"), ]
> PhenoSubset <- PhenoSubset[, -c(6, 5, 4, 2)]
> PhenoSubset$Sample_Name <-
factor(PhenoSubset$Sample_Name, levels =
unique(PhenoSubset$Sample_Name))
> PhenoSubset$Sample_Group <-
factor(PhenoSubset$Sample_Group, levels =
unique(PhenoSubset$Sample_Group))
# DMR hunting
> library("bumphunter")
# Create cluster for bumphunting
> cl <- clusterMaker(hm450$seqnames, hm450$probeTarget,
maxGap = 300)
# Enable multicore
> library("doParallel")
> registerDoParallel(cores = 10)
# Create design matrix for bumphunter
> designMatrix <- model.matrix(~as.factor(Sample_Group), data
= PhenoSubset)
# Perform bump hunting with multicores enabled, cutoff
difference: 15%, permutation: 1000, smooth function enabled)
> bumps <- bumphunter(object = as.matrix(DataSubset), design
= > designMatrix, chr = hm450$seqnames, pos =
hm450$probeTarget, cluster = cl, coef = 2, cutoff = 0.15, B =
1000, maxGap = 300, permutations = TRUE, smooth = TRUE,
smoothFunction = loessByCluster, useWeights = TRUE)
# Save bumps
> bumps <- bumps$table
> write.table(bumps, paste(resultDir, "Bumps.txt", sep=""),
sep= "\t", quote = FALSE)

```

Appendix 5

Shell script used for the trimming, alignment and methylation calling of bisulfite converted reads generated from MiSeq sequencer.

```
#!/bin/bash
#####
#####
### Script for trimming, alignment (hg38, hg38, rDNA) and
methylation calling ###
### Need to be executed in RAW folder ###
#####
#####
#create samples.txt file
> echo create samples name file
> ls *_L001_R1_001.fastq.gz > samples.txt
> vim -c "%s/_L001_R1_001.fastq.gz//g|wq" samples.txt
#Trimming, alignment and non-directional BS-seq library
> echo trimming
> mkdir ../trimmed &> /dev/null
> for i in `cat samples.txt`; do trim_galore --paired --
clip_R2 3 ${i}_L001_R1_001.fastq.gz ${i}_L001_R2_001.fastq.gz
--output_dir ../trimmed &> /dev/null
> done

#####
#Align to hg38
> echo align to hg38
> mkdir -p ../hg38/hg38_aligned &> /dev/null
> for i in `cat samples.txt`; do bismark --bowtie2 --
non_directional --bam --output_dir ../hg38/hg38_aligned --
temp_dir ../temp --multicore 10 /media/Sasha/Resources/hg38/
```

```
-1 ../trimmed/${i}_L001_R1_001_val_1.fq.gz -2
../trimmed/${i}_L001_R2_001_val_2.fq.gz &> /dev/null
> done

> echo methylation call
> mkdir -p ../hg38/hg38_methCall &> /dev/null
> for i in `cat samples.txt`; do
bismark_methylation_extractor --bedGraph --p --merge_non_CpG
--report --output ../hg38/hg38_methCall --multicore 10 --gzip
../hg38/hg38_aligned/${i}_L001_R1_001_val_1.fq.gz_bismark_bt2
_pe.bam &> /dev/null
> done
```

Appendix 6

R code used for the quantification of 5-mC at H19/IGF2:IG-DMR;

KCNQ1OT1:TSS-DMR and IGS-rDNA in each sample.

```
## Script to quantify methylation in target regions (ie. DMRs
or IGS-rDNA)
##
##Execute R script in parent folder of RAW, hg19, hg38 and
rDNA folders
library(GenomicRanges)
library(ggplot2)
library(matrixStats)
library(plotrix)
#####
#####
## Result for hg38
#####
#####
setwd("../hg38/hg38_methCall")
temp = list.files(pattern="*bismark.cov")
#get sample name
sample_name <- sapply(strsplit(temp, "_"), "[", 1)
sample_name <- as.factor(sample_name)
#read all table in the folder and store them in a list
methCall = lapply(temp, read.table,sep = "\t", header =
FALSE)
setwd("../")

#Convert methylation call file into GenomicRanges
for (i in 1:length(methCall)) {
  methCall[[i]] <- GRanges(methCall[[i]]$V1,
IRanges(methCall[[i]]$V2, methCall[[i]]$V3),
```

```

meth=methCall[[i]]$V4, countMeth=methCall[[i]]$V5,
countUnmeth=methCall[[i]]$V6)
}
names(methCall) <- sample_name

#Import target file and convert to GenomicRanges
target <- read.table("../hg38_target", sep="\t", header=F)
target <- GRanges(target$V1, IRanges(target$V2, target$V3,
names=target$V4))

#Find overlap between methylation call file and target file
for all samples and convert into data frame object
methSubset <- list()
for (i in 1:length(methCall)) {
  methSubset[[i]] <- subsetByOverlaps(methCall[[i]], target)
  #Add DMRs names in overlap object
  overlaps_tmp <- findOverlaps(methCall[[i]],target)
  match_hit <-
data.frame(names(target)[subjectHits(overlaps_tmp)],
stringsAsFactors=F)
  names(match_hit) <- "DMR"
  mcols(methSubset[[i]]) <- c(mcols(methSubset[[i]]),
match_hit)
  methSubset[[i]] <- as.data.frame(methSubset[[i]])
  methSubset[[i]] <-
methSubset[[i]][!rowSums(data.frame(methSubset[[i]]$countMeth
, methSubset[[i]]$countUnmeth)) < 1000,]
}
names(methSubset) <- sample_name

#Calculate mean and std.error for samples at DMRs
x <- data.frame(matrix(ncol = 4, nrow = length(target)))
y <- list()
for (i in 1:length(methSubset)) {
  for (j in 1:length(target)) {

```

```

    x[j,] <- c(sample=names(methSubset[i]),
locus=names(target[j]),
mean=mean(methSubset[[i]]$meth[methSubset[[i]]$DMR %in%
names(target[j]])),
std.error=std.error(methSubset[[i]]$meth[methSubset[[i]]$DMR
%in% names(target[j]])))
    y[[i]] <- x
  }}

```

```

methAnalysis <- do.call(rbind,y)
methAnalysis <- data.frame(as.factor(methAnalysis[,1]),
as.factor(methAnalysis[,2]), as.numeric(methAnalysis[,3]),
as.numeric(methAnalysis[,4]))
colnames(methAnalysis) <- c("sample", "locus", "mean",
"std.error")

```

```

sample.order <- c("0meth", "25meth", "50meth", "75meth",
"100meth", "sample01", " sample02", " sample03", "sample04")

```

```

#Barplot methylation level
dir.create("result", showWarnings = FALSE, recursive = TRUE)
setwd("result")
for (i in 1:length(target)) {
q <- ggplot(methAnalysis[methAnalysis$locus ==
names(target[i]),], aes(x=sample, y=mean)) +
  geom_bar(position=position_dodge(), stat="identity",
fill="#FF9999", colour="black", size=.3) +
  geom_errorbar(aes(ymin=mean-std.error,
ymax=mean+std.error), size=1, width=.2,
position=position_dodge(.9)) +
  ggtitle(paste("Methylation index at",
names(target[i]),"\nAverage nb CpG:",round(sum(do.call(rbind,
methSubset)$locus==
names(target[i]))/length(sample_name),0))) +
  ylab('Methylation level (%)') +

```

```

theme(panel.grid.minor.y = element_blank()) +
theme(plot.title=element_text(face="bold", hjust=0.5)) +
theme(axis.text.x = element_text(angle = 45, hjust=1, face
= "bold", colour = "black")) +
theme(axis.text.y = element_text(face = "bold", colour =
"black")) +
theme(axis.title.x = element_blank()) +
scale_y_continuous(limits=c(0,110), expand = c(0, 0)) +
scale_x_discrete(limits = sample.order)
ggsave(filename=paste("MI at_", names(target[i]), ".tiff",
sep=""), plot=q, dpi=600, compression="lzw")
}
#####
## FOR IGS-rDNA anaylsis ONLY
#####
#import file folder
setwd("rDNA/rDNA_methCall")
temp = list.files(pattern="*bismark.cov")
#get sample name
sample_name <- sapply(strsplit(temp, "_"), "[", 1)
sample_name <- as.factor(sample_name)
#read all table in the folder and store them in a list
methCall = lapply(temp, read.table,sep = "\t", header =
FALSE)
setwd("../")

#Re-name column name in methCall object and remove CpG with
low count reads (ie. total < 1000)
for (i in 1:length(methCall)) {
  colnames(methCall[[i]]) <- c("chr", "start", "end", "meth",
"countMeth", "countUnmeth")
  methCall[[i]] <-
methCall[[i]][!rowSums(data.frame(methCall[[i]]$countMeth,
methCall[[i]]$countUnmeth)) < 1000,]
}

```

```

names(methCall) <- sample_name

#Calculate mean and std.error for samples at DMRs
x <- data.frame(matrix(ncol = 4, nrow = 1))
y <- list()
for (i in 1:length(methCall)) {
  x <- c(sample=names(methCall[i]), locus="IGS-rDNA",
mean=mean(methCall[[i]]$meth),
std.error=std.error(methCall[[i]]$meth))
  y[[i]] <- x
}

methAnalysis <- do.call(rbind,y)
methAnalysis <- data.frame(as.factor(methAnalysis[,1]),
as.factor(methAnalysis[,2]), as.numeric(methAnalysis[,3]),
as.numeric(methAnalysis[,4]))
colnames(methAnalysis) <- c("sample", "locus", "mean",
"std.error")

sample.order <- c("0meth", "25meth", "50meth", "75meth",
"100meth", "sample01", " sample02", " sample03", "sample04")
#Barplot methylation level
dir.create("result", showWarnings = FALSE, recursive = TRUE)
setwd("result")
q <- ggplot(methAnalysis, aes(x=sample, y=mean)) +
  geom_bar(position=position_dodge(), stat="identity",
fill="#FF9999", colour="black", size=.3) +
  geom_errorbar(aes(ymin=mean-std.error,
ymax=mean+std.error), size=1, width=.2,
position=position_dodge(.9)) +
  ggtitle(paste("Methylation index at IGS-rDNA", "\nAverage
nb CpG:",round(nrow(do.call(rbind,
methCall))/length(sample_name),0))) +
  ylab('Methylation level (%)') +

```

```

theme(panel.grid.minor.y = element_blank()) +
theme(plot.title=element_text(face="bold", hjust=0.5)) +
theme(axis.text.x = element_text(angle = 45, hjust=1, face
= "bold", colour = "black")) +
theme(axis.text.y = element_text(face = "bold", colour =
"black")) +
theme(axis.title.x = element_blank()) +
scale_y_continuous(limits=c(0,110), expand = c(0, 0)) +
scale_x_discrete(limits = sample.order)
ggsave(filename=paste("MI at IGS-rDNA", ".tiff", sep=""),
plot=q, dpi=600, compression="lzw")

write.table(methAnalysis, "methTable_IGS.txt", sep="\t",
quote=F, row.names=F)

```

Appendix 7

R code used for the PCR amplification bias correction.

```
#Import data
Data <- read.table("/Users/NoName/Desktop/test.txt",
sep='\t', header=T, row.names = 1)

#Create empty DataCorrected object
DataCorrected <- data.frame(matrix(ncol = length(Data), nrow=
nrow(Data)))
rownames(DataCorrected) <- rownames(Data)
colnames(DataCorrected) <- colnames(Data)

#Theoric values
ytheo <- c(0, 25, 50, 75, 100)
xtheo <- c(0, 25, 50, 75, 100)

for (i in 1:nrow(Data)){
#Standard Curve
yobserved <- as.numeric(Data[i,1:5])
xexpected <- c(0, 25, 50, 75, 100)

### Methylation correction with cubic polynomiale regression
#Model
fit1 <- lm(xexpected ~ poly(yobserved,3, raw = TRUE))
#Correct standard curve
SCcorrected <- predict(fit1,data.frame(yobserved))
#Correct Samples
Samples <- as.numeric(Data[i,6:length(Data)])
SamplesCorrected <- predict(fit1,
data.frame(yobserved=Samples))
SamplesCorrected[SamplesCorrected<0] <- 0
#Store corrected values
```

```

DataCorrected[i,] <- c(SCcorrected,SamplesCorrected)
###

### Plot standard curve before and after correction
###BEFORE correction
#bias
bias <- (yobserved * (100 - xexpected))/(xexpected * (100 -
yobserved))
bias[bias==Inf] <- 0
bias[bias==-Inf] <- 0
bias[is.na(bias)] <- 0
bias <- bias[!bias==0]
MeanBias1 <- mean(bias)
#predicted curve for uncorrected standard curve
q <- seq(from=0, to=100, by=0.1)
fit2 <- lm(yobserved ~ poly(xexpected,3, raw = TRUE))
R.SQUARE1 <- summary(fit2)$r.squared
pred1 <- predict(fit2,data.frame(xexpected=q))

#AFTER correction
#bias
bias <- (SCcorrected * (100 - xexpected))/(xexpected * (100 -
SCcorrected))
bias[bias==Inf] <- 0
bias[bias==-Inf] <- 0
bias[is.na(bias)] <- 0
bias <- bias[!bias==0]
MeanBias2 <- mean(bias)
#predicted curve for uncorrected standard curve
q <- seq(from=0, to=100, by=0.1)
fit3 <- lm(SCcorrected ~ poly(xexpected,3, raw = TRUE))
R.SQUARE2 <- summary(fit3)$r.squared
pred2 <- predict(fit3,data.frame(xexpected=q))

#plot

```

```

pdf(paste(rownames(Data)[i],"_bias.pdf", sep=""), height = 5,
width = 10)
par(mfrow=c(1,2))
plot(yobserved~xexpected, col="red", ylim=c(0,100),
xlim=c(0,100), xlab="Actual methylation
(%)",ylab="Uncorrected estimated methylation (%)",
main="Standard curve before correction")
lines(x=q, y=pred1, col="red")
lines(ytheo~xtheo, lty=2)
text(x=10,y=98,labels = paste("b=",
round(MeanBias1,digits=2), sep=""), col="red")
text(x=80,y=0, labels= bquote(R^2 ==
.(round(R.SQUARE1,digits=3))))

plot(SCcorrected~xexpected, col="red", ylim=c(0,100),
xlim=c(0,100), xlab="Actual methylation (%)",ylab="Corrected
estimated methylation (%)", main="Standard curve after
correction")
lines(x=q, y=pred2, col="red")
lines(ytheo~xtheo, lty=2)
text(x=10,y=98,labels = paste("b=",
round(MeanBias2,digits=2), sep=""), col="red")
text(x=80,y=0, labels= bquote(R^2 ==
.(round(R.SQUARE2,digits=3))))
dev.off()
###
}

write.table(DataCorrected,"DataCorrected.txt", quote=FALSE,
sep='\t')

```

Chapter 9
List of References

Abu-Amero S, Monk D, Frost J, Preece M, Stanier P, Moore GE. 2008. The genetic aetiology of Silver-Russell syndrome. *Journal of Medical Genetics* 45:193–199.

Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, Kondrashov AS, Sunyaev SR. 2010. A method and server for predicting damaging missense mutations. *Nat Meth* 7:248–249.

Akoury E, Zhang L, Ao A, Slim R. 2014. NLRP7 and KHDC3L, the two maternal-effect proteins responsible for recurrent hydatidiform moles, co-localize to the oocyte cytoskeleton. *Hum. Reprod.* 30:159–169.

Albert TJ, Molla MN, Muzny DM, Nazareth L, Wheeler D, Song X, Richmond TA, Middle CM, Rodesch MJ, Packard CJ, et al. 2007. Direct selection of human genomic loci by microarray hybridization. *Nat Meth* 4:903–905.

Alders M, Ryan A, Hodges M, Bliet J, Feinberg AP, Privitera O, Westerveld A, Little PFR, Mannens M. 2000. Disruption of a Novel Imprinted Zinc-Finger Gene, ZNF215, in Beckwith-Wiedemann Syndrome. *The American Journal of Human Genetics* 66:1473–1484.

Algar E, Dagar V, Sebah M, Pachter N. 2011. An 11p15 imprinting centre region 2 deletion in a family with Beckwith Wiedemann syndrome provides insights into imprinting control at CDKN1C. El-Maarri O, editor. *PLoS ONE* 6:e29034.

Allum F, Shao X, Guénard F, Simon M-M, Busche S, Caron M, Lambourne J, Lessard J, Tandre K, Hedman ÅK, et al. 2015. Characterization of functional methylomes by

next-generation capture sequencing identifies novel disease-associated variants. *Nat Commun* 6:7211.

Arima T. 2005. ZAC, LIT1 (KCNQ1OT1) and p57KIP2 (CDKN1C) are in an imprinted gene network that may play a role in Beckwith-Wiedemann syndrome. *Nucleic Acids Research* 33:2650–2660.

Arima Y, Hirota T, Bronner C, Mousli M, Fujiwara T, Niwa S-I, Ishikawa H, Saya H. 2004. Down-regulation of nuclear protein ICBP90 by p53/p21Cip1/WAF1-dependent DNA-damage checkpoint signals contributes to cell cycle arrest at G1/S transition. *Genes Cells* 9:131–142.

Arnaud P. 2003. Conserved methylation imprints in the human and mouse GRB10 genes with divergent allelic expression suggests differential reading of the same mark. *Human Molecular Genetics* 12:1005–1019.

Aryee MJ, Jaffe AE, Corrada-Bravo H, Ladd-Acosta C, Feinberg AP, Hansen KD, Irizarry RA. 2014. Minfi: a flexible and comprehensive Bioconductor package for the analysis of Infinium DNA methylation microarrays. *Bioinformatics* 30:1363–1369.

Assenov Y, Müller F, Lutsik P, Walter J, Lengauer T, Bock C. 2014. Comprehensive analysis of DNA methylation data with RnBeads. *Nat Meth* 11:1138–1140.

Azzi S, Blaise A, Steunou V, Harbison MD, Salem J, Brioude F, Rossignol S, Habib WA, Thibaud N, Neves CD, et al. 2014. Complex tissue-specific epigenotypes in Russell-Silver Syndrome associated with 11p15 ICR1 hypomethylation. *Hum. Mutat.*

35:1211–1220.

Azzi S, Rossignol S, Steunou V, Sas T, Thibaud N, Danton F, Le Jule M, Heinrichs C, Cabrol S, Gicquel C, et al. 2009. Multilocus methylation analysis in a large cohort of 11p15-related foetal growth disorders (Russell Silver and Beckwith Wiedemann syndromes) reveals simultaneous loss of methylation at paternal and maternal imprinted loci. *Human Molecular Genetics* 18:4724–4733.

Azzi S, Salem J, Thibaud N, Chantot-Bastaraud S, Lieber E, Netchine I, Harbison MD. 2015. A prospective study validating a clinical scoring system and demonstrating phenotypical-genotypical correlations in Silver-Russell syndrome. *Journal of Medical Genetics* 52:446–453.

Bak M, Boonen SE, Dahl C, Hahnemann JMD, Mackay DJDG, Tümer Z, Grønskov K, Temple IK, Guldborg P, Tommerup N. 2016. Genome-wide DNA methylation analysis of transient neonatal diabetes type 1 patients with mutations in ZFP57. *BMC Med. Genet.* 17:29.

Ball MP, Li JB, Gao Y, Lee J-H, LeProust EM, Park I-H, Xie B, Daley GQ, Church GM. 2009. Targeted and genome-scale strategies reveal gene-body methylation signatures in human cells. *Nat Biotechnol* 27:361–368.

Barlow DP, Bartolomei MS. 2014. Genomic Imprinting in Mammals. *Cold Spring Harbor Perspectives in Biology* 6:a018382–a018382.

Barlow DP, Stöger R, Herrmann BG, Saito K, Schweifer N. 1991. The mouse insulin-

like growth factor type-2 receptor is imprinted and closely linked to the Tme locus. *Nature* 349:84–87.

Bartolomei MS, Ferguson-Smith AC. 2011. Mammalian Genomic Imprinting. *Cold Spring Harbor Perspectives in Biology* 3:a002592–a002592.

Bartolomei MS, Webber AL, Brunkow ME, Tilghman SM. 1993. Epigenetic mechanisms underlying the imprinting of the mouse H19 gene. *Genes & Development* 7:1663–1673.

Bartolomei MS, Zemel S, Tilghman SM. 1991. Parental imprinting of the mouse H19 gene. *Nature* 351:153–155.

Beckwith JB. 1963. Extreme cytomegaly of the adrenal fetal cortex, omphalocele, hyperplasia of kidneys and pancreas, and Leydig-cell hyperplasia: Another syndrome. *Western Society for Pediatric Research*.

Begemann M, Spengler S, Kanber D, Haake A, Baudis M, Leisten I, Binder G, Markus S, Rupprecht T, Segerer H, et al. 2011. Silver-Russell patients showing a broad range of ICR1 and ICR2 hypomethylation in different tissues. *Clin Genet* 80:83–88.

Begemann M, Zirn B, Santen G, Wirthgen E, Soellner L, Büttel H-M, Schweizer R, van Workum W, Binder G, Eggermann T. 2015. Paternally Inherited IGF2 Mutation and Growth Restriction. *N. Engl. J. Med.* 373:349–356.

Bell AC, Felsenfeld G. 2000. Methylation of a CTCF-dependent boundary controls imprinted expression of the Igf2 gene. *Nature* 405:482–485.

Bell AC, West AG, Felsenfeld G. 1999. The protein CTCF is required for the enhancer blocking activity of vertebrate insulators. *Cell* 98:387–396.

Belloq C, van Ginneken ACG, Bezzina CR, Alders M, Escande D, Mannens MMAM, Baró I, Wilde AAM. 2004. Mutation in the KCNQ1 gene leading to the short QT-interval syndrome. *Circulation* 109:2394–2397.

Benjamini Y, Hochberg Y. 1995. Controlling the false discovery rate: a practical and powerful approach to multiple testing. *Journal of the royal statistical society*.

Beygo J, Ammerpohl O, Gritzan D, Heitmann M, Rademacher K, Richter J, Caliebe A, Siebert R, Horsthemke B, Buiting K. 2013. Deep bisulfite sequencing of aberrantly methylated loci in a patient with multiple methylation defects. *PLoS ONE* 8:e76953.

Beygo J, Citro V, Sparago A, De Crescenzo A, Cerrato F, Heitmann M, Rademacher K, Guala A, Enklaar T, Anichini C, et al. 2013. The molecular function and clinical phenotype of partial deletions of the IGF2/H19 imprinting control region depends on the spatial arrangement of the remaining CTCF-binding sites. *Human Molecular Genetics* 22:544–557.

Bibikova M, Barnes B, Tsan C, Ho V, Klotzle B, Le JM, Delano D, Zhang L, Schroth GP, Gunderson KL, et al. 2011. High density DNA methylation array with single CpG site resolution. *Genomics* 98:288–295.

Bird A. 2002. DNA methylation patterns and epigenetic memory. *Genes & Development* 16:6–21.

Blagitko N, Mergenthaler S, Schulz U, Wollmann HA, Craigen W, Eggermann T, Ropers HH, Kalscheuer VM. 2000. Human GRB10 is imprinted and expressed from the paternal and maternal allele in a highly tissue- and isoform-specific fashion. *Human Molecular Genetics* 9:1587–1595.

Bliek J, Maas SM, Ruijter JM, Hennekam RC, Alders M, Westerveld A, Mannens MM. 2001. Increased tumour risk for BWS patients correlates with aberrant H19 and not KCNQ1OT1 methylation: occurrence of KCNQ1OT1 hypomethylation in familial cases of BWS. *Human Molecular Genetics* 10:467–476.

Bliek J, Verde G, Callaway J, Maas SM, De Crescenzo A, Sparago A, Cerrato F, Russo S, Ferraiuolo S, Rinaldi MM, et al. 2008. Hypomethylation at multiple maternally methylated imprinted regions including PLAGL1 and GNAS loci in Beckwith–Wiedemann syndrome. *Eur. J. Hum. Genet.* 17:611–619.

Bostick M, Kim JK, Esteve PO, Clark A, Pradhan S, Jacobsen SE. 2007. UHRF1 Plays a Role in Maintaining DNA Methylation in Mammalian Cells. *Science* 317:1760–1764.

Bourc'his D, Bestor TH. 2004. Meiotic catastrophe and retrotransposon reactivation in male germ cells lacking Dnmt3L. *Nature* 431:96–99.

Bourc'his D, Xu GL, Lin CS, Bollman B, Bestor TH. 2001. Dnmt3L and the

establishment of maternal genomic imprints. *Science* 294:2536–2539.

Boyle P, Clement K, Gu H, Smith ZD, Ziller M, Fostel JL, Holmes L, Meldrim J, Kelley F, Gnirke A, et al. 2012. Gel-free multiplexed reduced representation bisulfite sequencing for large-scale DNA methylation profiling. *Genome Biology* 13:R92.

Brioude F, Oliver-Petit I, Blaise A, Praz F, Rossignol S, Jule ML, Thibaud N, Faussat AM, Tauber M, Bouc YL, et al. 2013. CDKN1C mutation affecting the PCNA-binding domain as a cause of familial Russell Silver syndrome. *Journal of Medical Genetics* 50:823–830.

Bronner C, Krifa M, Mousli M. 2013. Increasing role of UHRF1 in the reading and inheritance of the epigenetic code as well as in tumorigenesis. *Biochem. Pharmacol.* 86:1643–1649.

Bruey JM, Bruey-Sedano N, Newman R, Chandler S, Stehlik C, Reed JC. 2004. PAN1/NALP2/PYPAF2, an inducible inflammatory mediator that regulates NF-kappaB and caspase-1 activation in macrophages. *Journal of Biological Chemistry* 279:51897–51907.

Bullman H, Lever M, Robinson DO, Mackay DJG, Holder SE, Wakeling EL. 2008. Mosaic maternal uniparental disomy of chromosome 11 in a patient with Silver-Russell syndrome. *Journal of Medical Genetics* 45:396–399.

Caliebe A, Richter J, Ammerpohl O, Kanber D, Beygo J, Bens S, Haake A, Jüttner E, Korn B, Mackay DJG, et al. 2014. A familial disorder of altered DNA-methylation.

Journal of Medical Genetics 51:407–412.

Campanero MR, Armstrong MI, Flemington EK. 2000. CpG methylation as a mechanism for the regulation of E2F activity. *Proc Natl Acad Sci USA* 97:6481–6486.

Carvill GL, Heavin SB, Yendle SC, McMahon JM, O'Roak BJ, Cook J, Khan A, Dorschner MO, Weaver M, Calvert S, et al. 2013. Targeted resequencing in epileptic encephalopathies identifies de novo mutations in CHD2 and SYNGAP1. *Nature Genetics* 45:825–830.

Cattanach BM, Kirk M. 1985. Differential activity of maternally and paternally derived chromosome regions in mice. *Nature* 315:496–498.

Cazaly E, Thomson R, Marthick JR, Holloway AF, Charlesworth J, Dickinson JL. 2016. Comparison of pre-processing methodologies for Illumina 450k methylation array data in familial analyses. *Clin Epigenetics* 8:75.

Cerrato F, Vernucci M, Pedone PV, Chiariotti L, Sebastio G, Bruni CB, Riccio A. 2002. The 5' end of the KCNQ1OT1 gene is hypomethylated in the Beckwith-Wiedemann syndrome. *Hum. Genet.* 111:105–107.

Charalambous M, Smith FM, Bennett WR, Crew TE, Mackenzie F, Ward A. 2003. Disruption of the imprinted Grb10 gene leads to disproportionate overgrowth by an Igf2-independent mechanism. *Proc Natl Acad Sci USA* 100:8292–8297.

Chen J, Bardes EE, Aronow BJ, Jegga AG. 2009. ToppGene Suite for gene list

enrichment analysis and candidate gene prioritization. *Nucleic Acids Research* 37:W305–11.

Chen M-L, Shen F, Huang W, Qi J-H, Wang Y, Feng Y-Q, Liu S-M, Yuan B-F. 2013. Quantification of 5-methylcytosine and 5-hydroxymethylcytosine in genomic DNA from hepatocellular carcinoma tissues by capillary hydrophilic-interaction liquid chromatography/quadrupole TOF mass spectrometry. *Clin. Chem.* 59:824–832.

Chen Y-H, Xu S-J, Bendahhou S, Wang X-L, Wang Y, Xu W-Y, Jin H-W, Sun H, Su X-Y, Zhuang Q-N, et al. 2003. KCNQ1 gain-of-function mutation in familial atrial fibrillation. *Science* 299:251–254.

Chen Z, Robbins KM, Wells KD, Rivera RM. 2013. Large offspring syndrome: a bovine model for the human loss-of-imprinting overgrowth syndrome Beckwith-Wiedemann. *epigenetics* 8:591–601.

Choi Y, Sims GE, Murphy S, Miller JR, Chan AP. 2012. Predicting the functional effect of amino acid substitutions and indels. *PLoS ONE* 7:e46688.

Chotalia M, Smallwood SA, Ruf N, Dawson C, Lucifero D, Frontera M, James K, Dean W, Kelsey G. 2009. Transcription is required for establishment of germline methylation marks at imprinted genes. *Genes & Development* 23:105–117.

Choufani S, Shuman C, Weksberg R. 2010. Beckwith-Wiedemann syndrome. Weksberg R; Temple K, editors. *Am. J. Med. Genet.* 154C:343–354.

Chung W. 1996. Chromosome 11p15.5 regional imprinting: comparative analysis of KIP2 and H19 in human tissues and Wilms' tumors. *Human Molecular Genetics* 5:1101–1108.

Ciccone DN, Su H, Hevi S, Gay F, Lei H, Bajko J, Xu G, Li E, Chen T. 2009. KDM1B is a histone H3K4 demethylase required to establish maternal genomic imprints. *Nature* 461:415–418.

Cleaton MAM, Dent CL, Howard M, Corish JA, Gutteridge I, Sovio U, Gaccioli F, Takahashi N, Bauer SR, Charnock-Jones DS, et al. 2016. Fetus-derived DLK1 is required for maternal metabolic adaptations to pregnancy and is associated with fetal growth restriction. *Nature Genetics* 48:1473–1480.

Cokus SJ, Feng S, Zhang X, Chen Z, Merriman B, Haudenschild CD, Pradhan S, Nelson SF, Pellegrini M, Jacobsen SE. 2008. Shotgun bisulphite sequencing of the *Arabidopsis* genome reveals DNA methylation patterning. *Nature* 452:215–219.

Condic ML. 2016. The Role of Maternal-Effect Genes in Mammalian Development: Are Mammalian Embryos Really an Exception? *Stem Cell Rev* 12:276–284.

Cooper WN, Curley R, Macdonald F, Maher ER. 2007. Mitotic recombination and uniparental disomy in Beckwith-Wiedemann syndrome. *Genomics* 89:613–617.

Court F, Martin-Trujillo A, Romanelli V, Garin I, Iglesias-Platas I, Salafsky I, Guitart M, Perez de Nanclares G, Lapunzina P, Monk D. 2013. Genome-wide allelic methylation analysis reveals disease-specific susceptibility to multiple methylation

defects in imprinting syndromes. *Hum. Mutat.* 34:595–602.

Court F, Tayama C, Romanelli V, Martin-Trujillo A, Iglesias-Platas I, Okamura K, Sugahara N, Simón C, Moore H, Harness JV, et al. 2014. Genome-wide parent-of-origin DNA methylation analysis reveals the intricacies of human imprinting and suggests a germline methylation-independent mechanism of establishment. *Genome Research* 24:554–569.

Cox GF, Bürger J, Lip V, Mau UA, Sperling K, Wu B-L, Horsthemke B. 2002. Intracytoplasmic sperm injection may increase the risk of imprinting defects. *Am. J. Hum. Genet.* 71:162–164.

Danecek P, Auton A, Abecasis G, Albers CA, Banks E, DePristo MA, Handsaker RE, Lunter G, Marth GT, Sherry ST, et al. 2011. The variant call format and VCFtools. *Bioinformatics* 27:2156–2158.

Davis TL, Trasler JM, Moss SB, Yang GJ, Bartolomei MS. 1999. Acquisition of the H19 methylation imprint occurs differentially on the parental alleles during spermatogenesis. *Genomics* 58:18–28.

De Crescenzo A, Coppola F, Falco P, Bernardo I, Ausanio G, Cerrato F, Falco L, Riccio A. 2011. A novel microdeletion in the IGF2/H19 imprinting centre region defines a recurrent mutation mechanism in familial Beckwith–Wiedemann syndrome. *Eur J Med Genet* 54:e451–e454.

Deaton AM, Bird A. 2011. CpG islands and the regulation of transcription. *Genes &*

Development 25:1010–1022.

DeBaun MR, Niemitz EL, Feinberg AP. 2003. Association of in vitro fertilization with Beckwith-Wiedemann syndrome and epigenetic alterations of LIT1 and H19. *Am. J. Hum. Genet.* 72:156–160.

DeBaun MR, Siegel MJ, Choyke PL. 1998. Nephromegaly in infancy and early childhood: a risk factor for Wilms tumor in Beckwith-Wiedemann syndrome. *The Journal of Pediatrics* 132:401–404.

DeChiara TM, Efstratiadis A, Robertson EJ. 1990. A growth-deficiency phenotype in heterozygous mice carrying an insulin-like growth factor II gene disrupted by targeting. *Nature* 345:78–80.

DeChiara TM, Robertson EJ, Efstratiadis A. 1991. Parental imprinting of the mouse insulin-like growth factor II gene. *Cell* 64:849–859.

Dedeurwaerder S, Defrance M, Bizet M, Calonne E, Bontempi G, Fuks F. 2014. A comprehensive overview of Infinium HumanMethylation450 data processing. *Briefings in Bioinformatics* 15:929–941.

Dedeurwaerder S, Defrance M, Calonne E, Denis H, Sotiriou C, Fuks F. 2011. Evaluation of the Infinium Methylation 450K technology. *Epigenomics* 3:771–784.

Demars J, Shmela ME, Rossignol S, Okabe J, Netchine I, Azzi S, Cabrol S, Le Caignec C, David A, Le Bouc Y, et al. 2010. Analysis of the IGF2/H19 imprinting

control region uncovers new genetic defects, including mutations of OCT-binding sequences, in patients with 11p15 fetal growth disorders. *Human Molecular Genetics* 19:803–814.

Deng J, Shoemaker R, Xie B, Gore A, LeProust EM, Antosiewicz-Bourget J, Egli D, Maherali N, Park I-H, Yu J, et al. 2009. Targeted bisulfite sequencing reveals changes in DNA methylation associated with nuclear reprogramming. *Nat Biotechnol* 27:353–360.

DePristo MA, Banks E, Poplin R, Garimella KV, Maguire JR, Hartl C, Philippakis AA, del Angel G, Rivas MA, Hanna M, et al. 2011. A framework for variation discovery and genotyping using next-generation DNA sequencing data. *Nature Genetics* 43:491–498.

Diep D, Plongthongkum N, Gore A, Fung H-L, Shoemaker R, Zhang K. 2012. Library-free methylation sequencing with bisulfite padlock probes. *Nat Meth* 9:270–272.

Djuric U, El-Maarri O, Lamb B, Kuick R, Seoud M, Coullin P, Oldenburg J, Hanash S, Slim R. 2006. Familial molar tissues due to mutations in the inflammatory gene, NALP7, have normal postzygotic DNA methylation. *Hum. Genet.* 120:390–395.

Docherty LE, Rezwan FI, Poole RL, Jagoe H, Lake H, Lockett GA, Arshad H, Wilson DI, Holloway JW, Temple IK, et al. 2014. Genome-wide DNA methylation analysis of patients with imprinting disorders identifies differentially methylated regions associated with novel candidate imprinted genes. *Journal of Medical Genetics*

51:229–238.

Docherty LE, Rezwan FI, Poole RL, Turner CLS, Kivuva E, Maher ER, Smithson SF, Hamilton-Shield JP, Patalan M, Gizewska M, et al. 2015. Mutations in NLRP5 are associated with reproductive wastage and multilocus imprinting disorders in humans. *Nat Commun* 6:8086.

Down TA, Rakyan VK, Turner DJ, Flicek P, Li H, Kulesha E, Gräf S, Johnson N, Herrero J, Tomazou EM, et al. 2008. A Bayesian deconvolution strategy for immunoprecipitation-based DNA methylome analysis. *Nat Biotechnol* 26:779–785.

Duncan PA, Hall JG, Shapiro LR, Vibert BK. 1990. Three-generation dominant transmission of the Silver-Russell syndrome. *Am. J. Med. Genet.* 35:245–250.

Eden A, Gaudet F, Waghmare A, Jaenisch R. 2003. Chromosomal instability and tumors promoted by DNA hypomethylation. *Science* 300:455–455.

Egger G, Liang G, Aparicio A, Jones PA. 2004. Epigenetics in human disease and prospects for epigenetic therapy. *Nature* 429:457–463.

Eggermann T, Meyer E, Obermann C, Heil I, Schüler H, Ranke MB, Eggermann K, Wollmann HA. 2005. Is maternal duplication of 11p15 associated with Silver-Russell syndrome? *Journal of Medical Genetics* 42:e26.

Eggermann T, Netchine I, Temple IK, Tümer Z, Monk D, Mackay D, Grønskov K, Riccio A, Linglart A, Maher ER. 2015. Congenital imprinting disorders: EUCID.net -

a network to decipher their aetiology and to improve the diagnostic and clinical care. Clin Epigenetics 7:23.

Eggermann T, Perez de Nanclares G, Maher ER, Temple IK, Tümer Z, Monk D, Mackay DJG, Grønskov K, Riccio A, Linglart A, et al. 2015. Imprinting disorders: a group of congenital disorders with overlapping patterns of molecular changes affecting imprinted loci. Clin Epigenetics 7:123.

Eggermann T, Spengler S, Bachmann N, Baudis M, Mau-Holzmann UA, Singer S, Rossier E. 2010. Chromosome 11p15 duplication in Silver-Russell syndrome due to a maternally inherited translocation t(11;15). Am. J. Med. Genet. 152A:1484–1487.

Eggermann T, Wollmann HA, Kuner R, Eggermann K, Enders H, Kaiser P, Ranke MB. 1997. Molecular studies in 37 Silver-Russell syndrome patients: frequency and etiology of uniparental disomy. Hum. Genet. 100:415–419.

El-Maarri O. 2003. Maternal alleles acquiring paternal methylation patterns in biparental complete hydatidiform moles. Human Molecular Genetics 12:1405–1413.

Engel JR. 2000. Epigenotype-phenotype correlations in Beckwith-Wiedemann syndrome. Journal of Medical Genetics 37:921–926.

Engel N, Thorvaldsen JL, Bartolomei MS. 2006. CTCF binding sites promote transcription initiation and prevent DNA methylation on the maternal allele at the imprinted H19/Igf2 locus. Human Molecular Genetics 15:2945–2954.

Fang J, Cheng J, Wang J, Zhang Q, Liu M, Gong R, Wang P, Zhang X, Feng Y, Lan W, et al. 2016. Hemi-methylated DNA opens a closed conformation of UHRF1 to facilitate its histone recognition. *Nat Commun* 7:11197.

Fedoriw AM, Stein P, Svoboda P, Schultz RM, Bartolomei MS. 2004. Transgenic RNAi reveals essential function for CTCF in H19 gene imprinting. *Science* 303:238–240.

Feng Q, Zhang Y. 2001. The MeCP1 complex represses transcription through preferential binding, remodeling, and deacetylating methylated nucleosomes. *Genes & Development* 15:827–832.

Ferguson-Smith AC. 2011. Genomic imprinting: the emergence of an epigenetic paradigm. *Nature Reviews Genetics* 12:565–575.

Ferguson-Smith AC, Cattanach BM, Barton SC, Beechey CV, Surani MA. 1991. Embryological and molecular investigations of parental imprinting on mouse chromosome 7. *Nature* 351:667–670.

Ferguson-Smith AC, Sasaki H, Cattanach BM, Surani MA. 1993. Parental-origin-specific epigenetic modification of the mouse H19 gene. *Nature* 362:751–755.

Ferrón SR, Charalambous M, Radford E, McEwen K, Wildner H, Hind E, Morante-Redolat JM, Laborda J, Guillemot F, Bauer SR, et al. 2011. Postnatal loss of Dlk1 imprinting in stem cells and niche astrocytes regulates neurogenesis. *Nature* 475:381–385.

Ficz G, Branco MR, Seisenberger S, Santos F, Krueger F, Hore TA, Marques CJ, Andrews S, Reik W. 2011. Dynamic regulation of 5-hydroxymethylcytosine in mouse ES cells and during differentiation. *Nature* 473:398–402.

Fiedler K, Ezcurra D. 2012. Predicting and preventing ovarian hyperstimulation syndrome (OHSS): the need for individualized not standardized treatment. *Reprod. Biol. Endocrinol.* 10:32.

Fortin J-P, Labbe A, Lemire M, Zanke BW, Hudson TJ, Fertig EJ, Greenwood CM, Hansen KD. 2014. Functional normalization of 450k methylation array data improves replication in large cancer studies. *Genome Biology* 15:503.

Fraga MF, Agrelo R, Esteller M. 2007. Cross-talk between aging and cancer: the epigenetic language. *Ann. N. Y. Acad. Sci.* 1100:60–74.

Frommer M, McDonald LE, Millar DS, Collis CM, Watt F, Grigg GW, Molloy PL, Paul CL. 1992. A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. *Proc Natl Acad Sci USA* 89:1827–1831.

Gagnon KB, Delpire E. 2013. Physiology of SLC12 transporters: lessons from inherited human genetic mutations and genetically engineered mouse knockouts. *Am. J. Physiol., Cell Physiol.* 304:C693–714.

Gambichler T, Sand M, Skrygan M. 2013. Loss of 5-hydroxymethylcytosine and ten-eleven translocation 2 protein expression in malignant melanoma. *Melanoma Res.*

23:218–220.

Gardner RJ, Mackay DJ, Mungall AJ, Polychronakos C, Siebert R, Shield JP, Temple IK, Robinson DO. 2000. An imprinted locus associated with transient neonatal diabetes mellitus. *Human Molecular Genetics* 9:589–596.

Gelato KA, Tauber M, Ong MS, Winter S, Hiragami-Hamada K, Sindlinger J, Lemak A, Bultsma Y, Houliston S, Schwarzer D, et al. 2014. Accessibility of Different Histone H3-Binding Domains of UHRF1 Is Allosterically Regulated by Phosphatidylinositol 5-Phosphate. *Mol. Cell* 54:905–919.

Gicquel C, Gaston V, Mandelbaum J, Siffroi J-P, Flahault A, Le Bouc Y. 2003. In vitro fertilization may increase the risk of Beckwith-Wiedemann syndrome related to the abnormal imprinting of the KCN1OT gene. *Am. J. Hum. Genet.* 72:1338–1341.

Gicquel C, Rossignol S, Cabrol S, Houang M, Steunou V, Barbu V, Danton F, Thibaud N, Merrer ML, Burglen L, et al. 2005. Epimutation of the telomeric imprinting center region on chromosome 11p15 in Silver-Russell syndrome. *Nature Genetics* 37:1003–1007.

Gilissen C, Hoischen A, Brunner HG, Veltman JA. 2012. Disease gene identification strategies for exome sequencing. *Eur. J. Hum. Genet.* 20:490–497.

Gore A, Li Z, Fung H-L, Young JE, Agarwal S, Antosiewicz-Bourget J, Canto I, Giorgetti A, Israel MA, Kiskinis E, et al. 2011. Somatic coding mutations in human induced pluripotent stem cells. *Nature* 471:63–67.

Greenberg MVC, Glaser J, Borsos M, Marjou FE, Walter M, Teissandier A, Bourc'his D. 2017. Transient transcription in the early embryo sets an epigenetic state that programs postnatal growth. *Nature Genetics* 49:110–118.

Grønskov K, Poole RL, Hahnemann JMD, Thomson J, Tümer Z, Brøndum-Nielsen K, Murphy R, Ravn K, Melchior L, Dedic A, et al. 2011. Deletions and rearrangements of the H19/IGF2 enhancer region in patients with Silver-Russell syndrome and growth retardation. *Journal of Medical Genetics* 48:308–311.

Gu H, Smith ZD, Bock C, Boyle P, Gnirke A, Meissner A. 2011. Preparation of reduced representation bisulfite sequencing libraries for genome-scale DNA methylation profiling. *Nat Protoc* 6:468–481.

Guilhamon P, Eskandarpour M, Halai D, Wilson GA, Feber A, Teschendorff AE, Gomez V, Hergovich A, Tirabosco R, Fernanda Amary M, et al. 2013. Meta-analysis of IDH-mutant cancers identifies EBF1 as an interaction partner for TET2. *Nat Commun* 4:2166.

Guo L, Choufani S, Ferreira J, Smith A, Chitayat D, Shuman C, Uxa R, Keating S, Kingdom J, Weksberg R. 2008. Altered gene expression and methylation of the human chromosome 11 imprinted region in small for gestational age (SGA) placentae. *Developmental Biology* 320:79–91.

Hackett JA, Sengupta R, Zyllicz JJ, Murakami K, Lee C, Down TA, Surani MA. 2013. Germline DNA Demethylation Dynamics and Imprint Erasure Through 5-

Hydroxymethylcytosine. *Science* 339:448–452.

Hajkova P, Erhardt S, Lane N, Haaf T, El-Maarri O, Reik W, Walter J, Surani MA. 2002. Epigenetic reprogramming in mouse primordial germ cells. *Mechanisms of Development* 117:15–23.

Hajkova P, Jeffries SJ, Lee C, Miller N, Jackson SP, Surani MA. 2010. Genome-wide reprogramming in the mouse germ line entails the base excision repair pathway. *Science* 329:78–82.

Halliday J, Oke K, Breheny S, Algar E, J Amor D. 2004. Beckwith-Wiedemann syndrome and IVF: a case-control study. *Am. J. Hum. Genet.* 75:526–528.

Hannula K, Lipsanen-Nyman M, Kontiokari T, Kere J. 2001. A narrow segment of maternal uniparental disomy of chromosome 7q31-qter in Silver-Russell syndrome delimits a candidate gene region. *Am. J. Hum. Genet.* 68:247–253.

Hansen KD, Timp W, Bravo HC, Sabunciyan S, Langmead B, McDonald OG, Wen B, Wu H, Liu Y, Diep D, et al. 2011. Increased methylation variation in epigenetic domains across cancer types. *Nature Genetics* 43:768–775.

Hao Y, Crenshaw T, Moulton T, Newcomb E, Tycko B. 1993. Tumour-suppressor activity of H19 RNA. *Nature* 365:764–767.

Hark AT, Schoenherr CJ, Katz DJ, Ingram RS, Levorse JM, Tilghman SM. 2000. CTCF mediates methylation-sensitive enhancer-blocking activity at the H19/Igf2

locus. *Nature* 405:486–489.

Hashimoto H, Liu Y, Upadhyay AK, Chang Y, Howerton SB, Vertino PM, Zhang X, Cheng X. 2012. Recognition and potential mechanisms for replication and erasure of cytosine hydroxymethylation. *Nucleic Acids Research* 40:4841–4849.

Hata K, Okano M, Lei H, Li E. 2002. Dnmt3L cooperates with the Dnmt3 family of de novo DNA methyltransferases to establish maternal imprints in mice. *Development* 129:1983–1993.

Hatada I, Ohashi H, Fukushima Y, Kaneko Y, Inoue M, Komoto Y, Okada A, Ohishi S, Nabetani A, Morisaki H, et al. 1996. An imprinted gene p57KIP2 is mutated in Beckwith–Wiedemann syndrome. *Nature Genetics* 14:171–173.

Hatada I, Nabetani A, Morisaki H, Xin Z, Ohishi S, Tonoki H, Niikawa N, Inoue M, Komoto Y, Okada A, et al. 1997. New p57 KIP2 mutations in Beckwith-Wiedemann syndrome. *Hum. Genet.* 100:681–683.

Hayward BE, De Vos M, Talati N, Abdollahi MR, Taylor GR, Meyer E, Williams D, Maher ER, Setna F, Nazir K, et al. 2009. Genetic and epigenetic analysis of recurrent hydatidiform mole. *Hum. Mutat.* 30:E629–39.

He Y-F, Li B-Z, Li Z, Liu P, Wang Y, Tang Q, Ding J, Jia Y, Chen Z, Li L, et al. 2011. Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA. *Science* 333:1303–1307.

Henikoff S, Smith MM. 2015. Histone variants and epigenetics. *Cold Spring Harb Perspect Biol* 7:a019364.

Henry I, Puech A, Riesewijk A, Ahnine L, Mannens M, Beldjord C, Bitoun P, Tournade MF, Landrieu P, Junien C. 1993. Somatic mosaicism for partial paternal isodisomy in Wiedemann-Beckwith syndrome: a post-fertilization event. *Eur. J. Hum. Genet.* 1:19–29.

Herrmann A, Haake A, Ammerpohl O, Martin-Guerrero I, Szafranski K, Stemshorn K, Nothnagel M, Kotsopoulos SK, Richter J, Warner J, et al. 2011. Pipeline for large-scale microdroplet bisulfite PCR-based sequencing allows the tracking of hepitype evolution in tumors. *PLoS ONE* 6:e21332.

Hiatt JB, Pritchard CC, Salipante SJ, O'Roak BJ, Shendure J. 2013. Single molecule molecular inversion probes for targeted, high-accuracy detection of low-frequency variation. *Genome Research* 23:843–854.

Hirasawa R, Chiba H, Kaneda M, Tajima S, Li E, Jaenisch R, Sasaki H. 2008. Maternal and zygotic Dnmt1 are necessary and sufficient for the maintenance of DNA methylation imprints during preimplantation development. *Genes & Development* 22:1607–1616.

Hitchins MP, Monk D, Bell GM, Ali Z, Preece MA, Stanier P, Moore GE. 2001. Maternal repression of the human GRB10 gene in the developing central nervous system; evaluation of the role for GRB10 in Silver-Russell syndrome. *Eur. J. Hum.*

Genet. 9:82–90.

Hiura H, Okae H, Chiba H, Miyauchi N, Sato F, Sato A, Arima T. 2014. Imprinting methylation errors in ART. *Reprod. Med. Biol.* 13:193–202.

Hiura H, Okae H, Miyauchi N, Sato F, Sato A, Van De Pette M, John RM, Kagami M, Nakai K, Soejima H, et al. 2012. Characterization of DNA methylation errors in patients with imprinting disorders conceived by assisted reproduction technologies. *Human Reproduction* 27:2541–2548.

Hodges E, Smith AD, Kendall J, Xuan Z, Ravi K, Rooks M, Zhang MQ, Ye K, Bhattacharjee A, Brizuela L, et al. 2009. High definition profiling of mammalian DNA methylation by array capture and single molecule bisulfite sequencing. *Genome Research* 19:1593–1605.

Hodges E, Xuan Z, Balija V, Kramer M, Molla MN, Smith SW, Middle CM, Rodesch MJ, Albert TJ, Hannon GJ, et al. 2007. Genome-wide in situ exon capture for selective resequencing. *Nature Genetics* 39:1522–1527.

Hon GC, Hawkins RD, Caballero OL, Lo C, Lister R, Pelizzola M, Valsesia A, Ye Z, Kuan S, Edsall LE, et al. 2012. Global DNA hypomethylation coupled to repressive chromatin domain formation and gene silencing in breast cancer. *Genome Research* 22:246–258.

Hoovers JM, Kalikin LM, Johnson LA, Alders M, Redeker B, Law DJ, Blik J, Steenman M, Benedict M, Wiegant J, et al. 1995. Multiple genetic loci within 11p15

defined by Beckwith-Wiedemann syndrome rearrangement breakpoints and subchromosomal transferable fragments. *Proc Natl Acad Sci USA* 92:12456–12460.

Horvath S. 2013. DNA methylation age of human tissues and cell types. *Genome Biology* 14:R115.

Howell CY, Bestor TH, Ding F, Latham KE, Mertineit C, Trasler JM, Chaillet JR. 2001. Genomic imprinting disrupted by a maternal effect mutation in the *Dnmt1* gene. *Cell* 104:829–838.

Hu L, Li Z, Wang P, Lin Y, Xu Y. 2011. Crystal structure of PHD domain of UHRF1 and insights into recognition of unmodified histone H3 arginine residue 2. *Cell Res.* 21:1374–1378.

Iguchi-Arigo SM, Schaffner W. 1989. CpG methylation of the cAMP-responsive enhancer/promoter sequence TGACGTCA abolishes specific factor binding as well as transcriptional activation. *Genes & Development* 3:612–619.

Inoue A, Shen L, Dai Q, He C, Zhang Y. 2011. Generation and replication-dependent dilution of 5fC and 5caC during mouse preimplantation development. *Cell Res.* 21:1670–1676.

Ishida M, Moore GE. 2013. The role of imprinted genes in humans. *Mol. Aspects Med.* 34:826–840.

Ito S, Shen L, Dai Q, Wu SC, Collins LB, Swenberg JA, He C, Zhang Y. 2011. Tet

proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine. *Science* 333:1300–1303.

Ivanov M, Kals M, Kacevska M, Metspalu A, Ingelman-Sundberg M, Milani L. 2013. In-solution hybrid capture of bisulfite-converted DNA for targeted bisulfite sequencing of 174 ADME genes. *Nucleic Acids Research* 41:e72.

Jaffe AE, Murakami P, Lee H, Leek JT, Fallin MD, Feinberg AP, Irizarry RA. 2012. Bump hunting to identify differentially methylated regions in epigenetic epidemiology studies. *Int J Epidemiol* 41:200–209.

Jian X, Boerwinkle E, Liu X. 2014. In silico prediction of splice-altering single nucleotide variants in the human genome. *Nucleic Acids Research* 42:13534–13544.

Johnson DR. 1974. Hairpin-tail: a case of post-reductional gene action in the mouse egg. *Genetics* 76:795–805.

Johnson WE, Li C, Rabinovic A. 2007. Adjusting batch effects in microarray expression data using empirical Bayes methods. *Biostatistics* 8:118–127.

Jones PA, Taylor SM. 1980. Cellular differentiation, cytidine analogs and DNA methylation. *Cell* 20:85–93.

Jones PL, Veenstra GJ, Wade PA, Vermaak D, Kass SU, Landsberger N, Strouboulis J, Wolffe AP. 1998. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. *Nature Genetics* 19:187–191.

Joyce CA, Sharp A, Walker JM, Bullman H, Temple IK. 1999. Duplication of 7p12. 1-p13, including GRB10 and IGFBP1, in a mother and daughter with features of Silver-Russell syndrome. *Hum. Genet.*

Judson H, Hayward BE, Sheridan E, Bonthron DT. 2002. A global disorder of imprinting in the human female germ line. *Nature* 416:539–542.

Kagami M, Mizuno S, Matsubara K, Nakabayashi K, Sano S, Fuke T, Fukami M, Ogata T. 2015. Epimutations of the IG-DMR and the MEG3-DMR at the 14q32.2 imprinted region in two patients with Silver-Russell Syndrome-compatible phenotype. *Eur. J. Hum. Genet.* 23:1062–1067.

Kagiwada S, Kurimoto K, Hirota T, Yamaji M, Saitou M. 2013. Replication-coupled passive DNA demethylation for the erasure of genome imprints in mice. *EMBO J* 32:340–353.

Kamiya M, Judson H, Okazaki Y, Kusakabe M, Muramatsu M, Takada S, Takagi N, Arima T, Wake N, Kamimura K, et al. 2000. The cell cycle control gene ZAC/PLAGL1 is imprinted--a strong candidate gene for transient neonatal diabetes. *Human Molecular Genetics* 9:453–460.

Kaneda M, Okano M, Hata K, Sado T, Tsujimoto N, Li E, Sasaki H. 2004. Essential role for de novo DNA methyltransferase Dnmt3a in paternal and maternal imprinting. *Nature* 429:900–903.

Karmakar S, Das C. 2002. Regulation of Trophoblast Invasion by IL-1beta and TGF-

beta1. *Am J Reprod Immunol* 48:210–219.

Kermicle JL. 1970. Dependence of the R-mottled aleurone phenotype in maize on mode of sexual transmission. *Genetics* 66:69–85.

Khare S, Dorfleutner A, Bryan NB, Yun C, Radian AD, de Almeida L, Rojanasakul Y, Stehlik C. 2012. An NLRP7-containing inflammasome mediates recognition of microbial lipopeptides in human macrophages. *Immunity* 36:464–476.

Kim K-H, Lee K-A. 2014. Maternal effect genes: Findings and effects on mouse embryo development. *Clin Exp Reprod Med* 41:47–61.

Kinoshita T, Wang Y, Hasegawa M, Imamura R, Suda T. 2005. PYPAF3, a PYRIN-containing APAF-1-like protein, is a feedback regulator of caspase-1-dependent interleukin-1beta secretion. *Journal of Biological Chemistry* 280:21720–21725.

Kobayashi H, Yanagisawa E, Sakashita A, Sugawara N, Kumakura S, Ogawa H, Akutsu H, Hata K, Nakabayashi K, Kono T. 2013. Epigenetic and transcriptional features of the novel human imprinted lncRNA GPR1AS suggest it is a functional ortholog to mouse *Zdbf2linc*. *epigenetics* 8:635–645.

Kobayashi S, Uemura H, Kohda T, Nagai T, Chinen Y, Naritomi K, Kinoshita EI, Ohashi H, Imaizumi K, Tsukahara M, et al. 2001. No evidence of PEG1/MEST gene mutations in Silver-Russell syndrome patients. *Am. J. Med. Genet.* 104:225–231.

Komori HK, LaMere SA, Torkamani A, Hart GT, Kotsopoulos S, Warner J, Samuels

ML, Olson J, Head SR, Ordoukhanian P, et al. 2011. Application of microdroplet PCR for large-scale targeted bisulfite sequencing. *Genome Research* 21:1738–1745.

Kotzot D, Schmitt S, Bernasconi F, Robinson WP, Lurie IW, Ilyina H, Méhes K, Hamel BC, Otten BJ, Hergersberg M. 1995. Uniparental disomy 7 in Silver-Russell syndrome and primordial growth retardation. *Human Molecular Genetics* 4:583–587.

Kou YC, Shao L, Peng HH, Rosetta R, del Gaudio D, Wagner AF, Al-Hussaini TK, Van den Veyver IB. 2008. A recurrent intragenic genomic duplication, other novel mutations in NLRP7 and imprinting defects in recurrent biparental hydatidiform moles. *Molecular Human Reproduction* 14:33–40.

Krueger F, Andrews SR. 2011. Bismark: a flexible aligner and methylation caller for Bisulfite-Seq applications. *Bioinformatics* 27:1571–1572.

Kurimoto K, Yabuta Y, Ohinata Y, Shigeta M, Yamanaka K, Saitou M. 2008. Complex genome-wide transcription dynamics orchestrated by Blimp1 for the specification of the germ cell lineage in mice. *Genes & Development* 22:1617–1635.

Kurukuti S, Tiwari VK, Tavoosidana G, Pugacheva E, Murrell A, Zhao Z, Lobanenkov V, Reik W, Ohlsson R. 2006. CTCF binding at the H19 imprinting control region mediates maternally inherited higher-order chromatin conformation to restrict enhancer access to Igf2. *Proc Natl Acad Sci USA* 103:10684–10689.

Lau MM, Stewart CE, Liu Z, Bhatt H, Rotwein P, Stewart CL. 1994. Loss of the imprinted IGF2/cation-independent mannose 6-phosphate receptor results in fetal overgrowth and perinatal lethality. *Genes & Development* 8:2953–2963.

Lee E-J, Luo J, Wilson JM, Shi H. 2013. Analyzing the cancer methylome through targeted bisulfite sequencing. *Cancer Letters* 340:171–178.

Lee E-J, Pei L, Srivastava G, Joshi T, Kushwaha G, Choi J-H, Robertson KD, Wang X, Colbourne JK, Zhang L, et al. 2011. Targeted bisulfite sequencing by solution hybrid selection and massively parallel sequencing. *Nucleic Acids Research* 39:e127.

Lee J, Inoue K, Ono R, Ogonuki N, Kohda T, Kaneko-Ishino T, Ogura A, Ishino F. 2002. Erasing genomic imprinting memory in mouse clone embryos produced from day 11.5 primordial germ cells. *Development* 129:1807–1817.

Lee MH, Reynisdottir I, Massague J. 1995. Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. *Genes & Development* 9:639–649.

Lee MP, DeBaun M, Randhawa G, Reichard BA, Elledge SJ, Feinberg AP. 1997. Low Frequency of p57KIP2 Mutation in Beckwith-Wiedemann Syndrome. *The American Journal of Human Genetics* 61:304–309.

Lee MP, DeBaun MR, Mitsuya K, Galonek HL, Brandenburg S, Oshimura M, Feinberg AP. 1999. Loss of imprinting of a paternally expressed transcript, with

antisense orientation to KVLQT1, occurs frequently in Beckwith-Wiedemann syndrome and is independent of insulin-like growth factor II imprinting. *Proc Natl Acad Sci USA* 96:5203–5208.

Leek JT, Johnson WE, Parker HS, Jaffe AE, Storey JD. 2012. The sva package for removing batch effects and other unwanted variation in high-throughput experiments. *Bioinformatics* 28:882–883.

Leek JT, Scharpf RB, Bravo HC, Simcha D, Langmead B, Johnson WE, Geman D, Baggerly K, Irizarry RA. 2010. Tackling the widespread and critical impact of batch effects in high-throughput data. *Nature Reviews Genetics* 11:733–739.

Lefebvre L, Viville S, Barton SC, Ishino F, Keverne EB, Surani MA. 1998. Abnormal maternal behaviour and growth retardation associated with loss of the imprinted gene *Mest*. *Nature Genetics* 20:163–169.

Leicher T, Bähring R, Isbrandt D, Pongs O. 1998. Coexpression of the *KCNA3B* gene product with *Kv1.5* leads to a novel A-type potassium channel. *Journal of Biological Chemistry* 273:35095–35101.

Leighton PA, Ingram RS, Eggenschwiler J, Efstratiadis A, Tilghman SM. 1995. Disruption of imprinting caused by deletion of the *H19* gene region in mice. *Nature* 375:34–39.

Leonhardt H, Page AW, Weier HU, Bestor TH. 1992. A targeting sequence directs DNA methyltransferase to sites of DNA replication in mammalian nuclei. *Cell* 71:865–

873.

Li E, Beard C, Jaenisch R. 1993. Role for DNA methylation in genomic imprinting. *Nature* 366:362–365.

Li E, Bestor TH, Jaenisch R. 1992. Targeted mutation of the DNA methyltransferase gene results in embryonic lethality. *Cell* 69:915–926.

Li E, Zhang Y. 2014. DNA methylation in mammals. *Cold Spring Harb Perspect Biol* 6:a019133.

Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis G, Durbin R, 1000 Genome Project Data Processing Subgroup. 2009. The Sequence Alignment/Map format and SAMtools. *Bioinformatics* 25:2078–2079.

Li J-Y, Lees-Murdock DJ, Xu G-L, Walsh CP. 2004. Timing of establishment of paternal methylation imprints in the mouse. *Genomics* 84:952–960.

Li JB, Gao Y, Aach J, Zhang K, Kryukov GV, Xie B, Ahlford A, Yoon J-K, Rosenbaum AM, Zaranek AW, et al. 2009. Multiplex padlock targeted sequencing reveals human hypermutable CpG variations. *Genome Research* 19:1606–1615.

Li JB, Levanon EY, Yoon JK, Aach J, Xie B, LeProust E, Zhang K, Gao Y, Church GM. 2009. Genome-Wide Identification of Human RNA Editing Sites by Parallel DNA Capturing and Sequencing. *Science* 324:1210–1213.

Li L, Baibakov B, Dean J. 2008. A subcortical maternal complex essential for

preimplantation mouse embryogenesis. *Dev. Cell* 15:416–425.

Li L, Keverne EB, Aparicio SA, Ishino F, Barton SC, Surani MA. 1999. Regulation of maternal behavior and offspring growth by paternally expressed *Peg3*. *Science* 284:330–333.

Li L, Zheng P, Dean J. 2010. Maternal control of early mouse development. *Development* 137:859–870.

Li W, Liu M. 2011. Distribution of 5-hydroxymethylcytosine in different human tissues. *J Nucleic Acids* 2011:870726.

Li X. 2010. Extending the maternal-zygotic effect with genomic imprinting. *Molecular Human Reproduction* 16:695–703.

Li X, Ito M, Zhou F, Youngson N, Zuo X, Leder P, Ferguson-Smith AC. 2008. A maternal-zygotic effect gene, *Zfp57*, maintains both maternal and paternal imprints. *Dev. Cell* 15:547–557.

Lian CG, Xu Y, Ceol C, Wu F, Larson A, Dresser K, Xu W, Tan L, Hu Y, Zhan Q, et al. 2012. Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma. *Cell* 150:1135–1146.

Lim D, Bowdin SC, Tee L, Kirby GA, Blair E, Fryer A, Lam W, Oley C, Cole T, Brueton LA, et al. 2009. Clinical and molecular genetic features of Beckwith-Wiedemann syndrome associated with assisted reproductive technologies. *Human Reproduction* 24:741–747.

Lister R, O'Malley RC, Tonti-Filippini J, Gregory BD, Berry CC, Millar AH, Ecker JR. 2008. Highly integrated single-base resolution maps of the epigenome in *Arabidopsis*. *Cell* 133:523–536.

Lister R, Pelizzola M, Dowen RH, Hawkins RD, Hon G, Tonti-Filippini J, Nery JR, Lee L, Ye Z, Ngo Q-M, et al. 2009. Human DNA methylomes at base resolution show widespread epigenomic differences. *Nature* 462:315–322.

Liu F, Roth RA. 1995. Grb-IR: a SH2-domain-containing protein that binds to the insulin receptor and inhibits its function. *Proc Natl Acad Sci USA* 92:10287–10291.

Liu X, Gao Q, Li P, Zhao Q, Zhang J, Li J, Koseki H, Wong J. 2013. UHRF1 targets DNMT1 for DNA methylation through cooperative binding of hemi-methylated DNA and methylated H3K9. *Nat Commun* 4:1563.

Liu Y, Aryee MJ, Padyukov L, Fallin MD, Hesselberg E, Runarsson A, Reinius L, Acevedo N, Taub M, Ronninger M, et al. 2013. Epigenome-wide association data implicate DNA methylation as an intermediary of genetic risk in rheumatoid arthritis. *Nat Biotechnol* 31:142–147.

Lubinsky M, Herrmann J, Kosseff AL, Opitz JM. 1974. Letter: Autosomal-dominant sex-dependent transmission of the Wiedemann-Beckwith syndrome. *Lancet* 1:932.

Lucifero D, Mann MRW, Bartolomei MS, Trasler JM. 2004. Gene-specific timing and epigenetic memory in oocyte imprinting. *Human Molecular Genetics* 13:839–849.

Lucifero D, Mertineit C, Clarke HJ, Bestor TH, Trasler JM. 2002. Methylation Dynamics of Imprinted Genes in Mouse Germ Cells. *Genomics* 79:530–538.

Ludwig T, Eggenschwiler J, Fisher P, D'Ercole AJ, Davenport ML, Efstratiadis A. 1996. Mouse mutants lacking the type 2 IGF receptor (IGF2R) are rescued from perinatal lethality in *Igf2* and *Igf1r* null backgrounds. *Developmental Biology* 177:517–535.

Ludwig T, Le Borgne R, Hoflack B. 1995. Roles for mannose-6-phosphate receptors in lysosomal enzyme sorting, IGF-II binding and clathrin-coat assembly. *Trends Cell Biol.* 5:202–206.

Ma J, Zeng F, Schultz RM, Tseng H. 2006. Basonuclin: a novel mammalian maternal-effect gene. *Development* 133:2053–2062.

Mackay DJG, Callaway JLA, Marks SM, White HE, Acerini CL, Boonen SE, Dayanikli P, Firth HV, Goodship JA, Haemers AP, et al. 2008. Hypomethylation of multiple imprinted loci in individuals with transient neonatal diabetes is associated with mutations in *ZFP57*. *Nature Genetics* 40:949–951.

Mackay DJG, Eggermann T, Buiting K, Garin I, Netchine I, Linglart A, de Nanclares GP. 2015. Multilocus methylation defects in imprinting disorders. *Biomol Concepts* 6:47–57.

Mackay DJG, Hahnemann JMD, Boonen SE, Poerksen S, Bunyan DJ, White HE, Durston VJ, Thomas NS, Robinson DO, Shield JPH, et al. 2006. Epimutation of the

TNDM locus and the Beckwith-Wiedemann syndrome centromeric locus in individuals with transient neonatal diabetes mellitus. *Hum. Genet.* 119:179–184.

Maeda T, Higashimoto K, Jozaki K, Yatsuki H, Nakabayashi K, Makita Y, Tonoki H, Okamoto N, Takada F, Ohashi H, et al. 2014. Comprehensive and quantitative multilocus methylation analysis reveals the susceptibility of specific imprinted differentially methylated regions to aberrant methylation in Beckwith-Wiedemann syndrome with epimutations. *Genet Med* 16:903–912.

Maher ER, Brueton LA, Bowdin SC, Luharia A, Cooper W, Cole TR, Macdonald F, Sampson JR, Barratt CL, Reik W, et al. 2003. Beckwith-Wiedemann syndrome and assisted reproduction technology (ART). *Journal of Medical Genetics* 40:62–64.

Maher ER, Reik W. 2000. Beckwith-Wiedemann syndrome: imprinting in clusters revisited. *J. Clin. Invest.* 105:247–845.

Maiti A, Drohat AC. 2011. Thymine DNA glycosylase can rapidly excise 5-formylcytosine and 5-carboxylcytosine: potential implications for active demethylation of CpG sites. *J. Biol. Chem.* 286:35334–35338.

Maksimovic J, Gordon L, Oshlack A. 2012. SWAN: Subset-quantile within array normalization for illumina infinium HumanMethylation450 BeadChips. *Genome Biology* 13:R44.

Marlow FL. 2010. *Maternal Control of Development in Vertebrates: My Mother Made Me Do It!*

Mason EF, Hornick JL. 2013. Succinate dehydrogenase deficiency is associated with decreased 5-hydroxymethylcytosine production in gastrointestinal stromal tumors: implications for mechanisms of tumorigenesis. *Mod. Pathol.* 26:1492–1497.

Matsubara K, Kagami M, Nakabayashi K, Hata K, Fukami M, Ogata T, Yamazawa K. 2015. Exploration of hydroxymethylation in Kagami-Ogata syndrome caused by hypermethylation of imprinting control regions. *Clin Epigenetics* 7:90.

Maunakea AK, Nagarajan RP, Bilenky M, Ballinger TJ, D'Souza C, Fouse SD, Johnson BE, Hong C, Nielsen C, Zhao Y, et al. 2010. Conserved role of intragenic DNA methylation in regulating alternative promoters. *Nature* 466:253–257.

Maupetit-Méhouas S, Azzi S, Steunou V, Sakakini N, Silve C, Reynes C, Perez de Nanclares G, Keren B, Chantot S, Barlier A, et al. 2013. Simultaneous hyper- and hypomethylation at imprinted loci in a subset of patients with GNAS epimutations underlies a complex and different mechanism of multilocus methylation defect in pseudohypoparathyroidism type 1b. *Hum. Mutat.* 34:1172–1180.

McGrath J, Solter D. 1983. Nuclear transplantation in mouse embryos. *J. Exp. Zool.* 228:355–362.

McGrath J, Solter D. 1984. Completion of mouse embryogenesis requires both the maternal and paternal genomes. *Cell* 37:179–183.

McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, Garimella K, Altshuler D, Gabriel S, Daly M, et al. 2010. The Genome Analysis Toolkit: a

MapReduce framework for analyzing next-generation DNA sequencing data. *Genome Research* 20:1297–1303.

Meissner A, Mikkelsen TS, Gu H, Wernig M, Hanna J, Sivachenko A, Zhang X, Bernstein BE, Nusbaum C, Jaffe DB, et al. 2008. Genome-scale DNA methylation maps of pluripotent and differentiated cells. *Nature* 454:766–770.

Messaed C, Akoury E, Djuric U, Zeng J, Saleh M, Gilbert L, Seoud M, Qureshi S, Slim R. 2011. NLRP7, a nucleotide oligomerization domain-like receptor protein, is required for normal cytokine secretion and co-localizes with Golgi and the microtubule-organizing center. *J. Biol. Chem.* 286:43313–43323.

Messerschmidt DM, Knowles BB, Solter D. 2014. DNA methylation dynamics during epigenetic reprogramming in the germline and preimplantation embryos. *Genes & Development* 28:812–828.

Meyer E, Lim D, Pasha S, Tee LJ, Rahman F, Yates JRW, Woods CG, Reik W, Maher ER. 2009. Germline Mutation in NLRP2 (NALP2) in a Familial Imprinting Disorder (Beckwith-Wiedemann Syndrome). Barsh GS, editor. *PLoS Genet* 5:e1000423.

Michels KB, Binder AM, Dedeurwaerder S, Epstein CB, Grealley JM, Gut I, Houseman EA, Izzi B, Kelsey KT, Meissner A, et al. 2013. Recommendations for the design and analysis of epigenome-wide association studies. *Nat Meth* 10:949–955.

Milani D, Pezzani L, Tabano S, Miozzo M. 2014. Beckwith-Wiedemann and IMAGE syndromes: two very different diseases caused by mutations on the same gene. *Appl*

Clin Genet 7:169–175.

Monk D, Bentley L, Hitchins M, Myler RA, Clayton-Smith J, Ismail S, Price SM, Preece MA, Stanier P, Moore GE. 2002. Chromosome 7p disruptions in Silver Russell syndrome: delineating an imprinted candidate gene region. *Hum. Genet.* 111:376–387.

Monk D, Morales J, Dunnen den JT, Russo S, Court F, Prawitt D, Eggermann T, Beygo J, Buiting K, Tümer Z. 2016. Recommendations for a nomenclature system for reporting methylation aberrations in imprinted domains. *Epigenetics.*

Monk D, Smith R, Arnaud P, Preece MA, Stanier P, Beechey CV, Peters J, Kelsey G, Moore GE. 2003. Imprinted methylation profiles for proximal mouse chromosomes 11 and 7 as revealed by methylation-sensitive representational difference analysis. *Mamm. Genome* 14:805–816.

Monk D, Wakeling EL, Proud V, Hitchins M, Abu-Amero SN, Stanier P, Preece MA, Moore GE. 2000. Duplication of 7p11.2-p13, including GRB10, in Silver-Russell syndrome. *Am. J. Hum. Genet.* 66:36–46.

Moon YS, Smas CM, Lee K, Villena JA, Kim KH, Yun EJ, Sul HS. 2002. Mice Lacking Paternally Expressed Pref-1/Dlk1 Display Growth Retardation and Accelerated Adiposity. *Molecular and Cellular Biology* 22:5585–5592.

Moore GE, Ishida M, Demetriou C, Al-Olabi L, Leon LJ, Thomas AC, Abu-Amero S, Frost JM, Stafford JL, Chaoqun Y, et al. 2015. The role and interaction of imprinted

genes in human fetal growth. *Philos. Trans. R. Soc. Lond., B, Biol. Sci.* 370:20140074.

Moore T, Haig D. 1991. Genomic imprinting in mammalian development: a parental tug-of-war. *Trends Genet.* 7:45–49.

Morgan HD, Dean W, Coker HA, Reik W, Petersen-Mahrt SK. 2004. Activation-induced cytidine deaminase deaminates 5-methylcytosine in DNA and is expressed in pluripotent tissues: implications for epigenetic reprogramming. *Journal of Biological Chemistry* 279:52353–52360.

Morgan HD, Santos F, Green K, Dean W, Reik W. 2005. Epigenetic reprogramming in mammals. *Human Molecular Genetics* 14 Spec No 1:R47–58.

Morison IM, Paton CJ, Cleverley SD. 2001. The imprinted gene and parent-of-origin effect database. *Nucleic Acids Research* 29:275–276.

Morris TJ, Beck S. 2015. Analysis pipelines and packages for Infinium HumanMethylation450 BeadChip (450k) data. *Methods* 72:3–8.

Moskalev EA, Zavgorodnij MG, Majorova SP, Vorobjev IA, Jandaghi P, Bure IV, Hoheisel JD. 2011. Correction of PCR-bias in quantitative DNA methylation studies by means of cubic polynomial regression. *Nucleic Acids Research* 39:e77.

Mudbhary R, Hoshida Y, Chernyavskaya Y, Jacob V, Villanueva A, Fiel MI, Chen X, Kojima K, Thung S, Bronson RT, et al. 2014. UHRF1 overexpression drives DNA

hypomethylation and hepatocellular carcinoma. *Cancer Cell* 25:196–209.

Murdoch S, Djuric U, Mazhar B, Seoud M, Khan R, Kuick R, Bagga R, Kircheisen R, Ao A, Ratti B, et al. 2006. Mutations in NALP7 cause recurrent hydatidiform moles and reproductive wastage in humans. *Nature Genetics* 38:300–302.

Murrell A, Heeson S, Reik W. 2004. Interaction between differentially methylated regions partitions the imprinted genes *Igf2* and *H19* into parent-specific chromatin loops. *Nature Genetics* 36:889–893.

Nady N, Lemak A, Walker JR, Avvakumov GV, Kareta MS, Achour M, Xue S, Duan S, Allali-Hassani A, Zuo X, et al. 2011. Recognition of Multivalent Histone States Associated with Heterochromatin by UHRF1 Protein. *Journal of Biological Chemistry* 286:24300–24311.

Nakamura K, Baba Y, Kosumi K, Harada K, Shigaki H, Miyake K, Kiyozumi Y, Ohuchi M, Kurashige J, Ishimoto T, et al. 2016. UHRF1 regulates global DNA hypomethylation and is associated with poor prognosis in esophageal squamous cell carcinoma. *Oncotarget* 7:57821–57831.

Nakamura T, Arai Y, Umehara H, Masuhara M, Kimura T, Taniguchi H, Sekimoto T, Ikawa M, Yoneda Y, Okabe M, et al. 2007. PGC7/Stella protects against DNA demethylation in early embryogenesis. *Nat. Cell Biol.* 9:64–71.

Nan X, Ng HH, Johnson CA, Laherty CD, Turner BM, Eisenman RN, Bird A. 1998. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a

histone deacetylase complex. *Nature* 393:386–389.

Nativio R, Sparago A, Ito Y, Weksberg R, Riccio A, Murrell A. 2011. Disruption of genomic neighbourhood at the imprinted IGF2-H19 locus in Beckwith-Wiedemann syndrome and Silver-Russell syndrome. *Human Molecular Genetics* 20:1363–1374.

Netchine I, Rossignol S, Dufourg M-N, Azzi S, Rousseau A, Perin L, Houang M, Steunou V, Esteva B, Thibaud N, et al. 2007. 11p15 Imprinting Center Region 1 Loss of Methylation Is a Common and Specific Cause of Typical Russell-Silver Syndrome: Clinical Scoring System and Epigenetic-Phenotypic Correlations. *Journal of Clinical Endocrinology & Metabolism* 92:3148–3154.

Neyroud N, Tesson F, Denjoy I, Leibovici M, Donger C, Barhanin J, Fauré S, Gary F, Coumel P, Petit C, et al. 1997. A novel mutation in the potassium channel gene KVLQT1 causes the Jervell and Lange-Nielsen cardioauditory syndrome. *Nature Genetics* 15:186–189.

Nicholls RD, Knoll JH, Butler MG, Karam S, Lalande M. 1989. Genetic imprinting suggested by maternal heterodisomy in nondeletion Prader-Willi syndrome. *Nature* 342:281–285.

Niemitz EL, DeBaun MR, Fallon J, Murakami K, Kugoh H, Oshimura M, Feinberg AP. 2004. Microdeletion of LIT1 in Familial Beckwith-Wiedemann Syndrome. *The American Journal of Human Genetics* 75:844–849.

Nishiyama A, Yamaguchi L, Sharif J, Johmura Y, Kawamura T, Nakanishi K,

Shimamura S, Arita K, Kodama T, Ishikawa F, et al. 2013. Uhrf1-dependent H3K23 ubiquitylation couples maintenance DNA methylation and replication. *Nature* 502:249–253.

Noggle S, Fung H-L, Gore A, Martinez H, Satriani KC, Prosser R, Oum K, Paull D, Druckenmiller S, Freeby M, et al. 2011. Human oocytes reprogram somatic cells to a pluripotent state. *Nature* 478:70–75.

Nuttall X, Huddleston J, O'Roak BJ, Antonacci F, Fichera M, Romano C, Shendure J, Eichler EE. 2013. Rapid and accurate large-scale genotyping of duplicated genes and discovery of interlocus gene conversions. *Nat Meth* 10:903–909.

O'Neill TJ, Rose DW, Pillay TS, Hotta K, Olefsky JM, Gustafson TA. 1996. Interaction of a GRB-IR splice variant (a human GRB10 homolog) with the insulin and insulin-like growth factor I receptors. Evidence for a role in mitogenic signaling. *Journal of Biological Chemistry* 271:22506–22513.

O'Roak BJ, Vives L, Fu W, Egertson JD, Stanaway IB, Phelps IG, Carvill G, Kumar A, Lee C, Ankenman K, et al. 2012. Multiplex targeted sequencing identifies recurrently mutated genes in autism spectrum disorders. *Science* 338:1619–1622.

Ohlsson R, Renkawitz R, Lobanenkov V. 2001. CTCF is a uniquely versatile transcription regulator linked to epigenetics and disease. *Trends Genet.* 17:520–527.

Okada K, Hirota E, Mizutani Y, Fujioka T, Shuin T, Miki T, Nakamura Y, Katagiri T. 2004. Oncogenic role of NALP7 in testicular seminomas. *Cancer Sci.* 95:949–954.

Okano M, Bell DW, Haber DA, Li E. 1999. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. *Cell* 99:247–257.

Okano M, Xie S, Li E. 1998. Cloning and characterization of a family of novel mammalian DNA (cytosine-5) methyltransferases. *Nature Genetics* 19:219–220.

Okou DT, Steinberg KM, Middle C, Cutler DJ, Albert TJ, Zwick ME. 2007. Microarray-based genomic selection for high-throughput resequencing. *Nat Meth* 4:907–909.

Ooi SKT, Qiu C, Bernstein E, Li K, Jia D, Yang Z, Erdjument-Bromage H, Tempst P, Lin S-P, Allis CD, et al. 2007. DNMT3L connects unmethylated lysine 4 of histone H3 to de novo methylation of DNA. *Nature* 448:714–717.

Oswald J, Engemann S, Lane N, Mayer W, Olek A, Fundele R, Dean W, Reik W, Walter J. 2000. Active demethylation of the paternal genome in the mouse zygote. *Curr. Biol.* 10:475–478.

Pandey RR, Mondal T, Mohammad F, Enroth S, Redrup L, Komorowski J, Nagano T, Mancini-Dinardo D, Kanduri C. 2008. Kcnq1ot1 Antisense Noncoding RNA Mediates Lineage-Specific Transcriptional Silencing through Chromatin-Level Regulation. *Mol. Cell* 32:232–246.

Parry DA, Logan CV, Hayward BE, Shires M, Landolsi H, Diggle C, Carr I, Rittore C, Tuitou I, Philibert L, et al. 2011. Mutations causing familial biparental hydatidiform mole implicate c6orf221 as a possible regulator of genomic imprinting in the human

oocyte. *Am. J. Hum. Genet.* 89:451–458.

Pastor WA, Pape UJ, Huang Y, Henderson HR, Lister R, Ko M, McLoughlin EM, Brudno Y, Mahapatra S, Kapranov P, et al. 2011. Genome-wide mapping of 5-hydroxymethylcytosine in embryonic stem cells. *Nature* 473:394–397.

Patten MM, Cowley M, Oakey RJ, Feil R. 2016. Regulatory links between imprinted genes: evolutionary predictions and consequences. *Proc. Biol. Sci.* 283.

Paul DS, Guilhamon P, Karpathakis A, Butcher LM, Thirlwell C, Feber A, Beck S. 2014. Assessment of RainDrop BS-seq as a method for large-scale, targeted bisulfite sequencing. *epigenetics* 9:678–684.

Peng H, Chang B, Lu C, Su J, Wu Y, Lv P, Wang Y, Liu J, Zhang B, Quan F, et al. 2012. *Nlrp2*, a maternal effect gene required for early embryonic development in the mouse. *PLoS ONE* 7:e30344.

Perez-Nanclares G, Romanelli V, Mayo S, Garin I, Zazo C, Fernandez-Rebollo E, Martínez F, Lapunzina P, de Nanclares GP, Spanish PHP Group. 2012. Detection of hypomethylation syndrome among patients with epigenetic alterations at the *GNAS* locus. *J. Clin. Endocrinol. Metab.* 97:E1060–7.

Pidsley R, Wong CC, Volta M, Lunnon K, Mill J, Schalkwyk LC. 2013. A data-driven approach to preprocessing Illumina 450K methylation array data. *BMC Genomics* 14:293.

Plongthongkum N, Diep DH, Zhang K. 2014. Advances in the profiling of DNA modifications: cytosine methylation and beyond. *Nature Reviews Genetics* 15:647–661.

Poole RL, Docherty LE, Sayegh AI A, Caliebe A, Turner C, Baple E, Wakeling E, Harrison L, Lehmann A, Temple IK, et al. 2013. Targeted methylation testing of a patient cohort broadens the epigenetic and clinical description of imprinting disorders. *Am. J. Med. Genet.* 161:2174–2182.

Poole RL, Leith DJ, Docherty LE, Shmela ME, Gicquel C, Splitt M, Temple IK, Mackay DJG. 2012. Beckwith-Wiedemann syndrome caused by maternally inherited mutation of an OCT-binding motif in the IGF2/H19-imprinting control region, ICR1. *Eur. J. Hum. Genet.* 20:240–243.

Porreca GJ, Zhang K, Li JB, Xie B, Austin D, Vassallo SL, LeProust EM, Peck BJ, Emig CJ, Dahl F, et al. 2007. Multiplex amplification of large sets of human exons. *Nat Meth* 4:931–936.

Prawitt D, Enklaar T, Gartner-Rupprecht B, Spangenberg C, Oswald M, Lausch E, Schmidtke P, Reutzel D, Fees S, Lucito R, et al. 2005. Microdeletion of target sites for insulator protein CTCF in a chromosome 11p15 imprinting center in Beckwith-Wiedemann syndrome and Wilms' tumor. *Proc Natl Acad Sci USA* 102:4085–4090.

Prawitt D, Enklaar T, Gärtner-Rupprecht B, Spangenberg C, Lausch E, Reutzel D, Fees S, Korzon M, Brozek I, Limon J, et al. 2005. Microdeletion and IGF2 loss of

imprinting in a cascade causing Beckwith-Wiedemann syndrome with Wilms' tumor. *Nature Genetics* 37:785–786.

Preece MA, Price SM, Davies V, Clough L, Stanier P, Trembath RC, Moore GE. 1997. Maternal uniparental disomy 7 in Silver-Russell syndrome. *Journal of Medical Genetics* 34:6–9.

Prendergast GC, Ziff EB. 1991. Methylation-sensitive sequence-specific DNA binding by the c-Myc basic region. *Science*.

Prickett AR, Ishida M, Böhm S, Frost JM, Puszyk W, Abu-Amero S, Stanier P, Schulz R, Moore GE, Oakey RJ. 2015. Genome-wide methylation analysis in Silver–Russell syndrome patients. *Hum. Genet.* 134:317–332.

Probst AV, Dunleavy E, Almouzni G. 2009. Epigenetic inheritance during the cell cycle. *Nat. Rev. Mol. Cell Biol.* 10:192–206.

Qi S, Wang Z, Li P, Wu Q, Shi T, Li J, Wong J. 2015. Non-germ Line Restoration of Genomic Imprinting for a Small Subset of Imprinted Genes in Ubiquitin-like PHD and RING Finger Domain-Containing 1 (Uhrf1) Null Mouse Embryonic Stem Cells. *J. Biol. Chem.* 290:14181–14191.

Qin W, Wolf P, Liu N, Link S, Smets M, La Mastra F, Forné I, Pichler G, Hörl D, Fellingner K, et al. 2015. DNA methylation requires a DNMT1 ubiquitin interacting motif (UIM) and histone ubiquitination. *Cell Res.* 25:911–929.

Quenneville S, Verde G, Corsinotti A, Kapopoulou A, Jakobsson J, Offner S, Baglivo I, Pedone PV, Grimaldi G, Riccio A, et al. 2011. In Embryonic Stem Cells, ZFP57/KAP1 Recognize a Methylated Hexanucleotide to Affect Chromatin and DNA Methylation of Imprinting Control Regions. *Mol. Cell* 44:361–372.

Rajakumara E, Wang Z, Ma H, Hu L, Chen H, Lin Y, Guo R, Wu F, Li H, Lan F, et al. 2011. PHD finger recognition of unmodified histone H3R2 links UHRF1 to regulation of euchromatic gene expression. *Mol. Cell* 43:275–284.

Rakyan VK, Down TA, Balding DJ, Beck S. 2011. Epigenome-wide association studies for common human diseases. *Nat. Rev. Genet.* 12:529–541.

Ramsahoye BH, Biniszkiwicz D, Lyko F, Clark V, Bird AP, Jaenisch R. 2000. Non-CpG methylation is prevalent in embryonic stem cells and may be mediated by DNA methyltransferase 3a. *Proc Natl Acad Sci USA* 97:5237–5242.

Reddy R, Akoury E, Phuong Nguyen NM, Abdul-Rahman OA, Dery C, Gupta N, Daley WP, Ao A, Landolsi H, Ann Fisher R, et al. 2013. Report of four new patients with protein-truncating mutations in C6orf221/KHDC3L and colocalization with NLRP7. *Eur. J. Hum. Genet.* 21:957–964.

Reddy R, Nguyen NMP, Sarrabay G, Rezaei M, Rivas MCG, Kavasoglu A, Berkil H, Elshafey A, Nunez KP, Dreyfus H, et al. 2016. The genomic architecture of NLRP7 is Alu rich and predisposes to disease-associated large deletions. *Eur. J. Hum. Genet.* 24:1445–1452.

Redeker E, Alders M, Hoovers JMN, Richard CW III, Westerveld A, Mannens M. 1995. Physical mapping of 3 candidate tumor suppressor genes relative to Beckwith-Wiedemann syndrome associated chromosomal breakpoints at 11p15.3. *Cytogenet Cell Genet* 68:222–225.

Rezaei M, Nguyen NMP, Foroughinia L, Dash P, Ahmadpour F, Verma IC, Slim R, Fardaei M. 2016. Two novel mutations in the KHDC3L gene in Asian patients with recurrent hydatidiform mole. *Hum Genome Var* 3:16027.

Rezwan FI, Docherty LE, Poole RL, Lockett GA, Arshad SH, Holloway JW, Temple IK, Mackay DJ. 2015. A statistical method for single sample analysis of HumanMethylation450 array data: genome-wide methylation analysis of patients with imprinting disorders. *Clin Epigenetics* 7:48.

Riesewijk AM, Blagitko N, Schinzel AA, Hu L, Schulz U, Hamel BC, Ropers HH, Kalscheuer VM. 1998. Evidence against a major role of PEG1/MEST in Silver-Russell syndrome. *Eur. J. Hum. Genet.* 6:114–120.

Robertson KD. 2005. DNA methylation and human disease. *Nat. Rev. Genet.* 6:597–610.

Robinson PN, Kohler S, Oellrich A, Sanger Mouse Genetics Project, Wang K, Mungall CJ, Lewis SE, Washington N, Bauer S, Seelow D, et al. 2014. Improved exome prioritization of disease genes through cross-species phenotype comparison. *Genome Research* 24:340–348.

Rochtus A, Martin-Trujillo A, Izzi B, Elli F, Garin I, Linglart A, Mantovani G, Perez de Nanclares G, Thiele S, Decallonne B, et al. 2016. Genome-wide DNA methylation analysis of pseudohypoparathyroidism patients with GNAS imprinting defects. *Clin Epigenetics* 8:10.

Rossignol S, Steunou V, Chalas C, Kerjean A, Rigolet M, Viegas-Pequignot E, Jouannet P, Le Bouc Y, Gicquel C. 2006. The epigenetic imprinting defect of patients with Beckwith--Wiedemann syndrome born after assisted reproductive technology is not restricted to the 11p15 region. *Journal of Medical Genetics* 43:902–907.

Rothbart SB, Dickson BM, Ong MS, Krajewski K, Houliston S, Kireev DB, Arrowsmith CH, Strahl BD. 2013. Multivalent histone engagement by the linked tandem Tudor and PHD domains of UHRF1 is required for the epigenetic inheritance of DNA methylation. *Genes & Development* 27:1288–1298.

Rothbart SB, Krajewski K, Nady N, Tempel W, Xue S, Badeaux AI, Barsyte-Lovejoy D, Martinez JY, Bedford MT, Fuchs SM, et al. 2012. Association of UHRF1 with methylated H3K9 directs the maintenance of DNA methylation. *Nat Struct Mol Biol* 19:1155–1160.

Rougier N, Bourc'his D, Gomes DM, Niveleau A, Plachot M, Pàldi A, Viegas-Pequignot E. 1998. Chromosome methylation patterns during mammalian preimplantation development. *Genes & Development* 12:2108–2113.

Russell A. 1954. A syndrome of intra-uterine dwarfism recognizable at birth with

cranio-facial dysostosis, disproportionately short arms, and other anomalies (5 examples). *Proc. R. Soc. Med.* 47:1040–1044.

Sanchez-Delgado M, Martin-Trujillo A, Tayama C, Vidal E, Esteller M, Iglesias-Platas I, Deo N, Barney O, Maclean K, Hata K, et al. 2015. Absence of Maternal Methylation in Biparental Hydatidiform Moles from Women with NLRP7 Maternal-Effect Mutations Reveals Widespread Placenta-Specific Imprinting. *PLoS Genet* 11:e1005644.

Sanchez-Delgado M, Riccio A, Eggermann T, Maher ER, Lapunzina P, Mackay D, Monk D. 2016. Causes and Consequences of Multi-Locus Imprinting Disturbances in Humans. *Trends Genet.* 32:444–455.

Santos F, Hendrich B, Reik W, Dean W. 2002. Dynamic Reprogramming of DNA Methylation in the Early Mouse Embryo. *Developmental Biology* 241:172–182.

Sarraf SA, Stancheva I. 2004. Methyl-CpG binding protein MBD1 couples histone H3 methylation at lysine 9 by SETDB1 to DNA replication and chromatin assembly. *Mol. Cell* 15:595–605.

Schofield PN, Joyce JA, Lam WK, Grandjean V, Ferguson-Smith A, Reik W, Maher ER. 2001. Genomic imprinting and cancer; new paradigms in the genetics of neoplasia. *Toxicology Letters* 120:151–160.

Schönherr N, Meyer E, Roos A, Schmidt A, Wollmann HA, Eggermann T. 2007. The centromeric 11p15 imprinting centre is also involved in Silver-Russell syndrome.

Journal of Medical Genetics 44:59–63.

Schöherr N, Jäger S, Ranke MB, Wollmann HA, Binder G, Eggermann T. 2008. No evidence for isolated imprinting mutations in the PEG1/MEST locus in Silver–Russell patients. *Eur J Med Genet* 51:322–324.

Schultz RM. 2002. The molecular foundations of the maternal to zygotic transition in the preimplantation embryo. *Hum. Reprod. Update* 8:323–331.

Seisenberger S, Andrews S, Krueger F, Arand J, Walter J, Santos F, Popp C, Thienpont B, Dean W, Reik W. 2012. The dynamics of genome-wide DNA methylation reprogramming in mouse primordial germ cells. *Mol. Cell* 48:849–862.

Sharif J, Muto M, Takebayashi S-I, Suetake I, Iwamatsu A, Endo TA, Shinga J, Mizutani-Koseki Y, Toyoda T, Okamura K, et al. 2007. The SRA protein Np95 mediates epigenetic inheritance by recruiting Dnmt1 to methylated DNA. *Nature* 450:908–912.

Sharp AJ, Stathaki E, Migliavacca E, Brahmachary M, Montgomery SB, Dupre Y, Antonarakis SE. 2011. DNA methylation profiles of human active and inactive X chromosomes. *Genome Research* 21:1592–1600.

Shen L, Wu H, Diep D, Yamaguchi S, D’Alessio AC, Fung H-L, Zhang K, Zhang Y. 2013. Genome-wide analysis reveals TET- and TDG-dependent 5-methylcytosine oxidation dynamics. *Cell* 153:692–706.

Silver HK, Kiyasu W, George J, Deamer WC. 1953. Syndrome of congenital hemihypertrophy, shortness of stature, and elevated urinary gonadotropins. *Pediatrics* 12:368–376.

Slatter RE, Elliott M, Welham K, Carrera M, Schofield PN, Barton DE, Maher ER. 1994. Mosaic uniparental disomy in Beckwith-Wiedemann syndrome. *Journal of Medical Genetics* 31:749–753.

Slim R, Wallace EP. 2013. NLRP7 and the Genetics of Hydatidiform Moles: Recent Advances and New Challenges. *Front. Immunol.* 4:242.

Smallwood SA, Kelsey G. 2012. De novo DNA methylation: a germ cell perspective. *Trends Genet.* 28:33–42.

Smallwood SA, Tomizawa S-I, Krueger F, Ruf N, Carli N, Segonds-Pichon A, Sato S, Hata K, Andrews SR, Kelsey G. 2011. Dynamic CpG island methylation landscape in oocytes and preimplantation embryos. *Nature Genetics* 43:811–814.

Smilnich NJ, Day CD, Fitzpatrick GV, Caldwell GM, Lossie AC, Cooper PR, Smallwood AC, Joyce JA, Schofield PN, Reik W, et al. 1999. A maternally methylated CpG island in KvLQT1 is associated with an antisense paternal transcript and loss of imprinting in Beckwith-Wiedemann syndrome. *Proc Natl Acad Sci USA* 96:8064–8069.

Smith FM, Garfield AS, Ward A. 2006. Regulation of growth and metabolism by imprinted genes. *Cytogenet. Genome Res.* 113:279–291.

Smith ZD, Gu H, Bock C, Gnirke A, Meissner A. 2009. High-throughput bisulfite sequencing in mammalian genomes. *Methods* 48:226–232.

Soellner L, Begemann M, Mackay DJG, Grønsvkov K, Tümer Z, Maher ER, Temple IK, Monk D, Riccio A, Linglart A, et al. 2016. Recent Advances in Imprinting Disorders. *Clin Genet* 91:3–13.

Sofos E, Pescosolido MF, Quintos JB, Abuelo D, Gunn S, Hovanes K, Morrow EM, Shur N. 2011. A novel familial 11p15.4 microduplication associated with intellectual disability, dysmorphic features, and obesity with involvement of the ZNF214 gene. *Am. J. Med. Genet.* 158A:50–58.

Sparago A, Cerrato F, Vernucci M, Ferrero GB, Silengo MC, Riccio A. 2004. Microdeletions in the human H19 DMR result in loss of IGF2 imprinting and Beckwith-Wiedemann syndrome. *Nature Genetics* 36:958–960.

Sparago A, Russo S, Cerrato F, Ferraiuolo S, Castorina P, Selicorni A, Schwienbacher C, Negrini M, Ferrero GB, Silengo MC, et al. 2006. Mechanisms causing imprinting defects in familial Beckwith-Wiedemann syndrome with Wilms' tumour. *Human Molecular Genetics* 16:254–264.

Srivastava M, Hsieh S, Grinberg A, Williams-Simons L, Huang SP, Pfeifer K. 2000. H19 and Igf2 monoallelic expression is regulated in two distinct ways by a shared cis acting regulatory region upstream of H19. *Genes & Development* 14:1186–1195.

Stöger R, Kubicka P, Liu CG, Kafri T, Razin A, Cedar H, Barlow DP. 1993. Maternal-

specific methylation of the imprinted mouse *Igf2r* locus identifies the expressed locus as carrying the imprinting signal. *Cell* 73:61–71.

Strakova Z, Srisuparp S, Fazleabas AT. 2002. IL-1beta during in vitro decidualization in primate. *J. Reprod. Immunol.* 55:35–47.

Suetake I, Shinozaki F, Miyagawa J, Takeshima H, Tajima S. 2004. DNMT3L stimulates the DNA methylation activity of Dnmt3a and Dnmt3b through a direct interaction. *Journal of Biological Chemistry* 279:27816–27823.

Surani MA, Barton SC. 1983. Development of gynogenetic eggs in the mouse: implications for parthenogenetic embryos. *Science* 222:1034–1036.

Surani MA, Barton SC, Norris ML. 1984. Development of reconstituted mouse eggs suggests imprinting of the genome during gametogenesis. *Nature* 308:548–550.

Szulwach KE, Li X, Li Y, Song C-X, Wu H, Dai Q, Irier H, Upadhyay AK, Gearing M, Levey AI, et al. 2011. 5-hmC-mediated epigenetic dynamics during postnatal neurodevelopment and aging. *Nat Neurosci* 14:1607–1616.

Taiwo O, Wilson GA, Morris T, Seisenberger S, Reik W, Pearce D, Beck S, Butcher LM. 2012. Methylome analysis using MeDIP-seq with low DNA concentrations. *Nat Protoc* 7:617–636.

Tee L, Lim DH, Dias RP, Baudement M-O, Slater AA, Kirby G, Hancocks T, Stewart H, Hardy C, Macdonald F, et al. 2013. Epimutation profiling in Beckwith-Wiedemann

syndrome: relationship with assisted reproductive technology. *Clin Epigenetics* 5:23.

Teschendorff AE, Marabita F, Lechner M, Bartlett T, Tegner J, Gomez-Cabrero D, Beck S. 2013. A beta-mixture quantile normalization method for correcting probe design bias in Illumina Infinium 450 k DNA methylation data. *Bioinformatics* 29:189–196.

Tittle RK, Sze R, Ng A, Nuckels RJ, Swartz ME, Anderson RM, Bosch J, Stainier DYR, Eberhart JK, Gross JM. 2011. Uhrf1 and Dnmt1 are required for development and maintenance of the zebrafish lens. *Developmental Biology* 350:50–63.

Tong ZB, Gold L, Pfeifer KE, Dorward H, Lee E, Bondy CA, Dean J, Nelson LM. 2000. Mater, a maternal effect gene required for early embryonic development in mice. *Nature Genetics* 26:267–268.

Tong ZB, Nelson LM. 1999. A mouse gene encoding an oocyte antigen associated with autoimmune premature ovarian failure. *Endocrinology* 140:3720–3726.

Tsugu A, Sakai K, Dirks PB, Jung S, Weksberg R, Fei Y-L, Mondal S, Ivanchuk S, Ackerley C, Hamel PA. 2000. Expression of p57KIP2 Potently Blocks the Growth of Human Astrocytomas and Induces Cell Senescence. *The American Journal of Pathology* 157:919–932.

Turner CLS, Mackay DM, Callaway JLA, Docherty LE, Poole RL, Bullman H, Lever M, Castle BM, Kivuva EC, Turnpenny PD, et al. 2010. Methylation analysis of 79 patients with growth restriction reveals novel patterns of methylation change at

imprinted loci. *Eur. J. Hum. Genet.* 18:648–655.

Tycko B. 2000. Epigenetic gene silencing in cancer. *J. Clin. Invest.* 105:401–407.

Ueda T, Abe K, Miura A, Yuzuriha M, Zubair M, Noguchi M, Niwa K, Kawase Y, Kono T, Matsuda Y, et al. 2000. The paternal methylation imprint of the mouse H19 locus is acquired in the gonocyte stage during foetal testis development. *Genes Cells* 5:649–659.

Van den Veyver IB, Al-Hussaini TK. 2006. Biparental hydatidiform moles: a maternal effect mutation affecting imprinting in the offspring. *Hum. Reprod. Update* 12:233–242.

Varrault A, Gueydan C, Delalbre A, Bellmann A, Houssami S, Aknin C, Severac D, Chotard L, Kahli M, Le Digarcher A, et al. 2006. *Zac1* regulates an imprinted gene network critically involved in the control of embryonic growth. *Dev. Cell* 11:711–722.

Waddington CH. 1942. The epigenotype. *Endeavour.* 1:18–20.

Wan L-B, Pan H, Hannenhalli S, Cheng Y, Ma J, Fedoriw A, Lobanenkov V, Latham KE, Schultz RM, Bartolomei MS. 2008. Maternal depletion of CTCF reveals multiple functions during oocyte and preimplantation embryo development. *Development* 135:2729–2738.

Wang Fengli, Yang Y, Lin X, Wang J-Q, Wu Y-S, Xie W, Wang D, Zhu S, Liao Y-Q, Sun Q, et al. 2013. Genome-wide loss of 5-hmC is a novel epigenetic feature of

Huntington's disease. *Human Molecular Genetics* 22:3641–3653.

Wang H, Chattopadhyay A, Li Z, Daines B, Li Y, Gao C, Gibbs R, Zhang K, Chen R. 2010. Rapid identification of heterozygous mutations in *Drosophila melanogaster* using genomic capture sequencing. *Genome Research* 20:981–988.

Wang Jingyu, Tang J, Lai M, Zhang H. 2014. 5-Hydroxymethylcytosine and disease. *Mutation Research/Reviews in Mutation Research* 762:167–175.

Wang Junwen, Xia Y, Li L, Gong D, Yao Y, Luo H, Lu H, Yi N, Wu H, Zhang X, et al. 2013. Double restriction-enzyme digestion improves the coverage and accuracy of genome-wide CpG methylation profiling by reduced representation bisulfite sequencing. *BMC Genomics* 14:11.

Wang Kai, Li M, Hakonarson H. 2010. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. *Nucleic Acids Research* 38:e164.

Wang Q, Curran ME, Splawski I, Burn TC, Millholland JM, VanRaay TJ, Shen J, Timothy KW, Vincent GM, de Jager T, et al. 1996. Positional cloning of a novel potassium channel gene: KVLQT1 mutations cause cardiac arrhythmias. *Nature Genetics* 12:17–23.

Wang X. 2003. A PCR primer bank for quantitative gene expression analysis. *Nucleic Acids Research* 31:154e–154.

Wang Xiaowei, Spandidos A, Wang H, Seed B. 2012. PrimerBank: a PCR primer

database for quantitative gene expression analysis, 2012 update. *Nucleic Acids Research* 40:D1144–9.

Watanabe T, Tomizawa S-I, Mitsuya K, Totoki Y, Yamamoto Y, Kuramochi-Miyagawa S, Iida N, Hoki Y, Murphy PJ, Toyoda A, et al. 2011. Role for piRNAs and noncoding RNA in de novo DNA methylation of the imprinted mouse *Rasgrf1* locus. *Science* 332:848–852.

Watt F, Molloy PL. 1988. Cytosine methylation prevents binding to DNA of a HeLa cell transcription factor required for optimal expression of the adenovirus major late promoter. *Genes & Development* 2:1136–1143.

Weber M, Davies JJ, Wittig D, Oakeley EJ, Haase M, Lam WL, Schübeler D. 2005. Chromosome-wide and promoter-specific analyses identify sites of differential DNA methylation in normal and transformed human cells. *Nature Genetics* 37:853–862.

Weksberg R, Shuman C, Beckwith JB. 2010. Beckwith-Wiedemann syndrome. *Eur. J. Hum. Genet.* 18:8–14.

Wiedemann HR. 1964. Complexe malformatif avec hernie ombilicale et macroglossie un " syndrome nouveau"? *J Hum Genet.*

Wilson VL, Smith RA, Ma S, Cutler RG. 1987. Genomic 5-methyldeoxycytidine decreases with age. *Journal of Biological Chemistry* 262:9948–9951.

Woodfine K, Huddleston JE, Murrell A. 2011. Quantitative analysis of DNA

methylation at all human imprinted regions reveals preservation of epigenetic stability in adult somatic tissue. *Epigenetics Chromatin* 4:1.

Wu X. 2009. Maternal depletion of NLRP5 blocks early embryogenesis in rhesus macaque monkeys (*Macaca mulatta*). *Human Reproduction* 24:415–424.

Xiong HY, Alipanahi B, Lee LJ, Bretschneider H, Merico D, Yuen RKC, Hua Y, Gueroussov S, Najafabadi HS, Hughes TR, et al. 2015. The human splicing code reveals new insights into the genetic determinants of disease. *Science* 347:1254806–1254806.

Xu Z, Niu L, Li L, Taylor JA. 2016. ENmix: a novel background correction method for Illumina HumanMethylation450 BeadChip. *Nucleic Acids Research* 44:e20–e20.

Yoon JK, Ahn J, Kim HS, Han SM, Jang H, Lee MG, Lee JH, Bang D. 2015. microDuMIP: target-enrichment technique for microarray-based duplex molecular inversion probes. *Nucleic Acids Research* 43:e28–e28.

Yoshihashi H, Maeyama K, Kosaki R, Ogata T, Tsukahara M, Goto Y, Hata J, Matsuo N, Smith RJ, Kosaki K. 2000. Imprinting of human GRB10 and its mutations in two patients with Russell-Silver syndrome. *Am. J. Hum. Genet.* 67:476–482.

Yoshimizu T, Miroglio A, Ripoche M-A, Gabory A, Vernucci M, Riccio A, Colnot S, Godard C, Terris B, Jammes H, et al. 2008. The H19 locus acts in vivo as a tumor suppressor. *Proc. Natl. Acad. Sci. U.S.A.* 105:12417–12422.

Young LE, Fernandes K, McEvoy TG, Butterwith SC, Gutierrez CG, Carolan C, Broadbent PJ, Robinson JJ, Wilmut I, Sinclair KD. 2001. Epigenetic change in IGF2R is associated with fetal overgrowth after sheep embryo culture. *Nature Genetics* 27:153–154.

Young LE, Sinclair KD, Wilmut I. 1998. Large offspring syndrome in cattle and sheep. *Rev. Reprod.* 3:155–163.

Yu X-J, Yi Z, Gao Z, Qin D, Zhai Y, Chen X, Ou-Yang Y, Wang Z-B, Zheng P, Zhu M-S, et al. 2014. The subcortical maternal complex controls symmetric division of mouse zygotes by regulating F-actin dynamics. *Nat Commun* 5:4887.

Zhang K, Li JB, Gao Y, Egli D, Xie B, Deng J, Li Z, Lee J-H, Aach J, LeProust EM, et al. 2009. Digital RNA allelotyping reveals tissue-specific and allele-specific gene expression in human. *Nat Meth* 6:613–618.

Zhang P, Dixon M, Zucchelli M, Hambiliki F, Levkov L, Hovatta O, Kere J. 2008. Expression analysis of the NLRP gene family suggests a role in human preimplantation development. *PLoS ONE* 3:e2755.

Zhao Q, Zhang J, Chen R, Wang L, Li B, Cheng H, Duan X, Zhu H, Wei W, Li J, et al. 2016. Dissecting the precise role of H3K9 methylation in crosstalk with DNA maintenance methylation in mammals. *Nat Commun* 7:12464.

Zhou Y, Zhang X, Klibanski A. 2012. MEG3 noncoding RNA: a tumor suppressor. *J. Mol. Endocrinol.* 48:R45–53.

Zhu K, Yan L, Zhang X, Lu X, Wang T, Yan J, Liu X, Qiao J, Li L. 2015. Identification of a human subcortical maternal complex. *Molecular Human Reproduction* 21:320–329.

Ziller MJ, Müller F, Liao J, Zhang Y, Gu H, Bock C, Boyle P, Epstein CB, Bernstein BE, Lengauer T, et al. 2011. Genomic distribution and inter-sample variation of non-CpG methylation across human cell types. *PLoS Genet* 7:e1002389.

Zollino M, Orteschi D, Marangi G, De Crescenzo A, Pecile V, Riccio A, Neri G. 2010. A case of Beckwith-Wiedemann syndrome caused by a cryptic 11p15 deletion encompassing the centromeric imprinted domain of the BWS locus. *Journal of Medical Genetics* 47:429–432.

Zuo X, Sheng J, Lau H-T, McDonald CM, Andrade M, Cullen DE, Bell FT, Iacovino M, Kyba M, Xu G, et al. 2012. Zinc finger protein ZFP57 requires its co-factor to recruit DNA methyltransferases and maintains DNA methylation imprint in embryonic stem cells via its transcriptional repression domain. *J. Biol. Chem.* 287:2107–2118.

Ørstavik KH, Eiklid K, van der Hagen CB, Spetalen S, Kierulf K, Skjeldal O, Buiting K. 2003. Another case of imprinting defect in a girl with Angelman syndrome who was conceived by intracytoplasmic semen injection. *Am. J. Hum. Genet.* 72:218–219.